

# Glucose Control and Vascular Complications in Veteran

New England Journal of Medicine

360, 129-139

DOI: [10.1056/nejmoa0808431](https://doi.org/10.1056/nejmoa0808431)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.9 BT / Overlock 10 T	0.9	10
3	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 BT / Ov	1.0	2,331
4	Diabetische Retinopathie und Makulopathie. Diabetologe, 2008, 4, 92-92.	0.0	3
5	Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Medical Journal of Australia, 2009, 191, 339-344.	0.8	58
6	Article Commentary: Glucose Control and Its Implications for the General Surgeon. American Surgeon, 2009, 75, 1031-1035.	0.4	1
7	Insulin glulisine in the management of diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 2, 111-115.	1.1	4
8	Diabetes Mellitus in the Older Adult. , 0, , 79-88.		0
10	DoenÃ§a arterial coronÃ¡ria e diabetes: do tratamento farmacolÃ³gico aos procedimentos de revascularizaÃ§Ã£o. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 398-413.	0.1	5
11	What does it take to put an ugly fact through the heart of a beautiful hypothesis?. Annals of Internal Medicine, 2009, 150, Jc3.	2.0	12
12	Fixed combination of repaglinide and metformin in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 2, 101-109.	1.1	6
13	Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. Clinical Medicine Therapeutics, 2009, 1, CMT.S2370.	0.1	1
14	What have we lost in the wake of the Rosiglitazone Controversy?. Endocrine Practice, 2009, 15, 273-274.	1.1	2
16	Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vascular Health and Risk Management, 2009, 5, 859.	1.0	30
18	Le rÃ´le d'Ã©tÃªre de l'hyperglycÃ©mie postprandiale. Sang Thrombose Vaisseaux, 2009, 21, 227-231.	0.1	1
19	DiabÃªte de type 2: prise en charge efficace du risque vasculaire. Sang Thrombose Vaisseaux, 2009, 21, 409-415.	0.1	0
20	Facts and Ideas from Anywhere. Baylor University Medical Center Proceedings, 2009, 22, 178-187.	0.2	2
21	The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. Review of Diabetic Studies, 2009, 6, 6-12.	0.5	25
22	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Current Medical Research and Opinion, 2009, 25, 2631-2641.	0.9	22

#	ARTICLE	IF	CITATIONS
23	Type 2 Diabetes Treatment and Macrovascular Complicationsâ€”Fat and Sugar Make a Dangerous SoufflÃ©. <i>Metabolic Syndrome and Related Disorders</i> , 2009, 7, 79-82.	0.5	1
24	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2009, 360, 2503-2515.	13.9	1,705
25	Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. <i>Circulation</i> , 2009, 120, 212-220.	1.6	223
26	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Woo and Eizirik. <i>Diabetes Care</i> , 2009, 32, e37-e38.	4.3	5
27	Circulating Biomarkers of Glycemia in Diabetes Management and Implications for Personalized Medicine. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 743-747.	1.3	31
28	Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?. <i>Diabetes</i> , 2009, 58, 1469-1470.	0.3	5
29	Changing the Treatment Paradigm for Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, S217-S222.	4.3	31
30	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Diabetes Care</i> , 2009, 32, 187-192.	4.3	624
31	Oxford International Programme in Evidence-Based Health Care. <i>Evidence-Based Medicine</i> , 2009, 14, 69-69.	0.6	11
32	Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. <i>Diabetes Care</i> , 2009, 32, S149-S150.	4.3	2
33	Antidiabetic agents and cardiovascular risk in type 2 diabetes. <i>Nature Reviews Endocrinology</i> , 2009, 5, 500-506.	4.3	23
34	Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3163-3170.	1.8	236
35	Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management. <i>Postgraduate Medicine</i> , 2009, 121, 82-93.	0.9	11
36	Recent clinical trials in diabetes â€” implications for managing older patients. <i>Reviews in Clinical Gerontology</i> , 2009, 19, 25-33.	0.5	0
37	Treatment of Type 2 Diabetes: One Extreme to Anotherâ€”Reply. <i>Archives of Internal Medicine</i> , 2009, 169, 1241.	4.3	0
38	The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. <i>Circulation</i> , 2009, 120, 2529-2540.	1.6	247
39	Progress in Diabetes Researchâ€”What's Next. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1599.	3.8	9
40	Variation in Event Rates in Trials of Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1698.	3.8	15

#	ARTICLE	IF	CITATIONS
41	Does strict glucose control improve outcome?. British Journal of Anaesthesia, 2009, 103, 331-334.	1.5	5
42	Initiating and Titrating Insulin in Patients With Type 2 Diabetes. Clinical Diabetes, 2009, 27, 72-76.	1.2	10
43	Coronary Artery Calcium: A Clue to the Enigma of Tight Glycemic Control and Cardiovascular Disease?. Diabetes, 2009, 58, 2448-2449.	0.3	2
44	What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research, 2009, 6, 283-287.	0.9	17
45	Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. Expert Review of Cardiovascular Therapy, 2009, 7, 541-549.	0.6	22
47	Review: Metabolic memory in type 1 diabetes. British Journal of Diabetes and Vascular Disease, 2009, 9, 254-257.	0.6	6
48	Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis. Diabetes, 2009, 58, 2642-2648.	0.3	167
49	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009, 32, e34-e34.	4.3	8
50	U-500 Insulin: When More With Less Yields Success. Diabetes Spectrum, 2009, 22, 116-122.	0.4	17
51	Dysglycemia and Cardiovascular Risk in the General Population. Circulation, 2009, 119, 773-775.	1.6	23
52	Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. European Heart Journal Supplements, 2009, 11, E4-E8.	0.0	2
53	The value of early detection of type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 95-99.	1.2	27
54	Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. European Heart Journal, 2009, 30, 1301-1304.	1.0	4
55	Trials Review: Cardiovascular Outcome with Intensive Glycemic Control and Implications for Patients with Type 2 Diabetes. Postgraduate Medicine, 2009, 121, 31-41.	0.9	3
56	Implementing Treatment Guidelines for Type 2 Diabetes in Primary Care. Postgraduate Medicine, 2009, 121, 125-138.	0.9	2
57	Implications of New Diabetes Treatment Trials: Should Current Clinical Practice be Altered?. Postgraduate Medicine, 2009, 121, 67-72.	0.9	2
58	Cardiovascular risk and glycemic control. Cmaj, 2009, 180, 907-908.	0.9	4
59	Pharmacoepidemiology of insulin initiation in diabetes care. Cmaj, 2009, 180, 1287-1288.	0.9	2

#	ARTICLE	IF	CITATIONS
60	Genes, diabetes and cardiovascular risk prediction. <i>Nature Reviews Endocrinology</i> , 2009, 5, 192-193.	4.3	0
61	Glucose Control and Vascular Complications in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 360, 2031-2032.	13.9	12
62	HOME reveals new data on a cornerstone of treatment. <i>Nature Reviews Endocrinology</i> , 2009, 5, 478-479.	4.3	1
64	Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder. <i>Postgraduate Medicine</i> , 2009, 121, 68-81.	0.9	25
68	Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. <i>Nature Reviews Endocrinology</i> , 2009, 5, 270-275.	4.3	10
69	Implications of recent clinical trials on pay-for-performance. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 864-867.	0.5	7
70	GHb Level and Subsequent Mortality Among Adults in the U.S.. <i>Diabetes Care</i> , 2009, 32, 1440-1446.	4.3	60
71	Motor Vehicle Crashes in Diabetic Patients with Tight Glycemic Control: A Population-based Case Control Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000192.	3.9	39
72	Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. <i>Heart</i> , 2009, 95, 917-923.	1.2	48
73	Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E685-E694.	1.8	43
74	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.	4.3	230
75	What does it take to put an ugly fact through the heart of a beautiful hypothesis?. <i>Evidence-Based Medicine</i> , 2009, 14, 68-69.	0.6	9
76	Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. <i>Diabetes Care</i> , 2009, 32, 1344-1345.	4.3	33
77	Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents. <i>Diabetes Care</i> , 2009, 32, S260-S265.	4.3	34
78	Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1186.	3.8	99
79	Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 507-513.	0.2	1
80	Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. <i>Diabetes Care</i> , 2009, 32, S342-S348.	4.3	27
81	What the headline giveth, the critique often taketh away: The "News and headlines" feature of EvidenceUpdates. <i>Evidence-Based Medicine</i> , 2009, 14, 69-69.	0.6	0

#	ARTICLE	IF	CITATIONS
82	The Munich Myocardial Infarction Registry. <i>Diabetes Care</i> , 2009, 32, S326-S330.	4.3	20
83	Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2009, 161, 1-9.	1.9	18
84	Target for Glycemic Control. <i>Diabetes Care</i> , 2009, 32, S199-S204.	4.3	55
85	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.3	1,236
86	Prevalence of daily hyperglycemia in obese type 2 diabetic men compared with that in lean and obese normoglycemic men: effect of consumption of a sucrose-containing beverage. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 511-518.	2.2	15
87	Arguments for and against the Role of Glucose Variability in the Development of Diabetes Complications. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 649-655.	1.3	29
88	Intensive versus Conventional Glucose Control in Critically Ill Patients. <i>New England Journal of Medicine</i> , 2009, 360, 1283-1297.	13.9	6,065
89	Glucose Control in Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1590.	3.8	14
90	Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4810-4819.	1.8	201
91	Clinically Significant Disagreement between Mean Blood Glucose and Estimated Average Glucose in Two Populations: Implications for Diabetes Management. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1128-1135.	1.3	16
92	The ADDITION-Cambridge trial protocol: a cluster " randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. <i>BMC Public Health</i> , 2009, 9, 136.	1.2	75
93	A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus. <i>Pharmacotherapy</i> , 2009, 29, 1280-1288.	1.2	13
94	Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. <i>Journal of Clinical Hypertension</i> , 2009, 11, .	1.0	1
95	Clinical benefits of tight glycaemic control: effect on the kidney. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2009, 23, 431-439.	1.7	7
96	Clinical benefits of tight glycaemic control: focus on the intensive care unit. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2009, 23, 421-429.	1.7	27
97	Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 393-402.	1.7	79
98	Exercise therapy in Type 2 diabetes. <i>Acta Diabetologica</i> , 2009, 46, 263-278.	1.2	101
100	How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 403-408.	1.3	10

#	ARTICLE	IF	CITATIONS
102	ACCORD, ADVANCE und VADT – Paradigmenwechsel in der Diabetologie?. Clinical Research in Cardiology Supplements, 2009, 4, 196-199.	2.0	0
103	Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Current Atherosclerosis Reports, 2009, 11, 281-288.	2.0	14
104	Serum glucose control in diabetic patients with cardiovascular disease: Should we be less aggressive?. Current Atherosclerosis Reports, 2009, 11, 384-390.	2.0	3
105	Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Current Cardiology Reports, 2009, 11, 258-263.	1.3	29
106	Glycemic control and cardiovascular disease in chronic kidney disease. Current Diabetes Reports, 2009, 9, 243-248.	1.7	10
107	Management of diabetes in dialysis patients. Current Diabetes Reports, 2009, 9, 466-472.	1.7	12
108	Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 2009, 6, 126-132.	1.3	3
109	All things considered-including glucose control in the ICU. Current Hypertension Reports, 2009, 11, 383-384.	1.5	1
112	Update in General Internal Medicine. Journal of General Internal Medicine, 2009, 24, 1327-1332.	1.3	0
114	Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia, 2009, 52, 1219-1226.	2.9	118
115	Rosiglitazone: to be or not to be?. Diabetologia, 2009, 52, 1448-1450.	2.9	1
116	Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Diabetologia, 2009, 52, 1434-1441.	2.9	23
117	Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia, 2009, 52, 2027-2036.	2.9	150
118	Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia, 2009, 52, 1990-2000.	2.9	109
119	Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52, 2288-2298.	2.9	1,033
120	Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovascular Diabetology, 2009, 8, 12.	2.7	21
121	Getting away from glucose: stop sugarcoating diabetes. Nature Medicine, 2009, 15, 372-373.	15.2	7
122	Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery, 2009, 8, 361-367.	21.5	39

#	ARTICLE	IF	CITATIONS
123	Dietary cholesterol and other nutritional considerations in people with diabetes. International Journal of Clinical Practice, 2009, 63, 15-21.	0.8	8
124	Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International Journal of Clinical Practice, 2009, 63, 1354-1368.	0.8	3
125	Le cholest�rol alimentaire et autres consid�rations nutritionnelles chez les personnes atteintes de diab�te. International Journal of Clinical Practice, 2009, 63, 44-51.	0.8	1
126	Type 2 diabetes and HbA1c goal: time for individualised therapy. International Journal of Clinical Practice, 2009, 63, 1408-1409.	0.8	0
127	Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. International Journal of Clinical Practice, 2009, 63, 1421-1425.	0.8	51
128	Where now for insulin glargine - a time for pragmatic medicine?. International Journal of Clinical Practice, 2009, 63, 1413-1415.	0.8	1
129	Insulin intensification "the rationale and the target. International Journal of Clinical Practice, 2009, 63, 1-5.	0.8	11
130	The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism, 2009, 11, 742-756.	2.2	26
131	Restaging insulin therapy for patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 1-5.	2.2	17
132	Long-term glycaemic control with metformin+sulphonylurea+pioglitazone triple therapy in PROactive (PROactive 17). Diabetic Medicine, 2009, 26, 1033-1039.	1.2	41
133	Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan. Diabetic Medicine, 2009, 26, 1255-1261.	1.2	30
134	Intensified multifactorial treatment of patients with Type 2 diabetes: What can be achieved and does it pay off?. Journal of Diabetes, 2009, 1, 83-89.	0.8	5
135	What is the evidence base for the randomized controlled trial?. Journal of Diabetes, 2009, 1, 73-75.	0.8	1
136	Recent cardiovascular trials: What are the drivers of benefit and adverse effect?. Journal of Diabetes, 2009, 1, 227-229.	0.8	1
137	Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. Journal of the American Geriatrics Society, 2009, 57, 2011-2019.	1.3	71
138	Glycemic Targets for Patients with Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine, 2009, 76, 227-233.	1.9	7
139	Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocrine Practice, 2009, 15, 540-559.	1.1	805
140	The Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview. Diabetes Technology and Therapeutics, 2009, 11, 623-633.	2.4	61



#	ARTICLE	IF	CITATIONS
141	Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1121-1127.	2.2	339
142	Delayed Arousal. <i>Anesthesiology Clinics</i> , 2009, 27, 429-450.	0.6	6
143	Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. <i>Diabetes and Metabolism</i> , 2009, 35, 425-430.	1.4	8
144	Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). <i>Diabetes Research and Clinical Practice</i> , 2009, 86, 74-81.	1.1	29
145	Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 365-377.	1.1	88
146	Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 604-612.	1.1	168
147	The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 596-603.	1.1	37
148	Extent of glycemic control in type 2 diabetes mellitus: Close, but no cigar. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 593-595.	1.1	1
150	Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 429-431.	1.2	6
151	The impact of glucose-lowering therapy on cardiovascular outcomes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 401-411.	2.2	14
152	Rosiglitazone. <i>Primary Care Diabetes</i> , 2009, 3, 123-124.	0.9	1
153	De los algoritmos a la práctica clínica en el manejo óptimo del paciente diabético. <i>Revista Clínica Española</i> , 2009, 209, 18-27.	0.2	0
154	Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 361, 1736-1747.	13.9	608
155	Present recommendations in type 2 diabetes treatment. <i>Endocrinología Y Nutricion: Organo De La Sociedad Española De Endocrinología Y Nutricion</i> , 2009, 56, 46-49.	0.8	1
156	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	0.7	351
157	Diabetic nephropathy. <i>Diabetology and Metabolic Syndrome</i> , 2009, 1, 10.	1.2	101
158	Revisiting clinical trials on glycemic control and cardiovascular risk. <i>Diabetology and Metabolic Syndrome</i> , 2009, 1, 12.	1.2	3
159	Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil. <i>Diabetology and Metabolic Syndrome</i> , 2009, 1, 22.	1.2	19

#	ARTICLE	IF	CITATIONS
160	Optimal Insulin Treatment in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 361, 1801-1803.	13.9	13
161	Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. <i>Annals of Internal Medicine</i> , 2009, 150, 803.	2.0	142
162	Development of CRiteria to Assess Appropriate Medication Use among Elderly Complex Patients (CRIME) Project. <i>Drugs and Aging</i> , 2009, 26, 3-13.	1.3	37
163	Treatment of Type 2 Diabetes Mellitus With Orally Administered Agents: Advances in Combination Therapy. <i>Endocrine Practice</i> , 2009, 15, 750-762.	1.1	5
164	Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 111-118.	1.2	1
165	Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1365-1373.	1.9	1
166	Changes in levels of haemoglobin A1cduring the first 6 years after diagnosis of clinical type 2 diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2009, 69, 851-857.	0.6	8
167	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. <i>Current Medical Research and Opinion</i> , 2009, 25, 1931-1940.	0.9	11
168	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke. <i>Alzheimer's and Dementia</i> , 2009, 5, 149-153.	0.4	1
169	Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?. <i>Diabetes Research and Clinical Practice</i> , 2009, 86, S22-S25.	1.1	15
170	How to interpret results of the HEART2D trial?. <i>Diabetes Research and Clinical Practice</i> , 2009, 86, S53-S56.	1.1	1
171	Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. <i>Diabetes Research and Clinical Practice</i> , 2009, 86, S57-S62.	1.1	42
172	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009, 373, 1765-1772.	6.3	1,234
173	Effect of the dual peroxisome proliferator-activated receptor- $\alpha/\delta$ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. <i>Lancet, The</i> , 2009, 374, 126-135.	6.3	196
174	Hyperglycaemia and coronary heart disease: the meta picture. <i>Lancet, The</i> , 2009, 373, 1737-1738.	6.3	12
175	Intensive glucose control and cardiovascular outcomes. <i>Lancet, The</i> , 2009, 374, 522-523.	6.3	1
176	Intensive glucose control and cardiovascular outcomes. <i>Lancet, The</i> , 2009, 374, 523-524.	6.3	2
177	Influence du contrÃle glycÃmique du diabÃtique de type 2 sur les complications cardiovasculaires: une apparente contradiction. <i>Medecine Des Maladies Metaboliques</i> , 2009, 3, 527-533.	0.1	4

#	ARTICLE	IF	CITATIONS
180	RÃ©flexions pour de nouvelles recommandations de traitement mÃ©dicamenteux du diabÃ©te de type 2 aprÃ©s post-UKPDS, ACCORD, VADT, ADVANCE. <i>Medecine Des Maladies Metaboliques</i> , 2009, 3, 147-150.	0.1	0
181	Diabetes and Cardiovascular Disease Prevention in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 607-641.	1.0	44
182	Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. <i>Diabetes Care</i> , 2009, 32, 381-386.	4.3	320
184	Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes. <i>Cardiology in Review</i> , 2009, 17, 165-175.	0.6	24
185	Strategies to enhance cardiovascular disease prevention in patients with diabetes. <i>Current Opinion in Cardiology</i> , 2009, 24, 461-467.	0.8	4
186	Therapy and clinical trials: glycaemic control and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2009, 20, 530-531.	1.2	0
187	Perioperative management of ambulatory surgical patients with diabetes mellitus. <i>Current Opinion in Anaesthesiology</i> , 2009, 22, 718-724.	0.9	45
188	An Algorithm for the Care of Type 2 Diabetes. <i>Critical Pathways in Cardiology</i> , 2009, 8, 156-165.	0.2	4
189	Providing cardiovascular benefits with safe diabetes therapy. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 455-457.	0.2	0
190	Trials of cardiovascular risk factor management in type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2009, 24, 288-294.	0.8	6
191	Does normalization of blood glucose reduce the rate of cardiovascular events?. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 459-461.	0.2	0
192	Diabetes and cardiovascular disease: time for individualized risk reduction. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 451-453.	0.2	0
193	Translating clinical guidelines into clinical practice: Role of the pharmacist in type 2 diabetes management. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, e152-e162.	0.7	8
194	Study on Japan Diabetes Outcome Intervention Trial (J-DOIT). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2009, 98, 2231-2240.	0.0	0
196	The Role of Glycemia Management in the Prevention of Cardiovascular Diseaseâ€”Starting Over?. <i>Annals of Internal Medicine</i> , 2009, 151, 888.	2.0	4
197	Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes. <i>Annals of Internal Medicine</i> , 2009, 151, 854.	2.0	147
198	Linking diabetes and atherosclerosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 603-624.	1.2	8
199	Effects of insulin resistance on endothelial progenitor cells and vascular repair. <i>Clinical Science</i> , 2009, 117, 173-190.	1.8	71

#	ARTICLE	IF	CITATIONS
200	Advances in Diabetes Therapy in the Elderly. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 63-67.	0.5	4
202	Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 515-529.	0.2	0
203	Multidisciplinary approach for the treatment of diabetes in the elderly. <i>Aging Health</i> , 2009, 5, 207-216.	0.3	4
205	Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2009, 151, 394.	2.0	308
206	Diabetes and Peripheral Vascular Disease. <i>Acta Chirurgica Belgica</i> , 2009, 109, 587-594.	0.2	63
207	Setting glycaemic targets in patients with type 2 diabetes. Where to now?. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2009, 14, 125-128.	0.4	1
208	Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. <i>Yearbook of Endocrinology</i> , 2009, 2009, 2-3.	0.0	1
209	Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. <i>Yearbook of Vascular Surgery</i> , 2009, 2009, 5-6.	0.0	1
210	Emphasizing the Burden of Proof. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 565-567.	0.9	11
211	Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution“or Part of the Problem?. <i>Diabetes</i> , 2010, 59, 1129-1131.	0.3	60
212	Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2010, 5, 25-32.	1.5	19
213	Herbal Medicines and Nutraceuticals for Diabetic Vascular Complications: Mechanisms of Action and Bioactive Phytochemicals. <i>Current Pharmaceutical Design</i> , 2010, 16, 3776-3807.	0.9	47
214	The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade. <i>Current Clinical Pharmacology</i> , 2010, 5, 89-95.	0.2	26
215	Incretin-Based Therapies in Patients with Type 2 Diabetes. <i>Current Drug Therapy</i> , 2010, 5, 75-85.	0.2	0
216	Diabetes, Obesity, And Heart Failure: The New Pandemic. <i>Methodist DeBakey Cardiovascular Journal</i> , 2010, 6, 20-26.	0.5	6
219	Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3' untranslated region of the PAI-1 gene and its pharmacologic implications. <i>Coronary Artery Disease</i> , 2010, 21, 144-150.	0.3	11
220	Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2010, 21, 8-14.	1.2	7
221	Diabetes Mellitus and the Importance of Self-care. <i>Journal of Cardiovascular Nursing</i> , 2010, 25, 93-98.	0.6	43

#	ARTICLE	IF	CITATIONS
223	Longitudinal Differences in Glycemic Control by Race/Ethnicity Among Veterans With Type 2 Diabetes. <i>Medical Care</i> , 2010, 48, 527-533.	1.1	36
224	Who Can Respond to Treatment?. <i>Medical Care</i> , 2010, 48, S9-S16.	1.1	44
226	Tailoring treatment to risk in type 2 diabetes. <i>British Journal of General Practice</i> , 2010, 60, 158-160.	0.7	1
227	Goals for HbA1c Need To Be Individualized Based on Clinical Judgment, Instead of Third Party Recommendations. <i>Southern Medical Journal</i> , 2010, 103, 854-855.	0.3	0
229	Type 2 Diabetes Mellitus: Managing Hemoglobin A1c and Beyond. <i>Southern Medical Journal</i> , 2010, 103, 911-916.	0.3	17
230	Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity. <i>American Journal of the Medical Sciences</i> , 2010, 340, 133-143.	0.4	6
232	The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). <i>British Journal of General Practice</i> , 2010, 60, 172-175.	0.7	41
235	Weight Management in Type 2 Diabetes Mellitus. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 533-548.	1.9	13
236	Blood Glucose Control and Coronary Heart Disease. <i>Herz</i> , 2010, 35, 148-159.	0.4	7
237	The time has come for incretins, a long time coming. <i>Journal of Molecular Medicine</i> , 2010, 88, 319-321.	1.7	0
238	Duration of diabetes, glucose control and cardiovascular risk. <i>Diabetologia</i> , 2010, 53, 214-215.	2.9	7
239	Using individual patient data in meta-analyses of glucose-lowering studies. <i>Diabetologia</i> , 2010, 53, 216-217.	2.9	3
240	Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis. <i>Diabetologia</i> , 2010, 53, 840-849.	2.9	90
241	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. <i>Diabetologia</i> , 2010, 53, 1270-1287.	2.9	678
242	Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. <i>Diabetologia</i> , 2010, 53, 1190-1198.	2.9	96
243	High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation. <i>Diabetologia</i> , 2010, 53, 1199-1209.	2.9	48
244	Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. <i>Diabetologia</i> , 2010, 53, 1761-1771.	2.9	59
245	The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. <i>Diabetologia</i> , 2010, 53, 1552-1561.	2.9	129

#	ARTICLE	IF	CITATIONS
246	Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study. <i>Diabetologia</i> , 2010, 53, 1612-1619.	2.9	41
247	Intensified glucose lowering in type 2 diabetes: time for a reappraisal. <i>Diabetologia</i> , 2010, 53, 2079-2085.	2.9	131
248	Guidelines: weâ€™ll always need them, we sometimes dislike them, and we have to make them better. <i>Diabetologia</i> , 2010, 53, 2280-2284.	2.9	8
249	Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 8-19.	0.5	61
251	Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap?. <i>Advances in Therapy</i> , 2010, 27, 321-333.	1.3	60
252	Engaging and empowering patients to manage their type 2 diabetes, Part II: Initiatives for success. <i>Advances in Therapy</i> , 2010, 27, 665-680.	1.3	16
253	Incretin therapy for type 2 diabetes mellitus. <i>Advances in Therapy</i> , 2010, 27, 881-894.	1.3	3
254	Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 3-4.	1.5	9
255	Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study. <i>Diabetology International</i> , 2010, 1, 35-41.	0.7	3
258	Diabetes in the Elderly. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 347-353.	0.8	0
259	Diabetes and cardiovascular disease. <i>Clinical Research in Cardiology Supplements</i> , 2010, 5, 27-34.	2.0	1
260	â€œDead in bedâ€: a tragic complication of type 1 diabetes mellitus. <i>Irish Journal of Medical Science</i> , 2010, 179, 585-587.	0.8	8
261	A Cardiologistâ€™s View of Hypoglycemia. <i>Current Atherosclerosis Reports</i> , 2010, 12, 88-95.	2.0	4
262	Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. <i>Current Atherosclerosis Reports</i> , 2010, 12, 432-439.	2.0	72
263	Screening Asymptomatic Patients with Type 2 Diabetes Mellitus for Coronary Artery Disease: Does It Improve Patient Outcome?. <i>Current Cardiology Reports</i> , 2010, 12, 140-146.	1.3	11
264	Challenges and Approaches to Managing Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2010, 10, 7-9.	1.7	3
265	Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?. <i>Current Diabetes Reports</i> , 2010, 10, 24-31.	1.7	5
266	Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2010, 10, 16-23.	1.7	17

#	ARTICLE	IF	CITATIONS
267	Relationship of Coronary Angiographic Findings to Choice of Antidiabetic Medication. Current Diabetes Reports, 2010, 10, 1-3.	1.7	0
268	Lessons Learned from Glycemia Control Studies. Current Diabetes Reports, 2010, 10, 133-138.	1.7	9
269	Update on the Safety of Thiazolidinediones. Current Diabetes Reports, 2010, 10, 116-123.	1.7	2
270	Racial Disparities in All-Cause Mortality Among Veterans with Type 2 Diabetes. Journal of General Internal Medicine, 2010, 25, 1051-1056.	1.3	18
271	Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis, 2010, 29, 8-24.	1.0	24
272	Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Reviews in Endocrine and Metabolic Disorders, 2010, 11, 21-30.	2.6	24
273	Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders, 2010, 11, 61-74.	2.6	464
274	Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Reviews in Endocrine and Metabolic Disorders, 2010, 11, 87-94.	2.6	9
275	Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors. American Journal of Kidney Diseases, 2010, 55, 426-430.	2.1	34
276	The Management of Diabetic Neuropathy in CKD. American Journal of Kidney Diseases, 2010, 55, 365-385.	2.1	50
277	HbA1c en los pacientes diab�ticos tipo 2: �cu�l ha de ser el objetivo?. FMC Formacion Medica Continuada En Atencion Primaria, 2010, 17, 351-352.	0.0	1
279	Preliminary report: Hepatic fat and inflammation in type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2010, 59, 430-432.	1.5	5
280	Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2010, 59, 1365-1371.	1.5	20
281	Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine, 2010, 38, 632-637.	0.2	0
282	Glycaemic control in type 2 diabetes: Targets and new therapies. , 2010, 125, 328-361.		155
283	Therapeutic advances in myocardial microvascular resistance: Unravelling the enigma. , 2010, 127, 131-147.		28
284	Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends in Cardiovascular Medicine, 2010, 20, 90-95.	2.3	135
285	Effect of Baseline Glycemic Level on Long-Term Cardiovascular Outcomes After Coronary Revascularization Therapy in Patients With Type 2 Diabetes Mellitus Treated With Hypoglycemic Agents. American Journal of Cardiology, 2010, 105, 960-966.	0.7	11

#	ARTICLE	IF	CITATIONS
286	Diabetes Mellitus Is Not a Coronary Heart Disease Equivalent. American Journal of Cardiology, 2010, 106, 754-755.	0.7	2
287	Equivalent lipid oxidation profiles in advanced atherosclerotic lesions of carotid endarterectomy plaques obtained from symptomatic type 2 diabetic and nondiabetic subjects. Free Radical Biology and Medicine, 2010, 49, 481-486.	1.3	16
290	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes/Metabolism Research and Reviews, 2010, 26, 239-244.	1.7	104
291	Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. Cardiovascular Diabetology, 2010, 9, 14.	2.7	32
292	Diabetes is an independent predictor of survival 17 years after myocardial infarction: follow-up of the TRACE registry. Cardiovascular Diabetology, 2010, 9, 22.	2.7	13
293	Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. Cardiovascular Diabetology, 2010, 9, 53.	2.7	27
294	Glycaemic outcomes following discharge from an intermediate care diabetes clinic. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 53-54.	0.2	4
295	Hypoglycaemia, cognition and the older person with diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 219-220.	0.2	7
296	Glycemic and weight changes after persistent use of incident oral diabetes therapy: a veterans administration retrospective cohort study. Pharmacoepidemiology and Drug Safety, 2010, 19, 1108-1112.	0.9	15
297	Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis, 2010, 23, 140-147.	0.7	20
298	Glycemic Control and Burden of Diabetes in ESRD. Seminars in Dialysis, 2010, 23, 148-156.	0.7	90
299	Comparative Effectiveness Research Priorities at Federal Agencies: The View from the Department of Veterans Affairs, National Institute on Aging, and Agency for Healthcare Research and Quality. Journal of the American Geriatrics Society, 2010, 58, 1187-1192.	1.3	17
300	DIABETES MELLITUS IN OLDER ADULTS: TIME FOR AN OVERTREATMENT QUALITY INDICATOR. Journal of the American Geriatrics Society, 2010, 58, 2244-2245.	1.3	5
301	"SPEED DATING" AS A TECHNIQUE TO EFFICIENTLY ALIGN MENTEEES AND MENTORS IN A GERIATRICS TRAINING PROGRAM. Journal of the American Geriatrics Society, 2010, 58, 2245-2246.	1.3	10
302	Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. International Journal of Clinical Practice, 2010, 64, 295-304.	0.8	58
303	Self-monitoring of blood glucose. International Journal of Clinical Practice, 2010, 64, 1-10.	0.8	33
304	Benefits and risks around glycaemic control in diabetes: where are we now?. International Journal of Clinical Practice, 2010, 64, 1001-1003.	0.8	1
305	Preventing diabetes complications: are we too gluco-centric?. International Journal of Clinical Practice, 2010, 64, 1024-1027.	0.8	7



#	ARTICLE	IF	CITATIONS
306	Clinical experience with liraglutide. <i>International Journal of Clinical Practice</i> , 2010, 64, 44-48.	0.8	4
307	The glucose triad and its role in comprehensive glycaemic control: current status, future management. <i>International Journal of Clinical Practice</i> , 2010, 64, 1705-1711.	0.8	59
308	New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). <i>Journal of Internal Medicine</i> , 2010, 268, 471-482.	2.7	137
309	Glycemia and cardiovascular diseases in type 2 diabetes. <i>Journal of Internal Medicine</i> , 2010, 268, 468-470.	2.7	3
310	Vascular Protection in Diabetic Stroke: Role of Matrix Metalloprotease-Dependent Vascular Remodeling. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1928-1938.	2.4	79
312	Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 124-132.	2.2	16
313	Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 47-53.	2.2	110
314	Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 288-298.	2.2	296
315	Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes—results of the GINGER study. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 115-123.	2.2	95
316	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 474-484.	2.2	25
317	The effect of intensive glycaemic control on cardiovascular outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 641-647.	2.2	19
318	Assessing the cardiovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 485-494.	2.2	153
319	Screening for type 2 diabetes: an update of the evidence. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 838-844.	2.2	38
320	In support of an early polypharmacy approach to the treatment of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 929-940.	2.2	25
322	Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. <i>Diabetic Medicine</i> , 2010, 27, 175-180.	1.2	40
323	Low-dose thiazide diuretics in and around diabetes—definitely yes, and how do they compare with other interventions?. <i>Diabetic Medicine</i> , 2010, 27, 127-129.	1.2	2
324	For debate. Glucose variability and diabetes complication risk: we need to know the answer. <i>Diabetic Medicine</i> , 2010, 27, 868-871.	1.2	42
325	Surrogate endpoints in clinical practice: are we providing worse care?. <i>Internal Medicine Journal</i> , 2010, 40, 395-398.	0.5	8

#	ARTICLE	IF	CITATIONS
326	Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. <i>Vascular Health and Risk Management</i> , 2010, 6, 17.	1.0	2
327	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 227-242.	1.1	4
328	Managing diabetes with new pharmaceutical agents. <i>Practice Nursing</i> , 2010, 21, 634-638.	0.1	0
329	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, Volume 3, 243-252.	1.1	3
330	Hypoglycemia, intensive glycemic control and diabetes care in care home residents with Type 2 diabetes. <i>Aging Health</i> , 2010, 6, 31-40.	0.3	2
331	Insulin therapy in critically ill patients. <i>Vascular Health and Risk Management</i> , 2010, 6, 1089.	1.0	19
332	Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2010, 6, 145.	1.0	82
333	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 155-163.	1.1	34
334	Achievement of cardiovascular risk factor targets in young adults with diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 387-394.	1.1	2
335	Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus. <i>Korean Diabetes Journal</i> , 2010, 34, 16.	0.8	1
336	Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years. <i>Clinical Ophthalmology</i> , 2010, 4, 1291.	0.9	3
338	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1
339	Relationship among glycated albumin, hemoglobin A1c, and daily blood glucose profile in diabetic patients on chronic hemodialysis. <i>Nihon Toseki Igakkai Zasshi</i> , 2010, 43, 433-441.	0.2	2
340	A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S3489.	0.4	0
341	The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 119-130.	0.9	52
342	Review: Does hypoglycaemia cause cardiovascular events?. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 5-13.	0.6	11
343	An Update on Diabetic Renal Disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 219-223.	0.6	2
344	Thiazolidinedione Drugs and Cardiovascular Risks. <i>Circulation</i> , 2010, 121, 1868-1877.	1.6	113

#	ARTICLE	IF	CITATIONS
345	The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1196-1206.	0.9	15
346	Glucose Supply and Insulin Demand Dynamics of Antidiabetic Agents. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 365-381.	1.3	4
347	Diabetic Polyneuropathy and Glucose Control—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 420.	3.8	0
348	Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 798-805.	0.5	22
349	Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. <i>Diabetes Care</i> , 2010, 33, 1578-1584.	4.3	435
350	Effects of Acute Insulin-Induced Hypoglycemia on Indices of Inflammation. <i>Diabetes Care</i> , 2010, 33, 1591-1597.	4.3	165
351	Cardiovascular risk and prevention in diabetes mellitus. <i>Clinical Medicine</i> , 2010, 10, 495-499.	0.8	5
352	Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target. <i>Diabetes Care</i> , 2010, 33, 1905-1907.	4.3	44
353	Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 116-120.	4.3	20
354	A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2010, 122, 16-27.	0.9	198
355	Drug Therapies for the Primary Prevention of Cardiovascular Events: Trials and Errors. <i>Circulation</i> , 2010, 121, 940-945.	1.6	6
356	Secular Trends in Treatment and Control of Type 2 Diabetes in an American Indian Population: A 30-Year Longitudinal Study. <i>Diabetes Care</i> , 2010, 33, 2383-2389.	4.3	10
357	Counterpoint: Postprandial Glucose Levels Are Not a Clinically Important Treatment Target. <i>Diabetes Care</i> , 2010, 33, 1908-1910.	4.3	8
358	Hypoglycaemia: a limiting factor. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 2-4.	0.6	5
359	Discontinuation of Antihyperglycemic Therapy and Clinical Outcomes After Acute Myocardial Infarction in Older Patients With Diabetes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 236-242.	0.9	31
360	Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2010, 33, 2642-2647.	4.3	41
361	Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes. <i>Circulation</i> , 2010, 122, 2201-2211.	1.6	61
363	Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. <i>Annals of the New York Academy of Sciences</i> , 2010, 1212, 29-40.	1.8	22

#	ARTICLE	IF	CITATIONS
364	Diabetes and Heart Failure in Patients With Coronary Disease: Separating Markers From Mediators. <i>Diabetes Care</i> , 2010, 33, 2120-2122.	4.3	5
365	Insulin intensification for people with type 2 diabetes: a practical approach. <i>Australasian Medical Journal</i> , 2010, , 808-813.	0.1	2
366	Hemoglobin A1c in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1539-1541.	2.2	17
367	Glycemic Control and Extended Hemodialysis Survival in Patients with Diabetes Mellitus. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1595-1601.	2.2	88
368	Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2010, 14, 1-248.	1.3	123
370	Effect of Trajectories of Glycemic Control on Mortality in Type 2 Diabetes: A Semiparametric Joint Modeling Approach. <i>American Journal of Epidemiology</i> , 2010, 171, 1090-1098.	1.6	27
371	Prevention and Treatment of Diabetic Nephropathy. , 2010, , 377-384.		0
372	Management of the Diabetic Patient with Chronic Kidney Disease. , 2010, , 385-391.		1
373	Principles and Practice of Nonpharmacological Interventions to Reduce Cardiometabolic Risk. <i>Medical Principles and Practice</i> , 2010, 19, 167-175.	1.1	49
374	Glucose lowering and cardiovascular disease: what do we know and what should we do?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s25-s31.	3.1	12
375	Clinical Care Guidelines: Too Much of a Good Thing?. <i>Diabetes Care</i> , 2010, 33, 2716-2718.	4.3	1
376	Diabetic Polyneuropathy and Glucose Control. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 420.	3.8	2
377	Prediabetes: The Importance of Early Identification and Intervention. <i>Postgraduate Medicine</i> , 2010, 122, 129-143.	0.9	41
378	Balancing Hypoglycemia and Glycemic Control. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2076.	3.8	34
379	After Cardiac Surgery, How Does Nutrition Fit in With Risk Factors?. <i>Journal of Parenteral and Enteral Nutrition</i> , 2010, 34, 163-168.	1.3	4
380	Diabetes mellitus in patients with myocardial infarction complicated by heart failure: a "low ejection fraction" equivalent?. <i>European Journal of Heart Failure</i> , 2010, 12, 1156-1158.	2.9	1
383	The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, S-15-S-21.	0.5	7
384	Novel therapeutics and targets for the treatment of diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 209-229.	1.3	19

#	ARTICLE	IF	CITATIONS
385	Characterization of Cardiovascular Outcomes in a Type 2 Diabetes Glucose Supply and Insulin Demand Model. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 382-390.	1.3	0
386	Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 675-681.	1.0	72
387	Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. <i>Diabetes Care</i> , 2010, 33, 2558-2560.	4.3	10
388	The enigma of glucose and cardiovascular disease. <i>Heart</i> , 2010, 96, 649-651.	1.2	3
389	Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. <i>Current Medical Research and Opinion</i> , 2010, 26, 1333-1342.	0.9	28
390	Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics. <i>Diabetes Care</i> , 2010, 33, 721-727.	4.3	159
391	Active Care Management Supported by Home Telemonitoring in Veterans With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 478-484.	4.3	171
392	Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. <i>Annals of Medicine</i> , 2010, 42, 305-315.	1.5	31
393	Cardiovascular Clinical Trials in Patients With Diabetes Mellitus. <i>Circulation</i> , 2010, 121, 2453-2455.	1.6	4
394	Laboratory Evaluation of a New Lateral-Flow-Based Point-of-Care Rapid Test for Assessment of Chronic Systemic Inflammation. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 717-722.	1.3	5
395	Simulated Physician Learning Program Improves Glucose Control in Adults With Diabetes. <i>Diabetes Care</i> , 2010, 33, 1727-1733.	4.3	20
396	Neuropathy: The Crystal Ball for Cardiovascular Disease?. <i>Diabetes Care</i> , 2010, 33, 1688-1690.	4.3	78
397	Translating "Nondiabetic" A1C Levels to Clinical Practice. <i>Diabetes</i> , 2010, 59, 1868-1869.	0.3	2
398	New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals. <i>Postgraduate Medicine</i> , 2010, 122, 52-60.	0.9	18
399	A Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 221-222.	0.9	0
400	The Growing Importance of Diabetes Screening. <i>Diabetes Care</i> , 2010, 33, 1695-1697.	4.3	17
401	Glycemic Control in Diabetes. <i>Oman Medical Journal</i> , 2010, 25, 232-233.	0.3	4
402	Hypoglycemia, Diabetes, and Cardiovascular Events. <i>Diabetes Care</i> , 2010, 33, 1389-1394.	4.3	374

#	ARTICLE	IF	CITATIONS
403	Use of Sensors in the Treatment and Follow-up of Patients with Diabetes Mellitus. <i>Sensors</i> , 2010, 10, 7404-7420.	2.1	16
404	Cardiovascular disease is preventable among women. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 175-187.	0.6	9
405	Strategies for Improving the Acquisition and Integration of Evidence Into Diabetes Care. <i>Diabetes Spectrum</i> , 2010, 23, 246-253.	0.4	0
406	Review of Liraglutide versus Sitagliptin for Patients with Uncontrolled Type 2 Diabetes: More Effective HbA1c Reduction with Subcutaneous GLP-1 Receptor Agonist Versus an Oral DPP-4 Inhibitor. <i>Postgraduate Medicine</i> , 2010, 122, 185-188.	0.9	3
407	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. <i>Circulation</i> , 2010, 122, e584-636.	1.6	1,009
408	Relationship between Blood Glucose Control and Improved Cardiovascular Outcome after Stent Implantation in Diabetic Patients. <i>Cardiology</i> , 2010, 116, 48-50.	0.6	7
409	Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. <i>European Heart Journal</i> , 2010, 31, 1159-1162.	1.0	11
410	Medical Management of Carotid Stenosis. <i>Perspectives in Vascular Surgery and Endovascular Therapy</i> , 2010, 22, 18-27.	0.6	9
411	Aggregate Cardiovascular Risk Is a Stronger Statistical Correlate of Clinically Evident Diabetic Peripheral Neuropathy Than HbA1c Alone. <i>Journal of the National Medical Association</i> , 2010, 102, 707-712.	0.6	3
412	Blood Pressure and Diabetic Nephropathy. <i>Diabetes Care</i> , 2010, 33, e30-e35.	4.3	7
414	Approach to the Patient with Type 2 Diabetes and Progressive Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3103-3110.	1.8	22
415	Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2010, 122, 172-183.	0.9	9
416	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 233-244.	13.9	1,091
417	Intensive glucose-lowering therapy“weighing up the evidence. <i>Nature Reviews Endocrinology</i> , 2010, 6, 9-10.	4.3	2
418	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. <i>BMJ: British Medical Journal</i> , 2010, 340, b5444-b5444.	2.4	359
419	Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. <i>BMJ: British Medical Journal</i> , 2010, 340, c103-c103.	2.4	26
420	Licensing drugs for diabetes. <i>BMJ: British Medical Journal</i> , 2010, 341, c4805-c4805.	2.4	18
421	Cardiovascular Disease and Glycemic Treatment. <i>Diabetes Care</i> , 2010, 33, e134-e139.	4.3	5

#	ARTICLE	IF	CITATIONS
422	Exenatide is Non-inferior to Insulin in Reducing HbA <sub>1c</sub> : An Integrated Analysis of 1423 Patients with Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2010, 122, 118-128.	0.9	28
425	Identifying Dysglycemic States in Older Adults: Implications of the Emerging Use of Hemoglobin A <sub>1c</sub> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5289-5295.	1.8	100
426	Contemporary management of patients with Type 2 diabetes. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 767-770.	0.6	1
427	Partnering with Patients to Improve Therapeutic Outcomes: Incretin-Based Therapy for Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2010, 122, 7-15.	0.9	99
428	Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome. <i>Postgraduate Medicine</i> , 2010, 122, 61-70.	0.9	11
429	Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. <i>Current Medical Research and Opinion</i> , 2010, 26, 9-15.	0.9	14
431	Analyse critique du consensus ADA/EASD 2009: "Back to the past and lost in translation". <i>Medicine Des Maladies Metaboliques</i> , 2010, 4, 191-196.	0.1	1
432	Diabetes, Cardiovascular Risk and Nephropathy. <i>Cardiology Clinics</i> , 2010, 28, 467-475.	0.9	26
433	Consensus ADA/EASD 2009: l'algorithme pour le traitement médical du diabète de type 2 est utile! **Note du rédacteur: Ce texte a été rédigé à partir de la présentation faite par Julio Rosenstock (Diabetes and) Tj ETQq0 0 0 rgBt mouvement», organisée à Paris, les 27 et 28 juin 2009, par Sanofi aventis. Son contenu ne saurait être considéré comme reflétant la position du rédacteur de ce texte.. <i>Medicine Des Maladies Metaboliques</i> , 2010, 4, 181-190.	0.1	1
434	Role of Oral Agents in Improving Cardiovascular Prognosis in Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2010, 85, 99.	1.4	1
435	Traitement du diabète de type 2: il est temps de regarder l'Evidence Based Medicine en face!. <i>Medicine Des Maladies Metaboliques</i> , 2010, 4, 718-720.	0.1	2
436	Respuesta del Dr. Marcos Lahera Vargas. <i>Avances En Diabetología</i> , 2010, 26, 366-369.	0.1	0
437	Complicanze neurologiche del diabete. <i>EMC - AKOS - Trattato Di Medicina</i> , 2010, 12, 1-8.	0.0	0
438	Regarder l'Evidence Based Medicine en face? OUI, mais de plus près!. <i>Medicine Des Maladies Metaboliques</i> , 2010, 4, 721-724.	0.1	1
439	Influence of Glycemic Control on the Development of Diabetic Cardiovascular and Kidney Disease. <i>Cardiology Clinics</i> , 2010, 28, 497-516.	0.9	6
441	The Cost of Diabetes: A Game Changer. <i>Canadian Journal of Diabetes</i> , 2010, 34, 16-18.	0.4	3
442	Respuesta del Dr. Manuel Delgado Gómez. <i>Avances En Diabetología</i> , 2010, 26, 440-444.	0.1	0
443	Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications. <i>Annales D'Endocrinologie</i> , 2010, 71, 505-510.	0.6	2

#	ARTICLE	IF	CITATIONS
444	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Avances En Diabetología, 2010, 26, 331-338.	0.1	39
445	Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings, 2010, 85, S50-S59.	1.4	39
447	Glycemic Control and Weight Reduction Without Causing Hypoglycemia: The Case for Continued Safe Aggressive Care of Patients With Type 2 Diabetes Mellitus and Avoidance of Therapeutic Inertia. Mayo Clinic Proceedings, 2010, 85, S15-S26.	1.4	26
448	Medication Issues in Older Individuals With CKD. Advances in Chronic Kidney Disease, 2010, 17, 320-328.	0.6	16
449	Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nature Reviews Nephrology, 2010, 6, 332-341.	4.1	107
450	Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine, 2010, 363, 1410-1418.	13.9	1,279
451	Intensive glycemic control and cardiovascular disease: an update. Nature Reviews Cardiology, 2010, 7, 369-375.	6.1	149
452	Proinflammatory and Prothrombotic Effects of Hypoglycemia. Diabetes Care, 2010, 33, 1686-1687.	4.3	69
454	Glucose, Obesity, Metabolic Syndrome, and Diabetes. Journal of the American College of Cardiology, 2010, 55, 283-293.	1.2	174
455	Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 55, 1348-1358.	1.2	96
456	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2010, 55, 1487-1498.	1.2	13
457	Thiazolidinedione Drugs and Cardiovascular Risks. Journal of the American College of Cardiology, 2010, 55, 1885-1894.	1.2	81
458	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology, 2010, 56, e50-e103.	1.2	1,150
459	Obesity and diabetes: the links and common approaches. Primary Care Diabetes, 2010, 4, 105-112.	0.9	32
460	Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. Drugs, 2010, 70, 2229-2245.	4.9	47
461	Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals With Type 1 Diabetes and Healthy Individuals. Diabetes Care, 2010, 33, 1529-1535.	4.3	190
462	Terapia del diabete di tipo 2: obiettivi glicemici in relazione al tipo di paziente. L Endocrinologo, 2010, 11, 254-259.	0.0	0
463	The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opinion on Therapeutic Targets, 2010, 14, 1333-1342.	1.5	29



#	ARTICLE	IF	CITATIONS
464	Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise. <i>Diabetes Care</i> , 2010, 33, 2217-2224.	4.3	628
466	La prise en charge du diabète de type 2: l'HbA1c reste-t-elle le seul objectif?. <i>Medecine Nucleaire</i> , 2010, 34, 560-563.	0.2	1
467	Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!. <i>Diabetes and Metabolism</i> , 2010, 36, 86-87.	1.4	0
468	It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. <i>Diabetes and Metabolism</i> , 2010, 36, 91-96.	1.4	31
469	Are elderly patients with diabetes being overtreated in French long-term-care homes?. <i>Diabetes and Metabolism</i> , 2010, 36, 272-277.	1.4	48
470	International Diabetes Federation: An update of the evidence concerning the prevention of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2010, 87, 143-149.	1.1	40
471	The importance of glycosylated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 1-9.	1.1	51
472	The efficacy of lowering glycosylated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 126-133.	1.1	39
473	The cardiorenal syndrome in diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 201-208.	1.1	37
474	DPP-4 inhibitors: What may be the clinical differentiators?. <i>Diabetes Research and Clinical Practice</i> , 2010, 90, 131-140.	1.1	85
475	Update of Cerebral Vascular Disease: Issues for the Primary Care Physician. <i>Disease-a-Month</i> , 2010, 56, 40-71.	0.4	11
476	Does glycosylated hemoglobin have clinical significance in ischemic stroke patients?. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 98-102.	0.6	13
477	Recomendaciones de la Sociedad Americana de Diabetes para el manejo de la diabetes mellitus. <i>Semergen</i> , 2010, 36, 386-391.	0.2	5
478	Glycemia and prognosis of patients with chronic heart failure—Subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial. <i>American Heart Journal</i> , 2010, 159, 90-97.	1.2	10
479	Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications. <i>American Journal of Medicine</i> , 2010, 123, 374.e9-374.e18.	0.6	55
480	Glycemic Control and Complications in Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 2010, 123, S3-S11.	0.6	249
481	Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 2010, 123, S12-S18.	0.6	59
482	The Past, Present, and Future of Comparative Effectiveness Research in the US Department of Veterans Affairs. <i>American Journal of Medicine</i> , 2010, 123, e3-e7.	0.6	24

#	ARTICLE	IF	CITATIONS
483	Methodological Issues in Comparative Effectiveness Research: Clinical Trials. American Journal of Medicine, 2010, 123, e8-e15.	0.6	10
484	Scientific and Organizational Collaboration in Comparative Effectiveness Research: The VA Cooperative Studies Program Model. American Journal of Medicine, 2010, 123, e24-e31.	0.6	16
485	THE DIABETIC CKD PATIENT—A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care, 2010, 36, 34-46.	0.6	15
486	In search of the holy grail? The quest to reduce macrovascular disease in type 2 diabetes mellitus. Insulin, 2010, 5, 2-6.	0.2	0
487	Hospital hypoglycemia: From observation to action. Insulin, 2010, 5, 16-36.	0.2	12
488	Diabetes and Cardiovascular Mortality: From Epidemiologic Data to Clinical Trial Evidence. Journal of the Chinese Medical Association, 2010, 73, 459-461.	0.6	0
489	Treat early, treat appropriately. Primary Care Diabetes, 2010, 4, S3-S10.	0.9	2
492	Coronary artery calcium and cardiovascular risk in diabetes. Atherosclerosis, 2010, 210, 331-336.	0.4	33
493	Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis, 2010, 211, 384-385.	0.4	5
494	Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis, 2010, 211, 565-573.	0.4	34
496	Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet, The, 2010, 375, 481-489.	6.3	770
497	Diabetic retinopathy. Lancet, The, 2010, 376, 124-136.	6.3	2,305
498	Survival in people with type 2 diabetes as a function of HbA1c. Lancet, The, 2010, 375, 438-440.	6.3	11
499	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet, The, 2010, 376, 419-430.	6.3	1,182
500	Survival as a function of HbA1c in people with type 2 diabetes. Lancet, The, 2010, 375, 1433.	6.3	0
501	Prandial inhaled insulin plus basal insulin glargine versus twice daily bipart insulin for type 2 diabetes: a multicentre randomised trial. Lancet, The, 2010, 375, 2244-2253.	6.3	111
502	Intensive treatment of hyperglycaemia: ACCORD. Lancet, The, 2010, 376, 391-392.	6.3	10
503	Comprehensive Evaluation and Medical Management of Infrainguinal Peripheral Artery Disease: "When to Treat, When Not to Treat" Techniques in Vascular and Interventional Radiology, 2010, 13, 2-10.	0.4	7

#	ARTICLE	IF	CITATIONS
504	Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 359-372.	0.6	97
505	Acute consequences of hypoglycaemia in diabetic patients. <i>Diabetes and Metabolism</i> , 2010, 36, S75-S83.	1.4	17
506	Hypoglycaemia and dementia in diabetic patients. <i>Diabetes and Metabolism</i> , 2010, 36, S106-S111.	1.4	42
507	Epigenetics. <i>Circulation Research</i> , 2010, 107, 1403-1413.	2.0	185
508	Standards of Medical Care in Diabetes—2010. <i>Diabetes Care</i> , 2010, 33, S11-S61.	4.3	2,863
509	Glucose control in the older patient: from intensive, to effective and safe. <i>Aging Clinical and Experimental Research</i> , 2010, 22, 274-280.	1.4	19
510	Role of Oral Agents in Improving Cardiovascular Prognosis in Diabetes Mellitus—Reply. <i>Mayo Clinic Proceedings</i> , 2010, 85, 99-101.	1.4	2
511	Concerns About Meta-analysis of Glucose Control and Cardiovascular Disease in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2010, 152, 63.	2.0	5
512	Effects of $\beta$ -blockers on glucose and lipid metabolism. <i>Current Medical Research and Opinion</i> , 2010, 26, 615-629.	0.9	122
513	Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. <i>Current Medical Research and Opinion</i> , 2010, 26, 1647-1656.	0.9	29
514	Regulatory Benefit-Risk Assessment and Comparative Effectiveness Research. <i>Pharmacoeconomics</i> , 2010, 28, 855-865.	1.7	14
515	Therapeutic Potential of Alogliptin, a New Dual PPAR- $\alpha/\beta$ Agonist. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 209-216.	1.0	38
516	Assessing the "relative value" of diabetic patients treated through an incentivized, corporate compliance model. <i>Anthropology and Medicine</i> , 2010, 17, 215-228.	0.6	16
517	Type 2 diabetes and cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2011, 27, 1-5.	0.9	16
518	Special considerations for treatment of type 2 diabetes mellitus in the elderly. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 500-509.	0.5	32
519	What Options Are Available When Considering Starting Insulin: Premix or Basal?. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-85-S-92.	2.4	8
520	Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-25-S-32.	2.4	73
521	Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2011, 343, d4169-d4169.	2.4	631

#	ARTICLE	IF	CITATIONS
522	Controversies in the cardiovascular management of type 2 diabetes. <i>Heart</i> , 2011, 97, 6-14.	1.2	24
523	Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 69-77.	1.8	18
525	Clinical Update on Nursing Home Medicine: 2011. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 615-626.e6.	1.2	7
526	Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 128-138.	1.4	50
527	HTA et diabète: nouveaux niveaux de preuves et prise en charge. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2011, 2011, 24-30.	0.0	0
528	Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 444-456.	1.4	104
529	Biliopancreatic Diversion with Duodenal Switch in the Treatment of Diabetes: An Argument that a Chance to Cut is a Chance to Cure. <i>Canadian Journal of Diabetes</i> , 2011, 35, 109-114.	0.4	4
530	Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-65-S-74.	2.4	42
532	Diabetes in the Elderly. <i>Canadian Journal of Diabetes</i> , 2011, 35, 13-16.	0.4	1
533	Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. <i>Diabetes Care</i> , 2011, 34, 1511-1513.	4.3	72
534	The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 813-818.	2.4	147
535	Predicting the Future Burden of Diabetes in Alberta from 2008 to 2035. <i>Canadian Journal of Diabetes</i> , 2011, 35, 274-281.	0.4	10
536	Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. <i>Endocrinologia Y Nutrición (English Edition)</i> , 2011, 58, 112-120.	0.5	9
537	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 153-159.	1.2	106
538	Glucocentricity or adipocentricity: A critical view of consensus and clinical guidelines for the treatment of type 2 diabetes mellitus. <i>Endocrinologia Y Nutrición (English Edition)</i> , 2011, 58, 541-549.	0.5	8
541	Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes. <i>Personalized Medicine</i> , 2011, 8, 445-456.	0.8	6
542	Telmisartan for the management of patients at high cardiovascular risk. <i>Current Medical Research and Opinion</i> , 2011, 27, 1673-1682.	0.9	23
543	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. , 2011, , CD008143.		57

#	ARTICLE	IF	CITATIONS
546	Should A1C Targets Be Individualized for All People With Diabetes?. <i>Diabetes Care</i> , 2011, 34, S191-S196.	4.3	16
549	Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimer's Disease. <i>Drugs</i> , 2011, 71, 1281-1320.	4.9	81
550	Choice of Long-Acting Insulin Therapy for Type 2 Diabetes. <i>Drugs and Aging</i> , 2011, 28, 935-941.	1.3	4
551	Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. <i>Drugs and Aging</i> , 2011, 28, 945-960.	1.3	15
552	Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. <i>Clinical Investigation</i> , 2011, 1, 145-156.	0.0	17
553	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
554	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2011, 42, 517-584.	1.0	1,289
555	Characteristics of Peripheral Arterial Disease and Its Relevance to the Diabetic Population. <i>International Journal of Lower Extremity Wounds</i> , 2011, 10, 152-166.	0.6	64
556	Type 2 diabetes mellitus' current therapies and the emergence of surgical options. <i>Nature Reviews Endocrinology</i> , 2011, 7, 408-419.	4.3	61
557	Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials. <i>Annals of Internal Medicine</i> , 2011, 154, 554.	2.0	325
558	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2011, 23, 40-48.	0.4	3
559	A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. <i>American Heart Journal</i> , 2011, 161, 210-219.e1.	1.2	51
560	Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. <i>American Heart Journal</i> , 2011, 162, 938-948.e2.	1.2	156
561	Heart failure and diabetes: Time to pay attention. <i>American Heart Journal</i> , 2011, 162, 795-797.	1.2	4
562	Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide-1-Based Therapies. <i>American Journal of Medicine</i> , 2011, 124, S35-S53.	0.6	59
563	Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities. <i>American Journal of Medicine</i> , 2011, 124, 1028-1035.	0.6	146
564	Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications. <i>American Journal of Medicine</i> , 2011, 124, 993-996.	0.6	114
565	Insulin Therapy in the Elderly Patient With Diabetes. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 24-36.	3.0	19

#	ARTICLE	IF	CITATIONS
566	Diabetes is More Lethal in Mexicans and Mexican-Americans Compared to Non-Hispanic Whites. <i>Annals of Epidemiology</i> , 2011, 21, 899-906.	0.9	23
567	Lipids, lipid-lowering therapy and diabetes complications. <i>Diabetes and Metabolism</i> , 2011, 37, 15-24.	1.4	25
568	Trends in the quality of care for elderly people with type 2 diabetes: The need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys). <i>Diabetes and Metabolism</i> , 2011, 37, 152-161.	1.4	60
569	Hemoglobin A1c proportion, mortality rate, and risk factors for death in diabetic patients with severe hypoglycemia: A multicenter retrospective survey over ten years. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, 17-20.	1.1	1
570	Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes. <i>Heart Lung and Circulation</i> , 2011, 20, 647-654.	0.2	71
571	The association between post-load low insulin level and high mortality rates in patients with no previous diagnosis of diabetes mellitus. <i>International Journal of Cardiology</i> , 2011, 148, 59-63.	0.8	0
572	Screening for overt diabetes by oral glucose tolerance test: Stratification by fasting blood glucose and patients' age improve practicability of guidelines in cardiological routine. <i>International Journal of Cardiology</i> , 2011, 150, 201-205.	0.8	3
573	Management of type 2 diabetes mellitus in the elderly. <i>Maturitas</i> , 2011, 70, 151-159.	1.0	33
575	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2011, 42, 227-276.	1.0	1,433
576	Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: Evidence of a sex difference? The Western New York experience. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 504-511.	1.1	18
578	Rehabilitation in patients with peripheral arterial disease. <i>Annals of Physical and Rehabilitation Medicine</i> , 2011, 54, 443-461.	1.1	20
579	Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. <i>Semergen</i> , 2011, 37, 74-82.	0.2	3
580	Expert consensus on management of diabetic patients with impairment of renal function. <i>Diabetes and Metabolism</i> , 2011, 37, S1-S25.	1.4	16
581	PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus—Study design. <i>Primary Care Diabetes</i> , 2011, 5, 231-239.	0.9	39
582	What can we learn from the recent blood glucose lowering megatrials?. <i>Journal of Diabetes Investigation</i> , 2011, 2, 1-5.	1.1	14
583	Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy. <i>Journal of Diabetes Investigation</i> , 2011, 2, 56-62.	1.1	7
584	HbA <sub>1c</sub> : The lower the better?. <i>Journal of Diabetes Investigation</i> , 2011, 2, 45-47.	1.1	0
585	Therapeutic management of diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2011, 2, 248-254.	1.1	12

#	ARTICLE	IF	CITATIONS
586	Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control. <i>Cardiovascular Therapeutics</i> , 2011, 29, e31-e42.	1.1	23
588	Prevençi3n de los accidentes cerebrovasculares. <i>EMC - Tratado De Medicina</i> , 2011, 15, 1-8.	0.0	0
589	Dynamic Nature of Coronary Plaques and Clinical Outcomes in Diabetic Patients: Is Change in Itself Bad?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 549-550.	0.4	1
590	Peregrinaje de un antidiab3tico hasta su aprobaci3n por las agencias internacionales del medicamento. Situaci3n actual. <i>Avances En Diabetolog3a</i> , 2011, 27, 107-114.	0.1	0
592	National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. <i>Lancet, The</i> , 2011, 377, 557-567.	6.3	3,476
593	Ultra-long-acting insulins for a lifestyle-related pandemic. <i>Lancet, The</i> , 2011, 377, 880-881.	6.3	1
594	Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S6227.	0.4	1
595	Diabetes education drives quality and fuels NHS efficiency savings. <i>Primary Health Care</i> , 2011, 21, 21-24.	0.0	0
596	Glycemic Control and Hypoglycemia in Veterans Health Administration Patients Converted from Glyburide to Glipizide. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 664-671.	2.2	15
598	Clinical utility of fixed-combination telmisartan&ndash;amlodipine in the treatment of hypertension. <i>Integrated Blood Pressure Control</i> , 2011, 4, 27.	0.4	3
599	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. <i>Endocrine Practice</i> , 2011, 17, 1-53.	1.1	387
600	Homeostasis and Compensatory Homeostasis: Bridging Western Medicine and Traditional Chinese Medicine. <i>Current Cardiology Reviews</i> , 2011, 7, 43-46.	0.6	13
601	Insulin Therapy and Hypoglycemia - Present and Future. , 0, , .		0
602	Metabolic Control Targets for Patients with Type 1 Diabetes in Clinical Practice. , 0, , .		0
603	Organic consequences of ileal transposition in rats with diet-induced obesity. <i>Nature Precedings</i> , 2011, , .	0.1	0
604	Glycaemic Control and Protection of the Vasculature from Glucose Toxicity. , 2011, , .		0
605	Short-term diabetes attenuates left ventricular dysfunction and mortality rates after myocardial infarction in rodents. <i>Clinics</i> , 2011, 66, 1437-1442.	0.6	9
606	Increasing Trend in the Number of Severe Hypoglycemia Patients in Korea. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 166.	1.8	33

#	ARTICLE	IF	CITATIONS
607	Pharmacologie et Thérapeutique Vasculaire. , 2011, , 687-843.		0
608	Structured assessments of diabetic residents. Nursing and Residential Care, 2011, 13, 19-25.	0.1	0
609	Using insulin in people with type 2 diabetes. NursePrescribing, 2011, 9, 496-498.	0.1	0
610	TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT. , 0, , 35-61.		0
611	Tissue Factor, Blood Coagulation, and Beyond: An Overview. International Journal of Inflammation, 2011, 2011, 1-30.	0.9	151
612	No evidence of benefit for universal screening with 75 g oral glucose tolerance test in polycystic ovary syndrome. Medical Journal of Australia, 2011, 195, 578-579.	0.8	2
613	Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients. Diabetes and Metabolism Journal, 2011, 35, 529.	1.8	32
614	Effects of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes in Diabetic Coronary Artery Bypass Graft Patients. Annals of Surgery, 2011, 254, 458-464.	2.1	117
615	Ask the Experts: Cardiovascular complications in diabetic patients. Diabetes Management, 2011, 1, 565-570.	0.5	0
616	Glycemic control and cardiovascular mortality. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 104-109.	1.2	15
617	Optimal glycemic control in the elderly: where is the evidence and who should be targeted?. Aging Health, 2011, 7, 89-96.	0.3	5
618	Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics, 2011, 18, 117-152.	0.5	134
619	Ideal Blood Glucose Control for Type 2 Diabetes Management: A New Clinical Equipose. Proceedings of Singapore Healthcare, 2011, 20, 115-118.	0.2	1
620	Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. Diabetes Management, 2011, 1, 615-626.	0.5	0
621	Predicting severe hypoglycemia in the community: a review of recent evidence. Diabetes Management, 2011, 1, 109-128.	0.5	1
622	Diabetes, hyperglycemia and the management of cerebrovascular disease. Current Opinion in Neurology, 2011, 24, 81-88.	1.8	32
625	Effects of Insulin on the Vasculature. Current Vascular Pharmacology, 2011, 9, 321-332.	0.8	27
626	Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit. Current Drug Targets, 2011, 12, 1498-1512.	1.0	19



#	ARTICLE	IF	CITATIONS
627	Reducing cardiovascular risk factors in patients with prediabetes. <i>Diabetes Management</i> , 2011, 1, 423-438.	0.5	1
628	Reducing the risk of macrovascular complications of diabetes: focus on visceral fat. <i>Diabetes Management</i> , 2011, 1, 439-449.	0.5	0
629	Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. <i>Annals of Internal Medicine</i> , 2011, 154, 602.	2.0	479
630	Combined Assessment of Myocardial Perfusion and Function by ECG-Gated Myocardial Perfusion Single-Photon Emission Computed Tomography for the Prediction of Future Cardiac Events in Patients With Type 2 Diabetes Mellitus. <i>Circulation Journal</i> , 2011, 75, 376-382.	0.7	12
631	Glycemic Control Is Another Target of PCI in Diabetic Patients. <i>Circulation Journal</i> , 2011, 75, 773-774.	0.7	3
632	ACCORD microvascular and Eye substudy: should the results change our practice?. <i>Diabetes Management</i> , 2011, 1, 389-396.	0.5	0
633	Hypoglycemia, diabetes and atherosclerosis: is there a link?. <i>Diabetes Management</i> , 2011, 1, 291-297.	0.5	1
636	Rapid-acting insulin glulisine: an update on clinical experience. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 527-542.	1.2	3
638	High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 759-764.	2.2	25
639	Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 869-879.	2.2	22
640	Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 921-927.	2.2	15
641	Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 1073-1087.	2.2	38
642	Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 1149-1157.	2.2	12
643	Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. <i>Diabetic Medicine</i> , 2011, 28, 73-80.	1.2	21
644	Autonomic imbalance: prophet of doom or scope for hope?. <i>Diabetic Medicine</i> , 2011, 28, 643-651.	1.2	172
645	Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse. <i>Diabetic Medicine</i> , 2011, 28, 876-879.	1.2	8
646	Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. <i>Diabetic Medicine</i> , 2011, 28, 1261-1267.	1.2	130
647	HbA <sub>1c</sub> 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. <i>Diabetic Medicine</i> , 2011, 28, 1520-1524.	1.2	19

#	ARTICLE	IF	CITATIONS
648	Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 260-274.	0.7	9
649	Repeat measurements of glycated haemoglobin A <sub>1c</sub> and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1292-1298.	1.7	14
650	Cost Implications to Health Care Payers of Improving Glucose Management among Adults with Type 2 Diabetes. <i>Health Services Research</i> , 2011, 46, 1158-1179.	1.0	8
651	Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline. <i>British Journal of Pharmacology</i> , 2011, 164, 2064-2072.	2.7	18
652	The Risks and Benefits of Implementing Glycemic Control Guidelines in Frail Older Adults with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 666-672.	1.3	51
653	Risk of Hypoglycemia in Older Veterans with Dementia and Cognitive Impairment: Implications for Practice and Policy. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2263-2272.	1.3	109
654	Patient adherence to medication requirements for therapy of type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2011, 65, 314-322.	0.8	210
655	Preventing diabetes complications and the "gluco-centric" dilemma: a word of caution. <i>International Journal of Clinical Practice</i> , 2011, 65, 225-225.	0.8	2
656	Tight glycaemic control-caution in high risk groups. <i>International Journal of Clinical Practice</i> , 2011, 65, 226-226.	0.8	0
657	Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). <i>International Journal of Clinical Practice</i> , 2011, 65, 415-419.	0.8	15
658	Quality of care of patients with type-2 diabetes in Galicia (NW Spain) [OBTEDIGA project]. <i>International Journal of Clinical Practice</i> , 2011, 65, 1067-1075.	0.8	11
659	Vascular Endothelial Dysfunction in Patients with Newly Diagnosed Type 2 Diabetes and Effects of 2-year and 5-year Multifactorial Intervention. <i>Echocardiography</i> , 2011, 28, 1133-1140.	0.3	11
660	Paradoxical effects of streptozotocin-induced diabetes on endothelial dysfunction in stroke-prone spontaneously hypertensive rats. <i>Journal of Physiology</i> , 2011, 589, 5153-5165.	1.3	12
661	Can Modeling of Health Outcomes Facilitate Regulatory Decision Making?: The Benefit-Risk Tradeoff for Rosiglitazone in 1999 vs. 2007. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 429-436.	2.3	3
662	Progress and challenges in translating the biology of atherosclerosis. <i>Nature</i> , 2011, 473, 317-325.	13.7	3,058
663	Prioritization of care in adults with diabetes and comorbidity. <i>Annals of the New York Academy of Sciences</i> , 2011, 1243, 69-87.	1.8	39
664	Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. <i>Annals of the New York Academy of Sciences</i> , 2011, 1243, 88-102.	1.8	387
666	Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. <i>Journal of Diabetes</i> , 2011, 3, 257-260.	0.8	3

#	ARTICLE	IF	CITATIONS
667	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2011, 13, 244-251.	1.0	333
668	Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 613-620.	1.0	18
669	Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 284-291.	1.5	14
670	Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1-23.	1.5	253
671	The quest for the perfect biomarker of long-term glycemia: new studies, new trials and tribulations. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1651-1654.	1.5	1
672	Concept paper: antihyperglycemic therapy and the diabetic heart – do we really know enough?. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 63-72.	1.2	0
673	The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 202-207.	1.2	17
674	Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 216-221.	1.2	86
675	Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 362-367.	1.2	9
676	The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 355-361.	1.2	131
678	Comprehensive Medical Management of Peripheral Arterial Disease. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 2-13.	1.6	24
679	Adverse events in medicine: Easy to count, complicated to understand, and complex to prevent. <i>Journal of Biomedical Informatics</i> , 2011, 44, 390-394.	2.5	48
680	Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes: An Analysis of Data From Electronic Medical Records. <i>Clinical Therapeutics</i> , 2011, 33, 110-120.	1.1	11
681	Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2011, 33, 393-407.	1.1	26
682	Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2011, 33, 665-678.	1.1	54
683	Review of the Therapeutic Uses of Liraglutide. <i>Clinical Therapeutics</i> , 2011, 33, 793-811.	1.1	31
684	Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy. <i>Clinical Therapeutics</i> , 2011, 33, 1281-1288.	1.1	23
685	Best Medical Therapy or Wishful Thinking in Carotid Disease? A Single-centre Audit in Germany. <i>European Journal of Vascular and Endovascular Surgery</i> , 2011, 41, 501-506.	0.8	6

#	ARTICLE	IF	CITATIONS
686	Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. <i>American Journal of Cardiology</i> , 2011, 107, 1856-1861.	0.7	15
687	Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. <i>American Journal of Cardiology</i> , 2011, 108, 25B-32B.	0.7	35
688	Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2011, 108, 52B-58B.	0.7	22
689	Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications. <i>American Journal of Cardiology</i> , 2011, 108, 59B-67B.	0.7	20
690	Cardiovascular Effects of Glucagonlike peptide-1 Agonists. <i>American Journal of Cardiology</i> , 2011, 108, 33B-41B.	0.7	65
691	Change in High-Density Lipoprotein Cholesterol and Risk of Subsequent Hospitalization for Coronary Artery Disease or Stroke Among Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2011, 108, 1124-1128.	0.7	21
693	The ADA Focus on Diabetes 2011. <i>Geriatric Nursing</i> , 2011, 32, 119-122.	0.9	0
694	Efficacy and Safety of Antioxidant Treatment With $\alpha$ -Lipoic Acid Over 4 Years in Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2011, 34, 2054-2060.	4.3	318
695	Intensive Glycemic Control and Renal Outcome. <i>Contributions To Nephrology</i> , 2011, 170, 196-208.	1.1	17
696	Intensive glycaemic control in type 2 diabetes: where are we now?. <i>The Prescriber</i> , 2011, 22, 6-8.	0.1	0
697	Factors impacting volumetric white matter changes following whole brain radiation therapy. <i>Journal of Neuro-Oncology</i> , 2011, 103, 111-119.	1.4	50
698	Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. <i>Amino Acids</i> , 2011, 40, 819-828.	1.2	92
700	Oral antidiabetic drug therapy in type 2 diabetes mellitus – focus on elderly patients. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 297-299.	0.5	4
704	Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. <i>Diabetologia</i> , 2011, 54, 25-31.	2.9	128
705	Intensified glucose lowering in type 2 diabetes: don't throw the baby out with the bathwater. <i>Diabetologia</i> , 2011, 54, 705-706.	2.9	2
706	Intensified glucose lowering in type 2 diabetes: time for a bolder reappraisal. <i>Diabetologia</i> , 2011, 54, 701-702.	2.9	6
707	Intensified glucose lowering in type 2 diabetes. Reply to Czupryniak L, Szymańska-Garbacz E, Pawłowski M et al. [letter], Aizawa T and Funase Y [letter] and DeVries JH [letter]. <i>Diabetologia</i> , 2011, 54, 707-708.	2.9	1
708	Finnish Current Care Guideline for Diabetes: interactive approach to improve individualised treatment. <i>Diabetologia</i> , 2011, 54, 1264-1265.	2.9	8

#	ARTICLE	IF	CITATIONS
709	Intensive glucose control and risk of cancer in patients with type 2 diabetes. <i>Diabetologia</i> , 2011, 54, 1608-1614.	2.9	32
710	Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. <i>Diabetologia</i> , 2011, 54, 1921-1929.	2.9	31
711	Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. <i>Diabetologia</i> , 2011, 54, 2237-2246.	2.9	55
712	Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. <i>Diabetologia</i> , 2011, 54, 2544-2551.	2.9	19
713	Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 309-319.	1.4	37
714	Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 471-476.	0.8	52
715	Diabetes Medication Assistance Service: The pharmacist's role in supporting patient self-management of type 2 diabetes (T2DM) in Australia. <i>Patient Education and Counseling</i> , 2011, 83, 288-294.	1.0	50
716	Treatment of Risk Factors to Prevent Stroke. <i>Neurotherapeutics</i> , 2011, 8, 463-474.	2.1	20
717	Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. <i>Diabetology International</i> , 2011, 2, 146-153.	0.7	53
720	Defining Medical Futility and Improving Medical Care. <i>Journal of Bioethical Inquiry</i> , 2011, 8, 123-131.	0.9	135
721	A Model for Predicting the Resolution of Type 2 Diabetes in Severely Obese Subjects Following Roux-en-Y Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2011, 21, 910-916.	1.1	89
722	The Growing Role of Bariatric Surgery in the Management of Type 2 Diabetes: Evidences and Open Questions. <i>Obesity Surgery</i> , 2011, 21, 1451-1457.	1.1	16
723	Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies. <i>Current Atherosclerosis Reports</i> , 2011, 13, 115-122.	2.0	28
724	What's Wrong with Too Low? Is Hypoglycemia a Marker or a Cause of CVD and Mortality Risk?. <i>Current Diabetes Reports</i> , 2011, 11, 71-74.	1.7	1
725	The impact of tailored diabetes registry report cards on measures of disease control: a nested randomized trial. <i>BMC Medical Informatics and Decision Making</i> , 2011, 11, 12.	1.5	6
726	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011, 10, 22.	2.7	137
727	Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. <i>Cardiovascular Diabetology</i> , 2011, 10, 26.	2.7	29
728	Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006. <i>Cardiovascular Diabetology</i> , 2011, 10, 5.	2.7	3

#	ARTICLE	IF	CITATIONS
729	Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. <i>Cardiovascular Diabetology</i> , 2011, 10, 61.	2.7	85
730	Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patients. <i>Cardiovascular Diabetology</i> , 2011, 10, 86.	2.7	16
731	Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2011, 10, 98.	2.7	65
732	The diabetes pandemic: is structured education the solution or an unnecessary expense?. <i>Practical Diabetes</i> , 2011, 28, 1-14.	0.1	10
733	Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 373-382.	1.7	34
734	The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 528-542.	1.7	86
735	Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 639-653.	1.7	675
736	Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study. <i>BMJ Open</i> , 2011, 1, e000132-e000132.	0.8	39
737	Glycated Hemoglobin A1c, Fasting Plasma Glucose, and Two-Hour Postchallenge Plasma Glucose Levels in Relation to Carotid Intima-Media Thickness in Chinese with Normal Glucose Tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1461-E1465.	1.8	35
738	The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach. <i>Current Diabetes Reviews</i> , 2011, 7, 313-324.	0.6	293
739	Intensive Glycemic Control and Cardiovascular Disease: Are There Patients Who May Benefit?. <i>Postgraduate Medicine</i> , 2011, 123, 114-123.	0.9	10
740	Loss of Canonical Insulin Signaling Accelerates Vascular Smooth Muscle Cell Proliferation and Migration Through Changes in p27Kip1 Regulation. <i>Endocrinology</i> , 2011, 152, 651-658.	1.4	27
742	Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy – A Pilot Study. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 255-263.	0.5	12
743	Screening Tests for Renal Impairment in Patients with Type 2 Diabetes: The what, when, and how. <i>Postgraduate Medicine</i> , 2011, 123, 7-14.	0.9	0
744	Cardiovascular Disease in Diabetes: Where Does Glucose Fit In?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2367-2376.	1.8	54
745	Control of Postprandial Glucose Levels with Insulin in Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2011, 123, 135-147.	0.9	21
746	Insights from the extended follow-up of the ACCORD trial. <i>Nature Reviews Cardiology</i> , 2011, 8, 308-310.	6.1	0
747	Interpreting and reporting clinical trials with results of borderline significance. <i>BMJ: British Medical Journal</i> , 2011, 343, d3340-d3340.	2.4	82

#	ARTICLE	IF	CITATIONS
748	Approach to the Hospitalized Patient with Severe Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2652-2662.	1.8	7
749	Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 173-180.	1.0	15
750	Hypoglycemia and Cardiovascular Risks. <i>Diabetes Care</i> , 2011, 34, S132-S137.	4.3	305
751	Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Clinical Chemistry</i> , 2011, 57, e1-e47.	1.5	583
753	Basal Plus Basalâ€“Bolus Approach in Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-75-S-83.	2.4	23
754	PIOfix-Study: Effects of Pioglitazone/Metformin Fixed Combination in Comparison with a Combination of Metformin with Glimepiride on Diabetic Dyslipidemia. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 637-643.	2.4	16
755	Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?. <i>Current Medical Research and Opinion</i> , 2011, 27, 7-11.	0.9	6
756	Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. <i>Diabetes Care</i> , 2011, 34, 1431-1437.	4.3	361
757	Alleviating the burden of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2011, 7, 71-73.	4.1	49
758	The Diabetic Hospice Patient. <i>Journal of Hospice and Palliative Nursing</i> , 2011, 13, 356-365.	0.5	2
760	Non-invited Review: Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 180-189.	0.9	30
761	Design of a Decision Support System to Help Clinicians Manage Glycemia in Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 402-411.	1.3	24
762	Loss of Residual Renal Function was Not Associated with Glycemic Control in Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2011, 31, 154-159.	1.1	9
763	Multidrug Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S231-S235.	4.3	39
764	Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. <i>BMJ: British Medical Journal</i> , 2011, 343, d6898-d6898.	2.4	312
765	Antiplatelet Therapy for Every Diabetic Person?. <i>Diabetes Care</i> , 2011, 34, S150-S154.	4.3	17
766	NT-proBNP and cardiac events in older diabetic patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 399-405.	3.1	2
767	Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S244-S250.	4.3	76

#	ARTICLE	IF	CITATIONS
769	Effects of Bilio-Pancreatic Diversion on Diabetic Complications. <i>Diabetes Care</i> , 2011, 34, 561-567.	4.3	136
770	Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment. <i>Diabetes Care</i> , 2011, 34, S330-S334.	4.3	23
771	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2&#x2013;3 liraglutide clinical development studies. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 237-240.	0.9	101
772	Observation on Renal Outcomes in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2011, 34, 2090-2094.	4.3	34
773	Treatment of diabetic vasculopathy: an overview. <i>Research and Reports in Endocrine Disorders</i> , 0, , 21.	0.4	2
774	Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry. <i>Cardiovascular Diabetology</i> , 2011, 10, 66.	2.7	32
775	Hypoglycaemia: current management and controversies. <i>Postgraduate Medical Journal</i> , 2011, 87, 298-306.	0.9	40
776	Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2011, 4, CMED.S5114.	1.0	16
777	A Review of Risk Factors and Cardiovascular Disease in Diabetes Care - 2011. <i>The European Journal of Cardiovascular Medicine</i> , 2011, , .	1.0	3
778	Effect of Diabetes Mellitus on Outcomes of Hyperglycemia in a Mixed Medical Surgical Intensive Care Unit. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 731-740.	1.3	8
779	Blood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2011, 34, 34-38.	4.3	83
780	Hypoglycemia Education Needs. <i>Qualitative Health Research</i> , 2011, 21, 1220-1228.	1.0	7
781	Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus. <i>Circulation</i> , 2011, 123, 2811-2818.	1.6	106
782	Long-Term Care Medicine. , 2011, , .		2
783	Glycated haemoglobin and the incidence of end-stage renal disease in diabetics. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2238-2244.	0.4	12
784	Prestroke Glycemic Control Is Associated With the Functional Outcome in Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 2788-2794.	1.0	134
785	Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. <i>European Heart Journal</i> , 2011, 32, 2247-2255.	1.0	39
786	Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case&#x2013;control study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1888-1894.	0.4	29



#	ARTICLE	IF	CITATIONS
787	Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension. <i>Diabetes Care</i> , 2011, 34, S297-S303.	4.3	34
788	Standards of Medical Care in Diabetes—2011. <i>Diabetes Care</i> , 2011, 34, S11-S61.	4.3	2,448
789	Intensive Control of Diabetes in the Hospital: Why, How, and What is in the Future?. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 1596-1601.	1.3	11
790	Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. <i>Diabetes Care</i> , 2011, 34, S101-S106.	4.3	69
791	Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S225-S230.	4.3	57
792	Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies. <i>Diabetes Care</i> , 2011, 34, 90-95.	4.3	230
793	Is Hyperglycemia a Cardiovascular Risk Factor?. <i>Diabetes Care</i> , 2011, 34, S128-S131.	4.3	55
794	A1C and Cardiovascular Outcomes in Type 2 Diabetes: A nested case-control study. <i>Diabetes Care</i> , 2011, 34, 77-83.	4.3	89
795	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1032-1040.	2.2	64
796	Diabetes and Biomarkers. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 192-197.	1.3	26
797	Decreases in Dietary Glycemic Index Are Related to Weight Loss among Individuals following Therapeutic Diets for Type 2 Diabetes. <i>Journal of Nutrition</i> , 2011, 141, 1469-1474.	1.3	21
798	Relationship Among A1C, Hypoglycemia, and Hyperglycemia in Japanese with Type 2 Diabetes—Results from Continuous Glucose Monitoring Data. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 667-670.	2.4	5
799	Impact of dementia on caring for patients with diabetes. <i>Aging and Mental Health</i> , 2011, 15, 894-903.	1.5	30
800	Management of patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2011, 27, 1931-1947.	0.9	12
801	Review of approved pioglitazone combinations for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1571-1584.	0.9	11
802	Building Multidimensional Biomarker Views of Type 2 Diabetes on the Basis of Protein Microheterogeneity. <i>Clinical Chemistry</i> , 2011, 57, 719-728.	1.5	27
803	Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Diabetes Care</i> , 2011, 34, e61-e99.	4.3	389
804	Hypothalamic-Pituitary-Adrenocortical Axis Hypersensitivity and Glucocorticoid Receptor Expression and Function in Women with Polycystic Ovary Syndrome. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 636-643.	0.6	26

#	ARTICLE	IF	CITATIONS
805	Serious Cardiovascular Outcomes in Diabetes. <i>Circulation</i> , 2011, 123, 342-348.	1.6	93
806	Glycemic Control, Complications, and Death in Older Diabetic Patients. <i>Diabetes Care</i> , 2011, 34, 1329-1336.	4.3	293
807	Hemoglobin A1c, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes. <i>Diabetes Care</i> , 2011, 34, 1952-1958.	4.3	21
808	New Models of Self-Management Education for Minority Ethnic Groups: Pilot Randomized Trial of a Story-Sharing Intervention. <i>Journal of Health Services Research and Policy</i> , 2011, 16, 28-36.	0.8	49
809	Screening for Type 2 Diabetes and Dysglycemia. <i>Epidemiologic Reviews</i> , 2011, 33, 63-87.	1.3	70
810	Clinical Efficacy of Colesevelam in Type 2 Diabetes Mellitus. <i>Journal of Pharmacy Practice</i> , 2011, 24, 417-425.	0.5	2
812	Intensive glucose control in type 2 diabetes reduces cardiovascular disease, but not cardiovascular or all-cause mortality, and increases risk of severe hypoglycaemia. <i>Evidence-based Nursing</i> , 2011, 13, 3-4.	0.1	0
813	Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report. <i>American Journal of Bioethics</i> , 2011, 11, 2-10.	0.5	24
814	Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1165-1170.	4.3	33
815	Glycemic Control during Coronary Artery Bypass Graft Surgery. <i>ISRN Cardiology</i> , 2012, 2012, 1-14.	1.6	24
816	A study of the natural history of diabetic kidney disease (DKD). <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1847-1854.	0.4	100
817	Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae. <i>Postgraduate Medicine</i> , 2012, 124, 90-97.	0.9	155
818	Type 2 Diabetes Mellitus. , 2012, , 1489-1499.		1
819	Stroke Prevention: Managing Modifiable Risk Factors. <i>Stroke Research and Treatment</i> , 2012, 2012, 1-15.	0.5	22
820	Glucose control and cardiovascular outcomes: reorienting approach. <i>Frontiers in Endocrinology</i> , 2012, 3, 110.	1.5	11
821	Diabetes management in Australian rural aged care facilities: A cross-sectional audit. <i>Australasian Medical Journal</i> , 2012, 5, 575-580.	0.1	3
822	Comparison of Peripheral Nerve Damages According to Glucose Control Timing in Experimental Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 451-459.	0.6	8
823	A New Preventive Strategy for Hypoglycemia Incorporating Added Food Diet in Patients with Type 2 Diabetes Who Received Sitagliptin Therapy. <i>Endocrine Research</i> , 2012, 37, 175-181.	0.6	4

#	ARTICLE	IF	CITATIONS
824	Does hypoglycemia cause cardiovascular events?. Indian Journal of Endocrinology and Metabolism, 2012, 16, 102.	0.2	16
825	A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death. Diabetes Care, 2012, 35, 1621-1624.	4.3	39
826	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice, 2012, 2012, 1-18.	0.5	26
827	Glucagon-Like Peptide-1 and Diabetes 2012. Experimental Diabetes Research, 2012, 2012, 1-1.	3.8	4
828	Endoplasmic Reticulum Stress-Related Factors Protect against Diabetic Retinopathy. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	25
829	Diabetes therapies in renal impairment. British Journal of Diabetes and Vascular Disease, 2012, 12, 167-171.	0.6	13
830	Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia. Diabetes Care, 2012, 35, 1897-1901.	4.3	458
831	Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?. Evidence-Based Medicine, 2012, 17, 98-99.	0.6	3
832	The Other Side of Quality Improvement in Diabetes for Seniors. Archives of Internal Medicine, 2012, 172, 1510.	4.3	35
833	Diabetic neuropathy. Current Opinion in Neurology, 2012, 25, 536-541.	1.8	131
834	Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Therapeutic Advances in Drug Safety, 2012, 3, 185-201.	1.0	4
835	Gene Silencing of the Mitochondrial Adaptor p66 <sup>Shc</sup> Suppresses Vascular Hyperglycemic Memory in Diabetes. Circulation Research, 2012, 111, 278-289.	2.0	219
836	The American Diabetes Association Diabetes Research Perspective. Diabetes, 2012, 61, 1338-1345.	0.3	14
837	Glycemic memory. Current Opinion in Lipidology, 2012, 23, 24-29.	1.2	42
838	Science, clinical outcomes and the popularization of diabetes surgery. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 359-366.	1.2	10
839	Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes. Diabetes Care, 2012, 35, 1126-1132.	4.3	93
840	Mortality Rates in Trials of Subjects With Type 2 Diabetes. Journal of the American Heart Association, 2012, 1, 8-15.	1.6	71
841	A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. European Journal of Preventive Cardiology, 2012, 19, 944-951.	0.8	29

#	ARTICLE	IF	CITATIONS
842	Insulin Therapy in Home Health. Home Health Care Management and Practice, 2012, 24, 298-308.	0.4	0
843	Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrology Dialysis Transplantation, 2012, 27, 2642-2649.	0.4	61
844	Reducing renal failure: how low do glucose levels need to go?. Diabetes Management, 2012, 2, 25-32.	0.5	1
845	Early signs of diabetic nephropathy in childhood. Diabetes Management, 2012, 2, 337-353.	0.5	0
847	Incretins and Preservation of Endothelial Function. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012, 10, 295-308.	0.4	13
848	Nonsurgical Options for the Treatment of Diabetic Macular Edema. ESASO Course Series, 2012, , 35-45.	0.1	0
849	Hyaline Cartilage Tissue Is Formed through the Co-culture of Passaged Human Chondrocytes and Primary Bovine Chondrocytes. Journal of Histochemistry and Cytochemistry, 2012, 60, 576-587.	1.3	10
850	In search of improved glucose control: helping the patient decide between insulin injections and infusion pump therapy. Diabetes Management, 2012, 2, 405-417.	0.5	0
852	Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR. Postgraduate Medicine, 2012, 124, 121-135.	0.9	8
854	Relationship between Sleep Disorders and the Risk for Developing Type 2 Diabetes Mellitus. Postgraduate Medicine, 2012, 124, 119-129.	0.9	21
855	Diabetes treatment: The coming paradigm shift. Journal of Diabetes, 2012, 4, 315-317.	0.8	5
856	Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2012, 3, 148-155.	1.1	32
857	Placing the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial in context. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2012, 17, 118-120.	0.4	0
858	Cardiovascular effects of the DPP-4 inhibitors. Diabetes and Vascular Disease Research, 2012, 9, 109-116.	0.9	73
859	Type 2 diabetes: the evolution of a disease. British Journal of Diabetes and Vascular Disease, 2012, 12, 290-298.	0.6	2
860	Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney International, 2012, 81, 698-706.	2.6	72
861	Increased Atherosclerosis and Endothelial Dysfunction in Mice Bearing Constitutively Deacetylated Alleles of Foxo1 Gene. Journal of Biological Chemistry, 2012, 287, 13944-13951.	1.6	37
862	Severe Hypoglycemia Predicts Mortality in Diabetes. Diabetes Care, 2012, 35, 1814-1816.	4.3	130

#	ARTICLE	IF	CITATIONS
863	The US Preventive Services Task Force Should Consider A Broader Evidence Base In Updating Its Diabetes Screening Guidelines. <i>Health Affairs</i> , 2012, 31, 35-42.	2.5	10
864	Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2076-2082.	4.3	270
865	Diabetes in Older Adults. <i>Diabetes Care</i> , 2012, 35, 2650-2664.	4.3	961
866	Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 209-221.	1.4	18
867	Ways To Reduce Cardiovascular Disease in Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, S-1-S-2.	2.4	3
868	Insulin initiation in elderly patients with type 2 diabetes in France: a subpopulation of the LIGHT study. <i>Current Medical Research and Opinion</i> , 2012, 28, 503-511.	0.9	6
869	Predictors of Emergency Department and Outpatient Visits for Hypoglycemia in Type 2 Diabetes: An Analysis of a Large US Administrative Claims Database. <i>Annals of Pharmacotherapy</i> , 2012, 46, 157-168.	0.9	18
871	Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With Diabetes. <i>Diabetes</i> , 2012, 61, 708-715.	0.3	163
872	Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2012, 35, 2390-2392.	4.3	86
873	Sixty years of diabetes management in primary care. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 315-320.	0.6	3
874	Drugs for type 2 diabetes mellitus: The imperative for cardiovascular outcome assessment. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 85-88.	0.9	4
875	Comparable short-term prognosis in diabetic and non-diabetic patients with acute coronary syndrome after cardiac rehabilitation. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 15-22.	0.8	15
876	Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research. <i>Kidney and Blood Pressure Research</i> , 2012, 36, 65-84.	0.9	127
877	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. <i>Circulation</i> , 2012, 126, 3097-3137.	1.6	1,188
878	Managing Diabetes in the Middle-Aged Patient When Loss of Glycemic Control Occurs. <i>The Diabetes Educator</i> , 2012, 38, 13S-21S.	2.6	0
879	Glycaemic control and cardiovascular outcome trials in type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 161-164.	0.6	1
880	A Look Ahead at the Future of Diabetes Prevention and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2517.	3.8	20
881	Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 6-16.	0.6	1

#	ARTICLE	IF	CITATIONS
882	Insulin Therapy and Cancer in Type 2 Diabetes. <i>Isrn Endocrinology</i> , 2012, 2012, 1-12.	2.0	15
883	Cerebrovascular Complications of Diabetes: Focus on Stroke. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2012, 12, 148-158.	0.6	149
884	Differential Changes of Aorta and Carotid Vasodilation in Type 2 Diabetic GK and OLETF Rats: Paradoxical Roles of Hyperglycemia and Insulin. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-16.	3.8	12
885	Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes. <i>International Journal of Vascular Medicine</i> , 2012, 2012, 1-19.	0.4	119
886	Diabetes and Stroke Prevention: A Review. <i>Stroke Research and Treatment</i> , 2012, 2012, 1-6.	0.5	29
887	Platelets Derived From the Bone Marrow of Diabetic Animals Show Dysregulated Endoplasmic Reticulum Stress Proteins That Contribute to Increased Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2141-2148.	1.1	34
888	Molecular Intricacies and the Role of ER Stress in Diabetes. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-2.	3.8	10
889	The Management of Type 2 Diabetic Patients with Hypoglycemic Agents. <i>Isrn Endocrinology</i> , 2012, 2012, 1-6.	2.0	1
890	Cardiovascular Benefits of GLP-1-Based Therapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-9.	3.8	34
891	The Role of Glucosamine-Induced ER Stress in Diabetic Atherogenesis. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-11.	3.8	17
892	Critical appraisal of trials for validation of "risk-guided" cardiovascular disease prevention therapy. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 33-36.	0.8	2
893	Endothelial Function in Patients With Newly Diagnosed Type 2 Diabetes Receiving Early Intensive Insulin Therapy. <i>American Journal of Hypertension</i> , 2012, 25, 1242-8.	1.0	12
894	Care Guides. <i>Journal of Ambulatory Care Management</i> , 2012, 35, 27-37.	0.5	16
895	Implementing High-Value, Cost-Conscious Diabetes Mellitus Care Through the Use of Low-Cost Medications and Less-Intensive Glycemic Control Target. <i>Archives of Internal Medicine</i> , 2012, 172, 1610.	4.3	4
896	Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2012, 1, e002832.	1.6	59
897	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Circulation</i> , 2012, 126, e354-471.	1.6	675
898	Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. <i>European Heart Journal</i> , 2012, 33, 1049-1057.	1.0	19
899	Impact of type 2 diabetes on serial changes in tissue characteristics of coronary plaques: an integrated backscatter intravascular ultrasound analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2012, 13, 717-723.	0.5	20

#	ARTICLE	IF	CITATIONS
900	Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2012, 7, 2-9.	1.5	11
901	Editorial: Thematic Issue-Topic "Diabetic Cardiovascular Disease" An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2012, 10, 185-189.	0.4	1
902	Do Clinical-Pathological Communication and Correlation Influence the Diagnosis and Incidence of Osteonecrosis?. <i>American Journal of Clinical Pathology</i> , 2012, 138, A291.2-A291.	0.4	0
904	Undiagnosed medical comorbidities in the uninsured. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 73, 1093-1099.	1.1	36
905	Long-Term Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetes Mellitus in Morbidly Obese Subjects. <i>Annals of Surgery</i> , 2012, 256, 1023-1029.	2.1	208
907	Discontinuation of Antihyperglycemic Therapy After Acute Myocardial Infarction: Medical Necessity or Medical Error?. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2012, 38, 403-407.	0.4	6
909	Evolving Treatment Strategies for the Management of Type 2 Diabetes. <i>American Journal of the Medical Sciences</i> , 2012, 343, 21-26.	0.4	20
910	Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, 613-621.	0.7	74
912	Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2012, 172, 761-9.	4.3	246
913	Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. <i>Yearbook of Cardiology</i> , 2012, 2012, 323-327.	0.0	0
914	CME Management of diabetes in patients with end-stage kidney disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 26-29.	0.1	0
915	Peer Mentoring and Financial Incentives to Improve Glucose Control in African American Veterans. <i>Annals of Internal Medicine</i> , 2012, 156, 416.	2.0	247
917	Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 514-520.	2.3	4
918	Benefits and Risks for Intensive Glycemic Control in Patients With Diabetes Mellitus. <i>American Journal of the Medical Sciences</i> , 2012, 343, 17-20.	0.4	37
919	Effects of Voglibose and Nateglinide on Glycemic Status and Coronary Atherosclerosis in Early-Stage Diabetic Patients. <i>Circulation Journal</i> , 2012, 76, 712-720.	0.7	29
920	Glycemic Management in Diabetes and the Associated Cardiovascular Risk. <i>Circulation Journal</i> , 2012, 76, 1572-1580.	0.7	9
921	Diabetes and cognitive dysfunction. <i>Lancet, The</i> , 2012, 379, 2291-2299.	6.3	722
922	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. <i>Lancet, The</i> , 2012, 380, 475-483.	6.3	310

#	ARTICLE	IF	CITATIONS
923	Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials. <i>European Heart Journal Supplements</i> , 2012, 14, B22-B29.	0.0	5
924	“Tight Control” in Geriatrics: The Emperor Wears a Thong. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 1571-1575.	1.3	12
925	A Clinical Action Measure to Assess Glycemic Management in the 65-74 Year Old Veteran Population. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 1442-1447.	1.3	2
926	Update on Insulin Therapy for Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1405-1413.	1.8	33
927	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2564-2603.	1.2	191
928	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, e44-e164.	1.2	1,423
929	Link between the renin-angiotensin system and insulin resistance: Implications for cardiovascular disease. <i>Vascular Medicine</i> , 2012, 17, 330-341.	0.8	134
930	Mapping body fat distribution: A key step towards the identification of the vulnerable patient?. <i>Annals of Medicine</i> , 2012, 44, 758-772.	1.5	54
931	Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline. <i>American Journal of Kidney Diseases</i> , 2012, 60, 747-769.	2.1	87
932	Evaluation of antihyperglycemic and antioxidant properties of <i>Streblus asper</i> Lour against streptozotocin-induced diabetes in rats. <i>Asian Pacific Journal of Tropical Disease</i> , 2012, 2, 139-143.	0.5	26
933	Diabetes therapy—focus on Asia: second-line therapy debate: insulin/secretagogues. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 85-89.	1.7	5
934	Management of diabetes in primary care: individualisation of care. <i>Practical Diabetes</i> , 2012, 29, 331.	0.1	2
936	Impact of Statins on the Coagulation Status of Type 2 Diabetes Patients Evaluated by a Novel Thrombin-Generation Assay. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 301-309.	1.3	12
937	Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities. <i>Atherosclerosis</i> , 2012, 222, 26-28.	0.4	16
938	Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention. <i>Atherosclerosis</i> , 2012, 223, 448-453.	0.4	6
939	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414
940	Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 163-168.	2.3	31
941	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 309-313.	0.4	13



#	ARTICLE	IF	CITATIONS
942	Actualización en el tratamiento de la diabetes mellitus tipo 2. <i>Medicine</i> , 2012, 11, 1397-1405.	0.0	0
943	Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 7-22.	1.0	65
944	Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2100-2107.	4.3	49
945	Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 101-110.	0.9	33
946	Key concepts in screening for depression in people with diabetes. <i>Journal of Affective Disorders</i> , 2012, 142, S72-S79.	2.0	19
947	Characteristics of Patients With Sulphonurea-Induced Hypoglycemia. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 234-238.	1.2	25
948	Atherosclerosis in Chronic Kidney Disease: Lessons Learned from Glycation in Diabetes. <i>Medical Clinics of North America</i> , 2012, 96, 57-65.	1.1	14
949	Achievement of therapeutic targets in Mexican patients with diabetes mellitus. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2012, 59, 591-598.	0.8	9
950	Doute concernant l'efficacité de la metformine dans le diabète de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2012, 6, 249-251.	0.1	0
952	Alas, a Patient-Centred Guidelines on the Glycemic Management in People with Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2012, 36, 87-89.	0.4	1
955	The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, S1-S95.	0.4	11
956	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
957	The Kidney as a Treatment Target for Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2012, 25, 29-36.	0.4	6
958	Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. <i>Journal of Drug Assessment</i> , 2012, 1, 34-39.	1.1	0
960	The American Diabetes Association Diabetes Research Perspective. <i>Diabetes Care</i> , 2012, 35, 1380-1387.	4.3	21
961	The 2012 SEMDSA Guideline for the Management of type 2 Diabetes. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, S1-S94.	0.4	54
962	Standards of Medical Care in Diabetes—2012. <i>Diabetes Care</i> , 2012, 35, S11-S63.	4.3	1,956
963	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 585-667.	0.8	359

#	ARTICLE	IF	CITATIONS
964	Diabetes and cardiovascular disease: the ties that bind. <i>European Heart Journal Supplements</i> , 2012, 14, B1-B3.	0.0	1
965	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. <i>Kidney International</i> , 2012, 81, 586-594.	2.6	53
966	AterogÃ©nesis y diabetes: resistencia a la insulina e hiperinsulinemia. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 309-313.	0.6	23
968	Diabetic cardiovascular autonomic neuropathy: clinical implications. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 747-765.	0.6	41
969	PPAR-Î³ as a therapeutic target in cardiovascular disease: evidence and uncertainty. <i>Journal of Lipid Research</i> , 2012, 53, 1738-1754.	2.0	54
970	Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes. <i>Diabetes</i> , 2012, 61, 2993-2997.	0.3	136
971	Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 296-300.	1.2	55
972	Predictive value of glycosylated hemoglobin for mortality of patients with acute myocardial infarction undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2012, 156, 110-112.	0.8	2
973	Biophysiologic Outcomes of the Enhancing Adherence in Type 2 Diabetes (ENHANCE) Trial. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2012, 112, 1147-1157.	0.4	35
974	Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. <i>Diabetes and Metabolism</i> , 2012, 38, 102-112.	1.4	33
975	The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts?. <i>Diabetes Research and Clinical Practice</i> , 2012, 95, 303-311.	1.1	67
976	Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 57-62.	1.1	11
977	Incidence and predictors of hypoglycaemia in type 2 diabetes â an analysis of the prospective DiaRegis registry. <i>BMC Endocrine Disorders</i> , 2012, 12, 23.	0.9	58
978	Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. <i>Cardiovascular Diabetology</i> , 2012, 11, 142.	2.7	61
979	Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. <i>Cardiovascular Diabetology</i> , 2012, 11, 67.	2.7	125
980	Characteristics of poorly controlled Type 2 diabetes patients in Swiss primary care. <i>Cardiovascular Diabetology</i> , 2012, 11, 70.	2.7	16
981	Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. <i>Cardiovascular Diabetology</i> , 2012, 11, 82.	2.7	69
982	Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study). <i>Cardiovascular Diabetology</i> , 2012, 11, 92.	2.7	73

#	ARTICLE	IF	CITATIONS
983	Drug safety assessment in clinical trials: methodological challenges and opportunities. <i>Trials</i> , 2012, 13, 138.	0.7	146
985	Personalizing Treatment in Type 2 Diabetes: A Self-Monitoring of Blood Glucose Inclusive Innovative Approach. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 373-378.	2.4	22
986	Progression of Subclinical Myocardial Dysfunction in Type 2 Diabetes after 5 years Despite Improved Glycemic Control. <i>Echocardiography</i> , 2012, 29, 1045-1053.	0.3	17
987	Diabetes in Older Adults: A Consensus Report. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2342-2356.	1.3	417
988	Thiazolidinedione safety. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 565-579.	1.0	175
989	Achievement of therapeutic targets in Mexican patients with diabetes mellitus. <i>Endocrinología Y Nutrición (English Edition)</i> , 2012, 59, 591-598.	0.5	8
990	Management of Type 2 Diabetes Mellitus. , 2012, , 167-191.		0
991	Management and Prevention of Diabetic Complications. , 2012, , 233-248.		1
992	Dipeptidyl Peptidase-4 Inhibitor. <i>Journal of the American College of Cardiology</i> , 2012, 59, 277-279.	1.2	27
994	Nonfasting Glucose, Ischemic Heart Disease, and Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2356-2365.	1.2	67
995	Congestive Heart Failure and Diabetes Mellitus: Balancing Glycemic Control with Heart Failure Improvement. <i>American Journal of Cardiology</i> , 2012, 110, 50B-57B.	0.7	34
996	Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival. <i>American Journal of Cardiology</i> , 2012, 110, 58B-68B.	0.7	64
997	Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2012, 38, 298-308.	1.4	12
998	Complicaciones macrovasculares del paciente diabético. <i>Medicine</i> , 2012, 11, 1011-1020.	0.0	0
999	Guía de insulinoterapia. <i>Medicine</i> , 2012, 11, 1096-1105.	0.0	0
1000	Recomendaciones para el empleo de antidiabéticos orales en la diabetes tipo 2. <i>Medicine</i> , 2012, 11, 1112-1116.	0.0	0
1001	Guía para el tratamiento preventivo del ictus isquémico y AIT (I). <i>Actuación sobre los factores de riesgo y estilo de vida. Neurología</i> , 2012, 27, 560-574.	0.3	37
1002	Guidelines for the preventive treatment of ischaemic stroke and TIA (I). Update on risk factors and life style. <i>Neurología (English Edition)</i> , 2012, 27, 560-574.	0.2	17

#	ARTICLE	IF	CITATIONS
1003	Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 1007-1012.	1.1	9
1004	Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany. Primary Care Diabetes, 2012, 6, 241-246.	0.9	76
1005	Hemoglobin A1C is independently associated with severity and prognosis of brainstem infarctions. Journal of the Neurological Sciences, 2012, 317, 87-91.	0.3	15
1008	Diabetes and Cardiovascular Disease. , 2012, , 75-84.		0
1012	C-Peptide: Connecting Diabetes with Macrovascular Complications. , 2012, , 129-144.		1
1014	Hypoglycemia, Diabetes, and Cardiovascular Disease. Diabetes Technology and Therapeutics, 2012, 14, S-51-S-58.	2.4	116
1015	Diabetes and the Heart. , 2012, , 165-189.		0
1016	Diabetes Mellitus and Peripheral Vascular Disease. , 2012, , 27-38.		0
1017	Diabetic Considerations in Cerebrovascular Disease. , 2012, , 181-195.		0
1019	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	0.8	224
1021	GuÃa europea sobre prevenciÃn de la enfermedad cardiovascular en la prÃctica clÃnica (versiÃn 2012). Revista Espanola De Cardiologia, 2012, 65, 937.e1-937.e66.	0.6	30
1022	Glucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus. Heart Failure Clinics, 2012, 8, 513-522.	1.0	5
1023	Podocytes and the struggle against glucose toxicity: New targets for treatment?. Metabolism: Clinical and Experimental, 2012, 61, 1051-1054.	1.5	1
1024	Insulin Therapy and Hypoglycemia. Endocrinology and Metabolism Clinics of North America, 2012, 41, 57-87.	1.2	115
1025	The importance of hypoglycemia in diabetic patients. Journal of Diabetes and Metabolic Disorders, 2012, 11, 17.	0.8	125
1026	Low HbA1c and mortality: causation and confounding. Diabetologia, 2012, 55, 2307-2311.	2.9	25
1030	Cause-specific mortality in diabetes: recent changes in trend mortality. European Journal of Preventive Cardiology, 2012, 19, 374-381.	0.8	84
1031	Enhanced glucose control for preventing and treating diabetic neuropathy. The Cochrane Library, 2012, , CD007543.	1.5	323

#	ARTICLE	IF	CITATIONS
1032	Diabetes and Peripheral Vascular Disease. , 2012, , .		6
1033	Reevaluating Goals of Insulin Therapy: Perspectives from Large Clinical Trials. Endocrinology and Metabolism Clinics of North America, 2012, 41, 41-56.	1.2	6
1034	KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases, 2012, 60, 850-886.	2.1	1,095
1035	Glycemic control and outcomes in people with diabetes and CKD. Nature Reviews Nephrology, 2012, 8, 133-134.	4.1	4
1036	Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Canadian Journal of Ophthalmology, 2012, 47, S1-S30.	0.4	51
1037	Canadian Ophthalmological Society Evidence-Based Clinical Practice Guidelines for the Management of Diabetic Retinopathy – Executive Summary. Canadian Journal of Ophthalmology, 2012, 47, 91-101.	0.4	24
1038	Colesevelam for type 2 diabetes mellitus. The Cochrane Library, 2012, 12, CD009361.	1.5	23
1039	An eicosanoid-centric view of atherothrombotic risk factors. Cellular and Molecular Life Sciences, 2012, 69, 3361-3380.	2.4	34
1040	Diabetes in an Undergraduate Class. , 2012, , 35-71.		0
1041	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
1042	Does Insulin Resistance Drive the Association between Hyperglycemia and Cardiovascular Risk?. PLoS ONE, 2012, 7, e39260.	1.1	17
1043	Type 2 Diabetes Mellitus. , 2012, , e95-e108.		2
1044	Management of Type 2 Diabetes Mellitus in Older Adults. Diabetes and Metabolism Journal, 2012, 36, 336.	1.8	58
1045	Managing the Broad Spectrum of Type 2 Diabetes. , 2012, , 43-56.		0
1046	Inpatient Treatment of Type 2 Diabetes. Deutsches A&#x0308;rztblatt International, 2012, 109, 466-74.	0.6	15
1047	AGE/RAGE as a Mediator of Insulin Resistance or Metabolic Syndrome: Another Aspect of Metabolic Memory?. , 2012, , .		0
1048	Is intensive glycaemic control important for patients with diabetes?Hemmingsen B, Lund SS, Gluud C (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ online ahead of print doi: 10.1136/bmj.d6898. British Journal of Cardiac Nursing, 2012, 7, 48-48.	0.0	0
1049	What Do We Need beyond Hemoglobin A1c to Get the Complete Picture of Glycemia in People with Diabetes?. International Journal of Medical Sciences, 2012, 9, 665-681.	1.1	33

#	ARTICLE	IF	CITATIONS
1050	Exploring the understanding of evidence-based concepts in people with type 2 diabetes. <i>International Journal of General Medicine</i> , 2012, 5, 781.	0.8	1
1051	Glycated Hemoglobin is Associated with the Complexity of Coronary Artery Disease, Even in Non-Diabetic Adults. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 1066-1072.	0.9	26
1052	Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. <i>Review of Diabetic Studies</i> , 2012, 9, 6-22.	0.5	261
1053	Measurement and Treatment Goal of Postprandial Hyperglycemia. <i>Journal of Korean Diabetes</i> , 2012, 13, 27.	0.1	0
1054	The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: expected outcome from the DD2 project and two intervention studies. <i>Clinical Epidemiology</i> , 2012, 4, 21.	1.5	10
1055	Chronic Kidney Disease and Associated Cardiovascular Risk Factors in Chinese with Type 2 Diabetes. <i>Diabetes and Metabolism Journal</i> , 2012, 36, 433.	1.8	28
1056	Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. <i>Cardiovascular Diabetology</i> , 2012, 11, 3.	2.7	203
1057	The Detection of Myocardial Fibrosis. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 9-11.	1.3	17
1058	Glycemic Management of Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2012, 366, 1319-1327.	13.9	142
1059	Economic burden of hypoglycemia in patients with Type 2 diabetes. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 47-51.	0.7	31
1060	Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 920-928.	0.9	25
1061	Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 99-113.	0.9	35
1062	Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 321-324.	1.7	12
1063	Potential cardiovascular effects of incretin-based therapies. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 337-351.	0.6	17
1064	Cardiovascular risk in double diabetes mellitus—when two worlds collide. <i>Nature Reviews Endocrinology</i> , 2012, 8, 476-485.	4.3	60
1065	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>Clinical Cardiology</i> , 2012, 35, 722-729.	0.7	19
1066	Drug-induced hypoglycaemia in type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 597-614.	1.0	47
1067	Clinical Implications of the ACCORD Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 41-48.	1.8	52

#	ARTICLE	IF	CITATIONS
1069	Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. <i>Herz</i> , 2012, 37, 264-272.	0.4	2
1071	Glycaemic control is improved by 7 days of aerobic exercise training in patients with type 2 diabetes. <i>Diabetologia</i> , 2012, 55, 1417-1423.	2.9	65
1072	Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. <i>Diabetologia</i> , 2012, 55, 2109-2117.	2.9	22
1073	Diabetes and cancer I: risk, survival, and implications for screening. <i>Cancer Causes and Control</i> , 2012, 23, 967-981.	0.8	107
1074	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. <i>Heart Failure Reviews</i> , 2012, 17, 325-344.	1.7	287
1077	Surgical Treatment of Type 2 Diabetes in Patients with BMI Below 35: Mid-term Outcomes of the Laparoscopic Ileal Interposition Associated with a Sleeve Gastrectomy in 202 Consecutive Cases. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 967-976.	0.9	53
1078	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. <i>Journal of General Internal Medicine</i> , 2012, 27, 458-468.	1.3	46
1079	Racial and Ethnic Differences in Cardio-Metabolic Risk in Individuals with Undiagnosed Diabetes: National Health and Nutrition Examination Survey 1999-2008. <i>Journal of General Internal Medicine</i> , 2012, 27, 893-900.	1.3	17
1080	Stroke prevention: an update. <i>Frontiers of Medicine</i> , 2012, 6, 22-34.	1.5	38
1081	A Review and Critical Analysis of Professional Societies'™ Guidelines for Pharmacologic Management of Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2012, 12, 246-254.	1.7	14
1082	Metformin Use Among Individuals at Risk for Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2012, 12, 265-273.	1.7	4
1083	Glycemic Control and Cardiovascular Disease: What's a Doctor to Do?. <i>Current Diabetes Reports</i> , 2012, 12, 255-264.	1.7	22
1084	The Diagnosis and Management of Cerebrovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , 2012, 12, 314-323.	1.7	26
1085	The Role of Combination Therapy in Type 2 Diabetes in the Post-ACCORD Era. <i>Current Diabetes Reports</i> , 2012, 12, 227-229.	1.7	0
1086	Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema. <i>Current Diabetes Reports</i> , 2012, 12, 346-354.	1.7	353
1087	Haptoglobin Genotype and Its Role in Diabetic Cardiovascular Disease. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 423-435.	1.1	44
1088	What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 463-478.	1.1	79
1090	Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 149-154.	2.2	19

#	ARTICLE	IF	CITATIONS
1091	Optimal management of type 2 diabetes: the evidence. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 3-8.	2.2	37
1092	Treating diabetes today with gliclazide MR: a matter of numbers. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 14-19.	2.2	22
1093	What matters in ADVANCE and ADVANCE-ON. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 20-29.	2.2	19
1094	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 5-14.	2.2	398
1095	Glycaemic control in patients with diabetes at the point of referral for a second opinion. <i>Diabetic Medicine</i> , 2012, 29, 285-286.	1.2	1
1096	Objetivo terapéutico en el anciano frágil. No siempre más es mejor. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2012, 19, 206-210.	0.0	2
1097	Diabetes, hyperglycaemia, and acute ischaemic stroke. <i>Lancet Neurology</i> , The, 2012, 11, 261-271.	4.9	377
1098	Diabetic neuropathy: clinical manifestations and current treatments. <i>Lancet Neurology</i> , The, 2012, 11, 521-534.	4.9	866
1099	Glucose control in diabetes: which target level to aim for?. <i>Journal of Internal Medicine</i> , 2012, 272, 1-12.	2.7	19
1100	Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 15-21.	1.4	46
1101	Diabetes Mellitus: Prevalence and Effect of Morbidities in the Oldest Old. The Octabaix Study. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 462-467.	1.3	27
1102	Diabetes mellitus and the heart. <i>International Journal of Clinical Practice</i> , 2012, 66, 640-647.	0.8	29
1103	HOW TO IDENTIFY AND MANAGE DIABETES MELLITUS AFTER RENAL TRANSPLANTATION. <i>Journal of Renal Care</i> , 2012, 38, 125-137.	0.6	4
1104	Emergency Department Patients With Diabetes Have Better Glycemic Control When They Have Identifiable Primary Care Providers. <i>Academic Emergency Medicine</i> , 2012, 19, 650-655.	0.8	11
1105	Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995-2007. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 17-22.	1.2	17
1106	Influence of the glucose-lowering rate on left ventricular function in patients with type 2 diabetes and coronary heart disease. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 83-88.	1.2	9
1107	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. <i>European Journal of Clinical Investigation</i> , 2012, 42, 470-477.	1.7	25
1108	Non-high-density lipoprotein cholesterol: An important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients. <i>Geriatrics and Gerontology International</i> , 2012, 12, 18-28.	0.7	40



#	ARTICLE	IF	CITATIONS
1109	Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 464-469.	2.2	38
1110	Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 717-726.	2.2	24
1111	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 973-982.	2.2	59
1112	Does Aggressive Glycemic Control Benefit Macrovascular and Microvascular Disease in Type 2 Diabetes?: Insights from ACCORD, ADVANCE, and VADT. <i>Current Cardiology Reports</i> , 2012, 14, 79-88.	1.3	83
1113	Unfavorable Effects of Intensive Glucose Lowering on Mortality: Lessons from the 5-Year Follow-up of the ACCORD Trial. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 1-3.	0.8	0
1114	Can a Protocol for Glycaemic Control Improve Type 2 Diabetes Outcomes After Gastric Bypass?. <i>Obesity Surgery</i> , 2012, 22, 90-96.	1.1	32
1115	Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. <i>Diabetologia</i> , 2012, 55, 636-643.	2.9	262
1117	Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment. <i>Lipids in Health and Disease</i> , 2013, 12, 15.	1.2	26
1118	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2013, 4, 331-345.	1.2	102
1119	Management of Type 2 Diabetes in Older People. <i>Diabetes Therapy</i> , 2013, 4, 13-26.	1.2	39
1120	Evaluation of stepwise insulin treatment as an add-on to current oral antidiabetic drugs therapy in Japanese patients with type 2 diabetes: STEADY study. <i>Diabetology International</i> , 2013, 4, 233-242.	0.7	0
1122	Obesity and Stroke. , 2013, , 95-112.		1
1123	Diabetes Mellitus Prevention and Treatment. , 2013, , 63-79.		0
1125	Diabetic Kidney Disease in Elderly Individuals. <i>Medical Clinics of North America</i> , 2013, 97, 75-89.	1.1	26
1126	HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3535-3542.	4.3	202
1127	Insulin as an Early Treatment for Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, S198-S204.	4.3	4
1128	Hypoglycemia: Minimizing Its Impact in Type 2 Diabetes. <i>Endocrine Practice</i> , 2013, 19, 526-535.	1.1	32
1129	Key Concepts in Screening for Depression in People with Diabetes. , 2013, , 47-65.		0

#	ARTICLE	IF	CITATIONS
1130	Clinical Manifestations and Natural History of Diabetic Kidney Disease. Medical Clinics of North America, 2013, 97, 19-29.	1.1	21
1131	Personalizing guidelines for diabetes management: twilight or dawn of the expert?. BMC Medicine, 2013, 11, 161.	2.3	20
1132	Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia. Cardiovascular Diabetology, 2013, 12, 92.	2.7	19
1133	Contemporary and Optimal Medical Management of Peripheral Arterial Disease. Surgical Clinics of North America, 2013, 93, 761-778.	0.5	6
1134	Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care, 2013, 36, S139-S144.	4.3	57
1135	Handbook of Clinical Nutrition and Stroke. , 2013, , .		7
1136	Diabetic Autonomic Neuropathy. Advances in Experimental Medicine and Biology, 2013, 771, 176-193.	0.8	22
1138	Independent Contribution of A1C, Systolic Blood Pressure, and LDL Cholesterol Control to Risk of Cardiovascular Disease Hospitalizations in Type 2 Diabetes: An Observational Cohort Study. Journal of General Internal Medicine, 2013, 28, 691-697.	1.3	42
1139	Insulin therapy for type 2 diabetes. Endocrine, 2013, 43, 529-534.	1.1	11
1140	Are current clinical trials in diabetes addressing important issues in diabetes care?. Diabetologia, 2013, 56, 1226-1235.	2.9	50
1141	Hypoglycemia as a Driver of Cardiovascular Risk in Diabetes. Current Atherosclerosis Reports, 2013, 15, 351.	2.0	24
1142	Subclinical Cardiovascular Disease Assessment in Persons with Diabetes. Current Cardiology Reports, 2013, 15, 358.	1.3	6
1143	Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes. Current Cardiology Reports, 2013, 15, 332.	1.3	3
1144	Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes. Current Diabetes Reports, 2013, 13, 319-328.	1.7	3
1145	Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial. Current Diabetes Reports, 2013, 13, 342-349.	1.7	24
1146	Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?. Current Diabetes Reports, 2013, 13, 350-361.	1.7	28
1147	Personalized Decision Support in Type 2 Diabetes Mellitus: Current Evidence and Future Directions. Current Diabetes Reports, 2013, 13, 205-212.	1.7	29
1148	Pharmacologic Management of Chronic Reno-Cardiac Syndrome. Current Heart Failure Reports, 2013, 10, 54-62.	1.3	14

#	ARTICLE	IF	CITATIONS
1149	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	13.9	3,017
1150	Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes. <i>Drugs and Aging</i> , 2013, 30, 429-438.	1.3	21
1151	The Risk for Coronary Heart Disease According to Insulin Resistance with and without Type 2 Diabetes. <i>Endocrine Research</i> , 2013, 38, 195-205.	0.6	10
1155	Glycemic Control: A Combination of Lifestyle Management and the Use of Drugs. <i>Cardiology and Therapy</i> , 2013, 2, 1-16.	1.1	4
1156	The Early Treatment of Type 2 Diabetes. <i>American Journal of Medicine</i> , 2013, 126, S2-S9.	0.6	49
1157	Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 673-679.	1.7	12
1159	Medical strategies to reduce amputation in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 893-900.	1.2	32
1160	Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?. <i>Diabetic Medicine</i> , 2013, 30, 289-299.	1.2	29
1161	Laparoscopic Sleeve Gastrectomy Compared to a Multidisciplinary Weight Loss Program for Obesity: Effects on Body Composition and Protein Status. <i>Obesity Surgery</i> , 2013, 23, 1957-1965.	1.1	43
1162	Le paiement À la performance est-il performant ?. <i>Medecine Des Maladies Metaboliques</i> , 2013, 7, 207-210.	0.1	5
1163	Impact of new-onset diabetes mellitus and glycemic control on the prognosis of heart failure patients: A propensity-matched study in the community. <i>International Journal of Cardiology</i> , 2013, 167, 1206-1216.	0.8	22
1164	Prise en charge des syndromes coronariens aigus. <i>Canadian Journal of Diabetes</i> , 2013, 37, S494-S498.	0.4	0
1165	Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States. <i>American Heart Journal</i> , 2013, 166, 315-324.e1.	1.2	5
1166	Impact of diabetes control on mortality by race in a national cohort of veterans. <i>Annals of Epidemiology</i> , 2013, 23, 74-79.	0.9	17
1167	Diabetes and Altered Glucose Metabolism with Aging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 333-347.	1.2	134
1168	Which patients should be evaluated for blood glucose variability?. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 9-12.	2.2	12
1169	Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 3-8.	2.2	80
1170	Daily glycaemic variability: benefits of optimal control. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 1-2.	2.2	1

#	ARTICLE	IF	CITATIONS
1171	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
1172	Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente con diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición. <i>Endocrinología Y Nutrición: Organó De La Sociedad Espanola De Endocrinología Y Nutrición</i> . 2013. 60. 517.e1-517.e18.	0.8	22
1173	Antihyperlipidemic effect of diosmin: A citrus flavonoid on lipid metabolism in experimental diabetic rats. <i>Journal of Functional Foods</i> , 2013, 5, 484-492.	1.6	47
1174	The Case for: Hypoglycemia Is of Cardiovascular Importance. <i>Diabetes Care</i> , 2013, 36, S264-S266.	4.3	4
1175	Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. <i>American Heart Journal</i> , 2013, 166, 199-207.e15.	1.2	347
1176	Diabetes Prevention and the Role of Risk Factor Reduction in the Medicare Population. <i>American Journal of Preventive Medicine</i> , 2013, 44, S307-S316.	1.6	8
1178	Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 436-442.	1.2	188
1179	Haptoglobin Genotype Is a Consistent Marker of Coronary Heart Disease Risk Among Individuals With Elevated Glycosylated Hemoglobin. <i>Journal of the American College of Cardiology</i> , 2013, 61, 728-737.	1.2	76
1180	What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 17-25.	2.2	24
1181	Selective Kinin Receptor Agonists as Cardioprotective Agents in Myocardial Ischemia and Diabetes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 23-30.	1.3	48
1182	IMMUNOASSAY OF MODIFIED FORMS OF HUMAN LOW DENSITY LIPOPROTEIN IN ISOLATED CIRCULATING IMMUNE COMPLEXES. <i>Journal of Immunoassay and Immunochemistry</i> , 2013, 34, 61-74.	0.5	7
1183	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013, 34, 2444-2452.	1.0	282
1184	Impact of Specific Glucose-Control Strategies on Microvascular and Macrovascular Outcomes in 58,000 Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3510-3516.	4.3	18
1185	Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes. <i>American Journal of Medicine</i> , 2013, 126, S38-S48.	0.6	118
1186	Diabetic autonomic neuropathy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 279-294.	1.0	103
1187	American Association of Clinical Endocrinologistsâ€™™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
1188	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
1189	Early outcome after laparoscopic sleeve gastrectomy of type two diabetes mellitus patients with extremely elevated glycated hemoglobin (HbA1c). <i>International Journal of Surgery</i> , 2013, 11, 869-871.	1.1	3

#	ARTICLE	IF	CITATIONS
1190	Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: Potential applications to cardiovascular disease and diabetes. <i>Proteomics - Clinical Applications</i> , 2013, 7, 528-540.	0.8	48
1191	Age-related differences in glycaemic control in diabetes. <i>Diabetologia</i> , 2013, 56, 2549-2551.	2.9	50
1192	Evidence-based clinical use of insulin premixtures. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 50.	1.2	7
1193	Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review. <i>Cardiovascular Diabetology</i> , 2013, 12, 135.	2.7	67
1194	Direct cardiovascular effects of glucagon like peptide-1. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 47.	1.2	32
1195	Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. <i>BMC Medical Research Methodology</i> , 2013, 13, 107.	1.4	10
1196	Structured personal care of type 2 diabetes: a 19-year follow-up of the study Diabetes Care in General Practice (DCGP). <i>Diabetologia</i> , 2013, 56, 1243-1253.	2.9	41
1197	Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c. <i>BMC Endocrine Disorders</i> , 2013, 13, 59.	0.9	36
1198	Treatment Strategies for the Prevention of Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 331-340.	1.3	9
1199	Chronic Kidney Disease in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2013, 29, 611-624.	1.0	19
1200	Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. <i>International Journal of Clinical Practice</i> , 2013, 67, 665-672.	0.8	164
1201	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 289-301.	0.9	132
1202	Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. <i>Annals of the New York Academy of Sciences</i> , 2013, 1281, 36-50.	1.8	85
1203	Effect of activity monitor-based counseling on physical activity and health-related outcomes in patients with chronic diseases: A systematic review and meta-analysis. <i>Annals of Medicine</i> , 2013, 45, 397-412.	1.5	92
1204	Cardiovascular Disease and the Use of Insulin. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 789-791.	2.4	1
1205	The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 1305-1313.	1.2	13
1206	Comparison of Glycemic Variability in Patients with Type 2 Diabetes Given Sitagliptin or Voglibose: A Continuous Glucose Monitoring-Based Pilot Study. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 378-385.	2.4	11
1210	Insulin treatment of type 2 diabetes: Considerations when converting from human insulin to insulin analogs. <i>Annals of Medicine</i> , 2013, 45, 129-140.	1.5	2

#	ARTICLE	IF	CITATIONS
1211	Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 21-35.	1.2	1
1212	Mechanisms of Diabetic Complications. <i>Physiological Reviews</i> , 2013, 93, 137-188.	13.1	1,943
1213	The Epidemiology of Diabetic Retinopathy. , 2013, , 907-924.		8
1214	Chapter 5: Referral to specialists and models of care. <i>Kidney International Supplements</i> , 2013, 3, 112-119.	4.6	38
1215	“Hard,” “soft” and “surrogate” endpoints in diabetes. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, 295-297.	2.0	6
1216	Effect of Tight Blood Glucose Control Versus Conventional Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. <i>Cardiovascular Therapeutics</i> , 2013, 31, 147-160.	1.1	35
1217	Will PPAR- $\beta$ agonist therapy still have a role in diabetes management in 2013?. <i>Diabetes Management</i> , 2013, 3, 41-51.	0.5	1
1218	The path to approval of new drugs for diabetes. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 195-207.	1.0	12
1219	Diabetes Management in the Kidney Patient. <i>Medical Clinics of North America</i> , 2013, 97, 135-156.	1.1	26
1220	Targets for Glycemic Control. <i>Canadian Journal of Diabetes</i> , 2013, 37, S31-S34.	0.4	78
1221	Effect of Strict Glycemic Control in Patients With Diabetes Mellitus on Frequency of Macrovascular Events. <i>American Journal of Cardiology</i> , 2013, 112, 1033-1038.	0.7	21
1222	Effects of the glucose-lowering rate on cTnI and hs-CRP serum levels in type 2 diabetics. <i>Human Immunology</i> , 2013, 74, 379-382.	1.2	3
1223	Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. <i>Endocrinología Y Nutrición (English Edition)</i> , 2013, 60, 517.e1-517.e18.	0.5	4
1224	Prevalence, Quality of Care, and Complications in Long Term Care Residents With Diabetes: A Multicenter Observational Study. <i>Journal of the American Medical Directors Association</i> , 2013, 14, 842-846.	1.2	44
1225	Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction. <i>Atherosclerosis</i> , 2013, 229, 277-281.	0.4	16
1226	Objectifs du contrôle de la glycémie. <i>Canadian Journal of Diabetes</i> , 2013, 37, S394-S397.	0.4	2
1229	Intensive versus conventional glycemic control: What is best for patients with type 2 diabetes?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2013, 7, 48-51.	1.8	2
1230	Glycemic Control and Risk of Cardiovascular Disease Hospitalization and All-Cause Mortality. <i>Journal of the American College of Cardiology</i> , 2013, 62, 121-127.	1.2	62

#	ARTICLE	IF	CITATIONS
1231	What was new about vascular risk in the year 2012?. Revista Clínica Española, 2013, 213, 442-452.	0.3	0
1232	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary. Endocrine Practice, 2013, 19, 536-557.	1.1	230
1233	Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial. Journal of Diabetes and Its Complications, 2013, 27, 627-632.	1.2	5
1234	Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet, The, 2013, 382, 409-416.	6.3	135
1235	Euglycemic progression: Worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities. Diabetes Research and Clinical Practice, 2013, 100, 362-367.	1.1	42
1236	La prévention primaire par les statines du risque cardiovasculaire des diabétiques : un mauvais procès en place publique. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 9-15.	0.0	0
1237	Why We Should Screen for Type 2 Diabetes in High-Risk Patients. American Journal of Preventive Medicine, 2013, 44, S371-S374.	1.6	2
1238	Diabetes and kidney disease. Apollo Medicine, 2013, 10, 118-125.	0.0	2
1239	Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surgery for Obesity and Related Diseases, 2013, 9, 7-14.	1.0	90
1240	HbA1c levels and all-cause mortality in type 2 diabetic patients: Epidemiological evidence of the need for personalised therapeutic targets. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 300-306.	1.1	18
1241	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). Revista Española De Cardiología, 2013, 66, 880.e1-880.e64.	0.6	24
1242	Sitagliptin "Another Option for Managing Type 2 Diabetes in Dialysis Patients?". American Journal of Kidney Diseases, 2013, 61, 532-535.	2.1	7
1243	Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis, 2013, 228, 502-507.	0.4	26
1244	Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes and Endocrinology, the, 2013, 1, 9-10.	5.5	31
1245	Revisiting hypoglycemia in diabetes. Osteopathic Family Physician, 2013, , .	0.2	0
1246	Five treatments nurses can better direct. Geriatric Nursing, 2013, 34, 328-331.	0.9	0
1247	Evidence-Informed Guidelines for Treating Frail Older Adults With Type 2 Diabetes: From the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) Program. Journal of the American Medical Directors Association, 2013, 14, 801-808.	1.2	75
1248	PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of diabetic patients) Tj ETQq1 1 0.784314 rgBT /Overlook 1365-1372.	1.2	253

#	ARTICLE	IF	CITATIONS
1249	Defective Counterregulation and Hypoglycemia Unawareness in Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 15-38.	1.2	41
1250	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 71-78.	5.5	39
1251	Quality scores do not predict discrepant statistical significances among meta-analyses on different targets of glycemic control in type 2 diabetes. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 1356-1366.	2.4	4
1252	Impact of Hypoglycemia in Hospitalized Patients. <i>Current Diabetes Reports</i> , 2013, 13, 107-113.	1.7	35
1253	Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. <i>Diabetic Medicine</i> , 2013, 30, 46-55.	1.2	166
1254	Macrovascular complication phenotypes in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2013, 12, 20.	2.7	43
1255	Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. <i>Cardiovascular Diabetology</i> , 2013, 12, 8.	2.7	66
1256	Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?. <i>Current Diabetes Reports</i> , 2013, 13, 403-410.	1.7	39
1257	Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 894-900.	4.3	213
1258	DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?. <i>Diabetes</i> , 2013, 62, 1029-1031.	0.3	31
1259	Reamputation after Minor Foot Amputation in Diabetic Patients: Risk Factors Leading to Limb Loss. <i>Journal of Foot and Ankle Surgery</i> , 2013, 52, 184-187.	0.5	29
1260	Reduced capacity of heart rate regulation in response to mild hypoglycemia induced by glibenclamide and physical exercise in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 717-724.	1.5	22
1261	Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 763-775.	1.5	47
1262	The Role of Diet in the Prevention and Treatment of Diabetes. , 2013, , 615-628.		0
1263	Chapter 3: Management of progression and complications of CKD. <i>Kidney International Supplements</i> , 2013, 3, 73-90.	4.6	121
1265	Standards of Medical Care in Diabetes—2013. <i>Diabetes Care</i> , 2013, 36, S11-S66.	4.3	3,076
1266	The Metabolic Syndrome and Cancer. , 2013, , 55-61.		4
1269	Management of Acute Coronary Syndromes. <i>Canadian Journal of Diabetes</i> , 2013, 37, S119-S123.	0.4	7



#	ARTICLE	IF	CITATIONS
1270	Vascular Calcification in Diabetes: Mechanisms and Implications. <i>Current Diabetes Reports</i> , 2013, 13, 391-402.	1.7	39
1271	Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)â€”TIMI 53 trial. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 417-426.	1.7	46
1272	Classification of Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2013, 771, 12-19.	0.8	41
1273	Herbal Medicines for the Management of Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2013, 771, 396-413.	0.8	39
1274	When diet and exercise are not enough, think immunomodulation. <i>Molecular Aspects of Medicine</i> , 2013, 34, 30-38.	2.7	11
1275	Diabetes Mellitus Type 2 and Proteinuria. , 0, , .		1
1276	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
1277	Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1845-1859.	1.8	223
1278	Revisiting the links between glycaemia, diabetes and cardiovascular disease. <i>Diabetologia</i> , 2013, 56, 686-695.	2.9	140
1280	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. , 2013, , CD008143.		130
1281	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
1282	Observational Study of Once-Daily Insulin Detemir in People with Type 2 Diabetes Aged 75ÂYears or Older. <i>Drugs and Aging</i> , 2013, 30, 167-175.	1.3	14
1283	Intensive insulin therapy. , 2013, , 28-38.		0
1284	Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. <i>BMJ, The</i> , 2013, 347, f4533-f4533.	3.0	402
1286	Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Endocrine Practice</i> , 2013, 19, 1025-1034.	1.1	26
1287	The metabolic syndrome and neuropathy: Therapeutic challenges and opportunities. <i>Annals of Neurology</i> , 2013, 74, 397-403.	2.8	88
1288	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. <i>European Heart Journal</i> , 2013, 34, 2436-2443.	1.0	870
1289	Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 776-785.	2.4	72

#	ARTICLE	IF	CITATIONS
1290	Evaluation of Type 2 Diabetes Mellitus Medication Management and Control in Older Adults. The Consultant Pharmacist, 2013, 28, 296-306.	0.4	4
1291	Association Between Hypoglycemia and Dementia in a Biracial Cohort of Older Adults With Diabetes Mellitus. JAMA Internal Medicine, 2013, 173, 1300.	2.6	337
1292	Intensive glycemic control in type 2 diabetics at high cardiovascular risk: do the benefits justify the risks?. Kidney International, 2013, 83, 346-348.	2.6	1
1293	Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. European Heart Journal, 2013, 34, 3102-3105.	1.0	3
1294	Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus. Postgraduate Medicine, 2013, 125, 17-33.	0.9	11
1295	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 2013, 83, 517-523.	2.6	256
1296	Insulin analogs for the management of type 2 diabetes. American Journal of Health-System Pharmacy, 2013, 70, 320-334.	0.5	5
1298	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. European Heart Journal, 2013, 34, 3137-3144.	1.0	211
1299	Participatory Surveillance of Hypoglycemia and Harms in an Online Social Network. JAMA Internal Medicine, 2013, 173, 345.	2.6	33
1300	Medical Treatment of Peripheral Artery Disease. , 2013, , 242-258.		6
1301	SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory. Diabetes, 2013, 62, 1800-1807.	0.3	96
1302	Weighty Matters. Circulation, 2013, 127, 157-159.	1.6	5
1303	Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials. Postgraduate Medicine, 2013, 125, 145-154.	0.9	9
1304	Acute and chronic complications of diabetes. , 2013, , 16-27.		0
1305	Challenges in the Management of Type 2 Diabetes Mellitus and Cardiovascular Risk Factors in Obese Subjects: What Is the Evidence and What Are the Myths?. International Journal of Endocrinology, 2013, 2013, 1-10.	0.6	11
1306	Glycemic Control in Type 2 Diabetes: The Tighter the Better?. Clinical Diabetes, 2013, 31, 25-27.	1.2	1
1307	Hypoglycemia: The neglected complication. Indian Journal of Endocrinology and Metabolism, 2013, 17, 819.	0.2	180
1308	Association of Glycation Gap With Mortality and Vascular Complications in Diabetes. Diabetes Care, 2013, 36, 3247-3253.	4.3	41

#	ARTICLE	IF	CITATIONS
1309	Systemic medical management of diabetic retinopathy. Middle East African Journal of Ophthalmology, 2013, 20, 301.	0.5	17
1310	Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes. Diabetes Care, 2013, 36, 3746-3753.	4.3	23
1311	Poor Glycaemic Control and Arrhythmias. Endocrine Research, 2013, 38, 206-214.	0.6	2
1312	Nutritional and Metabolic Management of the Diabetic Patient with Chronic Kidney Disease and Chronic Renal Failure. , 2013, , 485-502.		1
1313	Diabetes Cognitive Impairments and the Effect of Traditional Chinese Herbs. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	13
1314	Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes. Diabetes Care, 2013, 36, 3297-3304.	4.3	23
1315	Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian Journal of Endocrinology and Metabolism, 2013, 17, 588.	0.2	28
1316	Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?. Diabetes Care, 2013, 36, S259-S263.	4.3	96
1317	Basic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the veterans affairs diabetes trial. Frontiers in Endocrinology, 2013, 4, 183.	1.5	9
1318	Lessons from the Look Action for Health in Diabetes Study. Indian Journal of Endocrinology and Metabolism, 2013, 17, 650.	0.2	4
1319	Cardiovascular Importance of Hyperglycemia and Hypoglycemia. Diabetes Care, 2013, 36, S267-S271.	4.3	5
1320	The Role of the Kidney in Hyperglycemia. Journal of Cardiovascular Nursing, 2013, 28, 157-165.	0.6	9
1321	Myths in the Treatment of Type 2 Diabetes. American Journal of Therapeutics, 2013, 20, 543-548.	0.5	3
1322	Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations. Diabetes Care, 2013, 36, 3361-3367.	4.3	13
1323	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.3	4,251
1324	Should Glucose-Sparing Prescriptions Be Expected to Reduce the Cardiovascular Risk of Peritoneal Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2013, 24, 1713-1716.	3.0	4
1325	Hemoglobin A <sub>1c</sub> Is Associated With Increased Risk of Incident Coronary Heart Disease Among Apparently Healthy, Nondiabetic Men and Women. Journal of the American Heart Association, 2013, 2, e000077.	1.6	60
1326	Trends in Vascular Risk Factor Treatment and Control in US Stroke Survivors. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 270-277.	0.9	25

#	ARTICLE	IF	CITATIONS
1327	Characteristics Associated With Maintenance of Mean A1C <math>\leq 6.5\%</math> in People With Dysglycemia in the ORIGIN Trial. <i>Diabetes Care</i> , 2013, 36, 2915-2922.	4.3	26
1328	All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. <i>British Journal of Diabetes and Vascular Disease</i> , 2013, 13, 22-30.	0.6	1
1329	Teaching an Old Drug New Tricks: Can Paroxetine Ease the Burden of Cardiovascular Disease in Diabetes?. <i>Diabetes</i> , 2013, 62, 698-700.	0.3	7
1330	Self-Monitoring of Blood Glucose in Type 2 Diabetes: Recent Studies. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 478-488.	1.3	67
1331	Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. <i>Diabetes Care</i> , 2013, 36, 1384-1395.	4.3	1,125
1332	Mitiglinide/voglibose fixed-dose combination improves postprandial glycaemic excursions in Japanese patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 361-370.	0.9	14
1333	Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late. <i>Diabetes Care</i> , 2013, 36, 2582-2590.	4.3	90
1334	Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2013, 9, 681.	1.0	14
1335	Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 397-409.	0.9	39
1336	Ischemic Volumes and Early Neurologic Deterioration in Acute Brainstem Infarctions with Hemoglobin A<sub>1c</sub>. <i>European Neurology</i> , 2013, 70, 225-232.	0.6	12
1337	Effects of Dapagliflozin on Cardiovascular Risk Factors. <i>Postgraduate Medicine</i> , 2013, 125, 181-189.	0.9	100
1338	Public Health Implications of Recommendations to Individualize Glycemic Targets in Adults With Diabetes. <i>Diabetes Care</i> , 2013, 36, 84-89.	4.3	22
1339	Aortic stiffness and cardiovascular risk in type 2 diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1584-1592.	0.3	51
1340	Achievement of Goals in U.S. Diabetes Care, 1999-2010. <i>New England Journal of Medicine</i> , 2013, 368, 1613-1624.	13.9	851
1341	External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. <i>Diabetic Medicine</i> , 2013, 30, 300-308.	1.2	97
1342	Associations of HbA<sub>1c</sub> and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care. <i>Diabetic Medicine</i> , 2013, 30, e170-7.	1.2	30
1343	Cardiovascular protection in type 2 diabetes: time to ADVANCE management ACCORDing to the evidence. <i>Research Reports in Clinical Cardiology</i> , 2013, , 1.	0.2	0
1344	Impact of Diabetes on Cardiovascular Disease: An Update. <i>International Journal of Hypertension</i> , 2013, 1-15.	0.5	321

#	ARTICLE	IF	CITATIONS
1345	Technical Challenges and Clinical Outcomes of Using a Closed-Loop Glycemic Control System in the Hospital. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 238-246.	1.3	8
1346	Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels. <i>FASEB Journal</i> , 2013, 27, 3437-3445.	0.2	20
1348	Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 505-513.	0.9	77
1349	Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. <i>Journal of Medical Economics</i> , 2013, 16, 1453-1461.	1.0	55
1350	Impact of a quality improvement intervention on provider adherence to recommended standards of care for adults with type 2 diabetes mellitus. <i>Journal of the American Association of Nurse Practitioners</i> , 2013, 25, n/a-n/a.	0.5	7
1351	HbA <sub>1c</sub> targets in type 2 diabetes: guidelines and evidence. <i>Drug and Therapeutics Bulletin</i> , 2013, 51, 42-45.	0.3	5
1352	Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 2027-2037.	1.3	56
1353	A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 181-189.	0.7	3
1354	Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 455-462.	2.2	29
1355	Do Clinical Standards for Diabetes Care Address Excess Risk for Hypoglycemia in Vulnerable Patients? A Systematic Review. <i>Health Services Research</i> , 2013, 48, 1299-1310.	1.0	21
1356	Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 622-628.	2.2	20
1357	Cardiovascular safety and DPP-4 inhibitors. <i>Practical Diabetes</i> , 2013, 30, 78-81.	0.1	4
1358	Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1095-1105.	0.8	25
1359	Hypoglycemia Observed During Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Treated by Subcutaneous Insulin Injection. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 586-590.	2.4	3
1360	The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2013, 36, 2408-2414.	4.3	20
1361	Registry of people with diabetes in three Latin American countries: a suitable approach to evaluate the quality of health care provided to people with type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2013, 67, 1261-1266.	0.8	16
1362	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 209-217.	0.8	26
1363	Clinical, metabolic and psychological outcomes and treatment costs of a prospective randomized trial based on different educational strategies to improve diabetes care (PRODIACOR). <i>Diabetic Medicine</i> , 2013, 30, 1102-1111.	1.2	40

#	ARTICLE	IF	CITATIONS
1364	American Geriatrics Society Identifies Five Things That Healthcare Providers and Patients Should Question. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 622-631.	1.3	125
1366	Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3269-3275.	4.3	25
1367	Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults. <i>Circulation</i> , 2013, 128, 2422-2446.	1.6	166
1368	Expanded Granulocyte/Monocyte Compartment in Myeloid-Specific Triple FoxO Knockout Increases Oxidative Stress and Accelerates Atherosclerosis in Mice. <i>Circulation Research</i> , 2013, 112, 992-1003.	2.0	60
1369	Higher Accuracy of Self-Monitoring of Blood Glucose in Insulin-Treated Patients in Germany: Clinical and Economical Aspects. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 904-912.	1.3	11
1370	Diabetes in Argentina: cost and management of diabetes and its complications and challenges for health policy. <i>Globalization and Health</i> , 2013, 9, 54.	2.4	22
1372	Optimal diabetes care--can we afford it?: Evidence-based diabetes care could be highly cost effective. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 983-987.	0.2	2
1373	Are we overtreating cardiovascular disease in diabetic patients?. <i>Diabetes Management</i> , 2013, 3, 271-275.	0.5	0
1374	Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2013, 4, 14.	1.3	8
1376	Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. <i>Endocrine Journal</i> , 2013, 60, 1207-1214.	0.7	28
1377	Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011. <i>International Heart Journal</i> , 2013, 54, 93-97.	0.5	77
1378	A1c Variability Can Predict Coronary Artery Disease in Patients with Type 2 Diabetes with Mean A1c Levels Greater than 7. <i>Endocrinology and Metabolism</i> , 2013, 28, 125.	1.3	16
1379	Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 247.	1.1	9
1380	Recent HbA1c Values and Mortality Risk in Type 2 Diabetes. Population-Based Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e68008.	1.1	46
1381	Prevention of Chronic Kidney Disease and Subsequent Effect on Mortality: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e71784.	1.1	19
1382	Glycated Hemoglobin Independently Predicts Stroke Recurrence within One Year after Acute First-Ever Non-Cardioembolic Strokes Onset in A Chinese Cohort Study. <i>PLoS ONE</i> , 2013, 8, e80690.	1.1	30
1383	Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 192-197.	0.2	0
1384	Diabetes control in older people. <i>BMJ, The</i> , 2013, 346, f2625-f2625.	3.0	16

#	ARTICLE	IF	CITATIONS
1385	Diabetes in Women. , 2013, , 873-882.		0
1386	Dysregulation of the Mammalian Target of Rapamycin and p27Kip1 Promotes Intimal Hyperplasia in Diabetes Mellitus. <i>Pharmaceuticals</i> , 2013, 6, 716-727.	1.7	18
1387	The Science of Hypoglycemia in Patients with Diabetes. <i>Current Diabetes Reviews</i> , 2013, 9, 195-208.	0.6	56
1388	Predicting Mortality of Critically Ill Patients by Blood Glucose Levels. <i>Diabetes and Metabolism Journal</i> , 2013, 37, 385.	1.8	14
1389	Use of Available Glucose-Lowering Agents in Patients with Different Levels of Renal Impairment. <i>Endocrine Practice</i> , 2013, 19, 14-18.	1.1	0
1390	Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease. <i>Hormones</i> , 2013, 12, 483-494.	0.9	15
1391	Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis. , 0, , .		3
1392	Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 159.	1.1	16
1393	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 107.	1.1	24
1394	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 169.	1.1	135
1395	Mechanism of Protection by Soluble Epoxide Hydrolase Inhibition in Type 2 Diabetic Stroke. <i>PLoS ONE</i> , 2014, 9, e97529.	1.1	26
1396	Relationship of Glycated Hemoglobin Levels with Myocardial Injury following Elective Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e101719.	1.1	6
1397	All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels. <i>PLoS ONE</i> , 2014, 9, e109501.	1.1	18
1398	Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 129.	0.4	15
1401	Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 85.	1.1	14
1402	Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. <i>Clinical Interventions in Aging</i> , 2014, 9, 1963.	1.3	54
1403	Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2014, 3, 923-943.	1.0	46
1404	The Burden of Diabetes in Argentina. <i>Global Journal of Health Science</i> , 2014, 7, 124-33.	0.1	7

#	ARTICLE	IF	CITATIONS
1405	Treating the elderly diabetic patient: special considerations. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 391.	1.1	10
1406	Risk factors in diabetic nephropathy progression at present. <i>Bratislava Medical Journal</i> , 2014, 115, 517-521.	0.4	16
1407	Efficacy of treatment for hyperglycemic crisis in elderly diabetic patients in a day hospital. <i>Clinical Interventions in Aging</i> , 2014, 9, 843.	1.3	3
1408	The Treatment of Type 2 Diabetes. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2014, 111, 69-81; quiz 82.	0.6	77
1410	Identifying Risk Factors for Severe Hypoglycemia in Hospitalized Patients with Diabetes. <i>Endocrine Practice</i> , 2014, 20, 1051-1056.	1.1	29
1411	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. <i>Journal of Diabetes &amp; Metabolism</i> , 2014, 05, .	0.2	2
1412	Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2014, 8, 593.	0.8	62
1413	Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance. <i>Endocrinology and Metabolism</i> , 2014, 29, 536.	1.3	19
1414	Blood Pressure Control in Diabetic Nephropathy. <i>Journal of Nephrology &amp; Therapeutics</i> , 2014, 04, .	0.1	0
1415	Glucose Control in the ICU. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 652-657.	1.3	6
1416	The application of multiple reaction monitoring to assess ApoA-I methionine oxidations in diabetes and cardiovascular disease. <i>Translational Proteomics</i> , 2014, 4-5, 18-24.	1.2	26
1417	Adverse effects and safety of SGLT-2 inhibitors. <i>Diabetes and Metabolism</i> , 2014, 40, S28-S34.	1.4	102
1419	A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2014, 5, 521-534.	1.2	10
1420	Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study. <i>Diabetes Care</i> , 2014, 37, 2622-2631.	4.3	97
1421	Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data. <i>Diabetes Therapy</i> , 2014, 5, 483-498.	1.2	3
1422	The Association Between Different A1C-Based Measures of Glycemia and Risk of Cardiovascular Disease Hospitalization. <i>Diabetes Care</i> , 2014, 37, 167-172.	4.3	14
1423	Endovascular Versus Medical Therapy for Atherosclerotic Renovascular Disease. <i>Current Atherosclerosis Reports</i> , 2014, 16, 459.	2.0	7
1424	Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4 Inhibitors Beneficial?. <i>Hospital Pharmacy</i> , 2014, 49, 697-701.	0.4	0



#	ARTICLE	IF	CITATIONS
1425	Relationship between HgbA1c and Myocardial Blood Flow Reserve in Patients with Type 2 Diabetes Mellitus: Noninvasive Assessment Using Real-Time Myocardial Perfusion Echocardiography. <i>Journal of Diabetes Research</i> , 2014, 2014, 1-8.	1.0	13
1426	A New Paradigm to Understand and Treat Diabetic Neuropathy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 201-207.	0.6	31
1427	Plasma Antimicrobial Peptide LL-37 Level Is Inversely Associated with HDL Cholesterol Level in Patients with Type 2 Diabetes Mellitus. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-6.	0.6	10
1428	NAD(P)H oxidase isoforms as therapeutic targets for diabetic complications. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 111-122.	1.2	3
1429	Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?. <i>International Journal of Molecular Sciences</i> , 2014, 15, 18381-18406.	1.8	136
1430	Influence of Dialysis on the Glucose Profile in Patients with Diabetes: Usefulness of Continuous Glucose Monitoring. <i>Hormone and Metabolic Research</i> , 2014, 46, 810-813.	0.7	23
1431	Intensive Versus Intermediate Glucose Control in Surgical Intensive Care Unit Patients. <i>Diabetes Care</i> , 2014, 37, 1516-1524.	4.3	99
1432	Does the pay-for-performance programme reduce the emergency department visits for hypoglycaemia in type 2 diabetic patients?. <i>Health Policy and Planning</i> , 2014, 29, 732-741.	1.0	17
1433	Non-pharmaceutical factors for poor glycemic control in 13,970&nbsp;Chinese women with drug-treated type 2&nbsp;diabetes: a cross-sectional survey in 77&nbsp;tertiary hospitals in four Chinese cities. <i>Patient Preference and Adherence</i> , 2014, 8, 1161.	0.8	6
1434	The Role of Prestroke Glycemic Control on Severity and Outcome of Acute Ischemic Stroke. <i>Stroke Research and Treatment</i> , 2014, 2014, 1-6.	0.5	35
1435	Reactive metabolites as a cause of late diabetic complications. <i>Biochemical Society Transactions</i> , 2014, 42, 439-442.	1.6	23
1436	Autonomic Neuropathy in Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2014, 5, 205.	1.5	112
1437	Effects of Stress Reduction on Cardiovascular Risk Factors in Type 2 Diabetes Patients with Early Kidney Disease – Results of a Randomized Controlled Trial (HEIDIS). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 341-349.	0.6	43
1438	Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study. <i>BMJ Open</i> , 2014, 4, e006136-e006136.	0.8	1
1439	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	1.6	24
1440	The prognosis of patients with coronary artery disease complicated by postload hyperinsulinemia. <i>IJC Metabolic &amp; Endocrine</i> , 2014, 5, 7-10.	0.5	1
1441	Glycemic Targets and Medication Limitations for Type 2 Diabetes Mellitus in the Older Adult. <i>The Consultant Pharmacist</i> , 2014, 29, 110-123.	0.4	9
1444	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. <i>Annals of Medicine</i> , 2014, 46, 475-489.	1.5	15

#	ARTICLE	IF	CITATIONS
1445	Association of fasting insulin and C peptide with diabetic retinopathy in Latinos with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000027.	1.2	21
1446	Autoantibodies against Î²1 Receptor and AT1 Receptor in Type 2 Diabetes Patients with Left Ventricular Dilatation. <i>Cardiology</i> , 2014, 129, 191-196.	0.6	10
1447	Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function. <i>Postgraduate Medicine</i> , 2014, 126, 161-171.	0.9	2
1448	Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors. <i>Postgraduate Medicine</i> , 2014, 126, 172-189.	0.9	5
1449	Implications of different laboratory-based incident diabetic kidney disease definitions on comparative effectiveness studies. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 359-369.	0.6	4
1450	Physiological Changes in Older Adults and Their Effect on Diabetes Treatment. <i>Diabetes Spectrum</i> , 2014, 27, 20-29.	0.4	11
1451	Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. <i>Neurosurgical Focus</i> , 2014, 36, E10.	1.0	2
1452	Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor?. <i>Heart</i> , 2014, 100, 21-27.	1.2	26
1453	Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2014, 5, 95-123.	1.4	13
1454	Intensification of medication and glycaemic control among patients with type 2 diabetes—the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 426-432.	2.2	14
1455	Management of Type 1 Diabetes in Older Adults. <i>Diabetes Spectrum</i> , 2014, 27, 9-20.	0.4	64
1456	Individualizing Insulin Therapy in the Management of Type 2 Diabetes. <i>American Journal of Medicine</i> , 2014, 127, S3-S10.	0.6	18
1457	Aiming for better glucose control: is HbA <sub>1c</sub> of 7% the “holy grail”? The clinical approach or seven clinical questions about 7. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 346-349.	1.7	1
1458	Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 881-884.	2.2	6
1459	Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus. <i>Circulation</i> , 2014, 130, 1532-1558.	1.6	150
1460	Influence of glucose-lowering rate on CKMB and myoglobin serum levels in type-2 diabetes patients with coronary heart disease. <i>Human Immunology</i> , 2014, 75, 1182-1187.	1.2	7
1461	Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes. <i>Lancet, The</i> , 2014, 384, 1906-1907.	6.3	9
1462	American Geriatrics Society Identifies Another Five Things That Healthcare Providers and Patients Should Question. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 950-960.	1.3	78

#	ARTICLE	IF	CITATIONS
1463	Hypoglycemia From a Cardiologist's Perspective. <i>Clinical Cardiology</i> , 2014, 37, 499-504.	0.7	40
1464	Incidence of non-severe hypoglycaemia and intensity of treatment among veterans with Type 2 diabetes in the USA: a prospective observational study. <i>Diabetic Medicine</i> , 2014, 31, 1524-1531.	1.2	6
1465	Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: A narrative review (ÉÇ,,æ·èf°â²,ç±»ä¼¼ç%©âœ²âžž<ç³-â°¿ç-...æ²»ç—ä,çš,,ä¼²œç"i¼šâ™è¿æ€šç»¼4è¿). <i>Journal of Diabetes</i> , 2014, 17, 17-24.	0.8	17
1466	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2014, 37, 2015-2023.	4.3	56
1467	Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. <i>Journal of Medical Economics</i> , 2014, 17, 21-31.	1.0	23
1468	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting <scp>GLP</scp> analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 206-214.	2.2	8
1469	Do primary health care nurses address cardiovascular risk in diabetes patients?. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 212-220.	1.1	8
1470	Validation of the IMS CORE Diabetes Model. <i>Value in Health</i> , 2014, 17, 714-724.	0.1	163
1471	Association Between Severe Hypoglycemia, Adverse Macrovascular Events, and Inflammation in the Edinburgh Type 2 Diabetes Study. <i>Diabetes Care</i> , 2014, 37, 3301-3308.	4.3	68
1472	Quality improvement of metabolic control for patients with type 2 diabetes treated at a general hospital: a quantitative open cohort study. <i>Journal of Evaluation in Clinical Practice</i> , 2014, 20, 429-435.	0.9	2
1473	Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. <i>Clinical Endocrinology</i> , 2014, 80, 47-56.	1.2	168
1474	Targeted learning in real-world comparative effectiveness research with time-varying interventions. <i>Statistics in Medicine</i> , 2014, 33, 2480-2520.	0.8	40
1475	Is glycemic control a quinidine-like intervention? æžšâ°è¿ç³-äžž¼¿ç"âžž¼ä,æ²»ç—ä,çæ·â-i¼ÿ. <i>Journal of Diabetes</i> , 2014, 17, 17-24.	0.8	17
1476	The next revolution in stroke care. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 1307-1314.	1.4	30
1477	AGE-Breaker ALT-711 Plus Insulin Could Restore Erectile Function in Streptozocin-Induced Type 1 Diabetic Rats. <i>Journal of Sexual Medicine</i> , 2014, 11, 1452-1462.	0.3	24
1478	A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. <i>Diabetes and Metabolism Journal</i> , 2014, 38, 261.	1.8	66
1479	Insulin Therapy for Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2315.	3.8	121
1480	Roux-en-Y Gastric Bypass Surgery or Lifestyle With Intensive Medical Management in Patients With Type 2 Diabetes. <i>JAMA Surgery</i> , 2014, 149, 716.	2.2	218

#	ARTICLE	IF	CITATIONS
1481	Insights From Monogenic Diabetes and Glycemic Treatment Goals for Common Types of Diabetes. JAMA - Journal of the American Medical Association, 2014, 311, 249.	3.8	0
1482	RANKL and OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. Diabetologia, 2014, 57, 2251-2260.	2.9	50
1483	Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. Expert Opinion on Pharmacotherapy, 2014, 15, 1325-1335.	0.9	8
1484	Pistachio Nut Consumption Modifies Systemic Hemodynamics, Increases Heart Rate Variability, and Reduces Ambulatory Blood Pressure in Well-Controlled Type 2 Diabetes: a Randomized Trial. Journal of the American Heart Association, 2014, 3, .	1.6	42
1485	Impact of a Reduced Error Range of SMBG in Insulin-treated Patients in Germany. Journal of Diabetes Science and Technology, 2014, 8, 479-482.	1.3	8
1486	Bariatric Surgery and Microvascular Complications of Type 2 Diabetes Mellitus. Current Atherosclerosis Reports, 2014, 16, 453.	2.0	27
1487	Association of PAI-1 and Fibrinogen With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care, 2014, 37, 501-506.	4.3	29
1488	Insulin for glycaemic control in acute ischaemic stroke. The Cochrane Library, 2014, 2014, CD005346.	1.5	92
1489	Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage. BMC Cardiovascular Disorders, 2014, 14, 153.	0.7	24
1490	Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry. BMC Endocrine Disorders, 2014, 14, 48.	0.9	28
1491	Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Services Research, 2014, 14, 419.	0.9	19
1492	Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study. BMC Medicine, 2014, 12, 165.	2.3	72
1493	Diabetic hyperglycemia attenuates sympathetic dysfunction and oxidative stress after myocardial infarction in rats. Cardiovascular Diabetology, 2014, 13, 131.	2.7	20
1494	Treatment of albuminuria due to diabetic nephropathy: recent trial results. Clinical Investigation, 2014, 4, 327-341.	0.0	1
1495	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. Expert Review of Endocrinology and Metabolism, 2014, 9, 641-658.	1.2	1
1496	Updated management of chronic kidney disease in patients with diabetes. JAAPA: Official Journal of the American Academy of Physician Assistants, 2014, 27, 17-22.	0.1	5
1497	Type 2 Diabetes. , 2014, , .		1
1498	Pioglitazone Prevents the Endothelial Dysfunction Induced by Ischemia and Reperfusion in Healthy Subjects. Journal of Cardiovascular Pharmacology, 2014, 64, 326-331.	0.8	5

#	ARTICLE	IF	CITATIONS
1499	Diagnosis and Treatment of Diabetic Kidney Disease. American Journal of the Medical Sciences, 2014, 347, 406-413.	0.4	33
1500	A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes. Diabetes Therapy, 2014, 5, 385-402.	1.2	11
1501	Are closed-loop systems for intensive insulin therapy ready for prime time in the ICU?. Current Opinion in Clinical Nutrition and Metabolic Care, 2014, 17, 190-199.	1.3	10
1502	Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine, 2014, 126, 66-84.	0.9	10
1503	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	0.9	173
1504	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. Postgraduate Medicine, 2014, 126, 190-204.	0.9	11
1505	Personalized Diabetes Management: Moving from Algorithmic to Individualized Therapy. Diabetes Spectrum, 2014, 27, 87-91.	0.4	28
1506	Self-Monitoring of Blood Glucose. Journal of Diabetes Science and Technology, 2014, 8, 609-614.	1.3	28
1507	Chronic kidney disease in the elderly: evaluation and management. Clinical Practice (London, England), 2014, 11, 525-535.	0.1	161
1508	Treatment of Mild Hypoglycemia. Diabetes Spectrum, 2014, 27, 58-62.	0.4	15
1509	Haploinsufficiency of the Insulin-Like Growth Factor-1 Receptor Enhances Endothelial Repair and Favorably Modifies Angiogenic Progenitor Cell Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2051-2058.	1.1	16
1510	Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vascular Health and Risk Management, 2015, 11, 9.	1.0	9
1511	Rates of Complications and Mortality in Older Patients With Diabetes Mellitus. JAMA Internal Medicine, 2014, 174, 251.	2.6	397
1512	National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. JAMA Internal Medicine, 2014, 174, 1116.	2.6	324
1513	Clinical therapeutic strategies for early stage of diabetic kidney disease. World Journal of Diabetes, 2014, 5, 342.	1.3	42
1514	Diabetic nephropathy – complications and treatment. International Journal of Nephrology and Renovascular Disease, 2014, 7, 361.	0.8	413
1515	Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China. Journal of Endocrinological Investigation, 2014, 37, 843-852.	1.8	4
1516	Hyperglycemia and Blood Pressure Treatment Goal: A Cross Sectional Survey of 18350 Patients with Type 2 Diabetes in 77 Tertiary Hospitals in China. PLoS ONE, 2014, 9, e103507.	1.1	2

#	ARTICLE	IF	CITATIONS
1517	GTP Cyclohydrolase I Gene Polymorphisms Are Associated with Endothelial Dysfunction and Oxidative Stress in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e108587.	1.1	11
1518	Assessing Potential Glycemic Overtreatment in Persons at Hypoglycemic Risk. JAMA Internal Medicine, 2014, 174, 259.	2.6	133
1519	Diabetes Overtreatment in Elderly Individuals. JAMA - Journal of the American Medical Association, 2014, 311, 2326.	3.8	19
1520	Risk of Cardiovascular Disease among Diabetic Patients in Manipur, Northeast India. Journal of Anthropology, 2014, 2014, 1-9.	0.5	7
1521	Canagliflozin versus glimepiride treatment in patients with Type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial). Expert Review of Clinical Pharmacology, 2014, 7, 21-23.	1.3	8
1522	Treatment of glycaemia in type 2 diabetes. InnovAiT, 2014, 7, 174-181.	0.0	0
1523	Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review*. Diabetic Medicine, 2014, 31, 2-14.	1.2	36
1524	Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. Journal of Diabetes and Its Complications, 2014, 28, 353-359.	1.2	19
1525	Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: What is the level of evidence?. Diabetes and Metabolism, 2014, 40, 169-175.	1.4	23
1526	Calidad de vida y satisfacci3n con el tratamiento de sujetos con diabetes tipo 2: resultados en Espa±a del estudio PANORAMA. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2014, 61, 18-26.	0.8	56
1527	Carotid intima-media thickness is reduced 12months after gastric bypass surgery in obese patients with type 2 diabetes or impaired glucose tolerance. Journal of Diabetes and Its Complications, 2014, 28, 517-522.	1.2	23
1528	Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes and Metabolism, 2014, 40, 176-185.	1.4	61
1529	Is laparoscopic single-stage biliopancreatic diversion with duodenal switch safe in super morbidly obese patients?. Surgery for Obesity and Related Diseases, 2014, 10, 427-430.	1.0	15
1530	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 627-633.	5.5	73
1531	Type 2 diabetes mellitus in elderly institutionalized patients. Revista Cl&#x00e9;nica Espan&#x00f5;la, 2014, 214, 521-528.	0.3	1
1532	Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Research and Clinical Practice, 2014, 103, 402-411.	1.1	20
1533	Factors associated with glycemic variability in Japanese patients with diabetes. Diabetology International, 2014, 5, 36-42.	0.7	19
1534	Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?. Current Diabetes Reports, 2014, 14, 453.	1.7	437

#	ARTICLE	IF	CITATIONS
1535	Inpatient Hypoglycemia: A Challenge That Must Be Addressed. <i>Current Diabetes Reports</i> , 2014, 14, 445.	1.7	20
1536	Correspondence: Response to Letter to the Editor by K Scharf and J Morton. <i>Obesity Surgery</i> , 2014, 24, 146-147.	1.1	0
1537	Chronic effects of mild hyperglycaemia on left ventricle transcriptional profile and structural remodelling in the spontaneously type 2 diabetic Goto-Kakizaki rat. <i>Heart Failure Reviews</i> , 2014, 19, 65-74.	1.7	30
1538	Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?. <i>Diabetes Care</i> , 2014, 37, 1338-1345.	4.3	57
1539	New Developments in Diabetes Management: Medications of the 21st Century. <i>Clinical Therapeutics</i> , 2014, 36, 477-484.	1.1	27
1540	2013 Russell Ross Memorial Lecture in Vascular Biology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 705-714.	1.1	34
1541	Studies in Diabetes. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2014, , .	0.4	1
1542	Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. <i>Acta Diabetologica</i> , 2014, 51, 269-275.	1.2	5
1544	Quality of life and satisfaction with treatment in subjects with type 2 diabetes: Results in Spain of the PANORAMA study. <i>Endocrinología Y Nutrición (English Edition)</i> , 2014, 61, 18-26.	0.5	40
1545	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	2.0	4
1546	Diabetes in Long-Term Care Facilities. <i>Current Diabetes Reports</i> , 2014, 14, 464.	1.7	5
1547	Sulfonylureas: A New Look at Old Therapy. <i>Current Diabetes Reports</i> , 2014, 14, 473.	1.7	121
1548	Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. <i>Cardiovascular Diabetology</i> , 2014, 13, 33.	2.7	53
1549	The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. <i>Acta Diabetologica</i> , 2014, 51, 5-14.	1.2	45
1550	Trends in Insulin Initiation and Treatment Intensification Among Patients with Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2014, 29, 320-327.	1.3	22
1551	Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. <i>Diabetes Therapy</i> , 2014, 5, 97-111.	1.2	7
1553	Oxidative Stress and Cardiovascular Disease in Diabetes. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2014, , 189-235.	0.4	2
1554	Pain in Chronic Kidney Disease: A Scoping Review. <i>Seminars in Dialysis</i> , 2014, 27, 188-204.	0.7	122

#	ARTICLE	IF	CITATIONS
1555	Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. <i>Primary Care Diabetes</i> , 2014, 8, 57-63.	0.9	12
1556	Joint British Societies <sup>™</sup> consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	1.2	441
1557	The gut <sup>™</sup> renal axis: do incretin-based agents confer renoprotection in diabetes?. <i>Nature Reviews Nephrology</i> , 2014, 10, 88-103.	4.1	155
1558	Updates on the Management of Diabetes in Dialysis Patients. <i>Seminars in Dialysis</i> , 2014, 27, 135-145.	0.7	116
1559	Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk. <i>Diabetes</i> , 2014, 63, 1738-1747.	0.3	326
1560	Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: An analysis of 480 subjects. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 266-272.	1.1	54
1561	Periprocedural Glycemic Control in Patients With Diabetes Mellitus Undergoing Coronary Angiography With Possible Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1474-1480.	0.7	7
1562	Gu <sup>™</sup> de pr <sup>™</sup> ctica cl <sup>™</sup> nica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraci <sup>™</sup> 3n con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	0.6	15
1563	Impact of diabetes mellitus on characteristics of carotid plaques and outcomes after carotid endarterectomy. <i>Acta Neurochirurgica</i> , 2014, 156, 927-933.	0.9	6
1564	Pregnancy and Diabetic Nephropathy. , 2014, , 163-173.		2
1565	Glycemic Control. , 2014, , 205-214.		0
1566	Computerized Clinical Decision Support for Patients with Diabetes and Chronic Kidney Disease. , 2014, , 215-228.		1
1567	HbA1c and Heart Failure Risk Among Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E263-E267.	1.8	29
1568	Glycemic Control and All-Cause Mortality Risk in Type 1 Diabetes Patients: The EURODIAB Prospective Complications Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 800-807.	1.8	36
1570	Predictors of Response to Early Basal Insulin Treatment in Patients with Type 2 Diabetes <sup>™</sup> The EARLY Experience. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 241-246.	2.4	19
1571	Cardiovascular Complications of Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 273-280.	0.6	181
1572	Neurologic Complications of Diabetes. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 457.	2.0	17
1573	Insulin resistance and hyperglycaemia in cardiovascular disease development. <i>Nature Reviews Endocrinology</i> , 2014, 10, 293-302.	4.3	501



#	ARTICLE	IF	CITATIONS
1574	Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. <i>Nature Reviews Endocrinology</i> , 2014, 10, 276-281.	4.3	13
1576	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <i>Lancet, The</i> , 2014, 383, 1068-1083.	6.3	1,230
1577	Diabetic neuropathy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 120, 773-785.	1.0	36
1578	Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 116-123.	1.1	41
1579	Effect of an Optimized Treatment With Insulin on Platelet Reactivity After Discharge in Patients With an Acute Coronary Syndrome and Hyperglycemia. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 22-27.	0.4	1
1580	Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, 142, 375-415.		437
1581	Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 191-195.	1.2	47
1582	Diabetic Cardiomyopathy. , 2014, , .		4
1583	Exclusion of "nonRCT evidence"™ in guidelines for chronic diseases "is it always appropriate? The Look AHEAD study. <i>Current Medical Research and Opinion</i> , 2014, 30, 2009-2019.	0.9	12
1584	Guidelines for the Primary Prevention of Stroke. <i>Stroke</i> , 2014, 45, 3754-3832.	1.0	1,621
1586	Diabetes Medications and Heart Failure. <i>Circulation</i> , 2014, 130, 1565-1567.	1.6	22
1587	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 1223-1251.	2.5	23
1588	Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects. <i>Drug Safety</i> , 2014, 37, 1003-1010.	1.4	10
1589	Glucose data and the individualised diabetes consultation. How should we use it? What is enough? Can we ever have too much?. <i>Practical Diabetes</i> , 2014, 31, 143.	0.1	1
1590	Diabetes in the elderly living in care homes. <i>Revista Clinica Espanola</i> , 2014, 214, 517-518.	0.2	0
1591	Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up. <i>Diabetic Medicine</i> , 2014, 31, 1055-1063.	1.2	11
1592	Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: The Basque Country Prospective Complications and Mortality Study risk engine (BASCORE). <i>Diabetologia</i> , 2014, 57, 2324-2333.	2.9	35
1593	Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2014, 16, 541.	1.3	14

#	ARTICLE	IF	CITATIONS
1594	Cardiovascular Effects of Incretin Therapy in Diabetes Care. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 303-310.	0.5	9
1595	One size does not fit all glycemic targets for type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2014, 5, 134-141.	1.1	27
1596	Glycated Albumin Predicts the Risk of Mortality in Type 2 Diabetic Patients on Hemodialysis: Evaluation of a Target Level for Improving Survival. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 434-442.	0.4	33
1597	Use of insulin in type 2 diabetes: What we learned from recent clinical trials on the benefits of early insulin initiation. <i>Diabetes and Metabolism</i> , 2014, 40, 391-399.	1.4	28
1598	Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2014, 37, 2782-2788.	4.3	23
1599	Clinical Update on Nursing Home Medicine: 2014. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 786-801.	1.2	10
1600	Sitagliptin and the risk of hospitalization for heart failure: A population-based study. <i>International Journal of Cardiology</i> , 2014, 177, 86-90.	0.8	54
1602	Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. <i>Nature Reviews Endocrinology</i> , 2014, 10, 711-722.	4.3	358
1603	Stroke and diabetes mellitus. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 126, 167-174.	1.0	77
1604	Epidemiology of polyneuropathy in diabetes and prediabetes. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 126, 3-22.	1.0	166
1605	Glucokinase MODY and Implications for Treatment Goals of Common Forms of Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 559.	1.7	22
1608	Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 801-809.	5.5	247
1609	Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 225-233.	1.3	2
1610	Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 145-151.	1.8	17
1611	Long-acting Insulin Analogues and Diabetic Retinopathy: A Retrospective Cohort Study. <i>Clinical Therapeutics</i> , 2014, 36, 1255-1268.	1.1	3
1612	Secondary Prevention of Stroke in the Elderly: Focus on Drug Therapy. <i>Drugs and Aging</i> , 2014, 31, 721-730.	1.3	16
1613	The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. <i>Ophthalmology</i> , 2014, 121, 2443-2451.	2.5	239
1614	Novel metabolic biomarkers of cardiovascular disease. <i>Nature Reviews Endocrinology</i> , 2014, 10, 659-672.	4.3	85

#	ARTICLE	IF	CITATIONS
1615	The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications. <i>Diabetes Care</i> , 2014, 37, 2884-2894.	4.3	138
1616	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. <i>Circulation</i> , 2014, 130, 1579-1588.	1.6	594
1617	What are the pharmacotherapy options for treating prediabetes?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2003-2018.	0.9	21
1619	GLYCEMIC CONTROL AND CARDIOVASCULAR RISK FACTOR MANAGEMENT IN PATIENTS WITH DIABETES WITH AND WITHOUT CORONARY ARTERY DISEASE: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY. <i>Canadian Journal of Cardiology</i> , 2014, 30, S79-S80.	0.8	0
1620	Individualizing HbA <sub>1c</sub> targets for patients with diabetes: impact of an automated algorithm within a primary care network. <i>Diabetic Medicine</i> , 2014, 31, 839-846.	1.2	12
1621	The cardiovascular effects of insulin. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 955-966.	1.0	17
1622	Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study. <i>BMC Health Services Research</i> , 2014, 14, 306.	0.9	2
1623	Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?. <i>Cardiovascular Diabetology</i> , 2014, 13, 125.	2.7	20
1624	Association Between Different Hemoglobin A1c Levels and Clinical Outcomes Among Elderly Nursing Home Residents With Type 2 Diabetes Mellitus. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 757-762.	1.2	12
1625	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2014, 45, 2160-2236.	1.0	3,891
1626	Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 2705-2713.	1.6	21
1627	Treatment Patterns Among Older Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 833-839.	2.4	6
1628	Independent effects of circulating glucose, insulin and NEFA on cardiac triacylglycerol accumulation and myocardial insulin resistance in a swine model. <i>Diabetologia</i> , 2014, 57, 1937-1946.	2.9	8
1629	Telehealth Insulin Program: Managing Insulin in Primary Care. <i>Journal for Nurse Practitioners</i> , 2014, 10, 567-574.	0.4	2
1630	Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 793-800.	5.5	135
1633	Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetologia</i> , 2014, 57, 1124-1131.	2.9	29
1634	Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 965-974.	0.8	7
1635	Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 35.	1.2	16

#	ARTICLE	IF	CITATIONS
1636	Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 46.	1.2	21
1637	Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 58.	1.2	19
1638	Association between socioeconomic status, type 2 diabetes and its chronic complications in Argentina. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 241-247.	1.1	12
1639	When hypoglycemia is not obvious: Diagnosing and treating under-recognized and undisclosed hypoglycemia. <i>Primary Care Diabetes</i> , 2014, 8, 3-11.	0.9	26
1640	Standards of Medical Care in Diabetes – 2014. <i>Diabetes Care</i> , 2014, 37, S14-S80.	4.3	3,893
1641	Rational Use of Electronic Health Records for Diabetes Population Management. <i>Current Diabetes Reports</i> , 2014, 14, 479.	1.7	24
1642	Look Inside Look AHEAD: Why the Glass Is More than Half-Full. <i>Current Diabetes Reports</i> , 2014, 14, 500.	1.7	5
1643	Novel Urinary Biomarkers in Early Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2014, 14, 513.	1.7	28
1644	Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study. <i>Endocrine</i> , 2014, 47, 485-492.	1.1	6
1645	HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes. <i>Pharmacoeconomics</i> , 2014, 32, 825-839.	1.7	7
1646	Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic $\beta^2$ cells. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 667-673.	1.8	4
1647	A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study. <i>Cardiovascular Diabetology</i> , 2014, 13, 96.	2.7	24
1648	Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia. <i>Diabetes</i> , 2014, 63, 2188-2195.	0.3	196
1649	Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. <i>Diabetes Care</i> , 2014, 37, 634-643.	4.3	104
1650	Nutrici3n y enfermedades metab3licas en el anciano. Estrategias alimentarias. <i>Medicine</i> , 2014, 11, 3691-3704.	0.0	0
1651	Treatment of Type 2 Diabetes Mellitus in the Older Adult: A Review. <i>Endocrine Practice</i> , 2014, 20, 722-736.	1.1	7
1652	Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE – Latin America study. <i>Current Medical Research and Opinion</i> , 2014, 30, 1769-1776.	0.9	6
1653	Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. The Cochrane Library, 2016, 2016, CD009122.	1.5	170

#	ARTICLE	IF	CITATIONS
1654	Painful diabetic neuropathy. <i>BMJ, The</i> , 2014, 348, g1799-g1799.	3.0	160
1655	Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. <i>Current Diabetes Reports</i> , 2014, 14, 528.	1.7	200
1656	Comprehensive approach to diabetic nephropathy. <i>Kidney Research and Clinical Practice</i> , 2014, 33, 121-131.	0.9	78
1657	Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients. <i>European Journal of Operational Research</i> , 2014, 233, 727-738.	3.5	54
1658	How do health care professionals assess patients when initiating insulin therapy? A qualitative study. <i>Primary Care Diabetes</i> , 2014, 8, 49-55.	0.9	6
1659	Trends in Postoperative Infection Rates and Their Relationship to Glycosylated Hemoglobin Levels in Diabetic Patients Undergoing Foot and Ankle Surgery. <i>Journal of Foot and Ankle Surgery</i> , 2014, 53, 307-311.	0.5	27
1660	Association between HbA1c variability and mortality in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 494-499.	1.2	61
1661	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 713-735.	2.1	1,249
1662	Call-to-action: Timely and appropriate treatment for people with type 2 diabetes in Latin America. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 343-352.	1.1	12
1663	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 843-851.	5.5	260
1664	Diabetes mellitus tipo 2 en el paciente anciano institucionalizado. <i>Revista Clinica Espanola</i> , 2014, 214, 521-528.	0.2	1
1665	Secondary Prevention of Cardiovascular Disease in Older Adults. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 168-175.	1.6	13
1666	1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. <i>Journal of Cardiology</i> , 2014, 64, 297-301.	0.8	19
1667	Lessons from SAVOR and EXAMINE: Some important answers, but many open questions. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 430-433.	1.2	13
1668	Cardiovascular Disease in Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 25-40.	1.2	43
1669	Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes – An 11-year follow up study. <i>Indian Heart Journal</i> , 2014, 66, 5-10.	0.2	17
1670	Efecto del tratamiento optimizado con insulina en la reactividad plaquetaria tras el alta de pacientes hiperglicémicos con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 22-27.	0.6	11
1671	DIGAMI 1: 20 years later. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 603-604.	5.5	3

#	ARTICLE	IF	CITATIONS
1672	Association of reduced levels of serum 1,5-Anhydro-d-glucitol with carotid atherosclerosis in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 348-352.	1.2	9
1673	The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 10-16.	1.2	67
1674	Do not forget that type 2 diabetes does not only expose to cardiovascular complications. <i>Diabetes and Metabolism</i> , 2014, 40, 167-168.	1.4	7
1675	Relationships among protein tyrosine phosphatase 1B, angiotensin II, and insulin-mediated aortic responses in type 2 diabetic Goto-Kakizaki rats. <i>Atherosclerosis</i> , 2014, 233, 64-71.	0.4	11
1677	Glycemic Management in ESRD and Earlier Stages of CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, S22-S38.	2.1	77
1678	Guideline for management of postmeal glucose in diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 256-268.	1.1	102
1679	Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 175-181.	5.5	94
1680	Glycemic Exposure, Glycemic Control, and Metabolic Karma in Diabetic Complications. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 311-317.	0.6	35
1681	Diabetic kidney disease: from physiology to therapeutics. <i>Journal of Physiology</i> , 2014, 592, 3997-4012.	1.3	142
1682	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet</i> , 2014, 383, 2008-2017.	6.3	194
1683	Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 191-207.	1.0	14
1684	Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2014, 8, 187-195.	1.8	10
1685	Why Have the Complications of Diabetes Mellitus Declined Over the Past 30 Years?. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 449-453.	1.2	5
1686	Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. <i>Pharmaceutical Medicine</i> , 2014, 28, 109-117.	1.0	9
1687	Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 302-312.	1.1	82
1688	New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?. <i>Heart Lung and Circulation</i> , 2014, 23, 997-1008.	0.2	12
1689	Coronary Artery Disease and Diabetes Mellitus. <i>Cardiology Clinics</i> , 2014, 32, 439-455.	0.9	135
1691	8. Progress in Treatment of Diabetes. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2014, 103, 117b-118a.	0.0	0

#	ARTICLE	IF	CITATIONS
1693	Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control. <i>Cardiovascular Diabetology</i> , 2014, 13, 156.	2.7	25
1694	Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 147-152.	0.8	6
1695	Could Glucose Management After Acute Myocardial Infarction Cure Myocardial Damage?. <i>Circulation Journal</i> , 2014, 78, 67-68.	0.7	1
1696	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. <i>BMJ Open</i> , 2014, 4, e005378-e005378.	0.8	4
1697	Lixisenatide: clinical profile and available evidence. <i>Diabetes Management</i> , 2014, 4, 71-84.	0.5	2
1699	Type 2 diabetes mellitus control and atherosclerosis prevention in a non-obese rat model using duodenal-jejunal bypass. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 856-862.	0.8	5
1700	Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies. <i>Canadian Journal of Diabetes</i> , 2015, 39, S176-S182.	0.4	2
1701	Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin-induced diabetic rats. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 402.	3.7	31
1702	Visit-to-Visit Glucose Variability Predicts the Development of End-Stage Renal Disease in Type 2 Diabetes. <i>Medicine (United States)</i> , 2015, 94, e1804.	0.4	46
1703	Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database. <i>International Journal of Clinical Practice</i> , 2015, 69, 1486-1495.	0.8	47
1704	Prognostic Impact of Diabetes Mellitus in Chronic Heart Failure According to Presence of Ischemic Heart Diseaseâ€œ With Special Reference to Nephropathy â€œ. <i>Circulation Journal</i> , 2015, 79, 1764-1772.	0.7	10
1705	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15038.	18.1	12
1706	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 0, , .	1.5	5
1707	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€œ 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	1.1	443
1708	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
1709	Use of surrogate outcomes in US FDA drug approvals, 2003â€œ2012: a survey. <i>BMJ Open</i> , 2015, 5, e007960.	0.8	11
1710	Oral Anti-Diabetic Agents-Review and Updates. <i>British Journal of Medicine and Medical Research</i> , 2015, 5, 134-159.	0.2	3
1711	Inhibition of microRNA-9-3p reduces lipid accumulation in HepG2 cells by targeting the expression of sirtuin type 1. <i>Molecular Medicine Reports</i> , 2015, 12, 7742-7748.	1.1	5

#	ARTICLE	IF	CITATIONS
1712	In pursuit of normoglycaemia: the overtreatment of type 2 diabetes in general practice. <i>British Journal of General Practice</i> , 2015, 65, 334-335.	0.7	7
1713	Prevalence and Management of Diabetic Nephropathy in Western Countries. <i>Kidney Diseases (Basel)</i> , 2015, 1, 1-12.	1.2	49
1714	Histone Demethylase JMJD2A Inhibition Attenuates Neointimal Hyperplasia in the Carotid Arteries of Balloon-Injured Diabetic Rats via Transcriptional Silencing: Inflammatory Gene Expression in Vascular Smooth Muscle Cells. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 719-734.	1.1	22
1718	Impact of geography on the control of type 2 diabetes mellitus: a review of geocoded clinical data from general practice. <i>BMJ Open</i> , 2015, 5, e009504.	0.8	7
1719	Assessment of the Tear Meniscus Using Optical Coherence Tomography in Patients With Type 2 Diabetes Mellitus. <i>Cornea</i> , 2015, 34, 1534-1540.	0.9	16
1722	Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: Results from the DIMORA study. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1500-1506.	1.5	13
1723	Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical center. <i>Journal of Hospital Medicine</i> , 2015, 10, 228-235.	0.7	3
1724	Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions. <i>Practical Diabetes</i> , 2015, 32, 301-304.	0.1	0
1725	Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	9
1726	Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. <i>BMC Endocrine Disorders</i> , 2015, 15, 49.	0.9	12
1727	Insulin treatment increases myocardial ceramide accumulation and disrupts cardiometabolic function. <i>Cardiovascular Diabetology</i> , 2015, 14, 153.	2.7	17
1728	Similarities and differences between patients included and excluded from a randomized clinical trial of vitamin d supplementation for improving glucose tolerance in prediabetes: interpreting broader applicability. <i>Trials</i> , 2015, 16, 306.	0.7	3
1729	Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 84.	0.8	14
1730	Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 603-609.	1.7	8
1731	Type 2 diabetes and cardiac autonomic neuropathy screening using dynamic pupillometry. <i>Diabetic Medicine</i> , 2015, 32, 1470-1478.	1.2	21
1732	Safety of antidiabetes medications: An update. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 185-195.	2.3	26
1733	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 145-161.	2.3	31
1734	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. <i>Statistics in Medicine</i> , 2015, 34, 753-781.	0.8	36



#	ARTICLE	IF	CITATIONS
1736	Low HbA1c and Increased Mortality Risk-is Frailty a Confounding Factor?. , 2015, 6, 262.		30
1737	Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists. Journal of Diabetes & Metabolism, 2015, 06, .	0.2	2
1738	Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications. Drug Design, Development and Therapy, 2015, 9, 4355.	2.0	16
1739	Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 315.	1.1	8
1740	Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes. Diabetes and Metabolism Journal, 2015, 39, 498.	1.8	22
1741	Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. Vascular Health and Risk Management, 2015, 11, 107.	1.0	10
1742	The role of hormonal treatment in type 2 diabetes mellitus. Research and Reports in Endocrine Disorders, 2015, , 31.	0.4	0
1743	The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease. Current Diabetes Reviews, 2015, 11, 191-200.	0.6	13
1744	Causative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetes. World Journal of Diabetes, 2015, 6, 30.	1.3	27
1745	Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World Journal of Diabetes, 2015, 6, 1092.	1.3	12
1746	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. Endocrine Practice, 2015, 21, 1403-1414.	1.1	22
1747	Targeting composite treatment of type 2 diabetes in middle-income countries “ walking a tightrope between hyperglycaemia and the dangers of hypoglycaemia. South African Medical Journal, 2015, 106, 57.	0.2	3
1748	Atheroma Progression in Obese Early-stage Diabetic Japanese Patients in Response to Glycemic Control: Sub-analysis from the DIANA Study. Journal of Atherosclerosis and Thrombosis, 2015, 22, 697-705.	0.9	0
1749	Genetics of Type 2 Diabetes and Clinical Utility. Genes, 2015, 6, 372-384.	1.0	34
1750	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. Journal of Clinical Medicine, 2015, 4, 1866-1889.	1.0	18
1751	Ability of 1,5-Anhydro-d-glucitol Values to Predict Coronary Artery Disease in a Non-Diabetic Population. International Heart Journal, 2015, 56, 587-591.	0.5	10
1752	Weight Changes following the Diagnosis of Type 2 Diabetes: The Impact of Recent and Past Weight History before Diagnosis. Results from the Danish Diabetes Care in General Practice (DCGP) Study. PLoS ONE, 2015, 10, e0122219.	1.1	20
1753	Target Values of Cardiovascular Risk Factors Are Not Associated with All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2015, 10, e0124536.	1.1	3

#	ARTICLE	IF	CITATIONS
1754	Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. PLoS ONE, 2015, 10, e0131122.	1.1	17
1755	HbA1c Levels Are Associated with Chronic Kidney Disease in a Non-Diabetic Adult Population: A Nationwide Survey (KNHANES 2011-2013). PLoS ONE, 2015, 10, e0145827.	1.1	19
1756	Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2015, 15, 196-205.	0.6	336
1757	The imperative to prevent diabetes complications: a broadening spectrum and an increasing burden despite improved outcomes. Medical Journal of Australia, 2015, 202, 300-304.	0.8	10
1758	The Effect of a Diabetes Collaborative Care Management Program on Clinical and Economic Outcomes in Patients with Type 2 Diabetes. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 452-468.	0.5	28
1759	Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes. BioMed Research International, 2015, 2015, 1-8.	0.9	5
1760	Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2015, 2015, 1-13.	1.0	29
1761	Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	10
1762	Immunological Hypoglycemia Associated with Insulin Antibodies Induced by Exogenous Insulin in 11 Chinese Patients with Diabetes. Journal of Diabetes Research, 2015, 2015, 1-9.	1.0	18
1763	Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications. Journal of Diabetes Research, 2015, 2015, 1-17.	1.0	55
1764	Impact and duration effect of telemonitoring on $\hat{H}bA1c$ , BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study. Hormones, 2015, 14, 632-43.	0.9	22
1765	Pramlintide for diabetes mellitus. The Cochrane Library, 0, , .	1.5	0
1766	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. Review of Diabetic Studies, 2015, 12, 110-118.	0.5	169
1767	Impact of glucose level on morbidity and mortality in elderly with diabetes and pre-diabetes. World Journal of Diabetes, 2015, 6, 345.	1.3	19
1768	Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Review of Diabetic Studies, 2015, 12, 48-62.	0.5	150
1770	Treatment of prediabetes. World Journal of Diabetes, 2015, 6, 1207.	1.3	56
1771	Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World Journal of Diabetes, 2015, 6, 80.	1.3	136
1772	Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 372, 2197-2206.	13.9	541

#	ARTICLE	IF	CITATIONS
1773	The Mitochondria in Diabetic Heart Failure: From Pathogenesis to Therapeutic Promise. Antioxidants and Redox Signaling, 2015, 22, 1515-1526.	2.5	76
1774	Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. British Journal of Pharmacology, 2015, 172, 721-736.	2.7	21
1775	The Look AHEAD Trial: Implications for Lifestyle Intervention in Type 2 Diabetes Mellitus. Progress in Cardiovascular Diseases, 2015, 58, 69-75.	1.6	60
1776	DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. Contributions To Nephrology, 2015, 185, 98-115.	1.1	20
1777	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal, 2015, 36, 2288-2296.	1.0	210
1778	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes and Endocrinology, the, 2015, 3, 638-652.	5.5	84
1779	Management of diabetes mellitus in patients with chronic kidney disease. Clinical Diabetes and Endocrinology, 2015, 1, 2.	1.3	88
1780	A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nature Communications, 2015, 6, 7060.	5.8	111
1781	Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2015, 162, 765-776.	2.0	112
1782	Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia, 2015, 58, 2161-2168.	2.9	42
1783	Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges. Current Cardiology Reports, 2015, 17, 607.	1.3	24
1784	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	1.2	88
1785	Importance of risk factor management in diabetic patients and reduction in Stage B heart failure. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 307-314.	0.2	5
1786	The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2015, 109, 378-388.	1.1	75
1787	Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). Advances in Therapy, 2015, 32, 391-403.	1.3	6
1789	Psychosocial Factors Associated with Diabetes Self-Management. , 2015, , 45-56.		3
1790	Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 2289-2302.	3.0	39
1791	The interactive effect of diabetes and central obesity on stroke: a prospective cohort study of inner Mongolians. BMC Neurology, 2015, 15, 65.	0.8	12

#	ARTICLE	IF	CITATIONS
1792	Pharmacological Treatment and Current Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2015, 116, 1579-1598.	2.0	87
1793	Pharmacotherapy for type 2 diabetes in very elderly patients: practicing nihilism or pragmatism?. <i>Age and Ageing</i> , 2015, 44, 540-542.	0.7	4
1794	Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2015, 15, 44.	1.7	14
1795	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. <i>Circulation</i> , 2015, 132, 2345-2350.	1.6	42
1797	Sudden cardiac death in patients with diabetes mellitus and chronic heart failure. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 228-233.	0.9	37
1798	Defining, Treating, and Understanding Chronic Kidney Disease—A Complex Disorder. <i>Journal of Clinical Hypertension</i> , 2015, 17, 514-527.	1.0	18
1799	Hypoglycaemia, a global cause for concern. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 229-232.	1.1	13
1800	HbA <sub>1c</sub> overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study. <i>BMJ</i> , The, 2015, 351, h6138.	3.0	45
1801	Novel and Emerging Insulin Preparations for Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, S160-S166.	0.4	3
1802	An observational study of patient characteristics and mortality following hypoglycemia in the community. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000094.	1.2	45
1803	Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. <i>BMJ Open</i> , 2015, 5, e006341-e006341.	0.8	19
1804	Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	36
1805	Association of Hypoglycemia With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2015, 94, e771.	0.4	15
1807	Spécificité des accidents vasculaires cérébraux chez les diabétiques. <i>Medicine Des Maladies Metaboliques</i> , 2015, 9, 399-405.	0.1	1
1808	Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients. <i>Medicine (United States)</i> , 2015, 94, e1128.	0.4	19
1809	The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, S155-S159.	0.4	21
1811	Effets du contrôle de l'hyperglycémie sur la morbi-mortalité cardiovasculaire (type 1 & type 2). <i>Medicine Des Maladies Metaboliques</i> , 2015, 9, 747-751.	0.1	0
1812	Implementation of a Diabetes Management Flow Sheet in a Long-Term Care Setting. <i>Canadian Journal of Diabetes</i> , 2015, 39, 273-277.	0.4	4

#	ARTICLE	IF	CITATIONS
1814	Diabetic Kidney Disease: Much Progress, But Still More to Do. <i>Diabetes Spectrum</i> , 2015, 28, 154-156.	0.4	2
1815	Adherence to diabetes medication: a systematic review. <i>Diabetic Medicine</i> , 2015, 32, 725-737.	1.2	322
1816	The Effect of Intensive Glucose Lowering Therapy Among Major Racial/Ethnic Groups in the Veterans Affairs Diabetes Trial. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 218-225.	1.5	6
1817	“Mild dysglycemia” in type 2 diabetes: to be neglected or not?. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 451-458.	1.2	20
1818	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 540-556.	0.9	69
1819	Elevation in blood flow and shear rate prevents hyperglycemia-induced endothelial dysfunction in healthy subjects and those with type 2 diabetes. <i>Journal of Applied Physiology</i> , 2015, 118, 579-585.	1.2	23
1820	Advantage of Insulin Glulisine Over Regular Insulin in Patients With Type 2 Diabetes and Severe Renal Insufficiency. , 2015, 25, 129-134.		19
1821	6. Glycemic Targets. <i>Diabetes Care</i> , 2015, 38, S33-S40.	4.3	214
1822	Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2015, 8, 236-242.	1.6	41
1823	Benefits of timely basal insulin control in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 295-301.	1.2	43
1824	Microalbuminuria: A parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 1-8.	1.1	75
1825	Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats. <i>Diabetes</i> , 2015, 64, 1035-1045.	0.3	69
1826	Glycemic control and use of A1c in primary care patients with type 2 diabetes mellitus. <i>Primary Care Diabetes</i> , 2015, 9, 385-391.	0.9	19
1827	Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 673-686.	0.3	165
1829	Determinants of poor glycemic control in Chinese men with type 2 diabetes: a cross-sectional survey of 15,427 men in 77 tertiary hospitals in China. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 488-492.	0.3	2
1830	Relationship between glycosylated hemoglobin A1c and coronary flow reserve in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 445-453.	0.6	10
1831	Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans. <i>Diabetes</i> , 2015, 64, 2571-2580.	0.3	80
1832	Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation. <i>Acta Diabetologica</i> , 2015, 52, 753-761.	1.2	14

#	ARTICLE	IF	CITATIONS
1833	A case of hemiplegia with hypoglycemia possibly associated with hemodynamic change. <i>Diabetology International</i> , 2015, 6, 336-340.	0.7	0
1834	Change in Daily Ambulatory Activity and Cardiovascular Events in People with Impaired Glucose Tolerance. <i>Current Cardiology Reports</i> , 2015, 17, 562.	1.3	5
1835	Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study. <i>Osteoporosis International</i> , 2015, 26, 827-833.	1.3	65
1837	Effects of $\beta$ -Blocker Therapy on Active Duty Military and Military Retirees for Benign Prostatic Hypertrophy on Diabetic Complications. <i>Military Medicine</i> , 2015, 180, 355-360.	0.4	0
1838	EFFECT OF THE EARLY INTENSIVE MULTIFACTORIAL THERAPY ON THE CARDIOVASCULAR RISK IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES: AN OBSERVATIONAL, PROSPECTIVE STUDY. <i>Medicine and Pharmacy Reports</i> , 2015, 88, 168-174.	0.2	3
1839	Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1558-1566.	4.3	32
1840	Knowledge of hypoglycemia and its associated factors among type 2 diabetes mellitus patients in a Tertiary Care Hospital in South India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 378.	0.2	27
1841	Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus <sup>®</sup> to Oral Hypoglycemic Agents (ALOHA) study. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 127-133.	1.2	12
1842	Bénéfices à long terme du traitement antihypertenseur et du contrôle strict de la glycémie sur la prévention cardiovasculaire chez les patients diabétiques de type 2 : résultats de l'étude ADVANCE-ON. <i>Medicine Des Maladies Metaboliques</i> , 2015, 9, 70-71.		0
1843	Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 780-790.	2.2	251
1844	Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. <i>Value in Health Regional Issues</i> , 2015, 8, 20-27.	0.5	3
1845	Antioxidant treatment normalizes mitochondrial energetics and myocardial insulin sensitivity independently of changes in systemic metabolic homeostasis in a mouse model of the metabolic syndrome. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 85, 104-116.	0.9	28
1846	Cardiovascular Biomarker Assessment Across Glycemic Status. , 2015, , 245-268.		1
1847	Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): Residual risk of long-term mortality persists. <i>International Journal of Cardiology</i> , 2015, 179, 546-551.	0.8	21
1848	Minimizing Hypoglycemia in Diabetes. <i>Diabetes Care</i> , 2015, 38, 1583-1591.	4.3	156
1849	Hyperglycemia. , 2015, , 85-100.		0
1850	Adenosine accelerates the healing of diabetic ischemic ulcers by improving autophagy of endothelial progenitor cells grown on a biomaterial. <i>Scientific Reports</i> , 2015, 5, 11594.	1.6	15
1851	Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. <i>BMJ, The</i> , 2015, 350, h3234-h3234.	3.0	193

#	ARTICLE	IF	CITATIONS
1852	Relationship Between the Brain Natriuretic Peptide (BNP) Level and Remission of Diabetic Nephropathy with Microalbuminuria: A 3-Year Follow-Up Study. <i>Hormone and Metabolic Research</i> , 2015, 47, 138-144.	0.7	6
1853	Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 697-705.	1.1	11
1854	Relationships among different glycemic variability indices obtained by continuous glucose monitoring. <i>Primary Care Diabetes</i> , 2015, 9, 290-296.	0.9	29
1855	Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1266-1271.	1.2	12
1856	The Future of Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, 204-205.	0.4	1
1857	Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	44
1858	Antidiabetic Therapy in End-Stage Renal Disease. <i>Seminars in Dialysis</i> , 2015, 28, 337-344.	0.7	3
1859	Escalas de riesgo cardiovascular para pacientes con diabetes. ¿Qué son y de qué nos sirven?. <i>Avances En Diabetología</i> , 2015, 31, 102-112.	0.1	4
1860	Optimizing Care for Canadians with Diabetic Nephropathy in 2015. <i>Canadian Journal of Diabetes</i> , 2015, 39, 221-228.	0.4	8
1861	Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S83-S94.	0.1	0
1862	One-stage robotically assisted laparoscopic biliopancreatic diversion with duodenal switch: analysis of 179 patients. <i>Surgery for Obesity and Related Diseases</i> , 2015, 11, 367-371.	1.0	16
1863	High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events. <i>Atherosclerosis</i> , 2015, 240, 318-323.	0.4	28
1864	Percutaneous Coronary Interventions in the Diabetic Patient. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001944.	1.4	27
1865	Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study. <i>Diabetes and Metabolism</i> , 2015, 41, 116-125.	1.4	111
1866	Protocolo sobre manejo de la diabetes mellitus tipo 2. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2015, 22, 9-40.	0.0	0
1867	Evaluation of blood glucose fluctuation in Japanese patients with type 1 diabetes mellitus by self-monitoring of blood glucose and continuous glucose monitoring. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 342-349.	1.1	9
1868	Hypoglycaemia requiring medical assistance in patients with diabetes: A prospective multicentre survey in tertiary hospitals. <i>Diabetes and Metabolism</i> , 2015, 41, 126-131.	1.4	13
1869	Predicting risk of severe hypoglycaemia in type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1143-1145.	2.9	0

#	ARTICLE	IF	CITATIONS
1870	Distinct HbA1c trajectories in a type 2 diabetes cohort. <i>Acta Diabetologica</i> , 2015, 52, 267-275.	1.2	49
1871	Has evidence-based medicine left quackery behind?. <i>Internal and Emergency Medicine</i> , 2015, 10, 631-634.	1.0	18
1872	There is level 1 evidence for intensive glycemetic control for reducing the progression of diabetic retinopathy in persons with type 2 diabetes. <i>Endocrine</i> , 2015, 49, 1-3.	1.1	8
1873	Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015, 14, 14.	2.7	23
1874	Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 154-158.	1.0	31
1875	A model of mild hypoglycemia. <i>Current Medical Research and Opinion</i> , 2015, 31, 633-641.	0.9	12
1876	Non-ICU Hospital Care of Diabetes Mellitus in the Elderly Population. <i>Current Diabetes Reports</i> , 2015, 15, 26.	1.7	4
1877	Effects of vitamin D receptor gene polymorphism and clinical characteristics on risk of diabetic retinopathy in Han Chinese type 2 diabetes patients. <i>Gene</i> , 2015, 566, 212-216.	1.0	35
1878	Update on Glycemic Control for the Treatment of Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2015, 15, 42.	1.7	9
1879	Glycemic Variability: Assessing Glycemia Differently and the Implications for Dietary Management of Diabetes. <i>Annual Review of Nutrition</i> , 2015, 35, 389-424.	4.3	46
1880	Clq-TNF-related protein-9, a novel cardioprotective cardiokine, requires proteolytic cleavage to generate a biologically active globular domain isoform. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E891-E898.	1.8	38
1881	Diabetes, Myocardial Infarction and Stroke Are Distinct and Duration-Dependent Predictors of Subsequent Cardiovascular Events and All-Cause Mortality in Older Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1038-1047.	1.8	28
1882	Sodium-glucose co-transporter inhibition in the treatment of diabetes: Sweetening the pot. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 74-77.	0.9	3
1883	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 700-714.	0.9	23
1884	Antioxidant icariside II combined with insulin restores erectile function in streptozotocin-induced type 1 diabetic rats. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 960-969.	1.6	24
1885	Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 1000-1009.	1.1	26
1886	Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1325-1333.	0.9	7
1887	Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 523-532.	2.2	66



#	ARTICLE	IF	CITATIONS
1888	Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. <i>Diabetes and Metabolism</i> , 2015, 41, 195-201.	1.4	28
1889	Body Mass Index—Mortality Relationship in Severe Hypoglycemic Patients With Type 2 Diabetes. <i>American Journal of the Medical Sciences</i> , 2015, 349, 192-198.	0.4	7
1896	Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control. <i>JAMA Internal Medicine</i> , 2015, 175, 356.	2.6	317
1897	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 356-366.	5.5	224
1898	Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 78-89.	0.9	298
1899	Management of Glycemia in Diabetic Patients with Stage IV and V Chronic Kidney Disease. <i>Current Diabetes Reports</i> , 2015, 15, 25.	1.7	2
1900	Anatomy of success: 100 most cited articles in diabetes research. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 163-173.	1.4	32
1901	Potential Overtreatment of Older, Complex Adults With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1280.	3.8	12
1902	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. <i>Diabetes Care</i> , 2015, 38, 2293-2300.	4.3	42
1903	Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 12.	0.6	30
1904	Investigating the Evidence of the Real-Life Impact of Acute Hyperglycaemia. <i>Diabetes Therapy</i> , 2015, 6, 389-393.	1.2	4
1905	Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies. <i>Current Diabetes Reports</i> , 2015, 15, 117.	1.7	10
1906	Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 949-955.	2.2	16
1908	CASALUD: an innovative health-care system to control and prevent non-communicable diseases in Mexico. <i>Perspectives in Public Health</i> , 2015, 135, 180-190.	0.8	16
1909	Implantable cardioverter defibrillators in diabetics: efficacy and safety in patients at risk of sudden cardiac death. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 897-906.	0.6	5
1910	The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1791-1799.	1.2	40
1911	The new biology of diabetes. <i>Diabetologia</i> , 2015, 58, 2459-2468.	2.9	80
1912	The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 701-711.	2.4	16

#	ARTICLE	IF	CITATIONS
1913	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. <i>Circulation</i> , 2015, 132, 691-718.	1.6	303
1914	Contemporary Risk Estimates of Three HbA1c Variables for Myocardial Infarction in 101,799 Patients Following Diagnosis of Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1481-1486.	4.3	10
1915	Shortfalls of the use of HbA1C-derived eAG in older adults with diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 60-65.	1.1	24
1916	Epigenetics and Cardiovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 108.	1.7	32
1917	Current management of diabetes mellitus and future directions in care. <i>Postgraduate Medical Journal</i> , 2015, 91, 612-621.	0.9	54
1918	Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. <i>Postgraduate Medicine</i> , 2015, 127, 842-854.	0.9	5
1919	Saxagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2015, 75, 1783-1796.	4.9	22
1922	Baroreflex Sensitivity Impairment During Hypoglycemia: Implications for Cardiovascular Control. <i>Diabetes</i> , 2016, 65, 209-215.	0.3	20
1923	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 2000-2008.	4.3	33
1924	The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. <i>Diabetes Care</i> , 2015, 38, 1930-1936.	4.3	35
1925	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2015, 38, 1777-1803.	4.3	346
1926	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. <i>Diabetes Spectrum</i> , 2015, 28, 167-174.	0.4	18
1927	Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective. <i>Current Diabetes Reports</i> , 2015, 15, 87.	1.7	25
1928	Hypoglycemia and Comorbidities in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 80.	1.7	13
1929	Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1052.	3.8	305
1930	Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 977-978.	13.9	54
1931	Older people with diabetes "avoiding hospitalization. <i>Diabetes Management</i> , 2015, 5, 311-326.	0.5	2
1932	A randomized controlled trial comparing treatment with oral agents and basal insulin in elderly patients with type 2 diabetes in long-term care facilities. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000104.	1.2	33

#	ARTICLE	IF	CITATIONS
1933	Possible Computer Model for Predicting Cardiovascular Disease in Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 679-681.	2.4	0
1934	Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F889-F900.	1.3	113
1935	Distal Symmetric Polyneuropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2172.	3.8	186
1936	Systematic Review of Therapies for Stable Coronary Artery Disease in Diabetic Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 2383-2397.	0.7	12
1937	Development of an Educational Program on Prevention of Hypoglycemic Events Among Elderly Veterans With Type 2 Diabetes. <i>The Diabetes Educator</i> , 2015, 41, 690-697.	2.6	7
1938	Implementation of a pharmacotherapy clinic into the patient centered medical home model by a second year pharmacy resident. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, S83-S89.	0.5	10
1939	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Advances in Therapy</i> , 2015, 32, 1029-1064.	1.3	30
1940	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. <i>Kidney International</i> , 2015, 87, 649-659.	2.6	158
1941	Effects of intensive glycemic control in ocular complications in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. <i>Endocrine</i> , 2015, 49, 78-89.	1.1	29
1942	Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?. <i>Drug Safety</i> , 2015, 38, 17-32.	1.4	23
1943	Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. <i>Diabetes Care</i> , 2015, 38, 316-322.	4.3	276
1944	Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice. <i>Diabetologia</i> , 2015, 58, 845-853.	2.9	59
1946	Treating Coronary Disease and the Impact of Endothelial Dysfunction. <i>Progress in Cardiovascular Diseases</i> , 2015, 57, 431-442.	1.6	50
1947	Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 24-week trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 276-284.	2.2	9
1948	The Effect of Glycated Hemoglobin and Albumin-Corrected Glycated Serum Protein on Mortality in Diabetic Patients Receiving Continuous Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2015, 35, 566-575.	1.1	8
1949	Glycemic Targets. <i>Medical Clinics of North America</i> , 2015, 99, 47-67.	1.1	13
1950	Screening and Treatment by the Primary Care Provider of Common Diabetes Complications. <i>Medical Clinics of North America</i> , 2015, 99, 201-219.	1.1	16
1951	Handbook of Clinical Nutrition and Aging. , 2015, , .		15

#	ARTICLE	IF	CITATIONS
1952	Prognostic importance of baseline and serial glycosylated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. <i>Acta Diabetologica</i> , 2015, 52, 21-29.	1.2	22
1953	Random Effects Model for Multiple Pathway Analysis with Applications to Type II Diabetes Microarray Data. <i>Statistics in Biosciences</i> , 2015, 7, 167-186.	0.6	8
1954	The effects of good glycaemic control on left ventricular and coronary endothelial functions in patients with poorly controlled Type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2015, 82, 388-396.	1.2	9
1955	Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2015, 9, 30-33.	1.8	10
1956	Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 335-342.	2.2	9
1957	Reducing cardiovascular risk in type 2 diabetes mellitus. <i>Medicine</i> , 2015, 43, 7-12.	0.2	1
1958	Obesity and Diabetes in an Aging Population. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 1-15.	1.0	12
1959	Antidiabetic Medications and Polypharmacy. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 17-27.	1.0	74
1960	Clinical Autonomic Dysfunction. , 2015, , .		20
1961	NICE guidance on type 2 diabetes in adults – what's new?. <i>Independent Nurse</i> , 2016, 2016, 17-22.	0.0	6
1962	Causes of Hypoglycemia in Hospitalized Diabetic Patients Referred to Endocrine Department of a Tertiary Level Hospital of India. <i>Medical Journal of Shree Birendra Hospital</i> , 2016, 15, 26-31.	0.0	0
1963	Patients' empowerment, physicians' perceptions, and achievement of therapeutic goals in patients with type 1 and type 2 diabetes mellitus in Mexico. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1349-1357.	0.8	4
1964	Does Clinical Inertia Vary By Personalized A1C Goal? A Study of Predictors And Prevalence of Clinical Inertia In A U.S. Managed-Care Setting. <i>Endocrine Practice</i> , 2016, 22, 151-161.	1.1	43
1965	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
1966	Diabetes mellitus and cognitive impairments. <i>World Journal of Diabetes</i> , 2016, 7, 412.	1.3	174
1967	Baseline-Corrected QT (QTc) Interval Is Associated with Prolongation of QTc during Severe Hypoglycemia in Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 463.	1.8	11
1968	Type 2 diabetes: cost-effectiveness of medication adherence and lifestyle interventions. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2039-2049.	0.8	7
1969	Review of Cardiovascular Effects of Antidiabetic Drugs and Recent Cardiovascular Outcome Trials. <i>Journal of Korean Diabetes</i> , 2016, 17, 1.	0.1	0

#	ARTICLE	IF	CITATIONS
1970	Tapping into Mitochondria to Find Novel Targets for Diabetes Complications. <i>Current Drug Targets</i> , 2016, 17, 1341-1349.	1.0	21
1971	Improving Care in Older Patients with Diabetes: A Focus on Glycemic Control. , 2016, 20, 15-080.		6
1972	Characteristics of Hypoglycemia Patients Visiting the Emergency Department of a University Hospital. <i>Journal of Korean Diabetes</i> , 2016, 17, 202.	0.1	2
1973	Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 423.	1.8	46
1974	Type 2 Diabetes Mellitus. , 2016, , 1385-1450.		9
1975	Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion". <i>Current Vascular Pharmacology</i> , 2016, 14, 316-318.	0.8	2
1976	Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 922-931.	0.9	7
1977	Sodium&ndash;glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin&ndash;metformin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, 9, 71.	1.1	4
1978	Improving cardiovascular risk in type 2 diabetes: time to get personal. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 233-234.	1.8	3
1979	Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications. <i>Hormones</i> , 2016, 15, 170-185.	0.9	7
1980	Honey as a Sole Treatment of Type 2 Diabetes Mellitus. <i>Endocrinology &amp; Metabolic Syndrome: Current Research</i> , 2016, 05, .	0.3	14
1981	The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 354.	1.8	32
1982	A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-11.	1.0	15
1983	Interaction between Mean Arterial Pressure and HbA1c in Prediction of Cardiovascular Disease Hospitalisation: A Population-Based Case-Control Study. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	12
1985	Mechanism of Hypoglycemia-Associated Cardiovascular Diseases. <i>Journal of Korean Diabetes</i> , 2016, 17, 24.	0.1	0
1986	Updates in diabetic peripheral neuropathy. <i>F1000Research</i> , 2016, 5, 738.	0.8	183
1987	Predictors of Cognitive Decline in Older Adult Type 2 Diabetes from the Veterans Affairs Diabetes Trial. <i>Frontiers in Endocrinology</i> , 2016, 7, 123.	1.5	13
1988	Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2016, 15, 78.	2.7	10

#	ARTICLE	IF	CITATIONS
1989	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0166125.	1.1	188
1990	Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis. PLoS ONE, 2016, 11, e0160436.	1.1	6
1991	Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling. International Journal of Biological Sciences, 2016, 12, 1032-1040.	2.6	40
1992	Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes. Endocrinology and Metabolism, 2016, 31, 245.	1.3	53
1994	Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition. Journal of Cardiovascular Nursing, 2016, 31, 274-283.	0.6	6
1995	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. BMJ Open, 2016, 6, e012220.	0.8	6
1996	Identifying the independent effect of HbA <sub>1c</sub> variability on adverse health outcomes in patients with Type 2 diabetes. Diabetic Medicine, 2016, 33, 1640-1648.	1.2	36
1997	Current Therapies for the Medical Management of Diabetes. Obstetrics and Gynecology, 2016, 127, 780-794.	1.2	18
1998	Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane. Experimental Physiology, 2016, 101, 731-742.	0.9	29
1999	Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabetic Medicine, 2016, 33, 280-289.	1.2	36
2000	Glycosylated haemoglobin assessment in diabetic patients with acute coronary syndromes. Internal Medicine Journal, 2016, 46, 574-582.	0.5	4
2001	The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovascular Diabetology, 2016, 15, 85.	2.7	16
2002	Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 767-772.	1.1	10
2003	Prevalent Diabetes Mellitus: Mortality and Management in Norwegian Heart Failure Outpatients. Cardiology, 2016, 134, 413-422.	0.6	4
2004	Cardiovascular complications of diabetes. InnovAiT, 2016, 9, 694-701.	0.0	1
2005	Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model. Molecular Medicine Reports, 2016, 13, 2135-2142.	1.1	18
2006	The influence of baseline risk on the relation between HbA <sub>1c</sub> and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. Cardiovascular Diabetology, 2016, 15, 101.	2.7	17
2007	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm " 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	1.1	405

#	ARTICLE	IF	CITATIONS
2008	Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease. <i>Scientific Reports</i> , 2016, 6, 20028.	1.6	39
2009	Are Diabetes Care Providers Too Gluco-centric?. <i>Canadian Journal of Diabetes</i> , 2016, 40, 479-481.	0.4	4
2017	Sodium-glucose co-transporter 2 inhibitors: a review of their use in older people with type 2 diabetes mellitus. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 377-383.	0.5	3
2018	Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. <i>Lipids in Health and Disease</i> , 2016, 15, 204.	1.2	22
2019	Diabetes mellitus in the older adult. , 2016, , 421-435.		0
2020	Association of cystatin C proteoforms with estimated glomerular filtration rate. <i>Clinical Mass Spectrometry</i> , 2016, 1, 27-31.	1.9	5
2021	Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. <i>International Journal of Clinical Practice</i> , 2016, 70, 988-995.	0.8	36
2023	Is diabetes still a state of premature cardiovascular death?. <i>Practical Diabetes</i> , 2016, 33, 285-290.	0.1	1
2024	Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 211-219.	0.9	23
2025	Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. <i>Herz</i> , 2016, 41, 184-192.	0.4	48
2026	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. <i>Canadian Journal of Diabetes</i> , 2016, 40, 193-195.	0.4	32
2027	Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. <i>European Journal of Cancer</i> , 2016, 59, 90-98.	1.3	19
2028	Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 218, 50-58.	0.8	51
2029	Epigenetic Changes in Diabetes and Cardiovascular Risk. <i>Circulation Research</i> , 2016, 118, 1706-1722.	2.0	98
2030	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	2.0	51
2031	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016, 39, 1329-1337.	4.3	12
2032	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	1.0	5,370
2034	Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2016, 65, 1462-1471.	0.3	173

#	ARTICLE	IF	CITATIONS
2035	A Case Study of the Impact of Data-Adaptive Versus Model-Based Estimation of the Propensity Scores on Causal Inferences from Three Inverse Probability Weighting Estimators. <i>International Journal of Biostatistics</i> , 2016, 12, 131-155.	0.4	23
2036	Pharmacologic Therapy of Type 2 Diabetes. <i>Medical Clinics of North America</i> , 2016, 100, 647-663.	1.1	17
2037	Mortality risk in admitted patients with diabetes mellitus according to treatment. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1025-1031.	1.2	4
2038	Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 42.	0.4	13
2039	Treatment urgency: The importance of getting people with type 2 diabetes to target promptly. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 100-103.	1.1	9
2040	Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. <i>Diabetes Care</i> , 2016, 39, 973-981.	4.3	108
2041	Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?. <i>Indian Heart Journal</i> , 2016, 68, 564-571.	0.2	15
2042	Silent myocardial ischemia in asymptomatic patients with type 2 diabetes mellitus without previous histories of cardiovascular disease. <i>International Journal of Cardiology</i> , 2016, 216, 151-155.	0.8	9
2043	Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. <i>Postgraduate Medicine</i> , 2016, 128, 609-619.	0.9	17
2044	Diabetic cardiomyopathy: role of the E3 ubiquitin ligase. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E473-E483.	1.8	22
2045	Association of Blood Glucose Control and Lipids With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2016, 39, 816-822.	4.3	12
2046	Glycemic targets in diabetes. <i>International Journal of Diabetes in Developing Countries</i> , 2016, 36, 359-369.	0.3	0
2047	Costs associated with emergency care and hospitalization for severe hypoglycemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 345-351.	1.1	49
2048	High Quality of Diabetes Care Based Upon Individualised Treatment Goals – A Cross Sectional Study in 4784 Patients in Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 294-299.	0.6	11
2049	Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , 2016, 38, 66-88.e20.	1.1	54
2050	Diabetes Dyslipidemia. <i>Diabetes Therapy</i> , 2016, 7, 203-219.	1.2	259
2051	Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. <i>Diabetes Care</i> , 2016, 39, 668-676.	4.3	105
2052	Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness. <i>Current Diabetes Reports</i> , 2016, 16, 47.	1.7	20



#	ARTICLE	IF	CITATIONS
2053	The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-Centered Multidisciplinary Diabetes Program (the NADIR Study). <i>Canadian Journal of Diabetes</i> , 2016, 40, 120-125.	0.4	10
2054	Glucose-lowering therapy in type 2 diabetes. <i>Herz</i> , 2016, 41, 208-216.	0.4	3
2055	Serum apelin and ADMA levels in type 2 diabetics with and without vascular complications. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, S106-S109.	1.8	10
2056	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016, 39, 717-725.	4.3	244
2059	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1177-1185.	1.2	15
2060	Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG. <i>Clinical Therapeutics</i> , 2016, 38, 1279-1287.	1.1	18
2061	Sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead. <i>European Heart Journal</i> , 2016, 37, 3201-3202.	1.0	7
2062	Principles of self-adjustment of insulin dose in people with diabetes type 2 and flexible insulin therapy. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 165-170.	1.1	5
2063	Alternative Quantitative Tools in the Assessment of Diabetic Peripheral and Autonomic Neuropathy. <i>International Review of Neurobiology</i> , 2016, 127, 235-285.	0.9	27
2064	Stress Perfusion Cardiac Magnetic Resonance Imaging Effectively Risk Stratifies Diabetic Patients With Suspected Myocardial Ischemia. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004136.	1.3	31
2065	Association between hypoglycemia and dementia in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 279-287.	1.1	66
2066	Severe hypoglycemia in the Look AHEAD Trial. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 935-943.	1.2	9
2067	Wherefore Art Thou, O Treatment for Diabetic Neuropathy?. <i>International Review of Neurobiology</i> , 2016, 127, 287-317.	0.9	46
2068	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. <i>European Heart Journal</i> , 2016, 37, 3192-3200.	1.0	142
2069	Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice. <i>Journal of Pharmacological Sciences</i> , 2016, 131, 198-208.	1.1	32
2071	Maladie coronarienne et diabète de type 2 : des liens génétiques. <i>Medicine Des Maladies Metaboliques</i> , 2016, 10, 21-22.	0.1	1
2072	Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIC study baseline data. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 41.	1.2	10
2073	Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 922-932.	5.5	26

#	ARTICLE	IF	CITATIONS
2076	Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. <i>Atherosclerosis</i> , 2016, 253, 1-6.	0.4	15
2077	Increased Contractile Response to Noradrenaline Induced By Factors Associated with the Metabolic Syndrome in Cultured Small Mesenteric Arteries. <i>Pharmacology</i> , 2016, 97, 48-56.	0.9	2
2078	Ensayos clínicos de resultados de enfermedad cardiovascular en diabetes. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2016, 63, 317-319.	0.8	3
2079	Hypoglycémie et risque cardiovasculaire dans le diabète de type 1 et de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 13-14.	0.1	1
2081	Diabetes treatment and hypoglycaemic episodes in elderly patients at nursing homes in Uppsala County. <i>Upsala Journal of Medical Sciences</i> , 2016, 121, 179-183.	0.4	5
2082	Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians. <i>Postgraduate Medicine</i> , 2016, 128, 822-827.	0.9	0
2083	Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. <i>Postgraduate Medicine</i> , 2016, 128, 810-821.	0.9	17
2084	Intensive Glycemic Therapy in Patients With Type 2 Diabetes on $\beta$ -Blockers. <i>Diabetes Care</i> , 2016, 39, 1818-1826.	4.3	14
2085	Standards of care for type 2 diabetes in China. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 442-458.	1.7	236
2086	Established and Emerging Strategies in the Treatment of Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2016, 36, 331-342.	0.6	15
2087	Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer, Second report. <i>Cancer Science</i> , 2016, 107, 369-371.	1.7	10
2088	Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations. <i>International Journal of Clinical Practice</i> , 2016, 70, 236-243.	0.8	4
2089	Subject-driven titration of biphasic insulin aspart <sup>30</sup> twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial. <i>Journal of Diabetes Investigation</i> , 2016, 7, 85-93.	1.1	5
2090	Role of incretin-based therapies and sodium-glucose co-transporter <sup>2</sup> inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. <i>Diabetic Medicine</i> , 2016, 33, 864-876.	1.2	7
2091	Factors associated with failure to achieve a glycated haemoglobin target of $\leq$ 8.0% in the ACTION to CONTROL cardiovascular RISK in DIABETES (ACCORD) trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 92-95.	2.2	14
2092	Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 152-158.	2.2	30
2093	Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 907-915.	2.2	203
2094	Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2016, 7, 5-16.	1.1	40

#	ARTICLE	IF	CITATIONS
2095	Association between diabetes and prevalence and growth rate of abdominal aortic aneurysms: A meta-analysis. <i>International Journal of Cardiology</i> , 2016, 221, 484-495.	0.8	55
2096	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. <i>Current Diabetes Reports</i> , 2016, 16, 94.	1.7	2
2097	Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 504-512.	0.9	125
2098	Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c. <i>Clinica Chimica Acta</i> , 2016, 461, 146-150.	0.5	64
2099	Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 222, 957-962.	0.8	13
2100	Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 602.	3.8	669
2101	A Test in Context. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2479-2486.	1.2	23
2103	Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. <i>Scientific Reports</i> , 2016, 6, 26428.	1.6	119
2104	Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2016, 164, 740.	2.0	509
2105	Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2016, 63, 811-818.	0.7	9
2106	NG28: Promoting patient-centred care for adults with type 2 diabetes. <i>NursePrescribing</i> , 2016, 14, 236-245.	0.1	3
2107	Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1695-1705.	1.5	15
2108	Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study. <i>Annales D'Endocrinologie</i> , 2016, 77, 649-657.	0.6	3
2109	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.4	415
2110	Cerebrovascular complications of diabetes: focus on cognitive dysfunction. <i>Clinical Science</i> , 2016, 130, 1807-1822.	1.8	63
2111	Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. <i>The Cochrane Library</i> , 2016, 9, CD006992.	1.5	32
2112	Personalized Therapy by Phenotype and Genotype. <i>Diabetes Care</i> , 2016, 39, S127-S136.	4.3	13
2113	Treatment of Type 2 Diabetes: From â€œGuidelinesâ€ to â€œPosition Statementsâ€ and Back. <i>Diabetes Care</i> , 2016, 39, S146-S153.	4.3	22

#	ARTICLE	IF	CITATIONS
2114	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. <i>Diabetes Care</i> , 2016, 39, S154-S164.	4.3	36
2115	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2016, 39, S113-S114.	4.3	4
2116	Hypoglycemia and Cardiovascular Risk: Is There a Major Link?. <i>Diabetes Care</i> , 2016, 39, S205-S209.	4.3	91
2117	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. <i>Diabetes Care</i> , 2016, 39, S187-S195.	4.3	42
2118	Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. <i>Diabetes Care</i> , 2016, 39, S219-S227.	4.3	10
2119	Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1275-1281.	1.2	27
2122	Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. <i>Biomarkers in Medicine</i> , 2016, 10, 1153-1166.	0.6	10
2123	Results from Cardiovascular Outcome Trials in Diabetes. <i>Endocrinology &amp; Nutrition (English)</i> Tj ETQq1 1 0.784314 rgBT /Oyerlock 10 0.5	0.5	1
2124	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e535-e578.	1.6	285
2125	Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. <i>Heart</i> , 2016, 102, 1544-1551.	1.2	15
2126	Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2177-2185.	2.2	10
2127	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 749-758.	2.4	7
2128	Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E335-E345.	1.8	7
2129	Pathophysiology of Diabetic Nephropathy. , 2016, , 41-65.		2
2131	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. <i>Diabetes Therapy</i> , 2016, 7, 621-639.	1.2	21
2132	Interactions between kidney disease and diabetes: dangerous liaisons. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 50.	1.2	108
2134	Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 259.	0.7	17
2135	Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. <i>Annals of Internal Medicine</i> , 2016, 164, 542.	2.0	487

#	ARTICLE	IF	CITATIONS
2136	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1799-1802.	13.9	120
2137	Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2016, 9, CMED.s39761.	1.0	12
2138	Low-density lipoprotein cholesterol goals: still not in patients' best interest: Table A1. <i>Evidence-Based Medicine</i> , 2016, 21, 128-133.	0.6	1
2139	Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000123.	1.2	26
2140	Association between hyperglycaemic crisis and long-term major adverse cardiovascular events: a nationwide population-based, propensity score-matched, cohort study. <i>BMJ Open</i> , 2016, 6, e012233.	0.8	8
2141	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000206.	1.2	6
2142	Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 99.	0.7	18
2143	Survivors of intensive care with type 2 diabetes and the effect of shared care follow-up clinics: study protocol for the SWEET-AS randomised controlled feasibility study. <i>Pilot and Feasibility Studies</i> , 2016, 2, 62.	0.5	4
2146	Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2016, 15, 145.	2.7	14
2147	Association of self-reported recurrent mild hypoglycemia with incident cardiovascular disease and all-cause mortality in patients with type 2 diabetes. <i>Medicine (United States)</i> , 2016, 95, e5183.	0.4	14
2148	Biomarkers associated with severe hypoglycaemia and death in <sc>ACCORD</sc>. <i>Diabetic Medicine</i> , 2016, 33, 1076-1083.	1.2	4
2149	Cardiovascular effects of anti-diabetes drugs. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1239-1257.	1.0	14
2152	Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2016, 176, 969.	2.6	115
2153	Hypertension and Brain Damage. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , .	0.1	3
2154	The Contribution of Diabetes Education in the Treatment of People with Type 2 Diabetes and Risk of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 44.	2.0	4
2155	Do Veterans Health Administration Enrollees Generalize to Other Populations?. <i>Medical Care Research and Review</i> , 2016, 73, 493-507.	1.0	76
2156	Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain. <i>BMC Endocrine Disorders</i> , 2016, 16, 10.	0.9	15
2157	Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1251-1258.	1.3	22

#	ARTICLE	IF	CITATIONS
2158	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1378-1384.	1.2	9
2160	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2016, 12, 566-592.	4.3	292
2161	Has the safety of diabetes therapy improved? Lessons from an analysis of diabetic medication-induced severe hypoglycemic cases in an emergency department from 2005 to 2013. <i>Diabetology International</i> , 2016, 7, 274-280.	0.7	2
2162	IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes. <i>Primary Care Diabetes</i> , 2016, 10, 202-209.	0.9	15
2163	Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes. <i>Pharmacology</i> , 2016, 98, 134-170.	0.9	21
2164	Management of diabetes mellitus in older people with comorbidities. <i>BMJ</i> , The, 2016, 353, i2200.	3.0	52
2165	Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. <i>Cardiology</i> , 2016, 135, 108-126.	0.6	5
2166	Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 677-685.	5.5	60
2167	Optimizing management of glycaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 397-411.	2.2	10
2168	Managing hypoglycaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 413-430.	2.2	42
2169	Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy. <i>Cardiovascular Research</i> , 2016, 111, 172-183.	1.8	67
2170	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
2171	Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 244-255.	1.4	38
2174	SGLT2 inhibitors in the management of type 2 diabetes. <i>Endocrine</i> , 2016, 53, 364-372.	1.1	64
2176	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2016, 15, 37.	2.7	148
2177	Diabetes and the heart — the battle is not lost yet!. <i>Herz</i> , 2016, 41, 173-174.	0.4	0
2178	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	0
2179	Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report. <i>Diabetology International</i> , 2016, 7, 12-15.	0.7	11

#	ARTICLE	IF	CITATIONS
2180	Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1186-1195.	0.9	15
2181	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
2182	Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 598-606.	2.2	19
2183	The impact of ambient temperature on HbA1c in Taiwanese type 2 diabetic patients: The most vulnerable subgroup. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 343-349.	0.8	20
2184	Kinase-SUMO networks in diabetes-mediated cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 623-633.	1.5	33
2185	A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. <i>Journal of Vascular Surgery</i> , 2016, 63, 22S-28S.e2.	0.6	92
2186	Current Ideas on the Treatment Of Diabetic Neuropathies. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 187-195.	1.2	5
2187	General Concepts: Therapies for Rehabilitation and Recovery. , 2016, , 195-201.		3
2188	A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetes Care</i> , 2016, 39, 448-454.	4.3	31
2189	Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). <i>Diabetes Care</i> , 2016, 39, 455-464.	4.3	110
2190	A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 393-402.	1.0	16
2191	The Impact of Hypoglycemia on the Cardiovascular System. <i>Angiology</i> , 2016, 67, 802-809.	0.8	29
2192	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	0.5	1
2193	Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2016, 113, 108-115.	1.1	15
2194	A Diabetes-Atrial Fibrillation Conundrum. <i>Journal of the American College of Cardiology</i> , 2016, 67, 248-250.	1.2	3
2195	Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials. <i>Clinical Therapeutics</i> , 2016, 38, 372-386.e6.	1.1	18
2196	Treatment of hypertension in diabetes: a contemporary approach with a focus on improving cardiovascular outcomes. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 41-50.	1.2	3
2197	Coronary Artery Disease and Diabetes Mellitus. <i>Heart Failure Clinics</i> , 2016, 12, 117-133.	1.0	16

#	ARTICLE	IF	CITATIONS
2199	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. <i>Diabetes Research and Clinical Practice</i> , 2016, 112, 50-56.	1.1	11
2200	Dried Saliva Spot (DSS) as a Convenient and Reliable Sampling for Bioanalysis: An Application for the Diagnosis of Diabetes Mellitus. <i>Analytical Chemistry</i> , 2016, 88, 635-639.	3.2	41
2201	Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors. <i>Endocrine</i> , 2016, 53, 373-380.	1.1	6
2202	Diabetes and infection: assessing the association with glycaemic control in population-based studies. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 148-158.	5.5	220
2203	The EMPA-REG study: What has it told us? A diabetologist's perspective. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1-2.	1.2	38
2204	Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 91-101.	2.6	22
2205	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 273-284.	1.1	19
2206	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. <i>Postgraduate Medicine</i> , 2016, 128, 398-408.	0.9	2
2207	Extra-glycaemic properties of empagliflozin. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 230-237.	1.7	7
2208	Mean <math>\langle \text{HbA}_{1c} \rangle</math> and mortality in diabetic individuals with heart failure: a population cohort study. <i>European Journal of Heart Failure</i> , 2016, 18, 94-102.	2.9	76
2209	Intensive versus conventional glycaemic control for treating diabetic foot ulcers. <i>The Cochrane Library</i> , 2016, 2016, CD010764.	1.5	28
2210	Medical Practice Variations in Diabetes Mellitus. , 2016, , 323-359.		1
2211	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 277-284.	1.8	14
2212	Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice. <i>Journal of Diabetes Investigation</i> , 2016, 7, 94-99.	1.1	29
2213	Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 316-324.	1.7	48
2214	Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. <i>Diabetes Therapy</i> , 2016, 7, 187-201.	1.2	29
2215	The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis. <i>Diabetes Research and Clinical Practice</i> , 2016, 113, 152-159.	1.1	7
2216	Non-linear associations of risk factors with mild hypoglycemia among Chinese patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 462-468.	1.2	8



#	ARTICLE	IF	CITATIONS
2217	Associations between lower urinary tract dysfunction and glycemic control in women with type 2 diabetes: A cross-sectional study. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 415-419.	1.2	9
2218	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016, 39, 701-708.	4.3	150
2219	Type 2 Diabetes: Etiology, Epidemiology, Pathogenesis, Treatment. , 2016, , 601-617.		3
2221	The association between participation in a pay-for-performance program and macrovascular complications in patients with type 2 diabetes in Taiwan: A nationwide population-based cohort study. <i>Preventive Medicine</i> , 2016, 85, 53-59.	1.6	30
2222	Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: the Hoorn Diabetes Care System Cohort Study. <i>European Journal of Endocrinology</i> , 2016, 174, 563-571.	1.9	20
2223	Effect of Continuous Positive Airway Pressure on Glycemic Control in Patients with Obstructive Sleep Apnea and Type 2 Diabetes. A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 476-485.	2.5	169
2224	Polypharmacy in the Aging Patient. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1034.	3.8	236
2225	Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. <i>Journal of Lipid Research</i> , 2016, 57, 894-905.	2.0	41
2226	Treatment Goals in Diabetes. <i>Endocrine Development</i> , 2016, 31, 1-27.	1.3	25
2227	The 'Old' Anti-Diabetic Agents: A Systematic Inventory. <i>Endocrine Development</i> , 2016, 31, 28-42.	1.3	5
2228	Diabetes and Risk of Arterial Stiffness: A Mendelian Randomization Analysis. <i>Diabetes</i> , 2016, 65, 1731-1740.	0.3	62
2229	Risk factors for hypoglycemia in patients with type 2 diabetes, hospitalized in internal medicine wards: Findings from the FADOI-DIAMOND study. <i>Diabetes Research and Clinical Practice</i> , 2016, 115, 24-30.	1.1	26
2230	Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e003643.	1.3	74
2231	Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011. <i>Diabetes Care</i> , 2016, 39, 363-370.	4.3	121
2232	5. Glycemic Targets. <i>Diabetes Care</i> , 2016, 39, S39-S46.	4.3	222
2233	Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study. <i>Acta Diabetologica</i> , 2016, 53, 461-468.	1.2	21
2234	Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 207-219.	4.0	12
2235	Hypoglycemia in Diabetes Mellitus as a Coronary Artery Disease Risk Factor in Patients at Elevated Vascular Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 659-668.	1.8	21

#	ARTICLE	IF	CITATIONS
2236	Baseline glyceic status and mortality in 241,499 Korean metropolitan subjects: A Kangbuk Samsung Health Study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 68-77.	1.5	7
2237	Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 243-253.	1.8	11
2238	Ischemic Stroke Therapeutics. , 2016, , .		1
2240	Preventing a First Stroke. , 2016, , 280-291.		1
2241	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. <i>International Journal of Cardiology</i> , 2016, 202, 291-296.	0.8	33
2242	Approach to diabetes management in patients with CVD. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 165-179.	2.3	38
2244	Hypoglycemia and Hypoglycemic Syndromes. , 2016, , 816-838.e8.		2
2245	Diabetes and Long-Term Complications. , 2016, , 898-906.e3.		4
2246	Management of Type 2 Diabetes Mellitus. , 2016, , 839-853.e2.		6
2247	Diabetic Neurology. , 0, , .		7
2248	Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1036-1043.	0.4	34
2249	Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes. <i>Diabetic Medicine</i> , 2017, 34, 64-68.	1.2	26
2250	The association of cardiac function, structure, and glyceic control in patients with old myocardial infarction: a study using cardiac magnetic resonance. <i>Diabetology International</i> , 2017, 8, 23-29.	0.7	1
2251	Success of a sports-club led-community X-PERT Diabetes Education Programme. <i>Sport in Society</i> , 2017, 20, 269-280.	0.8	5
2252	The relationship of regional hemoglobin A1c testing and amputation rate among patients with diabetes. <i>Vascular</i> , 2017, 25, 142-148.	0.4	3
2253	Association between severity of hypoglycemia and loss of heart rate variability in patients with type 1 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2830.	1.7	22
2254	Management of Diabetes in the Pre-End-Stage Renal Disease and Chronic Kidney Disease. , 2017, , 57-75.		0
2256	Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. <i>Journal of Diabetes</i> , 2017, 9, 412-422.	0.8	9

#	ARTICLE	IF	CITATIONS
2257	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 375-377.	1.1	5
2258	Effects of Î²-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 800-808.	2.2	15
2259	Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. <i>Hypertension Research</i> , 2017, 40, 535-540.	1.5	33
2261	Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapies. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2883.	1.7	9
2262	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 664-671.	2.2	53
2263	Standards of Care and Treatment in Diabetes. <i>Physician Assistant Clinics</i> , 2017, 2, 13-23.	0.1	11
2264	An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. <i>Circulation</i> , 2017, 135, 180-195.	1.6	39
2265	Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 284-295.	0.7	54
2267	Cardiac Autonomic Regulation and Repolarization During Acute Experimental Hypoglycemia in Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 1322-1333.	0.3	36
2268	Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study. <i>Diabetes Care</i> , 2017, 40, 591-598.	4.3	70
2269	Prevention of complications in type 2 diabetes: is drug glucose control evidence based?. <i>British Journal of General Practice</i> , 2017, 67, 85-87.	0.7	17
2270	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 18.	2.7	43
2272	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 391-402.	5.5	56
2273	Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. <i>Cardiovascular Diabetology</i> , 2017, 16, 10.	2.7	46
2274	Cardiac Effects of Sulfonylurea-Related Hypoglycemia. <i>Diabetes Care</i> , 2017, 40, 663-670.	4.3	26
2275	Hemoglobin A1c and Mortality in Older Adults With and Without Diabetes: Results From the National Health and Nutrition Examination Surveys (1988-2011). <i>Diabetes Care</i> , 2017, 40, 453-460.	4.3	84
2276	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 19.	1.3	19
2277	American College of Foot and Ankle Surgeons® Clinical Consensus Statement: Perioperative Management. <i>Journal of Foot and Ankle Surgery</i> , 2017, 56, 336-356.	0.5	18

#	ARTICLE	IF	CITATIONS
2278	Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus. <i>Scientific Reports</i> , 2017, 7, 39965.	1.6	7
2279	Doing it hard in the bush: Aligning what gets measured with what matters. <i>Australian Journal of Rural Health</i> , 2017, 25, 246-251.	0.7	8
2280	Are diabetes guidelines truly evidence based?. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 70-79.	1.1	5
2281	Peripheral neuropathy in prediabetes and the metabolic syndrome. <i>Journal of Diabetes Investigation</i> , 2017, 8, 646-655.	1.1	183
2282	Diagnosis and Management of Type 2 Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1366-1373.	2.2	227
2283	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2017, 2, CD009966.	1.5	20
2284	Prediabetes definitions and clinical outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 94.	5.5	0
2285	Consensus statement on insulin therapy in chronic kidney disease. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 10-20.	1.1	19
2286	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 249-253.	0.9	45
2287	Type 2 diabetes. <i>Lancet</i> , 2017, 389, 2239-2251.	6.3	1,691
2288	Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 191-198.	2.1	50
2289	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. <i>Current Cardiology Reports</i> , 2017, 19, 25.	1.3	2
2290	Genome-wide mRNA analysis reveals a TUBD1 isoform profile as a potential biomarker for diabetic retinopathy development. <i>Experimental Eye Research</i> , 2017, 155, 99-106.	1.2	10
2291	Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 203-215.	1.0	5
2292	Epidemiology in diabetes mellitus and cardiovascular disease. <i>Cardiovascular Endocrinology</i> , 2017, 6, 8-16.	0.8	109
2293	Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H515-H527.	1.5	25
2294	Ensuring Patient Safety During the Transition to ESRD. <i>Seminars in Nephrology</i> , 2017, 37, 194-208.	0.6	4
2295	Five Simple Steps to Optimize Bolus Insulin Therapy in Type 2 Diabetes. <i>Clinical Diabetes</i> , 2017, 35, 108-111.	1.2	2

#	ARTICLE	IF	CITATIONS
2296	Combination therapy with <scp>GLP</scp>-1 receptor agonist and <scp>SGLT2</scp> inhibitor. Diabetes, Obesity and Metabolism, 2017, 19, 1353-1362.	2.2	120
2297	After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?. Diabetes and Metabolism, 2017, 43, 2S3-2S12.	1.4	26
2298	Mediators of diabetic neuropathy: is hyperglycemia the only culprit?. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 103-111.	1.2	71
2299	Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects. Kidney Diseases (Basel, Switzerland), 2017, 1, 1-14.	1.2	30
2300	Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus. Revista Clínica Española, 2017, 217, 201-206.	0.3	2
2301	Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine, 2017, 34, 1244-1251.	1.2	8
2302	Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells. Journal of Diabetes Investigation, 2017, 8, 750-761.	1.1	33
2303	Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obesity and Metabolism, 2017, 19, 1425-1435.	2.2	39
2304	Diabetes after Bariatric Surgery. Canadian Journal of Diabetes, 2017, 41, 401-406.	0.4	38
2305	Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 2017, 237, 185-222.	1.0	456
2306	Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes. European Journal of Preventive Cardiology, 2017, 24, 1181-1189.	0.8	12
2307	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research, 2017, 14, 172-183.	0.9	102
2308	Are targeted therapies for diabetic cardiomyopathy on the horizon?. Clinical Science, 2017, 131, 897-915.	1.8	83
2309	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 1645-1654.	2.2	24
2310	Jump starting shared medical appointments for diabetes with weight management: Rationale and design of a randomized controlled trial. Contemporary Clinical Trials, 2017, 58, 1-12.	0.8	11
2311	Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. Journal of Cardiology, 2017, 69, 511-517.	0.8	8
2312	Multiplex Biomarker Approaches in Type 2 Diabetes Mellitus Research. Methods in Molecular Biology, 2017, 1546, 37-55.	0.4	3
2313	A Unified Pathophysiological Construct of Diabetes and its Complications. Trends in Endocrinology and Metabolism, 2017, 28, 645-655.	3.1	71

#	ARTICLE	IF	CITATIONS
2314	EMPA-REG OUTCOME: The Endocrinologist's Point of View. American Journal of Cardiology, 2017, 120, S48-S52.	0.7	2
2316	Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2032-2045.	2.2	1,600
2317	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 313-329.	1.0	9
2318	Cardiovascular safety of noninsulin antidiabetic drugs: Facts and promises. Revista Clínica Espanola, 2017, 217, 473-477.	0.3	0
2319	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. Diabetes Care, 2017, 40, 813-820.	4.3	109
2320	Glucose targets for preventing diabetic kidney disease and its progression. The Cochrane Library, 2017, 2017, CD010137.	1.5	47
2321	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. Journal of General Internal Medicine, 2017, 32, 1044-1051.	1.3	20
2322	Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany. Diabetic Medicine, 2017, 34, 1212-1218.	1.2	7
2323	Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes. Diabetes Care, 2017, 40, 1050-1057.	4.3	26
2324	Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends in Endocrinology and Metabolism, 2017, 28, 561-586.	3.1	31
2325	Novel Approach to Non-Invasive Blood Glucose Monitoring Based on Transmittance and Refraction of Visible Laser Light. IEEE Access, 2017, 5, 9163-9174.	2.6	52
2326	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. American Journal of Medicine, 2017, 130, S18-S29.	0.6	67
2327	A review on cardiovascular effects of newer hypoglycaemic medications. Annals of Medicine, 2017, 49, 603-612.	1.5	10
2328	Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study. International Journal of Clinical Practice, 2017, 71, e12958.	0.8	6
2329	Development of glucose-responsive "smart" insulin systems. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 267-278.	1.2	47
2330	EMPA-REG OUTCOME: The Endocrinologist's Point of View. American Journal of Medicine, 2017, 130, S51-S56.	0.6	3
2331	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. European Journal of Internal Medicine, 2017, 42, 1-15.	1.0	11
2332	How good is the evidence to support primary care practice?. Evidence-Based Medicine, 2017, 22, 88-92.	0.6	43

#	ARTICLE	IF	CITATIONS
2333	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017, 120, S17-S27.	0.7	66
2334	Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy. <i>Clinical Therapeutics</i> , 2017, 39, 1085-1103.	1.1	47
2335	Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 423-433.	0.9	35
2336	Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
2337	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
2338	Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T). <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 161-168.	1.1	22
2339	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 121-129.	1.1	53
2340	How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?. <i>Diabetes</i> , 2017, 66, 1758-1765.	0.3	33
2341	Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. <i>The Cochrane Library</i> , 2017, 2017, CD003804.	1.5	114
2342	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 591-597.	0.4	6
2343	Eficacia y seguridad de una pauta basal plus con insulina glargina e insulina glulisina en pacientes ancianos de alto riesgo cardiovascular con diabetes mellitus tipo 2. <i>Revista Clínica Española</i> , 2017, 217, 201-206.	0.2	8
2344	Seguridad cardiovascular de los antidiabéticos no insulínicos: hechos y promesas. <i>Revista Clínica Española</i> , 2017, 217, 473-477.	0.2	1
2345	New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. <i>Neuron</i> , 2017, 93, 1296-1313.	3.8	599
2346	Pathophysiological Fundamentals of Diabetic Cardiomyopathy. , 2017, 7, 693-711.		85
2347	Evidence-based recommendations and expert consensus on enteral nutrition in the adult patient with diabetes mellitus or hyperglycemia. <i>Nutrition</i> , 2017, 41, 58-67.	1.1	31
2348	Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	32
2349	Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom. <i>Diabetes Therapy</i> , 2017, 8, 417-431.	1.2	21
2350	Diabetes control: Incidence of acute myocardial infarction and all-cause mortality among patients with 3-6 years disease duration. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1083-1092.	0.8	3

#	ARTICLE	IF	CITATIONS
2351	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
2352	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 431-437.	5.5	379
2353	Demographic and clinical profiles of type 2 diabetes mellitus patients initiating sitagliptin in the real-world setting. <i>Current Medical Research and Opinion</i> , 2017, 33, 1247-1253.	0.9	0
2354	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. <i>Advances in Therapy</i> , 2017, 34, 954-965.	1.3	18
2355	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 687-693.	4.3	45
2356	Overexpression of decorin promoted angiogenesis in diabetic cardiomyopathy via IGF1R-AKT-VEGF signaling. <i>Scientific Reports</i> , 2017, 7, 44473.	1.6	33
2357	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 324-327.	2.4	5
2358	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
2359	High rates of severe hypoglycemia among African American patients with diabetes: the surveillance, prevention, and Management of Diabetes Mellitus (SUPREME-DM) network. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 869-873.	1.2	44
2360	Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. <i>Journal of Medical Economics</i> , 2017, 20, 663-670.	1.0	18
2361	The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations. <i>Diabetes Care</i> , 2017, 40, 444-452.	4.3	122
2362	Diabetes and Aging: Unique Considerations and Goals of Care. <i>Diabetes Care</i> , 2017, 40, 440-443.	4.3	146
2363	Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 213-217.	1.2	3
2364	Understanding the impact of hypoglycemia on the cardiovascular system. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 21-33.	1.2	26
2365	Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 644-653.	2.2	16
2366	Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1195-1204.	0.7	18
2367	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. <i>Journal of Cardiology</i> , 2017, 69, 501-507.	0.8	28
2368	QT prolongation caused by insulin-induced hypoglycaemia – An interventional study in 119 individuals. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 165-172.	1.1	24



#	ARTICLE	IF	CITATIONS
2369	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nature Reviews Nephrology</i> , 2017, 13, 11-26.	4.1	398
2370	Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor. <i>Journal of Cardiology</i> , 2017, 69, 508-510.	0.8	2
2371	Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats. <i>Atherosclerosis</i> , 2017, 257, 152-163.	0.4	42
2372	Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S159-S168.	1.8	0
2373	6. Glycemic Targets. <i>Diabetes Care</i> , 2017, 40, S48-S56.	4.3	305
2374	Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2017, 167, 655.	2.0	80
2375	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. <i>Current Diabetes Reports</i> , 2017, 17, 124.	1.7	17
2376	Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. <i>Canadian Journal of Ophthalmology</i> , 2017, 52, S45-S74.	0.4	18
2377	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 422-434.	1.6	87
2378	Is glycemia control in Canadians with diabetes individualized? A cross-sectional observational study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000316.	1.2	12
2379	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. <i>Current Heart Failure Reports</i> , 2017, 14, 445-453.	1.3	7
2380	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 951-964.	5.5	228
2382	Challenges in Choosing a Medication for Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 557-559.	2.4	1
2383	Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes. <i>Postgraduate Medicine</i> , 2017, 129, 791-800.	0.9	6
2384	Predictors for the development of microalbuminuria and interaction with renal function. <i>Journal of Hypertension</i> , 2017, 35, 2501-2509.	0.3	14
2385	Insulin and Its Cardiovascular Effects: What Is the Current Evidence?. <i>Current Diabetes Reports</i> , 2017, 17, 120.	1.7	25
2386	Undocumented and documented migrants with chronic diseases in Family Practice in the Netherlands. <i>Family Practice</i> , 2017, 34, 649-655.	0.8	12
2387	The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective. <i>Clinical Cardiology</i> , 2017, 40, 970-973.	0.7	4

#	ARTICLE	IF	CITATIONS
2388	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. <i>Diabetes Care</i> , 2017, 40, 1144-1151.	4.3	50
2391	Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. <i>Medicine (United States)</i> , 2017, 96, e7638.	0.4	28
2392	Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 60-68.	1.1	15
2393	Review: The relationship of hemoglobin A1c to postoperative surgical risk with an emphasis on joint replacement surgery. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1710-1718.	1.2	19
2394	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017, 40, 1302-1313.	4.3	11
2395	Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. <i>Diabetes Care</i> , 2017, 40, 1506-1513.	4.3	64
2396	Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. <i>Diabetes Therapy</i> , 2017, 8, 999-1013.	1.2	12
2397	Diabetes Knowledge, Management, and Prevention Among Haitian Immigrants in Philadelphia. <i>The Diabetes Educator</i> , 2017, 43, 341-347.	2.6	11
2398	Epigenetic programming, early life nutrition and the risk of metabolic disease. <i>Atherosclerosis</i> , 2017, 266, 31-40.	0.4	114
2399	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
2400	Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 67.	1.7	4
2402	Effect of nurse-led randomised control trials on cardiovascular risk factors and HbA1c in diabetes patients: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 187-199.	1.1	25
2403	Corr�lation entre l�hypoglyc�mie s�v�re et l�hypoglyc�mie non-s�v�re et les r�sultats psychologiques chez les personnes alg�riennes atteintes de diab�te de type 1 et de type 2 : r�sultats de l��tude DAWN2�,�. <i>Medicine Des Maladies Metaboliques</i> , 2017, 11, 293-299.	0.1	0
2404	Retrospective analysis of the overt proteinuria diabetic kidney disease in the treatment of modified Shenzhuo formula for 2 years. <i>Medicine (United States)</i> , 2017, 96, e6349.	0.4	13
2405	Effect of Euterpe oleracea Mart. (A�sa� Oil) on Dyslipidemia Caused by Cocos nucifera L. Saturated Fat in Wistar Rats. <i>Journal of Medicinal Food</i> , 2017, 20, 830-837.	0.8	10
2406	Individualising treatment and care of patients with diabetes. <i>The Prescriber</i> , 2017, 28, 23-25.	0.1	2
2407	Prevalence of Prediabetes and Associated Factors in the Oldest Old. A Cross Sectional Study in the Octabaix Cohort. <i>International Journal of Gerontology</i> , 2017, 11, 90-94.	0.7	0
2409	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998�2013: A Retrospective Cohort Study. <i>Diabetes Care</i> , 2017, 40, 1651-1660.	4.3	49

#	ARTICLE	IF	CITATIONS
2410	Effects of dipeptidyl peptidase-4 inhibitor sitagliptin on coronary atherosclerosis as assessed by intravascular ultrasound in type 2 diabetes mellitus with coronary artery disease. <i>IJC Metabolic &amp; Endocrine</i> , 2017, 16, 1-9.	0.5	2
2411	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2017, 248, 301-307.	0.8	27
2412	Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1620-1623.	1.2	2
2414	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	1.2	125
2415	The Older Adult with Diabetes and The Busy Clinicians. <i>Primary Care - Clinics in Office Practice</i> , 2017, 44, 469-479.	0.7	2
2416	Vitamin D in the Spectrum of Prediabetes and Cardiovascular Autonomic Dysfunction. <i>Journal of Nutrition</i> , 2017, 147, jn250209.	1.3	16
2417	Mortality in older people with diabetes: A review of current research. <i>International Diabetes Nursing</i> , 2017, 14, 20-25.	0.1	1
2418	Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. <i>Diabetes Research and Clinical Practice</i> , 2017, 134, 17-28.	1.1	40
2419	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. <i>Current Geriatrics Reports</i> , 2017, 6, 175-186.	1.1	20
2420	Endothelial Progenitor Cell Dysfunction in the Pathogenesis of Vascular Complications of Diabetes. , 2017, , 159-208.		1
2421	Type 2 diabetes in general practice in Norway 2005–2014: moderate improvements in risk factor control but still major gaps in complication screening. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000459.	1.2	35
2422	Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings. <i>BMJ Open</i> , 2017, 7, e015135.	0.8	53
2423	Care of older people with diabetes. <i>Nursing Standard (Royal College of Nursing (Great Britain): 1987)</i> , 2017, 32, 50-63.	0.1	3
2424	Predictors of Development and Progression of Retinopathy in Patients with Type 2 Diabetes: Importance of Blood Pressure Parameters. <i>Scientific Reports</i> , 2017, 7, 4867.	1.6	50
2425	Hemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 200.	3.8	2
2426	Diabetes in sub-Saharan Africa: from clinical care to health policy. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 622-667.	5.5	328
2427	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1243-1260.	0.9	35
2430	IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. <i>Diabetes Therapy</i> , 2017, 8, 531-544.	1.2	17

#	ARTICLE	IF	CITATIONS
2431	Factors associated with peripheral neuropathy in type 2 diabetes: Subclinical versus confirmed neuropathy. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2017, 37, 337-342.	1.0	8
2433	Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 320-328.	2.2	3
2434	Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 537-543.	1.2	42
2435	Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 419-426.	1.2	22
2436	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. <i>Clinical Therapeutics</i> , 2017, 39, 1012-1025.	1.1	15
2437	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 368-375.	3.0	280
2438	Relationship between achieved personalized glycaemic targets and monitoring of clinical events in elderly diabetic patients. <i>Diabetes and Metabolism</i> , 2017, 43, 59-68.	1.4	1
2439	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. <i>Annals of Medicine</i> , 2017, 49, 51-62.	1.5	17
2440	Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. <i>Journal of Diabetes Investigation</i> , 2017, 8, 227-234.	1.1	37
2441	Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. <i>Journal of Diabetes</i> , 2017, 9, 141-148.	0.8	68
2442	Following the LEADER – why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 517-519.	1.2	9
2443	Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, 119-124.	1.8	44
2444	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. <i>Diabetes Care</i> , 2017, 40, 468-475.	4.3	249
2445	Lower prevalence of proliferative diabetic retinopathy in elderly onset patients with diabetes. <i>Diabetes Research and Clinical Practice</i> , 2017, 125, 47-52.	1.1	6
2446	Inpatient Glycemic Variability and Long-Term Mortality in Hospitalized Patients with Type 2 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 479-482.	1.2	29
2447	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	0.8	25
2448	Digging Deeper: Hidden Messages Beyond the Overall Prevalence of Diabetic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2017, 69, 495-497.	2.1	1
2449	A Proposal for an Out-of-Range Glycemic Population Health Safety Measure for Older Adults With Diabetes. <i>Diabetes Care</i> , 2017, 40, 518-525.	4.3	17

#	ARTICLE	IF	CITATIONS
2450	Personalised treatment targets in type 2 diabetes patients: The Dutch approach. <i>Primary Care Diabetes</i> , 2017, 11, 71-77.	0.9	16
2451	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4343-4410.	1.8	323
2452	Protocol for the specialist supervised individualised multifactorial treatment of new clinically diagnosed type 2 diabetes in general practice (IDA): a prospective controlled multicentre open-label intervention study. <i>BMJ Open</i> , 2017, 7, e017493.	0.8	6
2453	Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	7
2454	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. <i>Clinical Diabetes</i> , 2017, 35, 321-328.	1.2	4
2455	Deprescribing in Older Nursing Home Patients: Focus on Innovative Composite Measures for Dosage Deintensification. <i>Innovation in Aging</i> , 2017, 1, igx031.	0.0	8
2456	Type 2 diabetes in primary care. <i>InnovAiT</i> , 2017, 10, 705-712.	0.0	0
2457	KDM3A inhibition attenuates high concentration insulin-induced vascular smooth muscle cell injury by suppressing MAPK/NF- $\kappa$ B pathways. <i>International Journal of Molecular Medicine</i> , 2018, 41, 1265-1274.	1.8	23
2459	Investigation on the relationship between cholesterol and blood glucose levels using decision tree method in healthy subjects. , 2017, , .		2
2460	Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain. <i>Evidence-Based Medicine</i> , 2017, 22, 219-220.	0.6	1
2461	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	1.3	4
2463	Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!. , 2017, , .		0
2464	Review: Biomarkers and Role in the Prediction and Detection of Type 2 Diabetes and Its Complications. <i>Biomarkers Journal</i> , 2017, 3, .	0.2	2
2465	Diabetic: A Comparative Study. <i>Janaki Medical College Journal of Medical Science</i> , 2017, 4, 19-26.	0.1	0
2466	Guía de práctica clínica para el tratamiento de la diabetes mellitus tipo 2: metas de manejo. <i>Revista Universitas Medica</i> , 2017, 58, .	0.0	0
2467	Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2017, 8, 845.	1.6	10
2468	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 69-79.	0.9	6
2469	Homocysteine as a non-classical risk factor for atherosclerosis in relation to pharmacotherapy of type 2 diabetes mellitus. <i>Acta Biochimica Polonica</i> , 2017, 64, 603-607.	0.3	4

#	ARTICLE	IF	CITATIONS
2470	Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes. <i>Journal of UOEH</i> , 2017, 39, 1-9.	0.3	0
2471	The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. <i>Nutrients</i> , 2017, 9, 437.	1.7	169
2472	Cardio-Metabolic Benefits of Plant-Based Diets. <i>Nutrients</i> , 2017, 9, 848.	1.7	255
2473	Hypoglycemia and Dementia. <i>Endocrinology and Metabolism</i> , 2017, 32, 195.	1.3	13
2474	Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy. <i>Frontiers in Endocrinology</i> , 2017, 8, 89.	1.5	38
2475	Diabetic Neuropathy Evaluated by a Novel Device: Sural Nerve Conduction Is Associated with Glycemic Control and Ankle Brachial Pressure Index in Japanese Patients with Diabetes. <i>Frontiers in Endocrinology</i> , 2017, 8, 203.	1.5	14
2476	Influenza Virus and Glycemic Variability in Diabetes: A Killer Combination?. <i>Frontiers in Microbiology</i> , 2017, 8, 861.	1.5	91
2477	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. <i>BioMed Research International</i> , 2017, 2017, 1-15.	0.9	1
2478	Macrovascular Complications in Patients with Diabetes and Prediabetes. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	160
2479	Expression Profile of Genes Potentially Associated with Adequate Glycemic Control in Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-9.	1.0	8
2480	The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-15.	1.0	195
2481	Gene Expression Profiling Identifies Downregulation of the Neurotrophin-MAPK Signaling Pathway in Female Diabetic Peripheral Neuropathy Patients. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-11.	1.0	28
2482	Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated Diabetes. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-7.	1.0	22
2483	The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-7.	0.6	8
2484	Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-9.	1.0	39
2485	Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 157-168.	0.9	5
2486	Vegetarian Diets in People With Type 2 Diabetes. , 2017, , 369-393.		1
2487	Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries. <i>PLoS ONE</i> , 2017, 12, e0183235.	1.1	25

#	ARTICLE	IF	CITATIONS
2488	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 229.	0.7	25
2489	Identification of outliers and positive deviants for healthcare improvement: looking for high performers in hypoglycemia safety in patients with diabetes. <i>BMC Health Services Research</i> , 2017, 17, 738.	0.9	6
2490	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. <i>Cardiovascular Diabetology</i> , 2017, 16, 114.	2.7	27
2491	Effects of hypoglycemia on myocardial susceptibility to ischemiaâ€“reperfusion injury and preconditioning in hearts from rats with and without type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 148.	2.7	26
2492	Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0%. <i>Cardiovascular Diabetology</i> , 2017, 16, 151.	2.7	24
2493	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 53.	1.2	34
2494	Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis. <i>Journal of Diabetes and Metabolic Disorders</i> , 2017, 16, 45.	0.8	39
2495	Coronary Artery Disease and Type 2 Diabetes Mellitus. <i>International Heart Journal</i> , 2017, 58, 475-480.	0.5	123
2497	Glycated Hemoglobin and All-Cause Mortality in Korean Type 2 Diabetes. <i>Chonnam Medical Journal</i> , 2017, 53, 223.	0.5	1
2500	Diabetes mellitus and stroke: A clinical update. <i>World Journal of Diabetes</i> , 2017, 8, 235.	1.3	105
2501	Treatment of type 2 diabetes mellitus in the elderly. <i>World Journal of Diabetes</i> , 2017, 8, 278.	1.3	62
2502	The impact of type 2 diabetes mellitus on prognosis in patients with non-ST elevation myocardial infarction. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2017, 2, 127-132.	0.1	1
2503	Glycemic targets in patients with diabetes. <i>Journal of the Korean Medical Association</i> , 2017, 60, 889.	0.1	1
2504	Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus: A Cardiologistâ€™s View. , 2017, , .		1
2505	Monotherapy in Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 349.	1.8	13
2506	The Role of Diet in the Prevention and Treatment of Diabetes. , 2017, , 691-707.		0
2507	Anti-diabetic medications: How to make a choice?. <i>Sudanese Journal of Paediatrics</i> , 2017, 17, 11-20.	0.6	20
2508	Quality of diabetes mellitus therapy in patients with chronic kidney disease in the real world. <i>Italian Journal of Medicine</i> , 2017, 11, 48.	0.2	0

#	ARTICLE	IF	CITATIONS
2510	Metabolic surgery: gastric bypass for the treatment of type 2 diabetes mellitus. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 58-58.	1.5	15
2511	The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA1c(v)-Lowering Medications. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 1-3.	1.3	1
2512	The Landscape of Diabetic Kidney Disease in the United States. <i>Current Diabetes Reports</i> , 2018, 18, 14.	1.7	43
2513	EADSG Guidelines: Insulin Therapy in Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 449-492.	1.2	103
2514	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 189-222.	0.6	19
2515	Legacy effect in combined diabetic-renal multifactorial intervention in patients with advanced diabetic nephropathy. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 474-479.	1.2	8
2516	Incidence of hypoglycaemia among insulin-treated patients with type 1 or type 2 diabetes mellitus: South African cohort of International Operations Hypoglycaemia Assessment Tool (IO HAT) study. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2018, 23, 1-8.	0.4	2
2517	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
2518	Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	0
2519	Why prescribe exercise as therapy in type 2 diabetes? We have a pill for that!. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2999.	1.7	20
2521	Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 253-261.	1.1	37
2523	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 275-281.	0.1	4
2524	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. <i>Postgraduate Medicine</i> , 2018, 130, 381-393.	0.9	24
2525	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. <i>Annals of Vascular Diseases</i> , 2018, 11, 2-14.	0.2	8
2526	Putting Systems and Complexity Sciences Into Practice. , 2018, , .		2
2527	Targets for Glycemic Control. <i>Canadian Journal of Diabetes</i> , 2018, 42, S42-S46.	0.4	65
2528	Consensus on insulin treatment in type 2 diabetes. <i>Endocrinología y Nutrición (English Ed )</i> , 2018, 65, 1-8.	0.1	0
2529	Preventive Cardiology. , 2018, , 269-289.		0



#	ARTICLE	IF	CITATIONS
2530	Stable Ischemic Heart Disease. , 2018, , 591-630.		2
2531	Cardiovascular Protection in People With Diabetes. Canadian Journal of Diabetes, 2018, 42, S162-S169.	0.4	44
2532	Low serum creatinine predicts risk for type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3011.	1.7	18
2533	Chronic Kidney Disease in Diabetes. Canadian Journal of Diabetes, 2018, 42, S201-S209.	0.4	57
2534	Insulin Treatment. Endocrinology, 2018, , 1-24.	0.1	0
2535	Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics, 2018, 40, 776-788.e3.	1.1	14
2536	Relation between HbA1c and incident cardiovascular disease over a period of 6 years in the Hong Kong population. Diabetes and Metabolism, 2018, 44, 415-423.	1.4	5
2537	The Genetic Link Between Diabetes and Atherosclerosis. Canadian Journal of Cardiology, 2018, 34, 565-574.	0.8	15
2538	Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. Journal of Pediatrics, 2018, 196, 208-216.e2.	0.9	24
2539	Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. Diabetes Care, 2018, 41, 840-846.	4.3	18
2540	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Failure Reviews, 2018, 23, 377-388.	1.7	16
2541	Predictors of hypoglycemia in hospitalized patients with diabetes mellitus. Internal and Emergency Medicine, 2018, 13, 343-350.	1.0	12
2542	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia, 2018, 61, 1503-1516.	2.9	64
2543	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism Clinics of North America, 2018, 47, 81-96.	1.2	54
2544	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. Endocrinology and Metabolism Clinics of North America, 2018, 47, 137-152.	1.2	7
2545	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. Endocrinology and Metabolism Clinics of North America, 2018, 47, 1-32.	1.2	16
2546	Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Therapeutic Advances in Chronic Disease, 2018, 9, 33-50.	1.1	30
2547	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open, 2018, 6, E31-E38.	1.1	27

#	ARTICLE	IF	CITATIONS
2548	Effect of glucose-lowering therapies on heart failure. <i>Nature Reviews Cardiology</i> , 2018, 15, 282-291.	6.1	45
2549	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2018, 23, 445-459.	1.7	9
2550	Managing Dyslipidemia in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 153-173.	1.2	24
2551	Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.	1.2	17
2552	Antidiabéticos en prevención de ictus en pacientes con diabetes tipo 2. El punto de vista del neurólogo. <i>Medicina Clínica</i> , 2018, 150, 275-281.	0.3	5
2553	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
2554	Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1089-1095.	2.2	6
2555	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603.	4.3	59
2556	A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 399-404.e3.	1.2	30
2557	Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018, 17, 54.	2.7	33
2558	Severe hypoglycaemia in diabetic patients in Pre-hospital and Emergency Department care: a cross-sectional survey. <i>BMC Research Notes</i> , 2018, 11, 249.	0.6	5
2559	Comparison of the Effects of Tenziglipitin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. <i>Journal of UOEH</i> , 2018, 40, 1-9.	0.3	2
2560	Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2131-2139.	2.2	14
2561	Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 353-362.	2.4	79
2562	Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 476-486.	5.5	134
2563	Precision medicine in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 891-900.	5.5	115
2565	Targeted Learning in Data Science. <i>Springer Series in Statistics</i> , 2018, , .	0.9	92
2566	Research Questions in Data Science. <i>Springer Series in Statistics</i> , 2018, , 3-14.	0.9	0

#	ARTICLE	IF	CITATIONS
2567	Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 616-617.	1.2	0
2568	Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial. <i>Diabetes Therapy</i> , 2018, 9, 987-999.	1.2	5
2569	Preventing the development and progression of diabetic kidney disease: Where do we stand?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 585-590.	1.8	4
2570	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. <i>Current Diabetes Reports</i> , 2018, 18, 27.	1.7	54
2572	Glycemic Control as Primary Prevention for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 141-148.	0.6	26
2573	Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. <i>Atherosclerosis</i> , 2018, 272, 33-40.	0.4	34
2574	Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015. <i>Diabetes Care</i> , 2018, 41, 1164-1171.	4.3	39
2575	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2018, 20, 895-896.	0.7	24
2576	Alpha-lipoic acid for diabetic peripheral neuropathy. <i>The Cochrane Library</i> , 0, , .	1.5	5
2577	Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. <i>International Journal of Clinical Practice</i> , 2018, 72, e13075.	0.8	13
2578	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	1.2	50
2579	Sodium-glucose cotransporter type-2 inhibitors: pharmacology and perioperative considerations. <i>Anaesthesia</i> , 2018, 73, 1008-1018.	1.8	50
2580	State-of-the-Art Review on Diabetes Care in Italy. <i>Annals of Global Health</i> , 2018, 81, 803.	0.8	17
2581	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: perspective on glucose-lowering interventions. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 238-244.	2.2	58
2582	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. <i>Canadian Journal of Diabetes</i> , 2018, 42, 23-30.	0.4	16
2583	Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control. <i>Current Medical Research and Opinion</i> , 2018, 34, 337-343.	0.9	13
2584	Novel Biomarkers for Predicting Cardiovascular Disease in Patients With Diabetes. <i>Canadian Journal of Cardiology</i> , 2018, 34, 624-631.	0.8	11
2585	Metabolic memory: Evolving concepts. <i>Journal of Diabetes</i> , 2018, 10, 186-187.	0.8	34

#	ARTICLE	IF	CITATIONS
2586	HbA 1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 203-209.	1.2	17
2587	Blood glucose and pressure controls in diabetic kidney disease: Narrative review of adherence, barriers and evidence of achievement. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 104-112.	1.2	8
2588	Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 121-128.	1.4	36
2589	Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study. <i>Canadian Journal of Diabetes</i> , 2018, 42, 365-371.e2.	0.4	7
2590	Prevention of Type 2 Diabetes. <i>Contemporary Diabetes</i> , 2018, , 17-29.	0.0	0
2591	Diabetes structured self-management education programmes: a narrative review and current innovations. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 130-142.	5.5	233
2592	Effects of glucose control on arterial stiffness in patients with type 2 diabetes mellitus and hypertension: An observational study. <i>Journal of International Medical Research</i> , 2018, 46, 284-292.	0.4	12
2593	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , 2018, 61, 58-65.	2.9	124
2594	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , 2018, 61, 48-57.	2.9	126
2595	High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. <i>Journal of Vascular Surgery</i> , 2018, 67, 217-228.e1.	0.6	48
2596	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	1.5	144
2597	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. <i>Endocrine</i> , 2018, 60, 224-228.	1.1	11
2598	Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 925-936.	1.1	23
2599	Endothelial Cell Metabolism. <i>Physiological Reviews</i> , 2018, 98, 3-58.	13.1	351
2600	Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. <i>International Journal of Stroke</i> , 2018, 13, 420-443.	2.9	175
2601	Survival in Type 1 and Type 2 Diabetes in a Population Referred for Invasive Evaluation of Coronary Disease. <i>Cardiology</i> , 2018, 139, 43-52.	0.6	1
2602	Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 800-811.	2.2	10
2603	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 97-116.	1.2	5

#	ARTICLE	IF	CITATIONS
2604	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 136, 23-31.	1.1	14
2605	Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 570-576.	4.3	87
2606	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€”2018</i>. <i>Diabetes Care</i> , 2018, 41, S55-S64.	4.3	701
2607	Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). <i>Diabetologia</i> , 2018, 61, 295-299.	2.9	47
2608	Blood Pressureâ€”Lowering Targets in Patients With Diabetes Mellitus. <i>Canadian Journal of Cardiology</i> , 2018, 34, 644-652.	0.8	1
2609	Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 156-162.	4.3	26
2610	Impact of differing glucoseâ€”lowering regimens on the pattern of association between glucose control and survival. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 821-830.	2.2	9
2611	The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 104-111.	4.3	149
2612	Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programmeâ€”Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Usesâ€”A Population-Based and Propensity-Matched Cohort Study. <i>Diabetes Care</i> , 2018, 41, 49-59.	4.3	82
2613	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. <i>Canadian Journal of Diabetes</i> , 2018, 42, 325-334.	0.4	11
2614	Mortality associated with less intense risk-factor control among adults with diabetes in the United States. <i>Primary Care Diabetes</i> , 2018, 12, 3-12.	0.9	6
2615	Use of Spontaneous Reporting Systems to Detect Hostâ€”Medication Interactions: Sex Differences in Oral Antiâ€”Diabetic Drugâ€”Associated Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, e008959.	1.6	7
2617	Awareness of Symptoms and Early Management of Hypoglycemia among Patients with Diabetes Mellitus. <i>Journal of Diabetes and Endocrine Association of Nepal</i> , 2018, 1, 12-17.	0.1	4
2618	Interprofessional primary care electronic intervention to reduce hypoglycaemic agent use in high-risk veterans with diabetes. <i>BMJ Open Quality</i> , 2018, 7, e000221.	0.4	1
2619	VADT (Veterans Affairs Diabetes Trial) : quelles leÃ§Ãns aprÃs 15 ans de suivi ?. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 679-682.	0.1	0
2620	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 2018, 9, CD011798.	1.5	48
2621	Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association. <i>Journal of Korean Diabetes</i> , 2018, 19, 15.	0.1	1
2622	OBSOLETE: Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
2623	OBSOLETE: Diabetes Mellitus. , 2018, , .		0
2625	Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. The Cochrane Library, 2018, 12, CD013228.	1.5	33
2626	The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes. Current Diabetes Reports, 2018, 18, 144.	1.7	7
2627	Effect of glycemic control and disease duration on cardiac autonomic function and oxidative stress in type 2 diabetes mellitus. Journal of Diabetes and Metabolic Disorders, 2018, 17, 149-158.	0.8	11
2629	The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Molecular Medicine, 2018, 24, 59.	1.9	202
2630	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 72, 3200-3223.	1.2	251
2631	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-8.	1.0	69
2633	Association of HbA1C Variability and Renal Progression in Patients with Type 2 Diabetes with Chronic Kidney Disease Stages 3&#x2014;4. International Journal of Molecular Sciences, 2018, 19, 4116.	1.8	29
2634	Comparison Of Hba1C Goals Proposed By An Algorithm To Those Set By Different Members Of Healthcare Teams Within The Dartmouth Hitchcock Health System. Endocrine Practice, 2018, 24, 705-709.	1.1	2
2636	Fighting diabetic foot ulcers&#x2014;The diabetologist: A king maker of the fight. Seminars in Vascular Surgery, 2018, 31, 49-55.	1.1	5
2637	Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients, 2018, 10, 1872.	1.7	19
2638	Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Frontiers in Physiology, 2018, 9, 1669.	1.3	87
2639	Idegliira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared With Insulin Glargine U100 Plus Insulin Aspart in the U.S.. Endocrine Practice, 2018, 24, 796-804.	1.1	6
2640	The past decade in type 2 diabetes and future challenges. Hormones, 2018, 17, 451-459.	0.9	8
2641	Reprint of: Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention. Journal of the American College of Cardiology, 2018, 72, 3071-3086.	1.2	2
2642	Effect of a Health Coach Intervention for the Management of Individuals With Type 2 Diabetes Mellitus in China: A Pragmatic Cluster Randomized Controlled Trial. Frontiers in Public Health, 2018, 6, 252.	1.3	14
2643	Efficacy and tolerability of novel triple combination therapy in drug-na&#x2014;ve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. BMJ Open, 2018, 8, e022448.	0.8	5
2644	Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial. Nutrients, 2018, 10, 1315.	1.7	37

#	ARTICLE	IF	CITATIONS
2645	Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. <i>Current Diabetes Reports</i> , 2018, 18, 102.	1.7	6
2646	Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm” Drugs, 2018, 78, 1567-1592.	4.9	8
2647	Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. , 2018, , 446-455.		0
2648	Diabetes and the Nervous System. <i>Endocrinology</i> , 2018, , 1-82.	0.1	1
2649	Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1829-1844.	1.2	32
2651	Multifactorial intervention for diabetes control among older users of insulin. <i>Revista De Saude Publica</i> , 2018, 52, 60.	0.7	4
2652	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
2653	Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark. <i>Diabetes Care</i> , 2018, 41, 2586-2594.	4.3	67
2654	Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 73.	1.2	8
2655	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease “ Implications for Clinical Practice. <i>European Endocrinology</i> , 2018, 14, 40.	0.8	13
2656	Metformin attenuates increase of synaptic number in the rat spinal dorsal horn with painful diabetic neuropathy induced by type 2 diabetes: a stereological study. <i>Neurochemical Research</i> , 2018, 43, 2232-2239.	1.6	15
2657	Preventing Macrovascular Events With Bariatric Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1545.	3.8	4
2658	Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2625-2633.	4.3	44
2659	Glycaemic control for people with type 2 diabetes in Saudi Arabia “ an urgent need for a review of management plan. <i>BMC Endocrine Disorders</i> , 2018, 18, 62.	0.9	40
2660	Revisiting the Diabetes-Heart Failure Connection. <i>Current Diabetes Reports</i> , 2018, 18, 134.	1.7	10
2662	Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome. <i>Korean Circulation Journal</i> , 2018, 48, 430.	0.7	0
2663	Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2018, 6, 823-830.	1.9	33
2664	Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 180.	0.7	29

#	ARTICLE	IF	CITATIONS
2665	Primary and Secondary Prevention of Cardiovascular Disease. , 2018, , 63-76.		0
2666	Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. <i>Circulation Research</i> , 2018, 123, 886-904.	2.0	226
2667	Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. <i>Journal of Medical Economics</i> , 2018, 21, 1110-1118.	1.0	8
2668	Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort. <i>PLoS ONE</i> , 2018, 13, e0203533.	1.1	7
2669	Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, S42-S52.	0.5	6
2670	Self-management levels of diet and metabolic risk factors according to disease duration in patients with type 2 diabetes. <i>Nutrition Research and Practice</i> , 2018, 12, 69.	0.7	4
2671	Hemoglobin A<sub>1c</sub> Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. <i>Annals of Internal Medicine</i> , 2018, 168, 569.	2.0	314
2672	Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2018, 20, 97.	1.3	1
2673	Arginase inhibition improves endothelial function in patients with type 2 diabetes mellitus despite intensive glucose-lowering therapy. <i>Journal of Internal Medicine</i> , 2018, 284, 388-398.	2.7	26
2674	Beyond Hyperglycemia, Evidence for Retinal Neurodegeneration in Metabolic Syndrome. , 2018, 59, 1360.		27
2675	Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	58
2676	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. <i>Diabetes Care</i> , 2018, 41, 1121-1124.	4.3	43
2677	Insulin therapy, weight gain and prognosis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2085-2092.	2.2	29
2678	Platelet function following induced hypoglycaemia in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 431-436.	1.4	20
2679	The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2371-2378.	2.2	14
2681	Proteomics of the Rat Myocardium during Development of Type 2 Diabetes Mellitus Reveals Progressive Alterations in Major Metabolic Pathways. <i>Journal of Proteome Research</i> , 2018, 17, 2521-2532.	1.8	22
2682	Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2018, 41, 1646-1653.	4.3	43
2683	Effects of MGB on Type 2 Diabetes in Morbid Obesity, and Comparison with Other Operations. , 2018, , 119-130.		1



#	ARTICLE	IF	CITATIONS
2684	Evaluation of the Long-Term Impact of Improving Care for People with Type 2 Diabetes in China. <i>Value in Health Regional Issues</i> , 2018, 15, 169-174.	0.5	2
2685	Risk assessment of diabetes mellitus using dried saliva spot followed by ultra-performance liquid chromatography with fluorescence and mass spectrometry. <i>Microchemical Journal</i> , 2018, 142, 202-207.	2.3	13
2686	Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	1.0	26
2687	Changes in Serum Electrolytes, ECG, and Baroreflex Sensitivity during Combined Pituitary Stimulation Test. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	1
2688	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018, 138, 1537-1550.	1.6	200
2689	Comparative Effectiveness of Adaptive Treatment Strategies. <i>Springer Series in Statistics</i> , 2018, , 253-276.	0.9	0
2690	Intermittent High Glucose Exacerbates A-FABP Activation and Inflammatory Response through TLR4-JNK Signaling in THP-1 Cells. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	0.9	22
2691	Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	0.6	6
2692	Prognostic implications of microvascular complications in patients with diabetes and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1557-1558.	2.9	1
2693	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 1-14.	1.1	43
2694	Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8.	1.0	37
2696	Mendelian randomisation in type 2 diabetes and coronary artery disease. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 111-120.	1.5	13
2697	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. <i>Current Diabetes Reports</i> , 2018, 18, 53.	1.7	127
2698	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. <i>Physiology</i> , 2018, 33, 197-210.	1.6	3
2699	Cardiovascular Disease in Diabetes. , 2018, , 219-237.		0
2700	Exploring inhibitory mechanism of gallic acid on $\alpha$ -amylase and $\alpha$ -glucosidase relevant to postprandial hyperglycemia. <i>Journal of Functional Foods</i> , 2018, 48, 200-209.	1.6	80
2701	Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. <i>Cardiovascular Diabetology</i> , 2018, 17, 86.	2.7	2
2702	In Vivo Corneal Confocal Microscopy Detects Improvement of Corneal Nerve Parameters following Glycemic Control in Patients with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8.	1.0	21

#	ARTICLE	IF	CITATIONS
2703	Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> , 2018, 41, 2187-2194.	4.3	99
2704	Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. <i>World Journal of Diabetes</i> , 2018, 9, 1-24.	1.3	145
2705	Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care. <i>Annals of Internal Medicine</i> , 2018, 169, 300-310.	2.0	129
2706	Diabetes and the Nervous System. <i>Endocrinology</i> , 2018, , 1-80.	0.1	0
2708	Glycemic Targets and Prevention of Chronic Complications. <i>Endocrinology</i> , 2018, , 1-31.	0.1	0
2709	Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis. <i>American Journal of Kidney Diseases</i> , 2018, 72, 701-710.	2.1	17
2710	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 133-148.	1.1	21
2711	Is Management of Central Retinal Artery Occlusion the Next Frontier in Cerebrovascular Diseases?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2781-2791.	0.7	17
2712	Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 245-253.	1.1	7
2713	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , 2018, 41, 2229-2235.	4.3	74
2714	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. <i>Current Diabetes Reports</i> , 2018, 18, 64.	1.7	27
2715	Rehabilitation of Patients With Neuropathies. , 2018, , 287-298.e9.		1
2716	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
2717	HbA1c method performance: The great success story of global standardization. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 408-419.	2.7	32
2718	Management of adults with diabetes on the haemodialysis unit: summary of guidance from the Joint British Diabetes Societies and the Renal Association. <i>Diabetic Medicine</i> , 2018, 35, 1018-1026.	1.2	26
2719	Impact of written information on control and adherence in type 2 diabetes. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 140-147.	0.3	17
2720	Extracellular Vesicles: A Novel Target for Exercise-Mediated Reductions in Type 2 Diabetes and Cardiovascular Disease Risk. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-14.	1.0	29
2721	Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. <i>Cardiovascular Diabetology</i> , 2018, 17, 36.	2.7	37

#	ARTICLE	IF	CITATIONS
2722	Risk of hypoglycemia in youth with type 2 diabetes on insulin. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2018, 31, 625-630.	0.4	4
2723	Why, when and how to use insulin in type 2 diabetes mellitus. <i>Independent Nurse</i> , 2018, 2018, 23-26.	0.0	1
2724	Glycemic Control of Surgical Patients. What is Correct, What is Not. <i>Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2018, 90, 36-40.	0.1	0
2725	Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2169-2178.	2.2	40
2726	Cardiovascular Disease and Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 217-232.	0.6	52
2727	Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 749-763.	0.6	12
2728	Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. <i>Frontiers in Neuroscience</i> , 2018, 12, 591.	1.4	92
2729	Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000527.	1.2	22
2730	Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. <i>BMC Neurology</i> , 2018, 18, 126.	0.8	30
2731	Goals of Therapy. , 2018, , 227-233.		1
2732	Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study. <i>Diabetes Care</i> , 2018, 41, 2127-2135.	4.3	248
2733	Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 273, 1-7.	0.8	3
2734	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , 2018, 6, 813-822.	1.9	21
2735	SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. <i>Diabetologia</i> , 2018, 61, 2134-2139.	2.9	50
2736	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 1-29.	0.1	0
2737	Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic $\beta$ cells in <i>db/db</i> mice: The earlier and longer, the better. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2442-2457.	2.2	41
2738	Individual differences in regulatory mode moderate the effectiveness of a pilot mHealth trial for diabetes management among older veterans. <i>PLoS ONE</i> , 2018, 13, e0192807.	1.1	44
2739	Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. <i>Current Diabetes Reports</i> , 2018, 18, 45.	1.7	37

#	ARTICLE	IF	CITATIONS
2740	Exposure to hypoglycemia and risk of stroke. <i>Annals of the New York Academy of Sciences</i> , 2018, 1431, 25-34.	1.8	34
2741	Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1238-1249.	0.9	3
2742	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. <i>Diabetes and Metabolism</i> , 2019, 45, 238-247.	1.4	51
2743	Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1182-1188.	0.4	22
2744	Severe hypoglycemia due to insulin self-injection as a cause of acute ST elevation myocardial infarction. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 739-742.	0.8	3
2745	Intersections and Clinical Translations of Diabetes Mellitus with Cancer Promotion, Progression and Prognosis. <i>Postgraduate Medicine</i> , 2019, 131, 597-606.	0.9	10
2746	Glycated hemoglobin, admission blood glucose delta, and associated mortality in patients with acute ST-segment elevation myocardial infarction. <i>Baylor University Medical Center Proceedings</i> , 2019, 32, 325-330.	0.2	5
2747	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 578-589.	3.1	43
2748	Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 62.	1.2	9
2749	Risk of diabetes mellitus in physicians: a nationwide study in Taiwan. <i>BMC Public Health</i> , 2019, 19, 1047.	1.2	1
2750	Atherosclerosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 56.	18.1	1,601
2751	Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes. <i>Hormone and Metabolic Research</i> , 2019, 51, 487-494.	0.7	70
2752	Long-term follow-up of intensive glycaemic control in type 2 diabetes. <i>Nature Reviews Cardiology</i> , 2019, 16, 517-518.	6.1	4
2756	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019, 42, 2098-2107.	4.3	37
2757	The Different Roles of miRNA-92a-2-5p and let-7b-5p in Mitochondrial Translation in db/db Mice. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 424-435.	2.3	43
2758	Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality. <i>Postgraduate Medicine</i> , 2019, 131, 376-382.	0.9	11
2759	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019, , 1-29.	0.1	0
2760	Approaches to Risk Assessment Among Older Patients With Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 59.	1.7	17

#	ARTICLE	IF	CITATIONS
2761	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2450-2458.	2.2	8
2762	The "Old" Oral Antidiabetics. , 2019, , 501-513.		0
2763	Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?. <i>Diabetes Therapy</i> , 2019, 10, 1625-1643.	1.2	0
2764	Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease?. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1170-1180.	0.8	7
2765	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c"Translating Evidence into Practice. <i>Diabetes Therapy</i> , 2019, 10, 1595-1622.	1.2	36
2766	Iatrogenic hypoglycemia-related hospital admissions identified through databases: economic burden and causes. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1159-1165.	1.0	6
2767	Protocol of a Prospective Observational Study on the Relationship Between Glucose Fluctuation and Cardiovascular Events in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 1565-1575.	1.2	14
2768	Association of Glucose Concentrations at Hospital Discharge With Readmissions and Mortality: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3679-3691.	1.8	22
2769	New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. <i>Diabetologia</i> , 2019, 62, 1539-1549.	2.9	240
2770	Effects of coenzyme Q10 intervention on diabetic kidney disease. <i>Medicine (United States)</i> , 2019, 98, e15850.	0.4	22
2771	<p>Cognition and drug adherence to oral hypoglycemic and antihypertensive agents in older adults</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 891-899.	0.8	1
2772	Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2354-2367.	2.2	22
2773	Predictive modeling of hypoglycemia for clinical decision support in evaluating outpatients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2019, 35, 1885-1891.	0.9	20
2774	Diabetes and Hypertension. , 2019, , 573-585.		2
2775	Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 938-948.	5.5	240
2776	Genetic predisposition to type 2 diabetes is associated with severity of coronary artery disease in patients with acute coronary syndromes. <i>Cardiovascular Diabetology</i> , 2019, 18, 131.	2.7	16
2777	Risk Factors Management in Diabetic Patients. <i>Journal of Korean Diabetes</i> , 2019, 20, 157.	0.1	1
2778	Trace elements in saliva and plasma of patients with type 2 diabetes: Association to metabolic control and complications. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107871.	1.1	11

#	ARTICLE	IF	CITATIONS
2779	Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107410.	1.2	4
2780	Management of Diabetes in Patients Undergoing Bariatric Surgery. <i>Current Diabetes Reports</i> , 2019, 19, 112.	1.7	17
2781	Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. <i>Journal of Primary Care and Community Health</i> , 2019, 10, 215013271988063.	1.0	14
2782	RSSDI consensus recommendations on insulin therapy in the management of diabetes. <i>International Journal of Diabetes in Developing Countries</i> , 2019, 39, 43-92.	0.3	9
2783	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Medicine</i> , 2019, 132, S13-S20.	0.6	1
2785	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. <i>Cardiovascular Diabetology</i> , 2019, 18, 156.	2.7	17
2786	Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. <i>Diabetes Care</i> , 2019, 42, 2136-2142.	4.3	10
2787	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. <i>Value in Health</i> , 2019, 22, 1402-1409.	0.1	13
2788	Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. <i>Chronic Illness</i> , 2021, 17, 451-462.	0.6	17
2789	Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 86.	1.7	324
2790	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 1733-1752.	1.2	47
2791	What should governments be doing to prevent diabetes throughout the life course?. <i>Diabetologia</i> , 2019, 62, 1842-1853.	2.9	25
2792	An update on pharmacotherapies in diabetic dyslipidemia. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 334-341.	1.6	24
2793	Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. <i>Advances in Therapy</i> , 2019, 36, 2567-2586.	1.3	12
2794	A retrospective cross-sectional study of type 2 diabetes overtreatment in patients admitted to the geriatric ward. <i>BMC Geriatrics</i> , 2019, 19, 242.	1.1	11
2795	Metabolic Stress and Cardiovascular Disease in Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1911-1924.	1.1	42
2796	The Role of Bariatric Surgery in Managing the Macrovascular Complications of Obesity-Related Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1259.	3.8	0
2797	Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 1162-1171.	0.5	2

#	ARTICLE	IF	CITATIONS
2798	How to perform better intervention to prevent and control diabetic retinopathy among patients with type 2 diabetes: A meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019, 156, 107834.	1.1	8
2799	A comprehensive approach to type 2 diabetes mellitus – A recommendation document. <i>Endocrinologia e Nutricão</i> (English Ed ), 2019, 66, 443-458.	0.1	3
2800	Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1167.	3.8	45
2801	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , 2019, 40, 1447-1467.	8.9	210
2802	Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e011207.	1.6	4
2803	New approach to diabetes care: From blood glucose to cardiovascular disease. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019, 38, 53-63.	0.2	9
2804	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1237-1250.	2.2	190
2805	Glucocentric risk factors for macrovascular complications in diabetes: Glucose “legacy” and “variability”-what we see, know and try to comprehend. <i>Diabetes and Metabolism</i> , 2019, 45, 401-408.	1.4	26
2806	Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. <i>Medical Decision Making</i> , 2019, 39, 137-151.	1.2	4
2807	Nova abordagem para o tratamento da diabetes: da glicemia à doença cardiovascular. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 53-63.	0.2	9
2808	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 133-143.	0.9	155
2809	Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables. <i>Clinical Therapeutics</i> , 2019, 41, 352-367.	1.1	25
2810	Sodium-glucose cotransporter inhibitors: Medications that mimic fasting for cardiovascular prevention. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2211-2218.	2.2	14
2811	The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1159-1161.	4.3	13
2812	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
2813	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. <i>Diabetes Care</i> , 2019, 42, 1615-1623.	4.3	8
2814	Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00072.	1.0	1
2815	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> 2019;42:157-163. <i>Diabetes Care</i> , 2019, 42, e95-e95.	4.3	0

#	ARTICLE	IF	CITATIONS
2816	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2019, 25, 584-619.	0.7	56
2817	Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease. <i>Nature Communications</i> , 2019, 10, 2461.	5.8	59
2818	Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial. <i>New England Journal of Medicine</i> , 2019, 380, 2266-2267.	13.9	6
2819	Intensive Glucose Control in Patients with Type 2 Diabetes â€” 15-Year Follow-up. <i>New England Journal of Medicine</i> , 2019, 380, 2215-2224.	13.9	173
2820	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Metaâ€”Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. <i>Journal of the American Heart Association</i> , 2019, 8, e012356.	1.6	73
2821	Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 344-355.	2.4	10
2822	Diabetic neuropathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 41.	18.1	692
2823	Diabetic neuropathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 42.	18.1	82
2824	Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). <i>BMC Health Services Research</i> , 2019, 19, 284.	0.9	5
2825	Comparison of endothelial function and sympathetic nervous system activity along the glucose continuum in individuals with differing metabolic risk profiles and low dietary sodium intake. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000606.	1.2	6
2826	d-Ribose contributes to the glycation of serum protein. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2285-2292.	1.8	35
2827	Evaluation of testis hormonal and histopathological alterations in type I and type II diabetic rats. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16775-16785.	1.2	14
2828	Personâ€”Centered Primary Care and Type 2 Diabetes: Beyond Blood Glucose Control. <i>Journal of Midwifery and Women's Health</i> , 2019, 64, 312-323.	0.7	7
2829	Lifestyle Interventions in Diabetes and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2059-2061.	1.2	1
2830	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 6-16.	2.2	13
2831	Impact of Endocrine Disorders on the Kidney. <i>Endocrinology</i> , 2019, , 1-34.	0.1	0
2832	Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881984469.	1.4	100
2833	Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project. <i>Diabetes Therapy</i> , 2019, 10, 1099-1111.	1.2	4



#	ARTICLE	IF	CITATIONS
2834	Targeted learning with daily EHR data. <i>Statistics in Medicine</i> , 2019, 38, 3073-3090.	0.8	24
2835	Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR4 Gene Expression in CD34+Stem Cells. <i>Journal of the American Heart Association</i> , 2019, 8, e010012.	1.6	26
2836	Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 178-185.	0.9	17
2837	<p>Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 271-282.	0.7	3
2838	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COHoRtE (DIACORE) study. <i>PLoS ONE</i> , 2019, 14, e0213157.	1.1	8
2839	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 140, e596-e646.	1.6	1,789
2840	Glycemic Metrics and Targets in Kidney Disease. , 2019, , 39-48.		0
2841	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1284-1289.	4.3	42
2842	Diabetic kidney disease: A systematic review on the role of epigenetics as diagnostic and prognostic marker. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3155.	1.7	8
2843	Renal reabsorption in 3D vascularized proximal tubule models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5399-5404.	3.3	242
2844	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 781-790.	0.9	4
2845	Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1037-1047.	0.9	3
2846	Delays in antiâ€hyperglycaemic therapy initiation and intensification are associated with cardiovascular events, hospitalizations for heart failure and allâ€cause mortality. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1551-1557.	2.2	5
2847	Hypoglycemia does not affect the progression of preclinical atherosclerosis in subjects with type 2 diabetes. <i>PLoS ONE</i> , 2019, 14, e0212871.	1.1	2
2848	Optimal cardiac strategy based on the history of myocardial infarction in type 2 diabetic patients with coronary artery disease. <i>Scientific Reports</i> , 2019, 9, 3502.	1.6	1
2849	Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12â€month prospective observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1585-1595.	2.2	19
2850	Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1187-1199.	1.8	51
2851	Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. <i>Cardiovascular Diabetology</i> , 2019, 18, 22.	2.7	41

#	ARTICLE	IF	CITATIONS
2852	Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study. <i>Diabetes Therapy</i> , 2019, 10, 965-979.	1.2	2
2853	Poor glycemic control and posterior circulation ischemic stroke. <i>Neurology: Clinical Practice</i> , 2019, 9, 129-139.	0.8	9
2854	Designing for implementation: user-centered development and pilot testing of a behavioral economic-inspired electronic health record clinical decision support module. <i>Pilot and Feasibility Studies</i> , 2019, 5, 28.	0.5	14
2855	Cost-effectiveness analysis of a cluster-randomized, culturally tailored, community health worker home-visiting diabetes intervention versus standard care in American Samoa. <i>Human Resources for Health</i> , 2019, 17, 17.	1.1	19
2856	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, e177-e232.	1.2	1,038
2857	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 35.	1.3	14
2859	Treat-to-target HbA 1c and lipid profile to prolong $\beta$ -cell mass/function and optimize treatment goal attainment. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3166.	1.7	4
2862	Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 385-396.	5.5	298
2863	Consensus pour la prise en charge de l'hyperglycémie dans le diabète de type 2 en Afrique subsaharienne. Rédigé par un groupe d'experts africains du diabète. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 210-216.	0.1	4
2864	Clinical factors associated with persistently poor diabetes control in the Veterans Health Administration: A nationwide cohort study. <i>PLoS ONE</i> , 2019, 14, e0214679.	1.1	7
2866	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881983486.	1.4	76
2867	Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. <i>Journal of General and Family Medicine</i> , 2019, 20, 129-138.	0.3	13
2868	Facteurs de risque et maladies chroniques : le diabète en exemple. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 9-20.	0.1	1
2869	Evidence-Based Cardiovascular Risk Management in Diabetes. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 439-448.	1.0	10
2870	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A Person-centred Approach To Individualised (PROACTIVE) Glycemic Goals for older people. <i>Primary Care Diabetes</i> , 2019, 13, 330-352.	0.9	28
2872	Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes. <i>Clinical Diabetes</i> , 2019, 37, 211-220.	1.2	1
2873	Clinical implications of cardiovascular outcome trials in type 2 diabetes. <i>Herz</i> , 2019, 44, 192-202.	0.4	4
2874	Insulin resistance is a cardiovascular risk factor in humans. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 1449-1455.	1.8	146

#	ARTICLE	IF	CITATIONS
2875	Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population. <i>Scientific Reports</i> , 2019, 9, 1374.	1.6	37
2876	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1277-1290.	2.2	64
2877	Therapeutic Targeting of the Proinflammatory IL-6/JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-15.	0.5	50
2878	Management of hypoglycemia in older adults with type 2 diabetes. <i>Postgraduate Medicine</i> , 2019, 131, 241-250.	0.9	63
2879	Treatment of diabetes and heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 207-212.	0.8	4
2880	Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 70-86.	0.3	15
2881	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 45.	1.5	94
2882	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2019, 79, 231-242.	4.9	18
2883	Evaluating All Potential Oral Complications of Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2019, 10, 56.	1.5	155
2884	Randomized Controlled Trial of Physical Exercise in Diabetic Veterans With Length-Dependent Distal Symmetric Polyneuropathy. <i>Frontiers in Neuroscience</i> , 2019, 13, 51.	1.4	21
2885	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	1.1	245
2886	Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors. <i>Revista Clínica Espanola</i> , 2019, 219, 208-217.	0.3	2
2887	The Association Between Type 2 Diabetes and Cardiovascular Disease: The “For Your SweetHeart” Survey. <i>Advances in Therapy</i> , 2019, 36, 746-755.	1.3	9
2888	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , 2019, 10, 1-13.	1.2	15
2889	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2019, 171, ITC65-ITC80.	2.0	46
2890	Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2019, 171, 78.	2.0	4
2891	To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?. <i>Annals of Internal Medicine</i> , 2019, 171, 505.	2.0	2
2892	6. Glycemic Targets: Standards of Medical Care in Diabetes – 2019. <i>Diabetes Care</i> , 2019, 42, S61-S70.	4.3	583

#	ARTICLE	IF	CITATIONS
2893	Going to extremes: the Goldilocks/Lagom principle and data distribution. <i>BMJ Open</i> , 2019, 9, e027767.	0.8	9
2894	Individualised targets for insulin initiation in type 2 diabetes mellitus—the influence of physician and practice: a cross-sectional study in eight European countries. <i>BMJ Open</i> , 2019, 9, e032040.	0.8	3
2895	Implementation of A1C Point-of-Care Testing: Serving Under-Resourced Adults With Type 2 Diabetes in a Public Health Department. <i>Clinical Diabetes</i> , 2019, 37, 242-249.	1.2	5
2896	Documento de abordaje integral de la diabetes tipo 2. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 443-458.	0.1	24
2897	Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea. <i>Endocrinology and Metabolism</i> , 2019, 34, 282.	1.3	16
2898	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. <i>Italian Journal of Medicine</i> , 2019, 13, 205-224.	0.2	0
2899	SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus. , 2019, , .		1
2900	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2019, 367, l5887.	2.4	84
2901	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Cardiology</i> , 2019, 124, S12-S19.	0.7	15
2902	Visit-to-Visit Hemoglobin A1c Variability Is Associated With Later Cancer Development in Patients With Diabetes Mellitus. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 237-240.	1.0	10
2903	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <i>Clinical Diabetes</i> , 2019, 37, 316-337.	1.2	11
2904	Targets for blood glucose: What have the trials told us. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 64-72.	0.8	13
2905	Stroke in the elderly. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 393-418.	1.0	27
2906	Full title: High glucose protects mesenchymal stem cells from metformin-induced apoptosis through the AMPK-mediated mTOR pathway. <i>Scientific Reports</i> , 2019, 9, 17764.	1.6	7
2907	The Role of Nonenzymatic Post-translational Protein Modifications in Uremic Vascular Calcification. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 427-436.	0.6	2
2908	Cardioprotective diabetes drugs: what cardiologists need to know. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019, 8, 96-105.	0.5	11
2909	Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables. <i>Journal of Hypertension</i> , 2019, 37, 1939-1949.	0.3	7
2910	Diabetes and Cardiovascular Disease: an Update. <i>Current Diabetes Reports</i> , 2019, 19, 161.	1.7	53

#	ARTICLE	IF	CITATIONS
2911	Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials. <i>Frontiers in Diabetes</i> , 2019, , 119-130.	0.4	0
2913	The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL). <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 431-438.	0.7	4
2914	Outcomes associated with hyperglycemia after abdominal aortic aneurysm repair. <i>Journal of Vascular Surgery</i> , 2019, 69, 763-773.e3.	0.6	10
2915	Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study. <i>Journal of Diabetes Investigation</i> , 2019, 10, 714-722.	1.1	14
2916	Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 303-311.	2.2	3
2917	Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients. <i>Journal of Cellular Physiology</i> , 2019, 234, 2436-2446.	2.0	71
2918	A systematic review of risk factors for cataract in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3073.	1.7	58
2919	Improvement in infected wound healing in type 1 diabetic rat by the synergistic effect of photobiomodulation therapy and conditioned medium. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9906-9916.	1.2	29
2920	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. <i>Canadian Journal of Diabetes</i> , 2019, 43, 384-391.	0.4	11
2921	Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. <i>Diabetes Care</i> , 2019, 42, 288-296.	4.3	10
2922	Tratamiento diurético del paciente con diabetes e insuficiencia cardiaca. El papel de los inhibidores de la SGLT2 y semejanzas con los inhibidores de la anhidrasa carbónica. <i>Revista Clinica Espanola</i> , 2019, 219, 208-217.	0.2	3
2923	Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation Research</i> , 2019, 124, 121-141.	2.0	411
2924	Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?. <i>Kidney Diseases (Basel, Switzerland)</i> , 2019, 5, 69-80.	1.2	10
2925	Diabetes: the place of new therapies. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880759.	1.4	10
2926	Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: A nationwide study. <i>Journal of Evidence-Based Medicine</i> , 2019, 12, 22-28.	2.4	7
2927	Health Issues and Care System for the Elderly. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , .	0.1	0
2928	Glycemic and lipids control in patients with diabetes and cardiovascular or renal diseases across all the government health sectors in the Emirate of Dubai, United Arab Emirates. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 590-594.	1.8	1
2929	Evidence-based diabetes care for older people with Type 2 diabetes: a critical review. <i>Diabetic Medicine</i> , 2019, 36, 399-413.	1.2	59

#	ARTICLE	IF	CITATIONS
2930	Treatment Goals in Diabetic Nephropathy. , 2019, , 435-450.		1
2931	Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis. , 2019, 29, 82-90.		7
2932	Association Between Triglyceride Level and Glycemic Control Among Insulin-Treated Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1211-1220.	1.8	31
2933	Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2019, 21, 732-735.	2.2	12
2934	Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care, 2019, 42, 157-163.	4.3	86
2935	Improvement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 110-118.	4.3	51
2936	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
2937	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes, Obesity and Metabolism, 2019, 21, 1081-1087.	2.2	39
2938	Higher pulse pressure predicts initiation of dialysis in Japanese patients with diabetes. Diabetes/Metabolism Research and Reviews, 2019, 35, e3120.	1.7	8
2939	Relationship between HbA1c and all-cause mortality in older patients with insulin-treated type 2 diabetes: results of a large UK Cohort Study. Age and Ageing, 2019, 48, 235-240.	0.7	11
2940	Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 939-948.	2.2	3
2941	Epidemiologic Characterization of Risk for Cardiovascular Diseases. Contemporary Cardiology, 2019, , 3-20.	0.0	1
2942	Management of Diabetes Mellitus. Contemporary Cardiology, 2019, , 113-177.	0.0	0
2943	Diagnosis and Management of Ischemic Stroke. Contemporary Cardiology, 2019, , 349-363.	0.0	1
2944	Impact of currently used anti-diabetic drugs on myoendothelial communication. Current Opinion in Pharmacology, 2019, 45, 1-7.	1.7	8
2945	Cardiovascular outcome trials in type 2 diabetes: A critical analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 300-305.	1.8	1
2946	Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 533-540.	2.2	27
2947	Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. Journal of Endocrinological Investigation, 2019, 42, 495-503.	1.8	48

#	ARTICLE	IF	CITATIONS
2948	Novel ABCA1 peptide agonists with antidiabetic action. <i>Molecular and Cellular Endocrinology</i> , 2019, 480, 1-11.	1.6	5
2949	Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 218-230.	0.4	13
2950	Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats. <i>Indian Journal of Clinical Biochemistry</i> , 2020, 35, 109-114.	0.9	16
2951	Actualizaci3n sobre hiperglucemia posprandial: fisiopatolog4a, prevalencia, consecuencias e implicaciones para el tratamiento de la diabetes. <i>Revista Clinica Espanola</i> , 2020, 220, 57-68.	0.2	4
2952	Update on postprandial hyperglycemia: The pathophysiology, prevalence, consequences and implications of treating diabetes. <i>Revista Clinica Espanola</i> , 2020, 220, 57-68.	0.3	4
2953	Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 62-71.	0.7	4
2954	Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T). <i>Clinical and Experimental Hypertension</i> , 2020, 42, 197-204.	0.5	7
2955	Association of postoperative glycemic control with outcomes after carotid procedures. <i>Vascular</i> , 2020, 28, 16-24.	0.4	3
2956	The Potential Role of Undercarboxylated Osteocalcin Upregulation in Microvascular Insufficiency in a Rat Model of Diabetic Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 86-97.	1.0	9
2957	Predictive Value of the Acute-to-Chronic Glycemic Ratio for In-Hospital Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Angiology</i> , 2020, 71, 38-47.	0.8	31
2958	Effects of HbA1c on the Development and Progression of Chronic Kidney Disease in Elderly and Middle-Aged Japanese: Iki Epidemiological Study of Atherosclerosis and Chronic Kidney Disease (ISSA-CKD). <i>Internal Medicine</i> , 2020, 59, 175-180.	0.3	12
2959	Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 231-242.	2.2	32
2960	Slowing Progression of Chronic Kidney Disease. , 2020, , 937-959.		2
2961	Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107465.	1.2	4
2962	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. <i>Kidney International</i> , 2020, 97, 202-212.	2.6	225
2963	Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 6-15.	2.2	36
2964	Treatment-induced neuropathy of diabetes: a call for acknowledgement. <i>Diabetic Medicine</i> , 2020, 37, 369-370.	1.2	4
2965	Association Between Routine Nephropathy Monitoring and Subsequent Change in Estimated Glomerular Filtration Rate in Patients With Diabetes Mellitus: A Japanese Non-Elderly Cohort Study. <i>Journal of Epidemiology</i> , 2020, 30, 326-331.	1.1	2

#	ARTICLE	IF	CITATIONS
2966	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2020, 41, 209-217.	1.0	28
2967	Recommendations for improving clinical trial design to facilitate the study of youth-onset type 2 diabetes. <i>Clinical Trials</i> , 2020, 17, 87-98.	0.7	2
2968	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
2969	Frailty and Diabetes in Older Hospitalized Adults: The Case for Routine Frailty Assessment. <i>Canadian Journal of Diabetes</i> , 2020, 44, 241-245.e1.	0.4	19
2970	SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 173-188.	1.0	12
2971	Optimal fasting glucose levels with regard to cardiovascular and mortality outcomes in people treated with or without antidiabetic medication. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 243-253.	2.2	3
2972	Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes. <i>Primary Care Diabetes</i> , 2020, 14, 193-212.	0.9	7
2973	Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Tenzeligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial. <i>Diabetes Therapy</i> , 2020, 11, 347-358.	1.2	2
2974	12th Roche Diabetes Care Network Meeting: April 11-13, 2019, Copenhagen, Denmark. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 142-167.	2.4	0
2975	Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 426-432.	4.3	85
2976	Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 12-18.	2.2	0
2977	Risk of first stroke in people with type 2 diabetes and its relation to glycaemic control: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 182-190.	2.2	24
2978	Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 212-221.	2.2	12
2979	Hypoglycaemic episodes increase the risk of ventricular arrhythmia and sudden cardiac arrest in patients with type 2 diabetes: A nationwide cohort study. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3226.	1.7	11
2980	Effect of mean HbA1c on the association of HbA1c variability and all-cause mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 680-687.	2.2	9
2981	Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice. <i>Circulation</i> , 2020, 141, 968-983.	1.6	97
2982	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	4.3	38
2983	Prediabetes and structural brain abnormalities: Evidence from observational studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3261.	1.7	8



#	ARTICLE	IF	CITATIONS
2984	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 57-65.	2.6	24
2985	For debate; pharmacological priorities in advanced type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107510.	1.2	2
2986	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154045.	1.5	23
2987	Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2020, 95, 101-112.	1.4	6
2989	Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. <i>Diabetic Medicine</i> , 2020, 37, 573-579.	1.2	35
2990	Spectroscopy and molecular docking analysis reveal structural specificity of flavonoids in the inhibition of $\alpha$ -glucosidase activity. <i>International Journal of Biological Macromolecules</i> , 2020, 152, 981-989.	3.6	53
2991	The importance of the initial period of basal insulin titration in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 722-733.	2.2	24
2992	Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy. <i>Journal of the American Heart Association</i> , 2020, 9, e014328.	1.6	11
2993	Long-acting GLP-1 receptor agonists. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2020, 33, 19-30.	0.1	6
2994	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	2.6	692
2995	The trials and tribulations of determining HbA1c targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 717-730.	4.3	39
2996	Evaluation of the relationship between cardiac autonomic function and glucose variability and HOMA-IR in prediabetes. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095861.	0.9	8
2997	Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. <i>Clinical Diabetes</i> , 2020, 38, 371-381.	1.2	49
2998	Molecular phenotyping of oxidative stress in diabetes mellitus with point-of-care NMR system. <i>Npj Aging and Mechanisms of Disease</i> , 2020, 6, 11.	4.5	18
2999	Influence of guideline adherence and parameter control on the clinical outcomes in patients with diabetic nephropathy. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001166.	1.2	6
3000	Renal Complication and Glycemic Control in Korean Veterans with Type 2 Diabetes: A 10-Year Retrospective Cohort Study. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-13.	1.0	7
3001	Micrometer-scale light-addressable potentiometric sensor on an optical fiber for biological glucose determination. <i>Analytica Chimica Acta</i> , 2020, 1123, 36-43.	2.6	18
3002	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1926-1936.	1.1	7

#	ARTICLE	IF	CITATIONS
3003	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. <i>Cardiovascular Diabetology</i> , 2020, 19, 196.	2.7	52
3004	The Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2020, 11, 585487.	1.6	23
3005	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 172, 541.	2.0	53
3006	Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes: the Look AHEAD study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001753.	1.2	27
3007	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. <i>Pharmaceuticals</i> , 2020, 13, 427.	1.7	14
3008	Regulation of Gluconeogenesis by Aldo-keto-reductase 1a1b in Zebrafish. <i>IScience</i> , 2020, 23, 101763.	1.9	9
3009	Expression and Signaling of $\beta^2$ -Adrenoceptor Subtypes in the Diabetic Heart. <i>Cells</i> , 2020, 9, 2548.	1.8	6
3010	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <i>Lancet, The</i> , 2020, 396, 2019-2082.	6.3	327
3011	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1117-1145.	1.2	276
3012	Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1601-1610.	0.9	5
3013	Risk of Cardiovascular Disease and Chronic Kidney Disease According to 2017 Blood Pressure Categories in Diabetes Mellitus. <i>Hypertension</i> , 2020, 76, 766-775.	1.3	5
3014	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	1.1	159
3015	Management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 667-668.	5.5	2
3016	Antidiabetic drugs and blood pressure changes. <i>Pharmacological Research</i> , 2020, 161, 105108.	3.1	11
3017	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	0.7	266
3018	Associations between usual glycated haemoglobin and cardiovascular disease in patients with type 2 diabetes mellitus: A 10-year diabetes cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2325-2334.	2.2	5
3019	Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2364-2374.	2.2	33
3020	6. Glycemic Targets: Standards of Medical Care in Diabetes—2020. <i>Diabetes Care</i> , 2020, 43, S66-S76.	4.3	614

#	ARTICLE	IF	CITATIONS
3021	Diabetic Kidney Disease. Primary Care - Clinics in Office Practice, 2020, 47, 645-659.	0.7	74
3022	Global trend of diabetes mortality attributed to vascular complications, 2000â€“2016. Cardiovascular Diabetology, 2020, 19, 182.	2.7	54
3023	Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy. BMJ Open Diabetes Research and Care, 2020, 8, e001624.	1.2	5
3024	The Legacy Effect in the Prevention of Cardiovascular Disease. Nutrients, 2020, 12, 3227.	1.7	10
3025	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	0.7	17
3026	Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy. Nutrients, 2020, 12, 3254.	1.7	35
3027	Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. Diabetologia, 2020, 63, 2482-2485.	2.9	14
3028	Cardiovascular safety outcomes of onceâ€“weekly GLPâ€“1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 61-72.	0.7	9
3029	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63
3030	Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes. Journal of Clinical Medicine, 2020, 9, 2464.	1.0	2
3031	Long non coding RNAs involved in MAPK pathway mechanism mediates diabetic neuropathic pain. Cell Biology International, 2020, 44, 2372-2379.	1.4	3
3032	Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials. Scientific Reports, 2020, 10, 12837.	1.6	4
3033	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2020, 2020, CD009966.	1.5	9
3034	Diabetes and CVD Risk: Special Considerations in African Americans Related to Care. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	8
3035	Long-acting GLP-1RAs. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 3-18.	0.1	16
3036	Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovascular Diabetology, 2020, 19, 134.	2.7	64
3037	Implementation of a Behavioral Economics Electronic Health Record (BE-EHR) Module to Reduce Overtreatment of Diabetes in Older Adults. Journal of General Internal Medicine, 2020, 35, 3254-3261.	1.3	21
3038	Characteristics of Hypoglycemic Diabetic Patients Visiting the Emergency Room. Cardiovascular Therapeutics, 2020, 2020, 1-9.	1.1	1

#	ARTICLE	IF	CITATIONS
3039	Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 81-89.	0.5	14
3041	Association of early-onset diabetes, prediabetes and early glycaemic recovery with the risk of all-cause and cardiovascular mortality. <i>Diabetologia</i> , 2020, 63, 2305-2314.	2.9	17
3042	Glycosylated hemoglobin, but not advanced glycation end products, predicts severity of coronary artery disease in patients with or without diabetes. <i>Metabolism Open</i> , 2020, 7, 100050.	1.4	5
3043	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108488.	1.1	4
3045	(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD005613.	1.5	25
3046	A $\beta$ -Induced Damage Memory in hCMEC/D3 Cells Mediated by Sirtuin-1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8226.	1.8	3
3049	Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT. <i>Diabetes Care</i> , 2020, 43, 1471-1478.	4.3	25
3050	Use of the Burden of Diabetes Mellitus Score for Cardiovascular Disease Risk Assessment. <i>American Journal of Cardiology</i> , 2020, 125, 1829-1835.	0.7	3
3051	Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412091484.	0.9	3
3052	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 418-435.	5.5	105
3053	Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. <i>Endocrine Reviews</i> , 2020, 41, 756-774.	8.9	77
3054	Review of the veteran affairs diabetes trial: Lessons learned. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 537-546.	2.6	0
3055	Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial. <i>BMJ Open</i> , 2020, 10, e032594.	0.8	11
3056	Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108250.	1.1	4
3057	Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 52.	1.2	53
3058	Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options. <i>Drugs and Aging</i> , 2020, 37, 567-584.	1.3	9
3059	Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107639.	1.2	17
3060	Hypoglycaemia and cardiac arrhythmias in diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882091180.	1.4	25

#	ARTICLE	IF	CITATIONS
3061	Type 2 diabetes mellitus management in patients with chronic kidney disease: an update. <i>Hormones</i> , 2020, 19, 467-476.	0.9	6
3062	Diabetes and coronary artery disease: not just a risk factor. <i>Heart</i> , 2020, 106, 1357-1364.	1.2	13
3063	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928.	4.3	35
3064	Loss of association between HbA1c and vascular disease in older adults with type 1 diabetes. <i>PLoS ONE</i> , 2020, 15, e0234319.	1.1	1
3065	Association between glycaemic control and diabetic foot outcomes: Dark side of the moon?. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107650.	1.2	1
3066	Vasomodulation of peripheral blood flow by focused ultrasound potentiates improvement of diabetic neuropathy. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001004.	1.2	11
3067	A CASE STUDY ON CLINICAL PHARMACIST INTERVENTIONS IN THE MANAGEMENT OF DIABETES COMPLICATED CORONARY ARTERY DISEASE IN HEALTH-CARE PRACTICE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 1-4.	0.3	0
3068	Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 100.	1.1	15
3069	Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. <i>Scientific Reports</i> , 2020, 10, 4750.	1.6	69
3070	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108112.	1.1	21
3071	Type 2 Diabetes Mellitus Is Independently Associated With Decreased Neural Baroreflex Sensitivity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1420-1428.	1.1	18
3072	Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication. <i>Diabetic Medicine</i> , 2020, 37, 1326-1332.	1.2	5
3073	Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-10.	1.0	3
3074	Association between hemoglobin A1c and acute ischemic stroke among patients with type-2 diabetes: a case-control study. <i>International Journal of Diabetes in Developing Countries</i> , 2020, 40, 555-560.	0.3	2
3075	Relationship of ankle-brachial index, vibration perception threshold, and current perception threshold to glycemic variability in type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e19374.	0.4	7
3076	How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool. <i>Trials</i> , 2020, 21, 281.	0.7	4
3077	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. <i>Diabetes Care</i> , 2020, 43, 1293-1299.	4.3	15
3078	for Heterogeneity in the Algorithm for Type 2 Diabetes Management. <i>Current Diabetes Reports</i> , 2020, 20, 14.	1.7	6

#	ARTICLE	IF	CITATIONS
3079	The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062231989837.	1.1	20
3080	Influence of Ethnicity on Outcomes of Diabetes Inpatient Hypoglycemia: an Australian Perspective. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa009.	0.1	2
3081	How Significant Is Severe Hypoglycemia in Older Adults With Diabetes?. <i>Diabetes Care</i> , 2020, 43, 512-514.	4.3	13
3082	Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 639.	1.0	13
3083	Association between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes. <i>Journal of Stroke</i> , 2020, 22, 87-98.	1.4	13
3084	A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. <i>Cell</i> , 2020, 180, 862-877.e22.	13.5	397
3085	Type 2 diabetes “unmet need, unresolved pathogenesis, mTORC1-centric paradigm. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 613-629.	2.6	24
3087	Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years. <i>Scientific Reports</i> , 2020, 10, 4095.	1.6	6
3088	Introduction to SMBG. , 2020, , 3-31.		0
3089	Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 486-495.	1.4	3
3090	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 587-621.	0.6	7
3091	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. <i>European Heart Journal</i> , 2020, 41, 3421-3432.	1.0	138
3092	Diabetic polyneuropathy: Bridging the translational gap. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 66-75.	1.4	13
3093	Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort. <i>Cardiovascular Diabetology</i> , 2020, 19, 97.	2.7	11
3094	Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1937-1944.	1.1	3
3095	A longitudinal follow-up study of a type 2 diabetes “lost to follow-up” cohort “positive effect on glycaemic control after changes in medication. <i>International Journal of Circumpolar Health</i> , 2020, 79, 1773127.	0.5	0
3096	Clinical impact of CGM use. , 2020, , 135-158.		0
3098	GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 193-212.	0.8	24

#	ARTICLE	IF	CITATIONS
3099	Impact on guidelines: The general practitioner point of view. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108091.	1.1	4
3100	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease—A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1509.	1.8	29
3101	Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1231-1242.	2.2	13
3102	Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 736-745.	1.3	27
3103	Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2020, 19, 21.	2.7	12
3104	Cardiovascular autonomic neuropathy: A silent killer with long reach. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2020, 225, 102646.	1.4	27
3105	Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 512-521.	1.2	26
3106	Should the Haptoglobin Genotype Be Considered in Setting Glycemic Goals for Diabetes Patients?. <i>Journal of the American College of Cardiology</i> , 2020, 75, 522-524.	1.2	2
3108	A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. <i>Diabetes Therapy</i> , 2020, 11, 1045-1059.	1.2	14
3109	Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 246.	1.0	2
3110	Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins. <i>JAMA Network Open</i> , 2020, 3, e1918554.	2.8	14
3111	An update on the potential role of advanced glycation end products in glycolipid metabolism. <i>Life Sciences</i> , 2020, 245, 117344.	2.0	18
3112	Association of blood glucose and renal end points in advanced diabetic kidney disease. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108011.	1.1	4
3113	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
3114	High haemoglobin A1c level is a possible risk factor for ventricular fibrillation in sudden cardiac arrest among non-diabetic individuals in the general population. <i>Europace</i> , 2020, 22, 394-400.	0.7	5
3115	The Threshold of the Severity of Diabetic Retinopathy below Which Intensive Glycemic Control Is Beneficial in Diabetic Patients: Estimation Using Data from Large Randomized Clinical Trials. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-6.	1.0	12
3116	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. <i>Drugs</i> , 2020, 80, 147-165.	4.9	13
3117	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. <i>JAMA Network Open</i> , 2020, 3, e1919666.	2.8	14

#	ARTICLE	IF	CITATIONS
3118	The efficacy and safety of Chinese herbal medicine Shen-Qi Hua-Yu formula in patients with diabetic lower extremity artery disease. <i>Medicine (United States)</i> , 2020, 99, e18713.	0.4	4
3119	The intersecting role of glycaemia and cardiac function in the development of heart failure among patients with type 2 diabetes mellitus after an acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1144-1146.	2.9	1
3120	Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1185-1190.	4.3	66
3121	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 129-152.	0.8	31
3122	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 1168-1177.	1.4	14
3124	Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. <i>Redox Biology</i> , 2020, 32, 101527.	3.9	47
3125	Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus. <i>Scientific Reports</i> , 2020, 10, 5746.	1.6	4
3126	Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 32-45.	2.2	29
3127	ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 5-11.	2.2	12
3128	An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 3-15.	2.2	278
3129	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm “2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
3130	Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 545-551.	1.3	1
3131	Atherogenic dyslipidemia and diabetic nephropathy. <i>Journal of Nephrology</i> , 2020, 33, 1001-1008.	0.9	36
3132	Impact of Long-term Glycosylated Hemoglobin in Patients with Acute Myocardial Infarction: a retrospective cohort study. <i>Scientific Reports</i> , 2020, 10, 6726.	1.6	5
3133	Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1481-1495.	2.2	17
3134	Type 1 diabetes and periodontitis: prevalence and periodontal destruction—a systematic review. <i>Acta Diabetologica</i> , 2020, 57, 1405-1412.	1.2	29
3135	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	1.2	5
3136	Risk stratification tools for heart failure in the diabetes clinic. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1070-1079.	1.1	7



#	ARTICLE	IF	CITATIONS
3137	Second revolution in cardiovascular prevention. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 327-336.	0.6	6
3138	ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000810.	1.2	7
3139	Effective diabetes complication management is a step toward a carbon-efficient planet: an economic modeling study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001017.	1.2	4
3140	Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-18.	1.9	213
3141	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
3142	Reducing the Burden of Mortality in Older People With Diabetes: A Review of Current Research. <i>Frontiers in Endocrinology</i> , 2020, 11, 133.	1.5	8
3143	Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 2-6.	0.9	56
3144	Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naïve Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study. <i>Journal of Nippon Medical School</i> , 2021, 88, 71-79.	0.3	1
3145	Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 244-253.	1.1	25
3146	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , 2021, 44, 164-173.	4.3	31
3147	Hypoglycemia Induces Mitochondrial Reactive Oxygen Species Production Through Increased Fatty Acid Oxidation and Promotes Retinal Vascular Permeability in Diabetic Mice. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1245-1259.	2.5	14
3148	Factors Associated with Diabetes Control in Predominately African American and Hispanic Population with Newly Diagnosed Type 2 Diabetes. <i>Journal of Racial and Ethnic Health Disparities</i> , 2021, 8, 332-338.	1.8	3
3149	A primer on metabolic memory: why existing diabetes treatments fail. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 756-767.	1.4	2
3150	Prevençã3n de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Espa±ola de NeurologÅa. <i>NeurologÅa</i> , 2021, 36, 305-323.	0.3	5
3151	Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 155-169.	1.0	8
3152	Antihyperlipidemic potential of diosmin in Swiss Albino mice with high-fat diet induced hyperlipidemia. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 109-115.	1.8	8
3153	Chronic hyperglycemia before acute ischemic stroke impairs the bilateral cerebrovascular response to exercise during the subacute recovery period. <i>Brain and Behavior</i> , 2021, 11, e01990.	1.0	4
3154	Diabetes induced renal complications by leukocyte activation of nuclear factor Î²-B and its regulated genes expression. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 541-549.	1.8	8

#	ARTICLE	IF	CITATIONS
3155	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€”2021</i>. Diabetes Care, 2021, 44, S73-S84.	4.3	591
3156	Exploring the highs and lows of very low carbohydrate high fat diets on weight loss and diabetesâ€™and cardiovascular diseaseâ€™related risk markers: A systematic review. Nutrition and Dietetics, 2021, 78, 41-56.	0.9	8
3157	Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care, 2021, 44, 549-555.	4.3	125
3158	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney International, 2021, 99, 256-266.	2.6	46
3159	The impact of existing diabetes self-management education interventions on knowledge, attitudes and practices in public health care institutions in Harare, Zimbabwe. South African Journal of Clinical Nutrition, 2021, 34, 27-33.	0.3	3
3160	Time-in-range as a target in type 2 diabetes: An urgent need. Heliyon, 2021, 7, e05967.	1.4	11
3162	Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. Renal Failure, 2021, 43, 477-487.	0.8	9
3163	Prognostic Markers in Advanced Heart Failure. Journal of Evolution of Medical and Dental Sciences, 2021, 10, 39-44.	0.1	3
3164	All-cause mortality, cardiovascular mortality, major cardiovascular events and hypoglycaemia of patients with diabetes onset at an older age: results from the 10-year nationwide cohort study. Age and Ageing, 2021, 50, 2094-2104.	0.7	7
3165	Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia, 2021, 64, 1093-1102.	2.9	23
3166	Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 15.	2.7	30
3167	Sex and ethnic differences in the cardiovascular complications of type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110342.	1.4	10
3168	Improvement of the therapeutic capacity of insulin-producing cells trans-differentiated from human liver cells using engineered cell sheet. Stem Cell Research and Therapy, 2021, 12, 3.	2.4	8
3169	Impact of Age, Frailty, and Dementia on Prescribing for Type 2 Diabetes at Hospital Discharge 2012-2016. Journal of Frailty & Aging,the, 2021, 10, 1-7.	0.8	2
3170	HbA1c trajectory and cardiovascular outcomes: an analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110263.	1.1	4
3171	Forskolin Protected against Streptozotocin-Induced Diabetic Cardiomyopathy via Inhibition of Oxidative Stress and Cardiac Fibrosis in Mice. BioMed Research International, 2021, 2021, 1-8.	0.9	7
3172	Peritoneal Dialysis in Diabetic Patients. , 2021, , 247-258.		0
3173	Is weight regaining significant post laparoscopic Roux-en-Y gastric bypass surgery? â€™A 5-year follow-up study on Indian patients. Journal of Minimal Access Surgery, 2021, 17, 159.	0.4	3

#	ARTICLE	IF	CITATIONS
3174	Frequency and predictors of hypoglycemia in Type 2 diabetes: A population-based study. <i>Journal of Diabetology</i> , 2021, 12, 157.	0.1	0
3175	The relation of anatomical distribution of symptomatic peripheral arterial disease (PAD) with HbA1c level in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110005.	1.4	5
3176	Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2021, 33, 33-40.	0.1	1
3177	Neuropathies. , 2021, , 842-874.e4.		0
3179	Importance of Awareness and Treatment for Diabetes in Influenza Vaccination Coverage of Diabetic Patients under 65 Years: A Population-Based Study. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 55-66.	1.8	5
3180	Cardiovascular Disease Risk Factors in the Hispanic/Latino Population. <i>Contemporary Cardiology</i> , 2021, , 123-145.	0.0	0
3181	Factors Associated with Prolonged Poor Glycemic Control in Type 2 Diabetes Mellitus (T2DM) Patients Followed in the Department of Internal Medicine at the Yalgado Ouedraogo Teaching Hospital, Ouagadougou (Burkina Faso). <i>Open Journal of Internal Medicine</i> , 2021, 11, 1-26.	0.1	2
3182	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. <i>Revista Cl�nica Espanola</i> , 2021, 221, 101-108.	0.3	4
3183	Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. <i>Diabetes Care</i> , 2021, 44, 915-924.	4.3	16
3184	Rate of achievement of therapeutic outcomes and factors associated with control of non-communicable diseases in rural east Malaysia: implications for policy and practice. <i>Scientific Reports</i> , 2021, 11, 3812.	1.6	0
3185	Knowledge, Attitudes and Practices of Health Care Providers in the Philippine General Hospital towards In-Patient Hypoglycemia and its Management. <i>Acta Medica Philippina</i> , 2021, 55, .	0.0	0
3186	Liraglutide to Improve coronary haemodynamics during Exercise stress (LIONESS): a double-blind randomised placebo-controlled crossover trial. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 17.	1.2	2
3187	Effectiveness of integrated care on delaying chronic kidney disease progression in rural communities of Thailand ( ESCORT ) trials. <i>Nephrology</i> , 2021, 26, 333-340.	0.7	5
3188	Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2002.	1.8	27
3189	Tratamiento m�dico de la diabetes mellitus tipo 2: recomendaciones del Grupo de Diabetes, Obesidad y Nutrici�n de la Sociedad Espa�ola de Medicina Interna. <i>Revista Clinica Espanola</i> , 2021, 221, 101-108.	0.2	4
3191	Interstitial lung disease in a veterans affairs regional network; a retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0247316.	1.1	7
3192	Identifying Potential Intervention Points for Acute Hypoglycemic Events in Patients With Type 2 Diabetes Using Retrospective Clinical Data. <i>Clinical Diabetes</i> , 2021, 39, 304-312.	1.2	1
3193	Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease. <i>Seminars in Nephrology</i> , 2021, 41, 96-103.	0.6	8

#	ARTICLE	IF	CITATIONS
3194	Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 361-368.	1.0	3
3195	Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. <i>Current Drug Safety</i> , 2021, 16, 32-51.	0.3	1
3196	Diabetic Peripheral Neuropathy: Diagnosis and Treatment. <i>Current Drug Safety</i> , 2021, 16, 2-16.	0.3	18
3197	Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	11
3198	Diabetes and Stroke. <i>Journal of Korean Diabetes</i> , 2021, 22, 26-37.	0.1	1
3199	Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1397-1407.	0.8	5
3200	Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 146-157.	1.8	56
3201	Predictive value of stress hyperglycemia ratio for the occurrence of acute kidney injury in acute myocardial infarction patients with diabetes. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 157.	0.7	15
3202	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. <i>European Cardiology Review</i> , 2021, 16, e11.	0.7	2
3203	Smart™ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues. <i>Diabetologia</i> , 2021, 64, 1016-1029.	2.9	46
3204	Cardiovascular Disease in Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1157-1172.	1.6	680
3205	Glycemic variability and cardiovascular disease in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002032.	1.2	55
3206	New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk. <i>Current Cardiology Reports</i> , 2021, 23, 25.	1.3	7
3207	JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. <i>Circulation Journal</i> , 2021, 85, 402-572.	0.7	52
3208	Current concepts and clinical importance of glycemic variability. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 627-636.	1.8	7
3209	All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 173, 108688.	1.1	14
3210	Associations between attainment of incentivized primary care indicators and incident sight-threatening diabetic retinopathy in England: A population-based historical cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1322-1330.	2.2	3
3211	Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. <i>Hospital Practice (1995)</i> , 2021, 49, 164-175.	0.5	2

#	ARTICLE	IF	CITATIONS
3212	Cardiovascular Risk Reduction Following Metabolic and Bariatric Surgery. <i>Surgical Clinics of North America</i> , 2021, 101, 269-294.	0.5	11
3213	A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Therapy</i> , 2021, 12, 1661-1676.	1.2	6
3214	Relationship Between Glycosylated Hemoglobin and Short-Term Mortality of Spontaneous Intracerebral Hemorrhage. <i>Frontiers in Neurology</i> , 2021, 12, 648907.	1.1	1
3216	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 384, 1248-1260.	13.9	60
3217	Changes in diabetes mortality rate in Costa Rica 2007–2017. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108749.	1.1	1
3218	From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 92.	2.7	28
3219	The effects of different doses of exercise on pancreatic $\beta$ -cell function in patients with newly diagnosed type 2 diabetes: study protocol for and rationale behind the “DOSE-EX” multi-arm parallel-group randomised clinical trial. <i>Trials</i> , 2021, 22, 244.	0.7	7
3220	Relationship between cardiac autonomic neuropathy and cardio-metabolic risk profile in adults with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108721.	1.1	1
3221	Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY. <i>Redox Biology</i> , 2021, 40, 101855.	3.9	13
3222	Associations between attainment of incentivised primary care indicators and incident diabetic retinopathy in England: a population-based historical cohort study. <i>BMC Medicine</i> , 2021, 19, 93.	2.3	8
3223	Glucose Level Sensing Using Single Asymmetric Split Ring Resonator. <i>Sensors</i> , 2021, 21, 2945.	2.1	20
3224	The rational treatment of diabetes mellitus in older adults: The adequacy of treatment decisions based on individualized glycemic targets in primary and tertiary care. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107835.	1.2	4
3225	Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001923.	1.2	21
3226	Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group. <i>Neurología (English Edition)</i> , 2021, 36, 305-323.	0.2	2
3227	Efectos a un año de un programa educativo en el control metabólico de pacientes con diabetes de un servicio especializado en un hospital nacional peruano. <i>CES Medicina</i> , 2021, 35, 4-15.	0.1	0
3228	Management of diabetes mellitus in dialysis patients: Obstacles and challenges. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 1025-1036.	1.8	7
3229	The expression profile of circANKRD36 and ANKRD36 as diagnostic biomarkers of chronic kidney disease in patients with type 2 diabetes mellitus. <i>Egyptian Journal of Medical Human Genetics</i> , 2021, 22, .	0.5	1
3230	Interpretación de los ensayos clínicos sobre efectos cardiovasculares de los fármacos hipoglucemiantes en personas con diabetes tipo 2. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 741-750.	0.1	0

#	ARTICLE	IF	CITATIONS
3231	Effect of hypoglycaemia on measures of myocardial blood flow and myocardial injury in adults with and without type 1 diabetes: A prospective, randomised, open-label, blinded endpoint, crossover study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00258.	1.0	0
3232	Antidiabetic and Other Therapies Used in Subjects with Diabetes and Chronic Kidney Disease in a Hospital-Based Clinic Population in Greece. <i>Journal of Clinical Medicine</i> , 2021, 10, 2104.	1.0	2
3233	Islet microangiopathy and augmented $\beta^2$ cell loss in Japanese nonobese type 2 diabetes patients who died of acute myocardial infarction. <i>Journal of Diabetes Investigation</i> , 2021, 12, 2149.	1.1	4
3234	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. <i>Diabetes Therapy</i> , 2021, 12, 2101-2113.	1.2	6
3235	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 364-377.	4.3	70
3236	Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. <i>Hypertension Research</i> , 2021, 44, 897-905.	1.5	13
3237	A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults. <i>British Journal of Diabetes</i> , 2021, 21, 30-35.	0.1	7
3238	Reexamining the Classification of Older Adults With Diabetes by Comorbidities and Exploring Relationships With Frailty, Disability, and 5-year Mortality. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2071-2079.	1.7	7
3239	Timely insulin administration in type 2 diabetes mellitus: pros and cons. <i>Mã-Å¼narodnij Endokrinologã-Åñij Å½urnal</i> , 2021, 17, 169-174.	0.1	1
3240	Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 368-378.	1.8	23
3241	<scp>Glucagon-like peptide-1 receptor agonists</scp> improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1806-1822.	2.2	53
3242	Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus. <i>Meditinskiy Sovet</i> , 2021, , 56-67.	0.1	0
3243	Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 671257.	1.5	44
3244	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. <i>British Journal of Diabetes</i> , 2021, 21, 132-148.	0.1	0
3245	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.2	9
3246	The Aging Vasculature: Glucose Tolerance, Hypoglycemia and the Role of the Serum Response Factor. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 58.	0.8	4
3247	Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. <i>Nature Reviews Endocrinology</i> , 2021, 17, 400-420.	4.3	169
3248	Inconvenient relationship of haemoglobin A1c level with endothelial function in type 2 diabetes in a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e045415.	0.8	2

#	ARTICLE	IF	CITATIONS
3249	Microvascular Disease and Risk of Cardiovascular Events and Death From Intensive Treatment in Type 2 Diabetes. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1458-1469.	1.4	10
3250	Exposure to phthalates and cardiovascular diseases in Chinese with type 2 diabetes. <i>Environmental Science and Pollution Research</i> , 2021, 28, 58113-58122.	2.7	7
3251	Management of Patients with Newly Diagnosed Diabetic Mellitus: Ophthalmologic Outcomes in Intensive versus Conventional Glycemic Control. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 2767-2785.	0.9	2
3252	Longitudinal trajectories of metabolic syndrome on different neurocognitive domains: a cohort study from the Taiwan biobank. <i>Aging</i> , 2021, 13, 15400-15412.	1.4	6
3253	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 315-337.	0.3	57
3254	Blood-brain barrier dysfunction in ischemic stroke and diabetes: the underlying link, mechanisms and future possible therapeutic targets. <i>Anatomy and Cell Biology</i> , 2021, 54, 165-177.	0.5	9
3255	Eye Outcomes in Veteran Affairs Diabetes Trial (VADT) After 17 Years. <i>Diabetes Care</i> , 2021, 44, 2397-2402.	4.3	7
3256	Impact of frailty metabolic phenotypes on the management of older people with type 2 diabetes mellitus. <i>Geriatrics and Gerontology International</i> , 2021, 21, 614-622.	0.7	13
3257	Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 115.	0.6	5
3258	Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1073-1090.	2.6	5
3259	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. <i>Current Cardiology Reports</i> , 2021, 23, 75.	1.3	6
3260	Resident opinions of diabetes management in training: a survey. <i>Journal of Osteopathic Medicine</i> , 2021, 121, 755-762.	0.4	0
3261	Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. <i>Diabetologia</i> , 2021, 64, 1949-1962.	2.9	29
3262	Remission of Type 2 Diabetes with Very Low-Calorie Diets—A Narrative Review. <i>Nutrients</i> , 2021, 13, 2086.	1.7	17
3263	Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. <i>New England Journal of Medicine</i> , 2021, 384, 2219-2228.	13.9	327
3264	Prevalence of glycemic variability and factors associated with the glycemic arrays among end-stage kidney disease patients on chronic hemodialysis. <i>Medicine (United States)</i> , 2021, 100, e26729.	0.4	4
3266	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
3267	Prestroke Glucose Control and Functional Outcome in Patients With Acute Large Vessel Occlusive Stroke and Diabetes After Thrombectomy. <i>Diabetes Care</i> , 2021, 44, 2140-2148.	4.3	8

#	ARTICLE	IF	CITATIONS
3268	A short review: Characterization and Health Effects of Saffron Utilizing in Disease Treatment and Prevention. <i>Journal of Research in Clinical Medicine</i> , 2021, 9, 28-28.	0.3	3
3269	Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes. <i>Frontiers in Pharmacology</i> , 2021, 12, 687256.	1.6	18
3270	Up and down waves of glycemic control and lower-extremity amputation in diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 135.	2.7	7
3271	Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study. <i>Current Medical Research and Opinion</i> , 2021, 37, 1517-1528.	0.9	3
3272	Evolution of Type 2 Diabetes Management from a Gluco-centric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. <i>Drugs</i> , 2021, 81, 1373-1379.	4.9	13
3273	Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control. <i>Annals of Epidemiology</i> , 2022, 65, 101-108.	0.9	10
3274	Metformin Suppresses the Progress of Diabetes-Accelerated Atherosclerosis by Inhibition of Vascular Smooth Muscle Cell Migration Through AMPK-PP2A Pathway. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 690627.	1.1	17
3275	Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes. <i>Korean Journal of Family Medicine</i> , 2021, 42, 269-273.	0.4	2
3276	Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences. <i>Minerva Endocrinology</i> , 2021, 46, 272-292.	0.6	4
3277	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. <i>Diabetes Care</i> , 2021, 44, 2231-2237.	4.3	51
3278	Impact of type 2 diabetes and microvascular complications on mortality and cardiovascular outcomes in a multiethnic Asian population. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001413.	1.2	8
3279	The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?. <i>Journal of Membrane Biology</i> , 2021, 254, 513-529.	1.0	7
3280	Diagnostic circulating biomarkers to detect vision-threatening diabetic retinopathy: Potential screening tool of the future?. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	12
3281	Association of HbA1c With All-cause Mortality Across Varying Degrees of Glycemic Variability in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3160-3167.	1.8	18
3282	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	1.0	1,123
3283	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
3284	Reduced Cell Excitability of Cardiac Postganglionic Parasympathetic Neurons Correlates With Myocardial Infarction-Induced Fatal Ventricular Arrhythmias in Type 2 Diabetes Mellitus. <i>Frontiers in Neuroscience</i> , 2021, 15, 721364.	1.4	2
3285	Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?. <i>Biomolecules</i> , 2021, 11, 1281.	1.8	5



#	ARTICLE	IF	CITATIONS
3286	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-13.	0.9	2
3287	Incidence and Costs of Hypoglycemia among Type II Diabetes Mellitus Patients in Turkey. Journal of Biomedical Research & Environmental Sciences, 2021, 2, 705-712.	0.1	0
3288	Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes Spectrum, 2021, 34, 217-224.	0.4	0
3289	High-risk coronary artery plaque in asymptomatic patients with type 2 diabetes: clinical risk factors and coronary artery calcium score. Cardiovascular Diabetology, 2021, 20, 164.	2.7	7
3290	Promoting analysis of real-world data: Prospects for preventive cardiology in Japan. Global Health & Medicine, 2021, 3, 203-213.	0.6	0
3291	Cardiovascular disease in diabetes, beyond glucose. Cell Metabolism, 2021, 33, 1519-1545.	7.2	87
3292	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2539-2546.	1.1	17
3293	Recent Advancements in the Medical Treatment of Diabetic Retinal Disease. International Journal of Molecular Sciences, 2021, 22, 9441.	1.8	7
3294	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. Diabetes Spectrum, 2021, 34, 248-256.	0.4	1
3295	Better Islet Function and Cardiovascular Autonomic Function in Chinese Type 2 Diabetic Patients with Pure Small Fiber Neuropathy than with Mixed Neuropathy. Diabetes Therapy, 2021, 12, 2423-2436.	1.2	2
3296	Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. Diabetes Spectrum, 2021, 34, 235-242.	0.4	0
3297	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients, 2021, 13, 2830.	1.7	27
3298	Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction. Antioxidants, 2021, 10, 1306.	2.2	59
3299	High concentrations of triglycerides are associated with diabetic kidney disease in new-onset type 2 diabetes in China: Findings from the China Health and Nutrition Survey (CHNS) cohort (4C Study). Diabetes, Obesity and Metabolism, 2021, 23, 2551-2560.	2.2	10
3300	Glycation End-Products and their Receptors: Pathophysiology and Therapeutic Targeting in Diabetes Mellitus. Al-Rafidain Journal of Medical Sciences, 0, 1, 19-35.	0.0	0
3301	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
3302	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. Endocrine and Metabolic Science, 2021, 4, 100102.	0.7	0
3303	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2021, 35, 107980.	1.2	3

#	ARTICLE	IF	CITATIONS
3304	Potential Overtreatment and Undertreatment of Type 2 Diabetes Mellitus in Long-Term Care Facilities: A Systematic Review. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1889-1897.e5.	1.2	14
3305	A Clinical Conundrum: Intensifying Glycemic Control in the Presence of Advanced Diabetic Retinopathy. <i>Diabetes Care</i> , 2021, 44, 2192-2193.	4.3	7
3306	Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109037.	1.1	6
3307	ADVANCE research 20 years later. <i>Eurasian Heart Journal</i> , 2021, , 36-45.	0.2	0
3308	2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. <i>JACC Asia</i> , 2021, 1, 129-146.	0.5	1
3310	Glycaemic variabilities: Key questions in pursuit of clarity. <i>Diabetes and Metabolism</i> , 2021, 47, 101283.	1.4	9
3311	Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease. <i>Current Cardiology Reviews</i> , 2021, 17, e160721189014.	0.6	0
3312	Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control. <i>Molecular Therapy</i> , 2022, 30, 341-354.	3.7	10
3313	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. <i>International Journal of Cardiology</i> , 2021, 338, 248-257.	0.8	1
3314	Evaluation of Serum Glucose and Kidney Disease Progression Among Patients With Diabetes. <i>JAMA Network Open</i> , 2021, 4, e2127387.	2.8	6
3315	Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154890.	1.5	54
3317	Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment. <i>JAMA Network Open</i> , 2021, 4, e2126605.	2.8	6
3318	Association between time in range and cancer mortality among patients with type 2 diabetes: a prospective cohort study. <i>Chinese Medical Journal</i> , 2022, 135, 288-294.	0.9	6
3319	Quantifying the Risk Continuum for Cardiovascular Death in Adults with Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021, 45, 650-658.e2.	0.4	4
3320	Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies. <i>Primary Care Diabetes</i> , 2021, 15, 761-771.	0.9	5
3321	Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation. <i>Atherosclerosis</i> , 2021, 335, 16-22.	0.4	10
3322	Management of diabetic neuropathy. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154867.	1.5	20
3323	Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154838.	1.5	84

#	ARTICLE	IF	CITATIONS
3324	Significance of Glycemic Variability in Diabetes Mellitus. Internal Medicine, 2022, 61, 281-290.	0.3	10
3325	Risk Factors and Prevention. , 2022, , 187-206.e6.		0
3326	Stable Ischemic Heart Disease. , 2022, , 429-453.		0
3327	Preventive Cardiology. , 2022, , 341-375.		0
3328	Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice. Journal of Biological Chemistry, 2021, 296, 100761.	1.6	12
3329	¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?. Clínica E Investigaci3n En Arteriosclerosis, 2021, 33, 33-40.	0.4	2
3330	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	3.9	102
3337	Diabetes Care for the Older Patient. , 2012, , .		1
3338	Glycemic Variability in Type 2 Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2013, 771, 139-154.	0.8	29
3339	Weight Reduction in Diabetes. Advances in Experimental Medicine and Biology, 2013, 771, 438-458.	0.8	9
3340	Experimental Treatment of Acquired and Inherited Neuropathies. , 2014, , 437-472.		1
3341	Diabetes Mellitus and Chronic Kidney Disease (Stages 1-5). , 2014, , 103-136.		1
3342	Diabetes and the Nervous System. Endocrinology, 2020, , 275-353.	0.1	3
3343	Cardiovascular Disease Prevention in Women. Contemporary Cardiology, 2021, , 441-461.	0.0	3
3346	Diabetes and the Nervous System. Endocrinology, 2018, , 275-353.	0.1	1
3347	Insulin Resistance, Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology, 2017, 960, 277-304.	0.8	304
3348	Kidney Diseases in the Elderly. , 2019, , 131-144.		2
3349	Antidiabetika. , 2009, , 321-342.		1

#	ARTICLE	IF	CITATIONS
3350	Prevention of Cardiovascular Disease in Older Adults. , 2015, , 1763-1786.		1
3351	Stable Ischemic Heart Disease Stable Ischemic Heart Disease. , 2015, , 2109-2172.		1
3352	Stable Ischemic Heart Disease. , 2014, , 1-70.		1
3353	Typ-2 Diabetes. , 2015, , 1-26.		1
3354	A potent risk model for predicting new-onset acute coronary syndrome in patients with type 2 diabetes mellitus in Northwest China. Acta Diabetologica, 2020, 57, 705-713.	1.2	16
3355	Type 2 Diabetes Mellitus. , 2011, , 1371-1435.		22
3356	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
3357	Primary and Secondary Prevention of Coronary Heart Disease. , 2012, , 1010-1035.		18
3358	Diabetes and the Cardiovascular System. , 2012, , 1392-1409.		4
3359	Disorders of Peripheral Nerves. , 2012, , 1915-2015.		11
3360	Intensive glycemic control in younger and older U.S. adults with type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1299-1304.	1.2	9
3361	Les complications du diabète de type 2 exigent une prévention multifactorielle qui passe obligatoirement par un contrôle optimisé de l'équilibre glycémique. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 1211-1213.	0.0	2
3362	Exploring the inhibitory mechanism of piceatannol on $\alpha$ -glucosidase relevant to diabetes mellitus. RSC Advances, 2020, 10, 4529-4537.	1.7	15
3363	AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Bioscience Reports, 2019, 39, .	1.1	43
3364	Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy. Ophthalmic Epidemiology, 2016, 23, 209-222.	0.8	107
3365	Diabetic Kidney Disease. , 2019, , 277-286.		1
3367	Tight control of blood glucose in long standing type 2 diabetes. BMJ: British Medical Journal, 2009, 338, b800-b800.	2.4	39
3368	Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. BMJ Open Diabetes Research and Care, 2019, 7, e000731.	1.2	9

#	ARTICLE	IF	CITATIONS
3369	Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001007.	1.2	29
3370	Dynamic and Dual Effects of Glycated Hemoglobin on Estimated Glomerular Filtration Rate in Type 2 Diabetic Outpatients. <i>American Journal of Nephrology</i> , 2013, 38, 19-26.	1.4	17
3371	Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. <i>Circulation Research</i> , 2020, 126, 1526-1548.	2.0	58
3372	Glycemic Index and Diabetes Mellitus. , 2016, , 45-77.		1
3373	Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1150-1162.	1.8	12
3375	Lysozyme-Antimicrobial Peptide Fusion Protein Promotes the Diabetic Wound Size Reduction in Streptozotocin (STZ)-Induced Diabetic Rats. <i>Medical Science Monitor</i> , 2018, 24, 8449-8458.	0.5	6
3376	New hypoglycemic agents and the kidney: what do the major trials tell us?. <i>F1000Research</i> , 2018, 7, 1844.	0.8	2
3377	Cognitive dysfunctions in individuals with diabetes mellitus. <i>Yeungnam University Journal of Medicine</i> , 2019, 36, 183-191.	0.7	42
3378	Avoiding hypoglycaemia: a new target of care for elderly diabetic patients. <i>Hong Kong Medical Journal</i> , 2015, 21, 444-54.	0.1	9
3379	Comparing the incidence of major cardiovascular events and severe microvascular complications in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>World Journal of Meta-analysis</i> , 2020, 8, 400-410.	0.1	2
3380	Inflammation Determines the Pro-Adhesive Properties of High Extracellular D-Glucose in Human Endothelial Cells In Vitro and Rat Microvessels In Vivo. <i>PLoS ONE</i> , 2010, 5, e10091.	1.1	58
3381	Hypoglycemia Assessed by Continuous Glucose Monitoring Is Associated with Preclinical Atherosclerosis in Individuals with Impaired Glucose Tolerance. <i>PLoS ONE</i> , 2011, 6, e28312.	1.1	17
3382	Good Glycemic Control Is Associated with Better Survival in Diabetic Patients on Peritoneal Dialysis: A Prospective Observational Study. <i>PLoS ONE</i> , 2012, 7, e30072.	1.1	34
3383	Efficacy of Intensive Control of Glucose in Stroke Prevention: A Meta-Analysis of Data from 59197 Participants in 9 Randomized Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e54465.	1.1	26
3384	The Association between Postload Plasma Glucose Levels and 38-Year Mortality Risk of Coronary Heart Disease: The Prospective NHLBI Twin Study. <i>PLoS ONE</i> , 2013, 8, e69332.	1.1	11
3385	Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study. <i>PLoS ONE</i> , 2015, 10, e0130828.	1.1	16
3386	Trends in Emergency Department Visit Rates for Hypoglycemia and Hyperglycemic Crisis among Adults with Diabetes, United States, 2006-2011. <i>PLoS ONE</i> , 2015, 10, e0134917.	1.1	46
3387	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153502.	1.1	6

#	ARTICLE	IF	CITATIONS
3388	Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography. PLoS ONE, 2017, 12, e0171733.	1.1	7
3389	Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice. PLoS ONE, 2017, 12, e0186586.	1.1	18
3390	Clinical and economic burdens experienced by patients with painful diabetic peripheral neuropathy: An observational study using a Japanese claims database. PLoS ONE, 2017, 12, e0187250.	1.1	17
3391	Protective effect of metformin against retinal vein occlusions in diabetes mellitus – A nationwide population-based study. PLoS ONE, 2017, 12, e0188136.	1.1	10
3392	THE ASSOCIATION BETWEEN POOR GLYCAEMIC CONTROL (HBA1C LEVELS $\geq 7\%$ ) AND HIGHER INCIDENCE OF DIABETIC RETINOPATHY IN SMALL GROUP OF TYPE 2 DIABETES MELLITUS PATIENTS ATTENDING MAHATMA GANDHI MEMORIAL GOVERNMENT HOSPITAL, TRICHY. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 4761-4764.	0.1	2
3393	Algorithms of Specialized Medical Care for Diabetes Mellitus Patients. Diabetes Mellitus, 2011, 14, 2-72.	0.5	22
3394	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	0.5	16
3395	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes Mellitus, 2013, 16, 1-120.	0.5	31
3396	Hypoglycemia in type 2 diabetes patients treated with insulin: the advantages of continuous glucose monitoring. Diabetes Mellitus, 2014, 17, 75-80.	0.5	8
3397	Insulin degludec is a new ultra-long-acting insulin analogue. Diabetes Mellitus, 2014, 17, 91-104.	0.5	5
3398	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues. Diabetes Mellitus, 2014, 17, 108-119.	0.5	1
3399	The incretin system in type 2 diabetes mellitus: cardiovascular effects. Problemy Endokrinologii, 2012, 58, 33-42.	0.2	2
3400	Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013. Journal of Clinical Medicine Research, 2016, 8, 710-714.	0.6	3
3401	Type 2 Diabetes and Glycemic Variability: Various Parameters in Clinical Practice. Journal of Clinical Medicine Research, 2018, 10, 737-742.	0.6	18
3402	Management of adults with diabetes on the haemodialysis unit: summary of new guidance from the Joint British Diabetes Societies (JBDS) and the Renal Association. British Journal of Diabetes, 2016, 16, 69.	0.1	12
3403	Targeting beta-cell preservation in the management of type 2 diabetes. British Journal of Diabetes, 2017, 17, 134-144.	0.1	13
3404	Malignancy incidences by glycemic control among diabetic patients. Endocrine Connections, 2018, 7, 1457-1463.	0.8	4
3405	Diabetes Mellitus: An Overview. Pharmacy & Pharmacology International Journal, 2016, 4, .	0.1	2

#	ARTICLE	IF	CITATIONS
3406	Intimaâ€™media complex thickness and carotid atherosclerotic plaque formation in Lublinâ€™s population in the context of selected comorbidities. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ, SzopiÅska</i> , 2018, 18, 133-139.	0.7	7
3407	Concepts in Diabetic Nephropathy: From Pathophysiology to Treatment. <i>Journal of Renal and Hepatic Disorders</i> , 2017, 1, 10-24.	0.1	6
3408	Cardiovascular risk in type 2 diabetes patients. <i>Cardiovascular Therapy and Prevention (Russian)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.4	3
3409	Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e8652.	0.7	3
3410	Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2010, 28, 463-471.	0.6	58
3411	Unsatisfactory glycemic control in type 2 Diabetes mellitus patients: predictive factors and negative clinical outcomes with the use of antidiabetic drugs. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2016, 52, 801-812.	1.2	2
3412	Diabetes: An Update on the Pandemic and Potential Solutions. , 2017, , 209-234.		14
3414	Glycemic Variability: Clinical and Prognostic Significance. <i>Sports and Exercise Medicine - Open Journal</i> , 2015, 1, 48-53.	0.3	5
3415	Cardiovascular Benefits and Risk Profiles of Oral Anti-Diabetic Agents: Current Evidence and Ongoing Trials. <i>Journal of Cardiology and Therapy</i> , 2015, 2, 386-392.	0.1	1
3416	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. <i>US Endocrinology</i> , 2020, 16, 80.	0.3	7
3417	Obesity and poor glycemic control in patients with type 2 diabetes. <i>International Journal of Research in Medical Sciences</i> , 0, , 584-588.	0.0	8
3418	Modeling mtDNA hypermethylation vicious circle mediating A <sup>1</sup> <sub>2</sub> -induced endothelial damage memory in HCMEC/D3 cell. <i>Aging</i> , 2020, 12, 18343-18362.	1.4	5
3419	Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study. <i>Oncotarget</i> , 2017, 8, 78086-78095.	0.8	15
3420	The Kidney in Type 2 Diabetes Therapy. <i>Review of Diabetic Studies</i> , 2011, 8, 392-402.	0.5	66
3421	Metabolic Memory and Individual Treatment Aims in Type 2 Diabetes â€™ Outcome-Lessons Learned from Large Clinical Trials. <i>Review of Diabetic Studies</i> , 2011, 8, 432-440.	0.5	50
3422	Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics. <i>Review of Diabetic Studies</i> , 2015, 12, 351-362.	0.5	14
3423	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. <i>Annals of Translational Medicine</i> , 2017, 5, 261-261.	0.7	2
3424	A 7.0â€™7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus. <i>Annals of Translational Medicine</i> , 2019, 7, S122-S122.	0.7	3

#	ARTICLE	IF	CITATIONS
3425	Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 227.	1.1	10
3426	Insulin glulisine in the management of diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009, 2, 111.	1.1	4
3427	Fixed combination of repaglinide and metformin in the management of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009, 2, 101.	1.1	5
3428	Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 197.	1.1	7
3429	L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes. <i>Current Medicinal Chemistry</i> , 2020, 27, 1744-1763.	1.2	26
3430	The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 3665-3674.	0.9	38
3431	Standard and Emerging Treatment Options for Diabetic Neuropathy. <i>Current Pharmaceutical Design</i> , 2014, 20, 3689-3704.	0.9	10
3432	Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 531-543.	0.9	30
3433	Metabolic Syndrome and Cardiometabolic Risk Factors. <i>Current Vascular Pharmacology</i> , 2014, 11, 858-879.	0.8	49
3434	Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall. <i>Current Vascular Pharmacology</i> , 2018, 17, 6-15.	0.8	12
3435	Pharmacological Management of Diabetic Nephropathy. <i>Current Vascular Pharmacology</i> , 2020, 18, 139-147.	0.8	5
3436	Microvascular Complications of Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2020, 18, 117-124.	0.8	235
3437	Treatment of Diabetic Cardiovascular Autonomic, Peripheral and Painful Neuropathy. Focus on the Treatment of Cardiovascular Autonomic Neuropathy with ACE Inhibitors. <i>Current Vascular Pharmacology</i> , 2020, 18, 158-171.	0.8	10
3438	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. <i>Current Diabetes Reviews</i> , 2011, 7, 190-200.	0.6	37
3439	Prevalence of Chronic Diabetic Complications in Newly Diagnosed versus Known Type 2 Diabetic Subjects in a Sample of Alexandria Population, Egypt. <i>Current Diabetes Reviews</i> , 2018, 15, 74-83.	0.6	26
3440	Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review. <i>Current Diabetes Reviews</i> , 2020, 16, 820-832.	0.6	1
3441	Comprehensive Review on Diabetes Associated Cardiovascular Complications - The Vitamin D Perspective. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2019, 19, 139-153.	0.2	3
3442	Should we Fear Insulin Therapy in the Treatment of Type 2 Diabetes?. <i>The Open Obesity Journal</i> , 2014, 6, 70-75.	0.1	2



#	ARTICLE	IF	CITATIONS
3443	A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. <i>JMIR Diabetes</i> , 2017, 2, e5.	0.9	120
3445	12. Older Adults: Standards of Medical Care in Diabetes—2021. <i>Diabetes Care</i> , 2021, 44, S168-S179.	4.3	149
3446	The role of renal proximal tubule transport in the regulation of blood pressure. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 12-21.	0.9	21
3447	Type 2 Diabetes in the Elderly: Challenges in a Unique Patient Population. <i>Journal of Geriatric Medicine and Gerontology</i> , 2016, 2, .	0.1	23
3448	Morbidity and mortality of diabetes with surgery. <i>Nutricion Hospitalaria</i> , 2013, 28 Suppl 2, 47-52.	0.2	14
3449	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. <i>Health Technology Assessment</i> , 2016, 20, 1-86.	1.3	12
3450	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-64.	1.3	28
3451	Blood-Nerve Barrier (BNB) Pathology in Diabetic Peripheral Neuropathy and In Vitro Human BNB Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 62.	1.8	16
3452	Cardiovascular disease and 1,5-anhydro-d-glucitol. <i>Global Health &amp; Medicine</i> , 2019, 1, 83-87.	0.6	7
3453	Hypoglycemic Effect of Sargassum ringgoldianum Extract in STZ-induced Diabetic Mice. <i>Preventive Nutrition and Food Science</i> , 2012, 17, 8-13.	0.7	28
3455	Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 6.	0.7	33
3456	Monotherapy in patients with type 2 diabetes mellitus. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 959-966.	0.7	5
3457	The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S4-S10.	0.6	13
3458	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 403-6.	0.7	17
3459	Long-term glycaemic control (HbA1c), not admission glucose, predicts hospital re-admission in diabetic patients. <i>Australasian Medical Journal</i> , 2015, 8, 189-199.	0.1	5
3460	Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 555.	1.8	8
3461	Impact of Diabetes Control on Subclinical Atherosclerosis: Analysis from Coronary Computed Tomographic Angiography Registry. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 470.	1.8	8
3462	Hypoglycemic Morbidity and Mortality in Diabetes. <i>Journal of Korean Diabetes</i> , 2016, 17, 17.	0.1	1

#	ARTICLE	IF	CITATIONS
3463	Correlation between measures of hypoglycemia and glyceimic improvement in sulfonylurea treated patients with type 2 diabetes in India. <i>Journal of Postgraduate Medicine</i> , 2014, 60, 151-155.	0.2	8
3464	Does tight control of systemic factors help in the management of diabetic retinopathy?. <i>Indian Journal of Ophthalmology</i> , 2016, 64, 62.	0.5	19
3465	Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. <i>Indian Journal of Nephrology</i> , 2011, 21, 75.	0.2	19
3466	Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum?. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 546.	0.2	698
3467	The incidence of hypoglycemia among insulin-treated patients with Type 1 or Type 2 diabetes: Bangladeshi cohort of international operations-hypoglycemia assessment tool study. <i>Indian Journal of Endocrinology and Metabolism</i> , 2018, 22, 379.	0.2	3
3468	The effect of saffron ( <i>Crocus sativus</i> L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial. <i>Journal of Research in Medical Sciences</i> , 2018, 23, 16.	0.4	48
3469	Diabetes in the Elderly: Exercising Your Clinical Skills. <i>The Consultant Pharmacist</i> , 2010, 25, 1-37.	0.4	1
3470	Liraglutide and Insulin are Associated with a Decreased Risk of Acute Myocardial Infarction in Type 2 Diabetes Mellitus Patients. <i>Journal of Diabetes &amp; Metabolism</i> , 2014, 05, .	0.2	1
3471	Effects of Body Weight Reduction on Arterial Stiffness and Endothelial Function after Bariatric Surgery in Morbidly Obese Patients: A 4-Year Clinical Study. <i>Acta Endocrinologica</i> , 2018, 14, 491-497.	0.1	7
3472	Update on biomarkers of glyceimic control. <i>World Journal of Diabetes</i> , 2019, 10, 1-15.	1.3	53
3473	Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. <i>World Journal of Diabetes</i> , 2019, 10, 490-510.	1.3	56
3474	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. <i>World Journal of Diabetes</i> , 2019, 10, 291-303.	1.3	14
3475	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonists' role in treatment; from the past to future. <i>World Journal of Diabetes</i> , 2019, 10, 446-453.	1.3	17
3476	Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study. <i>World Journal of Diabetes</i> , 2013, 4, 8.	1.3	13
3477	Cardiac autonomic neuropathy in patients with diabetes mellitus. <i>World Journal of Diabetes</i> , 2014, 5, 17.	1.3	239
3478	Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe. <i>World Journal of Diabetes</i> , 2014, 5, 69.	1.3	2
3479	Is the present cut-point to define type 2 diabetes appropriate in Latin-Americans?. <i>World Journal of Diabetes</i> , 2014, 5, 747.	1.3	13
3480	Predictors of hypoglycemia in insulin-treated patients with type 2 diabetes mellitus in Basrah. <i>World Journal of Diabetes</i> , 2016, 7, 470.	1.3	5

#	ARTICLE	IF	CITATIONS
3481	Stopping the cardiovascular disease continuum: Focus on prevention. <i>World Journal of Cardiology</i> , 2010, 2, 43.	0.5	12
3482	Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics. <i>World Journal of Cardiology</i> , 2013, 5, 119.	0.5	2
3483	Diabetes care among older adults in primary care in Austria - a cross-sectional study. <i>Swiss Medical Weekly</i> , 2012, 142, w13646.	0.8	5
3484	Acute painful diabetic neuropathy: an uncommon, remittent type of acute distal small fibre neuropathy. <i>Swiss Medical Weekly</i> , 2015, 145, w14131.	0.8	13
3485	Current Clinical Evidence for Korean Red Ginseng in Management of Diabetes and Vascular Disease: A Toronto's Ginseng Clinical Testing Program. <i>Journal of Ginseng Research</i> , 2010, 34, 264-273.	3.0	20
3486	Control Status of Atherosclerotic Cardiovascular Risk Factors Among Japanese High-Risk Subjects:Analyses of a Japanese Health Check Database from 2008 to 2011. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 991-1003.	0.9	9
3487	Optimal utilisation of sulphonylureas in resource-constrained settings : review article. <i>Cardiovascular Journal of Africa</i> , 2014, 25, 83-85.	0.2	8
3488	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 787-891.	0.3	102
3489	Guidelines for diabetes mellitus: from the perspective of diagnosis and treatment. <i>Health Evaluation and Promotion</i> , 2014, 41, 533-539.	0.0	1
3490	Glycated albumin and HbA1c as predictors of mortality and vascular complications in type 2 diabetes patients with normal and moderately impaired renal function: 5-year results from a 380 patient cohort. <i>Journal of Diabetes Research &amp; Clinical Metabolism</i> , 2014, 3, 9.	0.2	5
3491	The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. <i>Annals of Internal Medicine</i> , 2012, 156, 541.	2.0	164
3492	Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020, 29, 215-221.	1.5	12
3493	Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes. <i>Drugs in Context</i> , 2013, 2013, 1-8.	1.0	8
3494	Prediction of morbidity and mortality in patients with type 2 diabetes. <i>PeerJ</i> , 2013, 1, e87.	0.9	18
3495	Thiazolidinediones: A 2010 Perspective. , 2010, 14, 64-72.		40
3496	Delaying and preventing diabetic retinopathy. <i>Practical Diabetes</i> , 2021, 38, 31-34.	0.1	0
3497	The potential role of C-peptide in sexual and reproductive functions in type 1 diabetes mellitus: An update. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	1
3498	Long-term effects of the mean hemoglobin A1c levels after percutaneous coronary intervention in patients with diabetes. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1365-1376.	0.7	7

#	ARTICLE	IF	CITATIONS
3499	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 1811-1824.	6.3	257
3500	Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: A meta-analysis of randomised control-trials. <i>Therapie</i> , 2022, 77, 413-423.	0.6	10
3501	Clinical and Pathological Characteristics of Patients With Nonproteinuric Diabetic Nephropathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 761386.	1.5	7
3502	Relevance of self-control of blood glucose in the aspect of prevention of cardiovascular complications in patients with diabetes mellitus. <i>Meditinskiy Sovet</i> , 2021, , 104-109.	0.1	2
3503	Predictors of outcome in diabetic patients undergoing infrapopliteal endovascular revascularization for chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2022, 75, 618-624.	0.6	6
3504	Relationship between skin autofluorescence levels and clinical events in patients with heart failure undergoing cardiac rehabilitation. <i>Cardiovascular Diabetology</i> , 2021, 20, 208.	2.7	11
3506	The impact of early intensive glucose control for prophylaxis of complications of type 2 diabetes mellitus (results of UKPDS study and 10-year follow-up study). <i>Obesity and Metabolism</i> , 2009, 6, 12-18.	0.4	2
3507	Actualit� de la prise en charge du diab�te de type 2 en France. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2009, 193, 1645-1661.	0.0	7
3508	DIABETES CONTROL � THE LEGACY OF A MEMORY. <i>Journal of the University of Malaya Medical Centre</i> , 2009, 12, 47-56.	0.0	1
3509	Glucose control in critically ill patients and clinical application of bedside-type artificial endocrine pancreas. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2010, 17, 464-467.	0.0	0
3510	Ath�roscl�rose. , 2010, , 287-491.		0
3511	Hypoglycaemia in Type 2 Diabetes � Clinical Consequences and Impact on Treatment. <i>European Endocrinology</i> , 2010, 06, 29.	0.8	2
3512	Hypoglycemia and Hypoglycemic Syndromes. , 2010, , 873-896.		0
3514	Management of Type 2 Diabetes Mellitus. , 2010, , 897-915.		0
3515	Diabetes Mellitus: Is the Presence of Nephropathy Important as a Cardiovascular Risk Factor for Cardioneral Syndrome?. , 2010, , 145-157.		0
3516	Diabetic Kidney Disease. , 2010, , 319-339.		0
3517	Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diab�tique. , 2010, , 250-262.		0
3518	BARI 2D - where has it taken us to and what the future has in store for us. <i>Cor Et Vasa</i> , 2010, 52, 168-175.	0.1	0

#	ARTICLE	IF	CITATIONS
3519	Quels enjeux thérapeutiques chez la personne atteinte diabétique ?. Bulletin De L'Academie Nationale De Medecine, 2010, 194, 819-831.	0.0	0
3520	Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors. , 2011, , 3-24.		0
3521	Diagnosis and Management of Ischemic Stroke. , 2011, , 373-390.		1
3522	Potentially Dangerous treatment. Deutsches Ärzteblatt International, 2010, 107, 444; author reply 445.	0.6	0
3524	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 243.	1.1	0
3529	The Gut, Brain, and Peripheral Tissue Connection: Metabolic Disease in the Incretin Era. Endocrine Practice, 2010, 16, 33-38.	1.1	0
3530	Effectiveness of Individual-Level Interventions to Prevent Vascular Complications. , 2010, , 343-372.		0
3531	Achievement of cardiovascular risk factor targets in young adults with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 387.	1.1	1
3532	Medication Management in Long-Term Care. , 2011, , 299-322.		0
3534	Primary Prevention of Stroke. , 2011, , 242-251.		0
3538	Intensivtherapie nach Transplantation solider Organe. , 2011, , 1035-1058.		1
3541	Complications cardiovasculaires du diabète. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 205-211.	0.0	2
3543	Consensus statement by a panel of experts of the Russian Association of Endocrinologists (RAE) on initiation and intensification of hypoglycemic therapy for type 2 diabetes mellitus. Diabetes Mellitus, 2011, 14, 95-105.	0.5	5
3544	3. Glycemic Management of Type 2 Diabetes. Translational Endocrinology & Metabolism, 2011, , 69-94.	0.2	0
3546	Diabetes mellitus and cardiovascular diseases. Cor Et Vasa, 2011, 53, 242-248.	0.1	0
3547	How can we avoid the danger of hypoglycemia, one of the most serious complications of therapy of type 2 diabetes mellitus? The role of DPP-4 inhibitors. Problemy Endokrinologii, 2011, 57, 48-52.	0.2	0
3548	Hemostasis effects of various glucose-lowering medications and angiopathy prevention. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 66-71.	0.4	0
3549	Basal insulin therapy in patients with type 2 diabetes mellitus: aspects of early initiation, advantages, constraints, and prospects. Problemy Endokrinologii, 2011, 57, 53-59.	0.2	0

#	ARTICLE	IF	CITATIONS
3550	Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. <i>Endocrine Practice</i> , 2011, 17, 13-19.	1.1	0
3553	Effective and safe control of glycemia with insulin Apidra - the recipe for success of type 2 diabetes prophylaxis. <i>Diabetes Mellitus</i> , 2011, 14, 46-50.	0.5	1
3555	The Treatment of Diabetes after an Acute Ischemic Stroke. <i>US Endocrinology</i> , 2012, 08, 88.	0.3	0
3556	References, Bibliography & Further Reading. , 2012, , 287-306.		0
3557	Stroke Update: Risk Factors and Primary Prevention of Stroke. <i>Korean Journal of Stroke</i> , 2012, 14, 12.	0.1	1
3560	RECOMENDACIONES EN PREVENCIÃ“N DEL RIESGO VASCULAR. , 2012, , 29-61.		0
3561	Management of Diabetic Nephropathy in the Elderly: Special Considerations. <i>Journal of Nephrology &amp; Therapeutics</i> , 2012, 02, .	0.1	2
3563	Peripheral Artery Diseases. , 2012, , 1338-1358.		1
3564	Management Strategies for Diabetes. , 2012, , 19-33.		0
3565	AvaliaÃ§Ã£o de resultados em um serviÃ§o de atenÃ§Ã£o secundÃ¡ria para pacientes com Diabetes mellitus. <i>ACTA Paulista De Enfermagem</i> , 2012, 25, 614-618.	0.1	0
3566	Literatur zu Schwartz F.W. et al.: <i>Public Health</i> â€“ Gesundheit und Gesundheitswesen. , 2012, , e1-e91.		0
3570	Peripheral Artery Diseases. , 0, , .		0
3571	Influence of intensive glycemic control on development and progression of diabetic nephropathy in patients with type 2 diabetes mellitus (based on results from ADVANCE study). <i>Diabetes Mellitus</i> , 2012, 15, 87-91.	0.5	0
3572	The results of DINASTIYA study - Diabeton MB: the observational program among the patients with type 2 diabetes mellitus under conditions of routine clinical practice. <i>Problemy Endokrinologii</i> , 2012, 58, 28-36.	0.2	0
3573	Glucose Tolerance and Elders â€“ Lessons We Have Learned and Challenges for the Future. , 0, , .		0
3574	Diabetes and the Cardiovascular System. , 2013, , 701-714.		0
3575	Glycemic Control in Diabetic Patients with Diabetic Nephropathy. <i>Journal of Korean Diabetes</i> , 2013, 14, 23.	0.1	0
3576	Type 2 Diabetes Mellitusâ€™A Pathology on the Rise How do we Monitor it?. <i>Pharmaceutica Analytica Acta</i> , 2013, 04, .	0.2	0

#	ARTICLE	IF	CITATIONS
3577	Evidence-Based Glycemic Target for the Prevention of the Complications of Diabetes Mellitus Towards Individualized Therapy. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 429-430.	0.1	0
3578	Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies. Journal of Diabetes & Metabolism, 2013, 01, .	0.2	2
3579	Hemoglobin A1c, Blood Pressure, and Serum Low-Density Lipoprotein Cholesterol Goals in Diabetics. Journal of Clinical & Experimental Cardiology, 2013, 04, .	0.0	0
3580	Emerging concepts in metformin therapy: Hyperglycaemia and beyond. Ibmossina Journal of Medicine and Biomedical Sciences, 2013, 5, 227.	0.2	0
3581	Obesity and Diabetes. , 2013, , 39-62.		0
3582	Self-monitoring of blood glucose as a basis for diabetes management. Cardiosomatics, 2013, 4, 47-54.	0.2	0
3583	CARBOHYDRATE METABOLISM DISORDERS AND CORONARY HEART DISEASE: PROGNOSTIC VALUE AND REVASCULARISATION EFFECTIVENESS. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 79-84.	0.4	0
3584	Hypoglycaemia as predictor of cardiovascular accidents. Cardiosomatics, 2013, 4, 67-71.	0.2	0
3585	Hypoglycaemia in Diabetes. , 2014, , 429-443.		0
3586	DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus. Problemy Endokrinologii, 2013, 59, 72-80.	0.2	0
3587	Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis. Swiss Medical Weekly, 2013, 143, w13871.	0.8	10
3590	Glycated Albumin: A More Sensitive Predictor of Cardiovascular Disease than Glycated Hemoglobin?. International Journal of Diabetology & Vascular Disease Research, 0, , 1-2.	0.2	0
3591	Aldose Reductase and Diabetic Cardiovascular Disease. , 2014, , 143-158.		0
3592	Glycosylated hemoglobin as a predictor for the occurrence of macroangiopathic complications in diabetic patients from bihor county. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2013, 20, 395-400.	0.3	0
3593	A Competing Risk Hazard Model for Complications of Diabetes Mellitus. Journal of Biosciences and Medicines, 2014, 02, 1-11.	0.1	1
3594	Complications cardiovasculaires macroangiopathiques etÂinsuffisance cardiaque chezÂleÂdiabÃ©tique. , 2014, , 265-275.		0
3595	Diabetes and Chronic Kidney Disease. , 2014, , 43-55.		0
3596	Pattern of macrovascular disease phenotypes amongst newly diagnosed type 2 diabetic patients in a rural institute in Uttar Pradesh, India. International Journal of Research in Medical Sciences, 2014, 2, 932.	0.0	0

#	ARTICLE	IF	CITATIONS
3597	The Effects of Therapeutic Lifestyle Change on Cardiovascular Disease and Mortality in Diabetic Patients. <i>Journal of Korean Diabetes</i> , 2014, 15, 129.	0.1	1
3598	Glycaemic Therapy for Diabetes. , 2014, , 43-74.		0
3599	Prevention of Cardiovascular Disease in Older Adults. , 2014, , 1-28.		0
3600	Medical Practice Variations in Diabetes Mellitus. , 2014, , 1-40.		1
3601	Diabetische Folgeerkrankungen. , 2014, , 239-296.		0
3602	D'ordres glycmiques et complications diabotiques : physiopathologie. , 2014, , 205-214.		0
3603	Insulin Resistance, Type 2 Diabetes and Atherosclerosis. <i>Journal of Diabetes &amp; Metabolism</i> , 2014, 5, .	0.2	1
3604	Interventional Treatment of the Chronic Ischemic Syndromes of the Lower Extremity. , 2014, , 1-37.		0
3605	Allgemeine Grundlagen des Diabetes mellitus. , 2014, , 1-31.		0
3608	Excess cardiovascular risk in patients with type 2 diabetes: do we need to look beyond LDL cholesterol?. <i>British Journal of Diabetes and Vascular Disease</i> , 2014, 14, 10.	0.6	0
3609	Cardiovascular Disease in Diabetes. <i>Developments in Cardiovascular Medicine</i> , 1992, , .	0.1	6
3610	Complications of Diabetes: How to Address & How to Manage?. <i>Journal of Diabetes, Metabolic Disorders &amp; Control</i> , 2014, 1, .	0.2	0
3612	Medical Specialties™ View of Autonomic System Measurements. , 2015, , 131-136.		1
3613	Individualizing treatment of type 2 diabetes. <i>Sri Lanka Journal of Diabetes Endocrinology and Metabolism</i> , 2014, 4, 56.	0.1	1
3614	Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. , 2015, , 179-202.		1
3615	Diabetes management: More than just cardiovascular risk?. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 672-676.	0.6	0
3616	Surgical Options in Type 2 Diabetes. , 2015, , 111-129.		2
3617	Self-monitoring of blood glucose in patients with diabetes and cardiac pathology with the Meter Contour TS use. <i>Cardiosomatics</i> , 2014, 5, 14-19.	0.2	0



#	ARTICLE	IF	CITATIONS
3618	Intensivbehandlung nach Transplantation solider Organe. , 2015, , 1219-1243.		0
3619	Cardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?. Journal of Diabetes Research & Clinical Metabolism, 2015, 4, 3.	0.2	0
3620	Diabetes Mellitus: Alterations in Vessel Wall Properties. , 2015, , 221-236.		0
3621	Improving Diabetes Care in Underserved Patients through a ?Learning Your Abcs? Education And Screening Program. Journal of Pharmaceutical Care & Health Systems, 2015, 02, .	0.1	0
3622	Intensivtherapie nach Transplantation solider Organe. , 2015, , 1-41.		1
3623	Interventional Treatment of the Chronic Ischemic Syndromes of the Lower Extremity. , 2015, , 3119-3149.		0
3624	Intensive Glycemic Control in Patients with Acute Myocardial Infarction: Diabetes Time Duration Counts!. International Journal of Cardiovascular Sciences, 2015, 28, .	0.0	0
3625	Type 2 Diabetes-Etiology, Epidemiology, Pathogenesis, Treatment. , 2015, , 1-19.		0
3626	Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes. , 2015, , 347-357.		0
3627	Relationship between Insulin Levels and Coronary Atherosclerosis in Newly Diagnosed Diabetes Mellitus and Impaired Glucose Toleranc. International Journal of Clinical Cardiology, 2015, 2, .	0.1	0
3629	Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015). Diabetes Mellitus, 2015, 18, 5-23.	0.5	13
3630	The Role Of Elevated NT-ProBNP And Albuminuria As Cardio-Vascular Risk Factors In Type 2 Diabetes Mellitus Patients After Acute Coronary Syndrome. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2015, 22, 141-149.	0.3	0
3631	Influence of Fixed Combination of Metformin SR and Glimepiride on Carbohydrate, Lipid Metabolism and Arterial Wall Stiffness in Patients with Diabetes Mellitus Type 2. MÃ¼nchener Medizinische Wochenschrift, 2016, .	0.1	0
3634	Biliopancreatic Diversion with Duodenal Switch. , 2016, , 187-195.		0
3635	Ileal Interposition with Sleeve Gastrectomy for the Treatment of Type 2 Diabetes. , 2016, , 197-205.		0
3636	Secondary Stroke Prevention. Updates in Hypertension and Cardiovascular Protection, 2016, , 173-182.	0.1	0
3637	Introduction and disease overview. , 2016, , 1-9.		0
3638	Some specificities in the management of hyperglycemia in patients with diabetic kidney disease. Vojnosanitetski Pregled, 2016, 73, 857-863.	0.1	0

#	ARTICLE	IF	CITATIONS
3639	Stable Ischemic Heart Disease. , 2016, , 1-70.		5
3640	The Difficulty of Diabetic Therapy: An Observational Retrospective Study from Actual Clinical Practice. <i>Advances in Pharmacoepidemiology &amp; Drug Safety</i> , 2016, 5, .	0.1	0
3641	The Future of Diabetes. , 2016, , 1-14.		0
3642	What news brought last year on oral antidiabetic drugs?. <i>Interni Medicina Pro Praxi</i> , 2016, 18, 14-18.	0.0	0
3643	Glycated Hemoglobin As a Risk Factor. <i>International Journal of Medical Science and Clinical Invention</i> , 0, , .	0.1	0
3644	Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S11-S17.	0.6	0
3645	Glucose lowering therapy of type 2 diabetes “the art of possible. <i>Clinical Endocrinology and Endocrine Surgery</i> , 2016, .	0.1	0
3646	Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?. <i>British Journal of Diabetes</i> , 2016, 16, 168.	0.1	0
3647	Glycemic Control and Diabetes Macroangiopathy. <i>International Journal of Medicine and Surgery</i> , 2017, 4, 21-25.	0.0	0
3649	Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure. <i>Indian Journal of Endocrinology and Metabolism</i> , 2017, 21, 618.	0.2	2
3650	Analysis of Therapeutic Outcome of Antidiabetic Medications in a Tertiary Care Hospital - An Observational Study. <i>Journal of Diabetes &amp; Metabolism</i> , 2017, 8, .	0.2	0
3651	Perioperative Management of Medical Comorbidities After Bariatric Surgery. , 2017, , 167-178.		0
3652	The Future of Diabetes. , 2017, , 999-1012.		0
3653	Sitosterol Blood Levels are Elevated in Diabetics and may be the Cause of Coronary Artery Disease and Stroke. <i>The Journal of Medical Sciences</i> , 2017, 3, 89-94.	0.0	0
3654	Perspectives on medical treatment of type 2 diabetes mellitus. <i>Journal of the Japanese Coronary Association</i> , 2017, 23, 113-116.	0.0	0
3655	3. Antidiabetic Agents. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 216-225.	0.0	0
3656	Development of a Pharmaceutical Care Service Model for Patients with Diabetes in Ambulatory Care Settings. <i>Korean Journal of Clinical Pharmacy</i> , 2017, 27, 1-8.	0.0	1
3657	Self-managing type 2 diabetes is a unique challenge for older patients. A systematic review and thematic synthesis of barriers and facilitators. <i>Psicologia Della Salute</i> , 2017, , 97-120.	0.3	0

#	ARTICLE	IF	CITATIONS
3659	Cardio Vascular Outcomes Trials (CVOTs) with Anti-Hyperglycemic Agents: Demystifying Statistical Complexities. <i>Journal of Diabetes, Metabolic Disorders &amp; Control</i> , 2017, 4, .	0.2	2
3660	Predictors for attending annual eye screening for diabetic retinopathy amongst patients with diabetes in an urban community of Beijing. <i>International Journal of Ophthalmology</i> , 2017, 10, 1144-1149.	0.5	5
3663	DIABETES MANAGEMENT AND CURRENT PROSPECTS FOR SELF-MONITORING OF BLOOD GLUCOSE. <i>Meditsinskiy Sovet</i> , 2017, , 17-21.	0.1	0
3664	CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. <i>Meditsinskiy Sovet</i> , 2017, , 32-37.	0.1	1
3665	Fall 56: PrÄvention â€“ 84 Jahre, â™€, DM Typ 2, periphere arterielle Verschlusskrankheit, Mikroalbuminurie. , 2018, , 225-228.		0
3666	Fall 63: Therapie â€“ 63 Jahre, â™„, DM Typ Umstellung auf Insulintherapie. , 2018, , 253-256.		0
3668	Fall 54: PrÄvention â€“ 55 Jahre, â™€, DM Typ 2, Aufnahme mit Herzinfarkt. , 2018, , 217-219.		0
3669	Insulin Treatment. <i>Endocrinology</i> , 2018, , 617-640.	0.1	1
3672	New Herbal Approaches for the Treatment of Diabetic Kidney Diseases and Its Therapeutic Implications. , 2018, , 321-360.		0
3673	Data-Adaptive Estimation in Cluster Randomized Trials. <i>Springer Series in Statistics</i> , 2018, , 195-215.	0.9	0
3674	Fall 59: SpÄtschÄden â€“ 51 Jahre, â™„, DM Typ 2, Herzinfarkt- und Schlaganfallrisiko. , 2018, , 237-240.		0
3675	Fall 48: Therapie â€“ 68 Jahre, â™€ und â™„, (Zwillinge), Albuminurie, Bluthochdruck. , 2018, , 191-194.		0
3676	Fall 75: SpÄtschÄden â€“ 77 Jahre, â™€, DM Typ 2, Retinopathie, Neuropathie. , 2018, , 301-304.		0
3677	Enfoque terapÄutico de la diabetes mellitus tipo 2 en adultos. MÄs allÄ de una meta glucÄmica. <i>Medicina UPB</i> , 2018, 37, 36-46.	0.1	1
3678	Glycemic Targets and Prevention of Chronic Complications. <i>Endocrinology</i> , 2018, , 421-450.	0.1	0
3680	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 131-159.	0.1	0
3681	Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study. <i>Annals of Translational Medicine</i> , 2018, 6, 55-55.	0.7	3
3682	Self-Reported Hypoglycemia in Insulin-Treated Patients with Diabetes: Results from the Philippines Cohort of the International Operations Hypoglycemia Assessment Tool (IO HAT) Study. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2018, 33, 12-21.	0.1	0

#	ARTICLE	IF	CITATIONS
3684	Hypoglycemia among Insulin-treated Patients with Diabetes: Egypt Cohort of IO HAT Study. The Open Diabetes Journal, 2018, 8, 34-47.	0.4	0
3685	The role of hypoglycemia in the development of cardiovascular catastrophes (experience of clinical) Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	0
3686	Effect of Theory-Based Individual Counseling on Physical Activity and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Quasi-Experimental Study. Iranian Red Crescent Medical Journal, 2018, 20, .	0.5	1
3687	Hypoglycemia in patients with type 1 and type 2 diabetes mellitus: incidence and risk factors (review of) Tj ETQq1 1 0.784314 rgBT /Que	0.1	0
3688	Stroke in the Elderly Population. Current Topics in Environmental Health and Preventive Medicine, 2019, , 121-135.	0.1	0
3689	Correlation of glycosylated haemoglobin (HbA1c) levels with subclinical atherosclerosis in patients with type 2 diabetes mellitus. The Medical Journal of Basrah University, 2018, 36, 103-114.	0.1	2
3690	Overtreatment and Hypoglycemia Prevalence in Geriatric Patients with Type-2 Diabetes in the Turkish Population. Acta Endocrinologica, 2019, 15, 311-316.	0.1	3
3691	Diabetes and the Nervous System. Endocrinology, 2019, , 1-79.	0.1	0
3692	Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. , 2019, , 377-390.		0
3693	Désordres glycémiques et complications diabétiques : physiopathologie. , 2019, , 271-281.		0
3695	Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 112, 649-705.	0.3	12
3696	Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients. Journal of Korean Diabetes, 2019, 20, 233.	0.1	0
3697	Épidémiologie des états diabétiques. , 2019, , 3-11.		0
3698	Hypoglycemias in elderly patients with type 2 diabetes mellitus: possible risks and ways to prevent them. Profilakticheskaya Meditsina, 2019, 22, 109.	0.2	0
3699	Effets des traitements anti-hyperglycémiques sur les complications cardiovasculaires et rénales du patient diabétique de type 2 : leçons des grands essais d'intervention. , 2019, , 283-295.		0
3700	Treatment Goals for Glycemia in Older Patients with Diabetes Mellitus. Journal of Korean Diabetes, 2019, 20, 220.	0.1	0
3701	Diabetes and the Cardiovascular System. Endocrinology, 2019, , 1-29.	0.1	0
3702	The Prevention of Cardiovascular Diseases in Diabetes Mellitus: Role of Glycemic Control. Family Medicine, 2019, .	0.1	0

#	ARTICLE	IF	CITATIONS
3703	3. Recent Progress in the Treatment of Type 2 Diabetes. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 460-467.	0.0	0
3704	Prevalence of Hypoglycemia, Treatment Satisfaction, Adherence and Their Associations with Glycemic Goals in Patients with Type 2 Diabetes Mellitus Treated with Sulfonylureas: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) in Romania. Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2019. 26. 55-64.	0.3	1
3705	A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus. Vnitri Lekarstvi, 2019, 65, 289-294.	0.1	2
3706	Pharmacotherapy of Diabetes Focused on Stroke. Journal of the Korean Neurological Association, 2019, 37, 235-250.	0.0	3
3707	Some aspects of the drug therapy of type 2 diabetes mellitus in overweight patients. MÃ¼narodnij EndokrinologÃ¼nj Å½urnal, 2019, 15, 410-418.	0.1	2
3708	Specialist Advice Does Not Modify the Risk of Death of Diabetic 2 Patients. , 2019, , 1-10.		0
3710	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology, 2019, , 98-111.	0.4	6
3711	Cardiovascular complications in diabetes mellitus: the role of hyperglycemia. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2019, 2019, 102-112.	0.0	0
3712	Diabetes Mellitus and Chronic Kidney Disease (Stages 1â€“5). , 2020, , 175-196.		0
3713	Inflammatory Mechanisms in Diabetic Kidney Disease. , 2020, , 437-455.		0
3714	Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 11.	0.0	0
3716	Efecto de terapias farmacolÃ³gicas para el control glicÃ©mico en pacientes con diabetes mellitus tipo 2 en los desenlaces vasculares. Revista Colombiana De NefrologÃ­a, 2020, 7, 44-59.	0.1	1
3717	Review of the evidence base of representatives of the group of sodium-glucose co-transporter 2 inhibitors available at the Ukrainian market (literature review). MÃ¼narodnij EndokrinologÃ¼nj Å½urnal, 2020, 16, 237-244.	0.1	1
3718	Incretin-based treatment of diabetes and cardiovascular complications. Vnitri Lekarstvi, 2020, 66, 74-80.	0.1	0
3720	Relationship of type 2 diabetes mellitus and cardiovascular pathology: significance of glycemic control on the way to solving the problem. Meditsinskiy Sovet, 2020, , 22-28.	0.1	0
3721	Exploring the Protective Effect of ShenQi Compound on Skeletal Muscle in Diabetic Macrovasculopathy Mice. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 943-951.	0.6	1
3722	Low Carbohydrate Lifestyle Reduces Significantly Insulin Need in Type 2 Diabetes Patients. Interventions in Obesity & Diabetes, 2020, 4, .	0.0	0
3723	Hypoglycaemia assessment tool (HAT) study: subanalysis of the Lebanese cohort. Eastern Mediterranean Health Journal, 2020, 26, 939-947.	0.3	2

#	ARTICLE	IF	CITATIONS
3724	Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2022, 48, 101299.	1.4	5
3726	Proatherogenic Changes in the Blood Lipid Profile in Patients with Cerebrovascular Disease and Type 2 Diabetes. <i>Human Physiology</i> , 2020, 46, 840-844.	0.1	0
3727	Glycemic Control and Future Perspectives for Treatment. , 2021, , 73-86.		0
3728	Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. <i>Current Pharmaceutical Design</i> , 2020, 26, 5637-5649.	0.9	13
3729	Nutritional and metabolic management of the diabetic patient with chronic kidney disease and chronic renal failure. , 2022, , 805-827.		0
3730	Standard Pharmacological Treatment of Diabetes Based on the Guidelines. <i>Stroke Revisited</i> , 2021, , 179-187.	0.2	0
3732	Incidence and Determinants of Reported Hypoglycaemia among Patients with Type 2 Diabetes Mellitus in a Tertiary Health Institution in Nigeria. <i>Journal of Diabetes Mellitus</i> , 2020, 10, 51-63.	0.1	2
3735	Correlation of Risk Factors with Severity of Diabetic Retinopathy - A Retrospective Study. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2020, 09, 101-104.	0.1	1
3736	Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential. <i>Doctor Ru</i> , 2020, 19, 6-12.	0.1	1
3737	Diabetic kidney disease: seven questions. <i>Journal of the Korean Medical Association</i> , 2020, 63, 6.	0.1	0
3738	Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View. , 2020, 2, 9-13.		5
3739	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2020, , 131-159.	0.1	0
3740	Medizinische Register im Market Access-Prozess. , 2020, , 361-375.		0
3741	Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 423-430.	0.6	0
3743	Evaluating the effectiveness of a support programme for people with type 2 diabetes mellitus in primary care: an observational prospective study in Ecuador. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101025.	0.9	0
3744	Desenvolvimento e avaliação de uma plataforma digital para orientar a conduta do Diabetes Mellitus tipo 2 para alunos de graduação em Medicina. <i>Research, Society and Development</i> , 2021, 10, e249101421823.	0.0	0
3747	Assessing the quality of the evidence underlying recommendations in type 2 diabetes™ commonly used clinical practice guidelines. <i>JBI Evidence Implementation</i> , 2021, 19, 31-38.	1.4	0
3748	New Herbal Approaches for the Treatment of Diabetic Kidney Diseases and Its Therapeutic Implications. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 0, , 368-406.	0.3	0

#	ARTICLE	IF	CITATIONS
3749	Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. <i>Journal of Nutrition, Health and Aging</i> , 0, , .	1.5	0
3750	Letter: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence ( <i>Diabetes Metab J</i> 2020;44:555-65). <i>Diabetes and Metabolism Journal</i> , 2020, 44, 775-776.	1.8	0
3751	Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor. <i>Bulletin of Siberian Medicine</i> , 2020, 19, 44-51.	0.1	1
3752	Glycated Haemoglobin and Outcomes of Percutaneous Coronary Intervention Among Type Two Diabetic Patients in Saudi Arabia. <i>Cureus</i> , 2020, 12, e11278.	0.2	0
3754	Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?. <i>Hormone and Metabolic Research</i> , 2021, 53, 75-84.	0.7	5
3755	Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. , 2021, , 295-313.		0
3756	Impact of Endocrine Disorders on the Kidney. <i>Endocrinology</i> , 2021, , 123-156.	0.1	0
3758	Sulfonylurea derivatives and risk of hypoglycaemia in type 2 diabetic patients. <i>Vnitri Lekarstvi</i> , 2020, 66, e35-e42.	0.1	1
3759	Is tight glycemic control in type 2 diabetes really worthwhile? Yes. <i>Canadian Family Physician</i> , 2009, 55, 580, 582, 584, 586, 588.	0.1	6
3760	Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians. <i>Canadian Family Physician</i> , 2009, 55, 803-4.	0.1	8
3761	A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus. <i>P and T</i> , 2009, 34, 368-78.	1.0	3
3762	Incretin agents in type 2 diabetes. <i>Canadian Family Physician</i> , 2010, 56, 639-48.	0.1	32
3763	Thiazolidinediones: a 2010 perspective. , 2010, 14, 64-72.		24
3765	Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. <i>P and T</i> , 2010, 35, 498-529.	1.0	20
3766	Diabetes & coronary heart disease: current perspectives. <i>Indian Journal of Medical Research</i> , 2010, 132, 584-97.	0.4	27
3767	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 155-63.	1.1	12
3769	To test or not to test? Self-monitoring of blood glucose in patients with type 2 diabetes managed without insulin. <i>Open Medicine</i> , 2010, 4, e114-6.	1.5	1
3770	Glycemia and cardiovascular risk: challenging evidence based medicine. <i>Hippokratia</i> , 2011, 15, 199-204.	0.3	3

#	ARTICLE	IF	CITATIONS
3771	Diabetes in the frail elderly: individualization of glyceic management. Canadian Family Physician, 2012, 58, 543-6.	0.1	12
3772	Diabetes: glycaemic control in type 2 (drug treatments). Clinical Evidence, 2012, 2012, .	0.2	6
3773	Glucose control and its implications for the general surgeon. American Surgeon, 2009, 75, 1031-5.	0.4	0
3776	Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P and T, 2012, 37, 687-96.	1.0	10
3778	Management of Diabetic Nephropathy in the Elderly: Special Considerations. Journal of Nephrology & Therapeutics, 2012, 2, .	0.1	1
3779	An inpatient hypoglycemia committee: development, successful implementation, and impact on patient safety. Ochsner Journal, 2013, 13, 407-12.	0.5	7
3780	Type 2 diabetes and hemoglobin A1c targets. Canadian Family Physician, 2013, 59, 1193.	0.1	0
3781	Neuroprotective effect of RYGB in Zucker fatty diabetic rats. International Journal of Clinical and Experimental Medicine, 2014, 7, 3297-304.	1.3	0
3782	Editorial on the original article entitled "Changes in diabetes-related complications in the United States, 1990-2010" published in the New England Journal of Medicine on April 17, 2014. Annals of Translational Medicine, 2014, 2, 118.	0.7	0
3783	Complications of diabetes: progress, but significant challenges ahead. Annals of Translational Medicine, 2014, 2, 120.	0.7	8
3784	Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes. Journal of Endocrinology, Diabetes & Obesity, 2014, 2, .	0.7	24
3785	Cardiovascular safety profile of currently available diabetic drugs. Ochsner Journal, 2014, 14, 616-32.	0.5	37
3786	The methodology of glucose monitoring in type 2 diabetes mellitus. Clujul Medical, 2013, 86, 93-6.	0.1	1
3787	Effect of glycated hemoglobin on heart function of the patients with revascularization of coronary artery. International Journal of Clinical and Experimental Pathology, 2015, 8, 7181-8.	0.5	1
3788	Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. Transactions of the American Clinical and Climatological Association, 2015, 126, 62-76.	0.9	6
3789	Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse. AMIA ... Annual Symposium proceedings, 2016, 2016, 2036-2042.	0.2	6
3790	Diabetic Kidney Disease. Missouri Medicine, 2016, 113, 390-394.	0.3	9
3791	Hypoglycemia Safety Initiative: Working With PACT Clinical Pharmacy Specialists to Individualize HbA Goals. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S14-S17.	0.6	1





#	ARTICLE	IF	CITATIONS
3811	Lungenfibrose: Eine Komplikation des Diabetes?. , 0, , .		0
3812	Metabolische Chirurgie: Diabetiker profitieren â€“ unabhÃ¤ngig vom Gewicht. , 0, , .		0
3814	Glycaemic Control in Diabetes. Handbook of Experimental Pharmacology, 2021, , 47-71.	0.9	1
3815	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. Advances in Chronic Kidney Disease, 2021, 28, 298-308.	0.6	6
3816	Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. Advances in Chronic Kidney Disease, 2021, 28, 337-346.	0.6	3
3817	Hypoglycaemia in the Treatment of Diabetes Mellitus. , 2022, , 2004-2022.		0
3818	Computerized Clinical Decision Support. , 2022, , 469-497.		1
3819	Diabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies. Journal of Diabetes Science and Technology, 2022, , 193229682110353.	1.3	4
3820	Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study. Journal of Diabetes Research, 2022, 2022, 1-9.	1.0	5
3822	Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care, 2022, 45, 684-691.	4.3	31
3823	Trends in the Incidence of Hospitalization for Major Diabetes-Related Complications in People With Type 1 and Type 2 Diabetes in Australia, 2010â€“2019. Diabetes Care, 2022, 45, 789-797.	4.3	30
3824	Adherence to the American Diabetes Associationâ€™s Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001â€“2018. Diabetes Care, 2022, 45, 1107-1115.	4.3	8
3825	Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-ÎºB activation in human endothelial cells and differentiated macrophages. European Journal of Pharmacology, 2022, 918, 174715.	1.7	51
3826	Diabetes and Kidney Disease. , 2022, , 23-33.		1
3827	GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice. Journal of the American Association of Nurse Practitioners, 2022, 34, 418-440.	0.5	2
3828	SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes. Current Cardiology Reports, 2022, 24, 183-189.	1.3	3
3829	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases, 2022, 79, 457-479.	2.1	18
3830	Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms. Antioxidants and Redox Signaling, 2022, 37, 597-612.	2.5	5

#	ARTICLE	IF	CITATIONS
3832	Strategies for the prevention or reversal of neuropathy. , 2022, , 259-281.		0
3833	The conundrum and enigma of painful and painless neuropathy. , 2022, , 123-133.		2
3835	Glucose-derived posttranslational modification in cardiovascular disease. Molecular Aspects of Medicine, 2022, , 101084.	2.7	3
3836	Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, 593-604.	0.8	1
3837	Identification of Sorafenib as a Treatment for Type 1 Diabetes. Frontiers in Immunology, 2022, 13, 740805.	2.2	0
3839	3-Hydroxybutyrate Ameliorates the Progression of Diabetic Nephropathy. Antioxidants, 2022, 11, 381.	2.2	5
3840	Hypoglycemia induces vascular endothelial dysfunction in subjects with normal glucose tolerance. Scientific Reports, 2022, 12, 2598.	1.6	7
3841	Long-Term Oral Administration of Salidroside Alleviates Diabetic Retinopathy in db/db Mice. Frontiers in Endocrinology, 2022, 13, 861452.	1.5	2
3842	Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults. Diabetes Care, 2022, 45, 1335-1345.	4.3	2
3843	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. European Journal of Internal Medicine, 2022, 97, 78-85.	1.0	2
3844	Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 1723.	1.0	1
3845	The proteasome activator REG <sup>1</sup> promotes diabetic endothelial impairment by inhibiting HMG2-GLUT1 pathway. Translational Research, 2022, 246, 33-48.	2.2	4
3846	Is Lower Better?. JACC Asia, 2022, , .	0.5	0
3847	Should Hemoglobin A1c Targets Be Re-Evaluated?. American Journal of Cardiology, 2022, 173, 141-142.	0.7	1
3848	The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. Advances in Therapy, 2022, 39, 2208-2221.	1.3	13
3849	Canagliflozin and Dapagliflozin Attenuate Glucolipototoxicity-Induced Oxidative Stress and Apoptosis in Cardiomyocytes via Inhibition of Sodium-Glucose Cotransporter-1. ACS Pharmacology and Translational Science, 2022, 5, 216-225.	2.5	10
3850	Identification of benzothiazole-rhodanine derivatives as $\alpha$ -amylase and $\alpha$ -glucosidase inhibitors: Design, synthesis, in silico, and in vitro analysis. Journal of Molecular Recognition, 2022, 35, e2959.	1.1	7
3851	Potential Over-Treatment and Over-Testing among Older Adults with Type-2 Diabetes across Canada: An Observational Retrospective Cohort Study. Canadian Journal of Diabetes, 2022, , .	0.4	0

#	ARTICLE	IF	CITATIONS
3852	Web-Based TangPlan and WeChat Combination to Support Self-management for Patients With Type 2 Diabetes: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2022, 10, e30571.	1.8	11
3853	Hemoglobin A1c monitoring practices before lower extremity bypass in patients with diabetes vary broadly and do not predict outcomes. <i>Journal of Vascular Surgery</i> , 2022, 76, 255-264.	0.6	4
3854	Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1310-1318.	2.2	10
3855	Stress, hypoglycemia, and the autonomic nervous system. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2022, 240, 102983.	1.4	7
3856	Hyperlipidemia management in diabetes: First line or supportive therapy?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102470.	1.8	3
3857	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
3858	J-curve relationship between long term glycemic control and mortality in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2021, 20, 234.	2.7	3
3859	Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER. <i>Diabetes Therapy</i> , 2022, 13, 251-264.	1.2	4
3860	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S83-S96.	4.3	388
3861	Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 249-273.	1.6	9
3862	Prescribing, monitoring, and deprescribing drugs in geriatric DM patients. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 282-285.	0.2	1
3863	Optimal Type 2 Diabetes Mellitus Management and Active Ageing. <i>Endocrines</i> , 2021, 2, 523-539.	0.4	1
3864	Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes. <i>Endocrinology &amp; Diabetes &amp; Nutrition (English Ed)</i> , 2021, 68, 741-750.	0.1	0
3865	Epigenetics in the pathogenesis of diabetic nephropathy. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 163-172.	0.9	26
3866	13. Older Adults: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S195-S207.	4.3	114
3867	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. <i>Cardiovascular Diabetology</i> , 2021, 20, 241.	2.7	17
3868	Profile of patients with type 2 diabetes and glycated haemoglobin â‰¥ 10% followed in general practice. <i>Family Practice</i> , 2021, , .	0.8	0
3869	Effect of Clinical Inertia on Diabetes Complications among Individuals with Type 2 Diabetes: A Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2022, 58, 63.	0.8	1

#	ARTICLE	IF	CITATIONS
3870	Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002480.	1.2	31
3871	Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention. <i>World Journal of Diabetes</i> , 2021, 12, 2036-2049.	1.3	36
3872	Hospital utilization for hypoglycemia among patients with type 2 diabetes using pooled data from six health systems. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002153.	1.2	5
3873	Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT). <i>Cardiovascular Diabetology</i> , 2021, 20, 232.	2.7	8
3874	Diabetic kidney disease—predisposing proinflammatory and profibrotic genes identified by weighted gene co-expression network analysis (WGCNA). <i>Journal of Cellular Biochemistry</i> , 2022, 123, 481-492.	1.2	18
3875	Hypoglycaemia among adults with Type 2 Diabetes mellitus in a Family Medicine Clinic. <i>Annals of Health Research</i> , 2021, 7, 336-346.	0.1	0
3877	Study on the Correlation between TyG, SAA and Atherosclerosis in Diabetic Nephropathy Patients. <i>Advances in Clinical Medicine</i> , 2022, 12, 2535-2540.	0.0	0
3878	Glycemic treatment deintensification practices in nursing home residents with type 2 diabetes. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2019-2028.	1.3	7
3879	Largest Amplitude of Glycemic Excursion Calculating from Self-Monitoring Blood Glucose Predicted the Episodes of Nocturnal Asymptomatic Hypoglycemia Detecting by Continuous Glucose Monitoring in Outpatients with Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 858912.	1.5	4
3880	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	0.6	27
3886	Prevention of the Consequences of Diabetes- a Commentary. , 0, , 266-272.		1
3889	Influence of acute glycaemic level on measures of myocardial infarction in non-diabetic pigs. <i>Scandinavian Cardiovascular Journal</i> , 2015, 49, 376-82.	0.4	6
3890	Current medical treatment of diabetes type 2 and long term morbidity: how to balance efficacy and safety?. <i>Nutricion Hospitalaria</i> , 2013, 28 Suppl 2, 3-13.	0.2	5
3891	Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications. <i>Nutricion Hospitalaria</i> , 2013, 28 Suppl 2, 17-22.	0.2	4
3893	Effectiveness of color coded diabetic control monitoring charts among elderly diabetics attending outreach primary care geriatric clinics in rural Karnataka: An open label randomized control trial. <i>Indian Journal of Community Medicine</i> , 2019, 44, 39.	0.2	0
3894	The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review. <i>Clinical Medicine</i> , 2022, 22, 257-265.	0.8	1
3896	The associations between health-related physical fitness and fasting blood glucose in war veterans: a population-based study. <i>Scientific Reports</i> , 2022, 12, 6997.	1.6	1
3897	The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 1.	0.3	2

#	ARTICLE	IF	CITATIONS
3898	Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 876795.	1.1	1
3899	Sarco/Endoplasmic Reticulum Ca <sup>2+</sup> ATPase 2 Activator Ameliorates Endothelial Dysfunction; Insulin Resistance in Diabetic Mice. <i>Cells</i> , 2022, 11, 1488.	1.8	4
3900	Hydrogen Peroxide Scavenging Restores N-Type Calcium Channels in Cardiac Vagal Postganglionic Neurons and Mitigates Myocardial Infarction-Evoked Ventricular Arrhythmias in Type 2 Diabetes Mellitus. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 871852.	1.1	0
3901	A Strategic Investigation on Diabetic Nephropathy; Its Conceptual Model and clinical Manifestations: A Review. <i>Current Diabetes Reviews</i> , 2022, 18, .	0.6	0
3902	European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. <i>European Stroke Journal</i> , 2022, 7, I-XLI.	2.7	51
3903	Heterogeneous treatment effects of intensive glycaemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, 58.	2.7	6
3904	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
3905	Recent advances in the pharmacotherapeutic management of diabetic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 791-803.	0.9	5
3906	Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials. <i>Acta Diabetologica</i> , 2022, 59, 1257-1263.	1.2	2
3907	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. <i>Heart Failure Reviews</i> , 2023, 28, 585-596.	1.7	11
3908	Efficacy and safety outcomes of dulaglutide by baseline <sc>HbA1c</sc>: A post hoc analysis of the <sc>REWIND</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1753-1761.	2.2	2
3909	Severe Hypoglycemia and Cardiovascular Disease. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, , 100357.	0.6	0
3910	Metabolic syndrome, hyperglycemia, and type 2 diabetes. , 2013, , 436-462.		0
3911	Association Between Fat Mass or Fat Fibrotic Gene Expression and Polyneuropathy in Subjects With Obesity: A Korean Metabolic Bariatric Surgery Cohort. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	2
3912	Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 458-464.	0.5	3
3915	Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. <i>Circulation</i> , 2022, 145, 1632-1641.	1.6	60
3916	Fear of hypoglycemiaâ€”An underestimated problem. <i>Brain and Behavior</i> , 2022, 12, .	1.0	31
3917	The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) â€” Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 1627-1638.	1.1	0

#	ARTICLE	IF	CITATIONS
3920	Diabetes: how to manage chronic kidney disease. <i>Drugs in Context</i> , 0, 11, 1-10.	1.0	0
3921	A retrospective study of diabetes treatment in older adults: what should we AIM for?. <i>Postgraduate Medicine</i> , 0, , 1-5.	0.9	0
3922	Cardiometabolic Comorbidities in Cancer Survivors. <i>JACC: CardioOncology</i> , 2022, 4, 149-165.	1.7	13
3923	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 1162-1170.	2.9	13
3924	Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	17
3925	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1472-1488.	1.1	2
3926	Asian Best Practices for Care of Diabetes in Elderly (ABCDE). <i>Review of Diabetic Studies</i> , 2022, 18, 100-134.	0.5	0
3927	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	0
3930	The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3
3931	Intensive, telemedicine-based, self-management program for rural, underserved patients with diabetes mellitus: Re-entry of retired endocrinologists into practice. <i>Journal of Telemedicine and Telecare</i> , 0, , 1357633X2211060.	1.4	1
3932	Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1897-1900.	2.2	2
3933	Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 682-698.	0.9	4
3934	Determination of Time in Range Associated With HbA1c $\leq 7\%$ in a Prospective Cohort of Patients With Type 1 Diabetes Using Continuous Glucose Monitoring for Three Months. <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 345-350.	1.3	2
3935	Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108255.	1.2	18
3936	Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium. <i>PLoS ONE</i> , 2022, 17, e0268451.	1.1	14
3937	Association of hemoglobin A1c time in range with risk for diabetes complications. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002738.	1.2	3
3938	GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Kidney and Dialysis</i> , 2022, 2, 386-398.	0.5	0
3940	The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy. <i>Journal of Personalized Medicine</i> , 2022, 12, 1253.	1.1	0

#	ARTICLE	IF	CITATIONS
3941	The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3990-e4003.	1.8	3
3942	Sustained Proinflammatory Effects of Hypoglycemia in People With Type 2 Diabetes and in People Without Diabetes. <i>Diabetes</i> , 2022, 71, 2716-2727.	0.3	14
3943	Time-in-range: a promising glycemic control metric for bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2022, 18, 1416-1423.	1.0	1
3944	Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-16.	1.3	2
3945	Control and complications of diabetes in urban primary care units in Thailand: a cross-sectional study. , 2022, 23, .		0
3946	Inhibitory effect of plant essential oils on $\alpha$ -glucosidase. <i>Food Science and Biotechnology</i> , 2022, 31, 1593-1602.	1.2	1
3947	Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial. <i>BMJ Open</i> , 2022, 12, e054100.	0.8	3
3949	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€™2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
3950	Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2297-2308.	2.2	14
3951	Revisiting â€˜intensiveâ€™ blood glucose control: A causal directed acyclic graphâ€‘guided systematic review of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2341-2352.	2.2	4
3952	Epidemiology, Pathophysiology, and Management of Coronary Artery Disease in the Elderly. <i>International Journal of Angiology</i> , 2022, 31, 244-250.	0.2	2
3953	Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapyâ€™ Subanalysis of the REAL-CAD Trial â€™. <i>Circulation Reports</i> , 2022, 4, 422-428.	0.4	3
3954	Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8777.	1.8	6
3955	Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation. <i>Phytomedicine</i> , 2022, 106, 154389.	2.3	5
3956	Relationship among Insulin Therapy, Insulin Resistance, and Severe Coronary Artery Disease in Type 2 Diabetes Mellitus. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-6.	0.5	3
3957	Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2023, 28, 7-13.	0.4	1
3958	Effect of high-sensitivity C-reactive protein on the relationship between haemoglobin A1c and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cohort study. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 614-625.	0.7	1
3959	Herz und Diabetes. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0



#	ARTICLE	IF	CITATIONS
3960	Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	14
3961	Targeting pancreatic $\beta^2$ cells for diabetes treatment. <i>Nature Metabolism</i> , 2022, 4, 1097-1108.	5.1	11
3962	Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 1673.	1.0	2
3963	Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
3964	Effect of Glucose Levels on Cardiovascular Risk. <i>Cells</i> , 2022, 11, 3034.	1.8	9
3965	Associations of Age at Diagnosis and Duration of Diabetes With Morbidity and Mortality Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e2232766.	2.8	13
3967	Time trends (2012â€“2020) in glycated hemoglobin and adherence to the glycemic targets recommended for elderly patients by the Japan Diabetes Society/Japan Geriatrics Society Joint Committee among memory clinic patients with diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2022, 13, 2038-2046.	1.1	0
3968	The Role of Metabolic Memory in Diabetes Mellitus. <i>GÃ¼mÃ¼shane Ãœniversitesi SaÄŸliÄŸ Bilimleri Dergisi</i> , 2022, 11, 1257-1264.	0.1	0
3969	Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
3970	Delaying the Onset and Progression of CKD in People with Diabetes: Technology and Effectiveness in Achieving Glucose Control. , 2022, , 121-127.		0
3971	Effectiveness of the SUGAR intervention on hypoglycaemia in elderly patients with type 2 diabetes: A pragmatic randomised controlled trial. <i>Research in Social and Administrative Pharmacy</i> , 2023, 19, 322-331.	1.5	2
3972	Hypoglycemia is associated with a higher risk of mortality and arrhythmias in ST-elevation myocardial infarction, irrespective of diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
3973	New strategies to improve clinical outcomes for diabetic kidney disease. <i>BMC Medicine</i> , 2022, 20, .	2.3	20
3974	Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. <i>Annals of Medicine</i> , 2022, 54, 3038-3050.	1.5	1
3975	Continuous glucose monitoring reveals a novel association between duration and severity of hypoglycemia, and small nerve fiber injury in patients with diabetes. <i>Endocrine Connections</i> , 2022, 11, .	0.8	1
3976	Comprehensive assessment of cardiovascular complications in a patient with type 1 diabetes mellitus, chronic kidney disease and diabetic neuroosteoarthropathy. <i>Almanah KlinikiÄŸ Mediciny</i> , 2022, 50, 205-215.	0.2	0
3977	Time in range, assessed with continuous glucose monitoring, is associated with brachial-ankle pulse wave velocity in type 2 diabetes: A retrospective single-center analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
3978	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2022, 102, S1-S127.	2.6	246

#	ARTICLE	IF	CITATIONS
3979	Type 2 diabetes. <i>Lancet, The</i> , 2022, 400, 1803-1820.	6.3	176
3981	Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus. <i>European Medical Journal Diabetes</i> , 0, , 73-81.	4.0	5
3982	Recent Trends in Diabetes-Associated Hospitalizations in the United States. <i>Journal of Clinical Medicine</i> , 2022, 11, 6636.	1.0	4
3983	Influence of fasting plasma glucose-lowering rate on BNP levels in type 2 diabetes mellitus patients with coronary microcirculation dysfunction. <i>Hormones</i> , 0, , .	0.9	2
3984	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	1.2	3
3986	Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models. <i>Diabetologia</i> , 0, , .	2.9	1
3987	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 40-53.	0.5	0
3988	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodiumâ€“Glucose Co-transporter-2 Inhibitors. <i>European Endocrinology</i> , 2022, 18, 106.	0.8	4
3989	Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	1
3990	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. <i>Nature Reviews Endocrinology</i> , 2023, 19, 151-163.	4.3	21
3991	6. Glycemic Targets: <i>Standards of Care in Diabetesâ€“2023</i>. <i>Diabetes Care</i> , 2023, 46, S97-S110.	4.3	205
3992	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Circulation</i> , 2022, 146, 1882-1894.	1.6	58
3993	Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 113-126.	1.0	2
3994	Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts. <i>Movement Disorders</i> , 2023, 38, 162-177.	2.2	8
3995	13. Older Adults: <i>Standards of Care in Diabetesâ€“2023</i>. <i>Diabetes Care</i> , 2023, 46, S216-S229.	4.3	71
3996	Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0
3997	Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	0
3998	Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies. <i>Presse Medicale</i> , 2023, 52, 104159.	0.8	1

#	ARTICLE	IF	CITATIONS
3999	Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. <i>Presse Medicale</i> , 2023, 52, 104160.	0.8	1
4000	Caring for Patients With Diabetes in Stroke Neurology. <i>Stroke</i> , 2023, 54, 894-904.	1.0	5
4001	Machine learning for the prediction of minor amputation in University of Texas grade 3 diabetic foot ulcers. <i>PLoS ONE</i> , 2022, 17, e0278445.	1.1	5
4002	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. <i>Vascular Medicine</i> , 2023, 28, 62-76.	0.8	4
4003	Cardiovascular outcomes in type 1 and type 2 diabetes. <i>Diabetologia</i> , 2023, 66, 425-437.	2.9	32
4004	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. <i>Contemporary Cardiology</i> , 2023, , 67-138.	0.0	0
4005	Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. <i>Swiss Medical Weekly</i> , 2023, 153, 40004.	0.8	4
4007	Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 389-403.	0.1	0
4008	Control of Blood Glucose and Cardiovascular Risk Profile. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 451-469.	0.1	0
4009	The Clinical Impact of Flash Glucose Monitoringâ€”a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review. <i>JMIR Diabetes</i> , 0, 8, e42389.	0.9	2
4010	Association between the severity of nocturnal asymptomatic hypoglycemia and heart rate variability change in patients with type 2 diabetes. <i>International Journal of Diabetes in Developing Countries</i> , 0, , .	0.3	0
4011	Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 474-487.	0.8	4
4012	Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 95-110.	1.2	0
4013	Revert diabetes. , 0, 2, 5.		0
4014	The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature. <i>Biomolecules</i> , 2023, 13, 241.	1.8	0
4015	Exploring the inhibitory mechanism of p-coumaric acid on Î±-amylase via multi-spectroscopic analysis, enzymatic inhibition assay and molecular docking. <i>Food Hydrocolloids</i> , 2023, 139, 108524.	5.6	10
4016	Mechanisms of Nerve Injury in Diabetes: Dyslipidemia, Bioenergetics, and Oxidative Damage. <i>Contemporary Diabetes</i> , 2023, , 279-306.	0.0	0
4017	Intensive glucose control and recurrent cardiovascular events: 14â€”year followâ€”up investigation of the ACCORDION study. <i>Diabetes/Metabolism Research and Reviews</i> , 2023, 39, .	1.7	1

#	ARTICLE	IF	CITATIONS
4018	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-14.	2.2	4
4019	Glycaemic control in people with diabetes following acute myocardial infarction. <i>Diabetes Research and Clinical Practice</i> , 2023, 199, 110644.	1.1	2
4020	Geriatric Syndromes in Older Adults with Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 341-353.	1.2	0
4021	Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the <sc>CAROLINA</sc> cardiovascular outcome trial. <i>Diabetes, Obesity and Metabolism</i> , 0, , .	2.2	1
4022	Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1547-1556.	2.2	1
4023	Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	15
4024	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Diabetes Research</i> , 2023, 2023, 1-11.	1.0	0
4025	Data-driven classification of health status of older adults with diabetes: The diabetes and aging study. <i>Journal of the American Geriatrics Society</i> , 0, , .	1.3	3
4026	Association between hemoglobin glycation index and diabetic kidney disease in type 2 diabetes mellitus in China: A cross-sectional inpatient study. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
4027	Intensivtherapie im Rahmen der Transplantation solider Organe. <i>Springer Reference Medizin</i> , 2023, , 1-40.	0.0	0
4028	Prognostic implications of stress hyperglycemia ratio in patients with myocardial infarction with nonobstructive coronary arteries. <i>Annals of Medicine</i> , 2023, 55, 990-999.	1.5	6
4029	Paradigm shift of the medical care in diabetes. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2023, 19, 32-41.	0.0	0
4030	Circulating metabolic signatures of heart failure in precision cardiology. <i>Precision Clinical Medicine</i> , 2023, 6, .	1.3	2
4031	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	4
4032	Cardiovascular Autonomic Neuropathy. <i>Contemporary Diabetes</i> , 2023, , 203-220.	0.0	0
4033	Targeting the Mitochondrion in Diabetic Neuropathy. <i>Contemporary Diabetes</i> , 2023, , 307-326.	0.0	0
4034	Neuropathy in Type 1 and Type 2 Diabetes. <i>Contemporary Diabetes</i> , 2023, , 51-66.	0.0	0
4035	Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	1

#	ARTICLE	IF	CITATIONS
4036	Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management. <i>Presse Medicale</i> , 2023, 52, 104164.	0.8	3
4037	Complex metabolic“endocrine syndromes: associations with cardiovascular disease. , 2023, , 39-81.		1
4038	Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction. , 2023, , 221-232.		0
4039	Diabetes: evolution of multifactorial vascular risk reduction. , 2023, , 311-335.		0
4040	Association of hemoglobin A1c stability with mortality and diabetes complications in older adults with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2023, 11, e003211.	1.2	0
4041	Development and validation of an insulin resistance model for a population without diabetes mellitus and its clinical implication: a prospective cohort study. <i>EClinicalMedicine</i> , 2023, 58, 101934.	3.2	8
4042	Diabetic Kidney Disease. <i>Medical Clinics of North America</i> , 2023, 107, 689-705.	1.1	12
4043	Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	42
4044	Effects of glycemic control on frailty: a multidimensional perspective. <i>Hospital Practice (1995)</i> , 2023, 51, 124-134.	0.5	0
4045	Treatment of type 2 diabetes patients with heart conditions. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 255-265.	1.2	9
4046	Trends in dietary patterns over the last decade and their association with long-term mortality in general US populations with undiagnosed and diagnosed diabetes. <i>Nutrition and Diabetes</i> , 2023, 13, .	1.5	0
4047	An Assessment of How Clinicians and Staff Members Use a Diabetes Artificial Intelligence Prediction Tool: Mixed Methods Study. , 0, 2, e45032.		1
4060	Diabetes and Hypertension. , 2023, , 627-643.		0
4061	The “Old” Oral Antidiabetics. , 2023, , 551-563.		0
4066	The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review. <i>Advances in Therapy</i> , 0, , .	1.3	0
4069	The Role of Lipids and Lipoproteins in Peripheral Neuropathy. <i>Contemporary Diabetes</i> , 2023, , 485-502.	0.0	0
4075	Tight Control of Diabetes in Adult Patients (ACCORD)-2008. , 2023, , 83-86.		0
4079	Insulin Treatment of Diabetes Mellitus-Tight vs. Conventional Control. <i>Contemporary Cardiology</i> , 2023, , 969-987.	0.0	0

#	ARTICLE	IF	CITATIONS
4080	Diabetes and Cerebrovascular Disease. Contemporary Cardiology, 2023, , 551-576.	0.0	0
4081	Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781.	0.0	0
4087	Medication Management in Long-Term Care. , 2023, , 341-368.		0
4113	Type 2 Diabetes-Etiology, Epidemiology, Pathogenesis, Treatment. , 2023, , 1-20.		0
4117	Neuropathic Ulcers. , 2023, , 179-195.		0
4120	From a glyco-centric approach in the patient with type 2 diabetes mellitus to a multi-organ prevention treatment and a decrease in the neuro-nephro-cardiovascular outcomes.. , 0, , .		0
4122	Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin. Diabetes Therapy, 2023, 14, 1997-2014.	1.2	1
4137	Haptoglobin Phenotypes in Patients with Type 2 Diabetes and Carotid Atherosclerosis. , 2023, , .		0
4139	Type 1 and Type 2 Diabetes Mellitus. , 2023, , 117-140.		0
4147	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
4172	Hypoglycemia, insulin resistance, and cardiovascular disease: A possible link. , 2024, , 597-608.		0
4175	The cardiometabolic syndrome and vascular disease: pivotal role of insulin. , 2023, , 261-284.		0
4176	Type 2 Diabetes: Etiology, Epidemiology, Pathogenesis, and Treatment. , 2023, , 509-528.		0
4192	Age-related disease: Kidneys. , 2024, , 91-117.		0
4196	Multimodale kardiovaskuläre Prävention. Springer Reference Medizin, 2023, , 1-13.	0.0	0